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ABSTRACT	  
Small	  bowel	  motility	  is	  an	  essential,	  physiological	  process	  central	  to	  the	  processing	  of	   ingested	   food.	   The	   small	   bowel	   is	   however	   anatomically	   and	   functionally	  complex,	  varying	  greatly	  between	  individuals	  and	  located	  deep	  within	  the	  abdomen	  making	  it	  extremely	  difficult	  to	  access	  with	  instrumentation.	  As	  a	  consequence,	  and	  in	  spite	  of	  its	  known	  or	  suspected	  role	  in	  a	  range	  of	  diseases,	  there	  remain	  little	  in	  the	  way	  of	  objective	  tests	  to	  evaluate	  or	  even	  observe	  this	  process	  in	  vivo.	  	  This	   thesis	   details	   the	   validation	   and	   application	   of	   a	   novel	   computer	   post-­‐processing	   technique	   that	   allows	   the	   quantification	   of	   Magnetic	   Resonance	  Enterography	   derived	   time-­‐series	   image	   data.	   A	   background	   to	   small	   bowel	  physiology	  and	  existing	   techniques	   is	   first	  provided	  along	  with	  an	   introduction	   to	  the	   registration	   algorithm	   used	   throughout	   this	   thesis	   to	   quantify	   small	   bowel	  motility.	   The	   technique	   is	   then	   applied	   retrospectively	   to	   two	   Crohn’s	   disease	  patient	   cohorts	   to	   explore	   how	   this	   inflammatory	   bowel	   disease	   influences	  contractility.	   A	   prospective	   evaluation	   of	   segmental	   motility	   analysis	   is	   then	  presented	  drawing	  attention	  to	  large	  within	  subject	  variation,	  in	  a	  cohort	  of	  healthy	  volunteers,	   as	   a	   limitation	   for	   this	   technique.	   As	   an	   alternative,	   a	   global	   motility	  analysis	  approach	  is	  described	  and	  validated.	  Although	  global	  measures	  of	  motility	  appeared	   robust,	   factors	   influencing	   clinical	   application	   are	   further	   addressed	   by	  expanding	   the	   technique	   to	   allow	   motility	   analysis	   in	   free-­‐breathing	   data.	   In	   the	  final	  piece	  of	  research	  presented,	  the	  application	  of	  the	  global	  technique	  to	  a	  cohort	  of	   Chronic	   Intestinal	   Pseudo-­‐Obstruction	   patients	   is	   detailed.	   The	   thesis	   is	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concluded	  with	  a	  reflection	  of	  the	  results	  and	  a	  chapter	  dedicated	  to	  the	  commercial	  exploitation	   of	   the	   research	   to	   address	   the	   ongoing	   need	   for	   a	   robust	   test	   to	  quantise	  intestinal	  motility.	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Thesis	  Overview	  
	  This	  thesis	  comprises	  of	  ten	  chapters	  grouped	  into	  four	  sections	  outlined	  below.	  All	  of	   the	   work	   is	   that	   of	   the	   author	   unless	   otherwise	   stated.	   The	   beginning	   of	   each	  chapter	  (with	  the	  exclusion	  of	  Chapter	  1	  that	   is	   literature	  review)	  will	  consist	  of	  a	  
study	  question,	  rational,	  hypothesis	  and	  aim(s)	  along	  with	  a	  declaration	  of	  published	  work.	  	  	  
Section	  A	  summarises	  the	  literature	  and	  background	  underlying	  this	  PhD	  thesis	  and	  introduces	   the	   core	   registration	   technique	   used	   throughout.	   In	   Chapter	   1,	   an	  overview	   is	   provided	   of	   the	   basic	   physiology	   alongside	   a	   literature	   review	   of	   the	  available	   methods	   for	   small	   bowel	   motility	   analysis	   with	   a	   specific	   focus	   on	  emerging	   techniques	  using	  MRI	  and	   the	   landmark	  papers	   in	   this	   field.	   	  Chapter	   2	  introduces	   the	   registration	   algorithm	  developed	  by	  Dr	  Freddy	  Odille	   and	  explains	  some	  of	  the	  key	  concepts	  underlying	  the	  analysis	  technique	  used	  through	  this	  thesis.	  The	   focus	   of	   this	   chapter	   lies	   primarily	   in	   the	   validation	   of	   the	   registration	  technique	  accuracy	  and	  ability	  to	  quantitatively	  grade	  motility.	  	  	  
Section	  B	   introduces	  the	  first	  clinical	  application	  of	  quantified	  motility	  assessment	  using	   Magnetic	   Resonance	   Enterography	   in	   two	   retrospective	   Crohn’s	   disease	  cohorts.	  Chapter	  3	  investigates	  the	  relationship	  between	  terminal	  ileal	  motility	  and	  inflammatory	  activity	  assessed	  against	  histopathological	  and	  anatomical	  measures	  and	   specifically	   explores	   motility	   as	   an	   independent	   marker	   of	   inflammation.	  
Chapter	   4	   evaluates	  more	  broadly	  motility	   changes	   in	   stricturing	  Crohn’s	  disease	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and	   the	   relation	   between	   bowel	   diameter	   and	   motility	   potential	   in	   obstructive	  episodes.	  	  	  
Section	   C	   focuses	   on	   prospective	   investigation	   in	   healthy	   individuals	   to	   establish	  normal	  ranges	  and	  address	  inherent	  methodological	  limitations	  identified	  in	  section	  B.	   Chapter	   5	   presents	   data	   to	   assess	   the	   impact	   of	   intra-­‐subject	   variability	   on	  segmental	  bowel	  motility	  assessment.	  Here	  it	  is	  shown	  that	  motility,	  even	  in	  healthy	  controls,	   is	   heterogeneous	   and	   a	   potential	   source	   of	   confirmation	   bias	   in	   the	  assessment	  of	  this	  form	  of	  analysis.	  Chapter	  6	  directly	  addresses	  this	  limitation	  by	  presenting	  a	  novel	  method	   for	  global	  bowel	  motility	  assessment	   that	   removes	   the	  requirement	   to	   subjectively	   pick	   specific	   bowel	   loops	   for	   analysis.	   The	   global	  method	   is	   assessed	   for	   intra-­‐reader	   variability,	   intra-­‐subject	   variability	   and	  provides	  evidence	  for	  sensitivity	  using	  pro-­‐kinetic	  and	  paralytic	  agents	  to	  provoke	  changes	  in	  motility.	  	  	  Building	   on	   the	   results	   from	   section	   C,	   Section	   D	   addresses	   the	   clinical	  implementation	   of	   motility	   analysis.	   Chapter	   7	   details	   an	   extension	   of	   the	  registration	  methodology	   to	   evaluate	   free-­‐breathing	   acquisition	   series	   of	   not	   just	  the	   small	   bowel	   but	   also	   the	   colon	   broadening	   the	   applicability	   of	   the	   technique.	  
Chapter	   8	   goes	   on	   to	   recruit	   a	   cohort	   of	   Chronic	   Intestinal	   Pseudo-­‐Obstruction	  patients	  and	  for	  the	  first	  time	  draws	  a	  direct	  comparison	  between	  healthy	  controls	  and	  a	  disease	  group	  in	  terms	  of	  their	  small	  bowel	  motility.	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Section	   E	   Concludes	   this	   thesis	   with	   Chapter	   9	   summarising	   key	   findings	   and	  discussing	  potential	  future	  objectives	  for	  the	  research.	  Finally	  Appendix	  4	  presents	  the	  commercialisation	  strategy	  for	  the	  exploitation	  of	  this	  thesis.	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SECTION	   A:	   INTRODUCTION	   TO	   SMALL	   BOWEL	  MOTILITY	   AND	   REGISTRATION	   AS	   METHODS	   OF	  QUANTITATIVE	  ASSESSMENT	  	  
	  
Small	   bowel	   motility	   is	   a	   collection	   of	   contractile	   actions	   coordinated	   by	   the	  myenteric	  plexus	  or	  ‘gut	  brain’	  in	  response	  to	  intrinsic	  and	  extrinsic	  factors.	  Behind	  this	  statement	  is	  a	  nervous	  system	  with	  more	  neurons	  that	  the	  spinal	  cord,	  a	  range	  of	   specific	   hormones	   that	   modulate	   the	   nature	   of	   the	   contractile	   actions	   and	   an	  inherent	  sensitivity	  to	  lumen	  contents	  and	  biophysical	  properties	  including	  stretch,	  that	  fundamentally	  influence	  the	  way	  in	  which	  the	  gut	  behaves.	  Conditions	  affecting	  motility	   are	   common	   and	   characterised	   clinically	   by	   pain,	   bloating	   and	   altered	  bowel	  habit	  and	  include	  both	  primary	  diseases	  of	  the	  gut	   like	  Crohn’s	  Disease	  and	  also	  secondary	  involvement	  in	  a	  range	  of	  conditions	  including	  Parkinson’s,	  diabetes	  and	  amyloidosis	  etc.	  Collectively,	   treating	  the	  GI	  symptoms	  of	  these	  diseases	  has	  a	  dramatic	   effect	   on	   the	   patients’	   quality	   of	   life	   but	   attracts	   a	   significant	   healthcare	  cost,	  estimated	  to	  be	  at	  £5.6	  billion	  per	  year	  in	  the	  UK	  alone.	  A	  range	  of	  investigative	  techniques	   including	  manometry	   and	   scintigraphy	  have	   been	  developed	   and	  used	  over	  the	  past	  several	  decades	  to	  investigate	  motility	  in	  disease	  and	  health.	  Despite	  this,	   clinical	   uptake	   remains	   low	   and	   basic	   understanding	   of	   normality	   is	   largely	  absent.	   In	  addition,	   cost	  and	   low	  patient	   tolerability	  of	  existing	   techniques	   further	  inhibits	   widespread	   use	   of	   motility	   investigation	   as	   part	   of	   a	   clinical	   work	   up.	  Magnetic	  resonance	  enterography	  has	  become	  an	   increasingly	  popular	  method	  for	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non-­‐invasively	   evaluating	   small	   bowel	   motility.	   As	   scanner	   hardware	   and	   post-­‐processing	   has	   improved,	   a	   range	   of	   novel	  methods	   that	   directly	   address	   existing	  limitations	   have	   emerged	   with	   the	   potential	   to	   fundamentally	   drive	   scientific	  research	  in	  this	  field.	  	  
	  
Chapter	   1	   presents	   a	   literature	   review	   and	   up	   to	   date	   perspective	   on	   the	  techniques	   and	   background	   surrounding	   the	   assessment	   of	   gastrointestinal	  motility	   and	   highlights	   the	   key	   methodological	   limitations	   within	   this	   niche	   but	  expanding	  field.	  Chapter	  2	  introduces	  a	  novel	  method	  for	  the	  objective	  evaluation	  of	   small	   bowel	   motility	   through	   the	   registration	   of	   2D	   time-­‐series	   images	   from	  Magnetic	  Resonance	  Enterography.	  	  The	  focuses	  lies	  specifically	  with	  the	  validation	  of	   the	  optic-­‐flow	  algorithm	  developed	  by	  Freddy	  Odille	  and	  an	  explanation	  of	   the	  key	  methods	  used	  throughout	  this	  thesis	  to	  quantify	  small	  bowel	  motility.	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CHAPTER	   1:	   BACKGROUND	   AND	   LITERATURE	  REVIEW	   OF	   SMALL	   BOWEL	   PHYSIOLOGY,	   MOTILITY	  AND	  METHODS	  OF	  ASSESSMENT	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Rationale:	  Small	   bowel	  motility	   has	   long	   been	   an	   active	   but	   limited	   area	   of	   research	  within	  human	  investigations	  complicated	  by	  the	  functional	  complexity	  of	  the	  bowel	  and	  its	  deep	   anatomical	   location.	   Invasive	   techniques	   like	  manometry	   can	   only	   reach	   the	  very	  distal	  or	  proximal	  regions	  of	  the	  small	  bowel	  and	  remain	  largely	  limited	  to	  use	  as	  a	  research	  tool.	  More	  recently,	  MRE	  has	  allowed	  the	  real-­‐time	   ‘cine’	  or	  dynamic	  imaging	   of	   the	   bowel	  with	   the	   high-­‐resolution	   images	   then	   used	   to	   perform	   non-­‐invasive,	   quantitative	   analysis.	   MRE	   therefore	   represents	   an	   important	   and	  clinically	  practical	  advance	  for	  the	  investigation	  of	  dysmotility	  in	  disease.	  	  
Aim(s):	  i)	   Provide	   an	   overview	   of	   small	   bowel	   physiology	   and	   the	   clinical	   circumstances	  where	  motility	  assessment	  might	  be	  required.	  	  ii)	   Summarise	   history	   and	   background	   of	   small	   bowel	   motility	   assessment	   and	  introduce	  MRI.	  	  iii)	  Discuss	  the	  notable	  methods	  for	  motility	  assessment	  using	  MRE	  with	  reference	  to	  the	  current	  literature.	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Physiology	  Background	  
	  
The	   purpose	   of	   the	   small	   bowel	   is	   to	   absorb	   the	   nutrients	   from	   our	   food.	   This	  process	   occurs	   largely	   at	   the	   micro-­‐level	   with	   digestive	   enzymes	   being	   used	   to	  break	  up	  and	  translocate	  the	  prerequisite	  components	  of	  our	  meal	  across	  the	  lumen	  into	  the	  mesenteric	  vasculature.	  Facilitating	  this	  process	  is	  the	  physiological	  action	  of	   the	  bowel	   itself,	  mechanically	  churning	  and	  homogenising	   intestinal	  contents	  to	  disperse	   digestive	   enzymes	   and	   propel	   the	   chyme	   through	   approximately	   7m	   of	  bowel	  from	  the	  stomach	  towards	  the	  large	  intestine[1].	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Bowel	  state	   Contractile	  pattern	   Duration	  
Length	  of	  Bowel	  
Segment	  Postprandial	   Stationary	  contraction	   short	   short	  Postprandial	   Peristaltic	  waves	   short	   long	  	   	   	   	  Inter-­‐digestive	   Stationary	  cluster	  of	  contractions	  (Phase	  I)	   long	   short	  Inter-­‐digestive	   Migrating	  cluster	  of	  contractions	  (Phase	  II)	   long	   short,	  migrating	  aborally	  Inter-­‐digestive	   Migrating	  motor	  complex	  (Phase	  III)	   long	   long,	  migrating	  aborally	  
	  
Table	  1.1	  Summary	  of	  contractile	  actions	  present	  in	  the	  small	  bowel.	  
	  
A	   range	   of	   influences	   acting	   predominantly	   via	   the	   myenteric	   plexus	   function	   to	  modulate	  the	  frequency	  or	  pattern	  of	  motile	  actions,	  split	  largely	  into	  three	  groups;	  hormonal,	   dietary	   and	   neurological.	   These	   factors	   may	   act	   intrinsically	  (acetylcholine,	   tachykinin	   nitric	   oxide,	   glucagon-­‐like	   protein,	   vasoactive	   intestinal	  peptide	   (VIP)),	   as	   well	   as	   extrinsically	   (motilin,	   insulin,	   adrenalin)[2],	   [3].	   Food	  content	   further	   influences	  motility;	   glucose	   for	   example	   increases	   peristaltic	   rate	  and	   pH	   affects	   transit	   time.	   	   However	   much	   of	   the	   evidence	   surrounding	   direct	  dietary	   modulation	   of	   motility	   remains	   speculative[1],	   [11].	   The	   third	   effector	   of	  motility,	  and	  perhaps	  the	  most	  obscure	  and	  difficult	  to	  study	  is	  the	  enteric	  nervous	  system	  itself,	   together	  with	   its	   interaction	  with	   the	  central	  nervous	  system[1],	   [3],	  [12],	   [13].	   The	   basic	   doctrines	   of	   physiology	   dictate	   that	   the	   actions	   of	  parasympathetic	  nervous	  system	  stimulate	  activity	  along	  the	  GI	  tract	  via	  the	  vagus	  nerve	  while	  the	  sympathetic	  nervous	  system	  precipitates	  the	  contrary	  response.	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Key	  point:	   Intestinal	  motility	  summarises	  a	  collection	  of	  contractile	  actions	  initiated	  
by	   the	  myenteric	   plexus	   ‘gut	   brain’	   in	   response	   to	   a	   range	   of	   intrinsic	   and	   extrinsic	  
factors.	  	  
Normal	  values	  for	  virtually	  any	  part	  of	  the	  GI	  tract,	  especially	  the	  small	  intestine,	  are	  either	  non-­‐existent	  or	  occupy	  a	   large	   range.	  Earlier,	   the	   length	  of	   the	   small	  bowel	  was	  noted	   to	  be	  on	  average	  7m	  although	   this	   can	   range	   from	  3m	  to	  9m	   in	  adults.	  With	   respect	   to	   function,	   the	   bowel	   contracts	   at	   8-­‐11	   contractions	   per	   minute	  unequally	   distributed	   as	   periods	   of	   rapid	   contraction	   and	   silence.	   Beyond	   this,	  normal	   transit	   time	   for	   the	   contents	   of	   the	   small	   intestine	   take	   between	   30-­‐60	  minutes	  for	  liquids	  and	  between	  4-­‐5h	  for	  solids	  depending	  on	  meal	  composition[2]–[4].	  	  
	  
Small	  bowel	  motility	  in	  disease	  
	  
Numerous	   studies	   have	   documented	   the	   involvement	   of	   small	   bowel	   motility	   in	  many	  disease	  processes,	  although	  the	  mechanistic	  process	  in	  many	  remains	  unclear.	  In	   inflammatory	   bowel	   diseases	   such	   as	   Crohn’s	   Disease,	   inflammation,	   and	   the	  subsequent	  fibrotic	  process	  that	  occurs	  directly	  results	  in	  varying	  decreases	  in	  small	  bowel	  motility[14]–[17].	  Conversely	  in	  bacterial	  overgrowth,	  the	  absence	  of	  motility	  is	   postulated	   as	   the	   cause	   of	   the	   disease	   symptoms	   characterized	   mainly	   by	   a	  reduced	   frequency	  of	   the	  migrating	  myoelectric	   complex	   (MMC)	   –	   a	  motile	   action	  regarded	  as	  being	  fundamental	  to	  keeping	  the	  intestine	  free	  from	  bacteria[12],	  [18],	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[19].	  In	  a	  number	  of	  diseases,	  including	  the	  somewhat	  controversial	  irritable	  bowel	  syndrome	   where	   dysmotility	   has	   never	   been	   empirically	   confirmed,	   it	   is	   the	  proposed	  absence	  of	  these	  motile	  actions	  that	  are	  believed	  to	  precipitate	  a	  response	  that	  manifests	  as	  pain,	  change	  in	  bowel	  habit	  or	  altered	  sense	  of	  ‘well-­‐being’	  in	  the	  patient	   [20],	   [21].	   In	   some	   cases	   the	   disease	   is	   largely	   idiopathic	   for	   example,	  chronic	   intestinal	   pseudo-­‐obstruction	   (CIPO)	   where	   patients	   present	   with	  abdominal	  pain	  and	  the	  symptoms	  of	  obstructed	  bowel	  in	  the	  absence	  of	  causative	  lesion,	  with	  only	   full	   thickness	  biopsies	  of	   the	  bowel	  wall	   able	   to	   characterise	   the	  origins	  of	   the	  disease	   [22]–[26].	  Several	   studies	  have	  documented	   the	  presence	  of	  altered	  gut	  motility	  and	  symptom	  improvement	  following	  administration	  of	  motility	  effecting	   drugs	   (neostigmine)	   in	   CIPO	   that	   further	   reinforce	   role	   of	   abnormal	  motility	   in	   this	  disease.	   	  However	   it	   is	   entirely	  unclear	  as	   to	  whether	  motility	   is	   a	  cause	  or	  effect	  in	  the	  disease	  process[27].	  
Key	  point:	  Symptoms	  suggestive	  of	  dysmotility	  are	  extremely	  common	  in	  diseases	  that	  
primarily	   affect	   the	   gut	   and	   secondary	   to	   assorted	   neurological	   conditions	   and	  
medication	   regimens,	   leading	   to	   a	  marked	  decrease	   in	   quality	   of	   life	   for	   the	   patient	  
and	  increased	  healthcare	  costs.	  	  
Beyond	   conditions	   that	   appear	   to	   originate	   in	   the	   small	   bowel,	   motility	  derangement	  may	   often	   be	   the	   systemic	   effect	   of	   a	   central	   neurological	   disorder,	  indirectly	  affecting	  the	  small	  bowel	  via	  the	  enteric	  nervous	  system,	  with	  Parkinson’s	  disease	  and	  diabetic	  neuropathy	  being	  some	  of	  the	  more	  prominent	  examples[28]–[31].	  The	  data,	  detailing	  the	  impact	  on	  motility	  in	  these	  disorders	  is	  scant	  although	  a	  wealth	  of	   anecdotal,	   indirect	  and	  circumstantial	   evidence	  exists	   to	   implicate	   small	  bowel	   dysfunction.	   Specifically	   in	   Parkinson’s	   disease,	   dysmotility	   has	   been	  
	  	   30	  
	  
	  
	   	  
described	  in	  the	  oesophagus,	  stomach	  and	  colon,	  leading	  in	  the	  case	  of	  the	  latter	  to	  constipation,	   one	   the	   of	   most	   common	   symptoms	   of	   the	   disease.	   	   Interestingly	  constipation	   is	   a	  disease	   risk	   factor	  associated	  with	  Parkinson’s	   in	  males	  over	   the	  age	  of	  50[31],	  [32].	  	  
	  
Due	  to	  its	  relative	  accessibility,	  the	  colon	  has	  been	  researched	  relatively	  thoroughly	  with	  respect	  to	  its	  physiology	  but	  the	  small	  intestine	  remains	  enigmatic.	  In	  Rats,	  the	  use	  of	  MPTP	  (a	  compound	  that	  induces	  Parkinson	  like	  changes)	  was	  demonstrated	  to	   disrupt	   the	   MMC,	   a	   process	   that	   could	   be	   reversed	   through	   administration	   of	  levodopa[33].	   Radiology	   has	   demonstrated	   a	   dilation	   of	   small	   bowel	   loops	  suggesting	   a	   loss	   of	   tone	   and	   manometry	   has	   suggested	   changes	   in	   basal	   motor	  patterns	   and	   auscultation	   of	   the	   abdomen	   has	   shown	  marked	   decrease	   in	   bowel	  sounds	   compared	   to	  healthy	   controls.	   Symptomologically,	   patients	   complain	  often	  of	  bloating	  and	  experience	  weight	   loss	  as	   the	  disease	  progresses	   implicating	  small	  bowel	   function[28].	   Again,	   very	   little	   is	   known	   and	   the	   field,	   as	   it	   is	   stands,	   is	   in	  equipoise	  with	  respect	  to	  the	  role	  of	  the	  small	  bowel	  motility	  be	  it	  causal,	  or,	  more	  likely,	   a	   result	   of	   disease	   pathology.	   In	   any	   case,	   dysfunction	   stands	   to	   generate	  additional	   problems	   and	   substantial	   further	   cost	   in	   healthcare	   and	   is	   therefore	   of	  interest	  to	  researchers	  and	  clinicians	  alike[28].	  
	  
Part	  of	  the	  reason	  for	  our	  collective	  ignorance	  of	  small	  bowel	  function	  and	  variable	  findings	  with	  respect	  to	  normality,	  let	  alone	  disease,	  is	  the	  extraordinary	  complexity	  of	   the	   system	   and	   its	   deep	   location	   within	   the	   abdomen,	   largely	   prohibiting	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mechanistic	  investigation.	  	  Nevertheless,	  numerous	  techniques	  have	  been	  tried	  and	  tested	   with	   varying	   degrees	   of	   success.	   The	   aim	   of	   this	   first	   section	   has	   been	   to	  partially	  familiarize	  the	  reader	  with	  the	  nature	  of	  the	  bowel	  and	  in	  the	  next	  section	  the	  key	  investigative	  techniques	  will	  be	  explored	  together	  with	  their	  limitations.	  	  
	  
Non-­‐MRI	   based	   techniques	   for	   investigating	   small	   bowel	  
motility	  	  
Manometry	  	  
Manometry	   has	   been	   used	   extensively	   to	   study	   motion	   patterns	   suggestive	   of	  myopathy	   (abnormal	   muscular	   function),	   neuropathy	   (nerve	   damage)	   or	  obstruction	   with	   varying	   degrees	   of	   success	   and	   has	   subsequently	   obtained	   the	  status	   as	   the	   ‘gold	   standard’	   for	  motility	   assessment	   in	   the	   small	   bowel[21],	   [34].	  Under	  endoscopic	  guidance,	  a	  catheter	  is	  inserted	  via	  the	  oral	  or	  anal	  route	  into	  the	  upper	  or	  lower	  segments	  of	  the	  small	  bowel.	  Regular	  apertures	  along	  the	  catheters	  length	  detect	  pressure	  changes	  associated	  with	  segmental	  contraction	  in	  the	  bowel	  and	  allow	  graphical	  depiction	  of	  the	  peristaltic	  wave	  as	  it	  propagates	  along	  the	  small	  bowel	  (Figure	  1.2).	  In	  this	  figure,	  pressure	  apertures	  in	  the	  antrum	  (A),	  duodenum	  (D)	   and	   jejunum	   (J)	   provide	   contractile	   activity	   profiles	   across	   the	   fasted	   (Figure	  1.2a)	  and	  fed	  (Figure	  1.2b)	  states	  (diagram	  from	  Hansen	  et	  al.[34])	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Key	   point:	  Manometry	   presents	   contractile	   activity	   as	   transient	   changes	   in	   luminal	  
pressure	  offering	  high	  temporal	  resolution	  at	  the	  cost	  of	  patient	  comfort,	  limited	  intra-­‐
luminal	  field	  of	  view	  and	  difficulty	  in	  interpreting	  results.	  	  
	  
Motility	   quantitation	   using	   manometry	   is	   extremely	   difficult	   with	   results	   being	  variable,	  difficult	  to	  interpret	  and	  extremely	  sensitive	  to	  artefact	  including	  changes	  in	   interstitial	   pressure	   (coughing,	   sneezing,	   laughing),	   meals,	   body	   position,	  breathing	  and	  confounding	  pulsatile	  actions	  (eg.	  contraction	  in	  adjacent	  bowel).	   In	  addition	  to	  this,	  it	  is	  uncomfortable	  for	  the	  subject,	  invasive	  and	  therefore	  likely	  to	  bias	  the	  state	  of	  activity	  one	  intends	  to	  observe[34].	  	  
	  
Figure	  1.2	  Small	   intestinal	  manometry	  readings	   for	  an	   individual	   in	   fasting	  (a)	  and	  
postprandial	  state	  (b).	  Diagram	  from	  Hansen	  et	  al	  2002.	  	  	  	  
Manometry	   is	   also	   one	   of	   the	   few	   techniques	   to	   deliver	   ‘real’	   and	   physiologically	  intuitive	   data	   based	   on	   contractile	   action	   within	   the	   bowel	   as	   opposed	   to	   a	  surrogate	   for	  motile	   action	   eg.	   transit	   time.	   Furthermore,	   it	   allows	   discrimination	  
a)	   b) 
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between	   different	   phases	   of	   the	   contractile	   cycle	   and	   relational	   information	  between	   the	   sites	   of	   contraction	   based	   on	   the	   known	   distance	   between	   the	  apertures	   on	   the	   catheter[9],	   [19],	   [21],	   [34],	   [35].	   As	   sensor	   technology	   has	  improved,	  new	  ‘high	  resolution’	  techniques	  have	  been	  implemented	  that,	  along	  with	  improved	   signal	   processing,	   has	   allowed	   greater	   diagnostic	   yield	   and	   a	   continued	  place	  in	  the	  specialised	  physiology	  clinic[36].	  
	  
Scintigraphy	  	  
Scintigraphy	  addresses	  some	  of	  the	  limitations	  of	  manometry	  and	  provides	  a	  simple	  and	  non-­‐invasive	  method	   to	   track	  and	  measure	   small	  bowel	   transit	   velocity	  using	  radio-­‐labelled	   solid	   and/or	   liquid	   foods[37].	   For	   small	   bowel	   and	   colon	   transit	  studies,	  3.7MBq	  of	  In-­‐111	  (half-­‐life:	  2.8	  days)	  is	  administered	  along	  with	  a	  meal[37].	  The	   movement	   of	   the	   radiation-­‐emitting	   bowel	   content	   is	   tracked	   using	   repeat	  gamma	  camera	  measurements	  over	   a	  6h	  period	   for	   the	   small	   bowel	   and	  between	  24-­‐48h	  for	  the	  colon.	  Transit	  times	  are	  defined	  by	  the	  time	  it	  takes	  for	  the	  tip	  of	  the	  radiolabelled	  meal	  to	  reach	  various	  biological	  land	  marks	  e.g.	  the	  terminal	  ileum	  for	  the	   small	   bowel.	   As	   this	   is	   observationally	   intensive,	   semi-­‐quantitative	   reader	  dependent	   approximate	   measurements	   are	   recorded	   at	   standardised	   time	   points	  after	  ingestion	  of	  the	  tracer.	  A	  normal	  small	  bowel	  would	  be	  expected	  to	  clear	  more	  than	  41%	  of	  the	  radiolabelled	  meal	  after	  6h	  into	  the	  large	  bowel.	  Scintigraphy	  has	  shown	  clinical	  value	  particularly	   in	  the	   large	  bowel	  where	  the	  ascending,	  traverse,	  descending	   and	   recto-­‐sigmoid	   colon	   may	   be	   easily	   identified	   and	   used	   in	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conjunction	   with	   the	   Colon	   Transit	   Index	   (CTI)	   to	   provide	   semi-­‐quantitative	  observations	  [35],	  [37]–[39].	  
Key	  point:	  Scintigraphy	  uses	  radioisotopes	  to	  look	  at	  net	  movement	  of	  a	  tagged	  meal	  
through	  the	  GI	  tract.	  The	  transit	  time	  of	  the	  meal	  serves	  as	  a	  surrogate	  for	  motility	  and	  
is	  relatively	  inexpensive	  although	  lacking	  in	  detailed	  physiological	  information.	  	  
The	  CTI	  offers	  somewhat	  transferable	  methodology	  to	  experimental	  small	  bowel	  MR	  studies	  were	  MRI	  compatible	  tracers	  have	  been	  used	  in	  an	  analogous	  manner	  to	  the	  radioisotopes	   further	   enhanced	   by	   the	   anatomical	   information	   that	   this	   modality	  provides[40].	  Despite	  this,	  owing	  to	  the	  variability	  in	  small	  bowel	  shape	  and	  the	  lack	  of	  distinct	  anatomical	  features	  by	  which	  one	  can	  subdivide	  the	  bowel,	  more	  specific	  transit	   times	   through	  discrete	   regions	  of	   the	  bowel	   are	   inaccurate	   even	  using	  MR	  guidance	   and	   unfortunately	   provide	   little	   in	   the	   way	   of	   quantitative	   information	  relating	  to	  even	  gross	  motility	  patterns	  in	  the	  intestine.	  	  	  
	  
Electrogastrography	  	  
Electrogastrography	  (EGG)	  was	  initially	  developed	  to	  record	  electrical	  signals	  in	  the	  contractile	   tissue	  of	   the	   stomach.	   Subsequent	   research	   investigated	   its	   application	  to	  the	  small	  bowel	  whereby	  surface	  electrodes	  could	  be	  placed	  in	  regions	  proximal	  to	   sections	   of	   the	   small	   intestine[41].	   The	   large	   amount	   of	   noise	   produced	   from	  other	   organs	   however	  makes	   readings	   ostensibly	   unusable	   and	   in	   the	   absence	   of	  standard	  techniques	  or	  electrophysiological	  parameters	  is	  likely	  to	  be	  of	  little	  use	  in	  the	  clinical	  setting.	  Despite	  these	  fundamental	  limitations,	  this	  work	  is	  important	  as	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it	  offers	  the	  only	  direct	  observation	  of	  the	  physiological	  control	  mechanisms	  behind	  the	  observed	  motility	  and	  is	  therefore	  worthy	  of	  mention.	  In	  addition,	  the	  excellent	  temporal	   resolution	   and	   potential	   for	   ambulatory	   studies	   being	   completely	   non-­‐intrusive	   (analogous	   to	   a	   24-­‐Hour	   ECG)	   make	   this	   approach	   appealing[41].	  Subcutaneous	   insertion	   of	   electrodes	   (during	   surgery)	   has	   been	   reported	   in	   an	  experiment	   designed	   to	   record	   direct	   measurements	   of	   small	   bowel	   electrical	  activity	  and	  could	  go	  some	  distance	  to	  validating	  observations	  made	  from	  cutaneous	  studies	  but	  are	  unlikely	  to	  make	  a	  clinical	  impact	  in	  the	  short	  term[41],	  [42].	  	  	  
	  
Capsule	  endoscopy	  	  
Wireless	  capsule	  endoscopy	   (WCE)	  permits	  visualisation	  of	   the	  whole	   intestine	  as	  the	  capsule	  moves	  along	  the	  tract	  under	  the	  power	  of	  largely	  peristaltic	  action.	  WCE	  has	  become	  increasingly	  popular	  with	  gastroenterologists	  for	  visualising	  the	  lumen	  of	  the	  bowel	  with	  features	  such	  as	  ulceration,	  largely	  invisible	  radiologically,	  being	  identifiable	   in	   the	   mid	   portions	   of	   the	   intestine	   beyond	   the	   reaches	   of	   the	  endoscope[43].	   As	   the	   technology	   has	   grown	   increasingly	   sophisticated	   and	  compact,	  additional	  instrumentation	  has	  been	  designed	  to	  assess	  features	  including	  pH	  and	  pressure,	  the	  latter	  bearing	  relevance,	  as	  seen	  in	  manometry,	  to	  peristaltic	  action[43]–[46].	  However	  unlike	  manometry,	  the	  focal	  nature	  of	  this	  technique,	  that	  is,	   all	   observations	   being	   taken	   from	   a	   single	   moving	   location	   over	   time,	   makes	  assessment	  of	  the	  data	  from	  WCE	  insensitive	  to	  specific	  motile	  actions	  like	  Phase	  III	  migrating	   contractions.	   Nevertheless,	   assessment	   of	   pressure	   curves	   from	   the	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capsule	   or	   image	   processing	   of	   shear	   from	   the	   video	   series	   has	   revealed	   some	  intriguing	   data	   on	   motile	   actions	   through	   the	   bowel	   and	   this	   certainly	   has	   an	  application	  for	  detecting	  the	  absence	  or	  presence	  of	  activity[44].	  	  
The	   precise	   utility	   of	   such	   analysis	   remains	   elusive	   although	   there	   is	   a	   clear	  advantage	   to	  wrapping	   information	   of	   anatomical	   features,	   transit	   time,	   transient	  pressure	   changes	   into	   a	   single	   well-­‐tolerated	   modality.	   As	   sensor	   technology	  improves,	  it	  is	  likely	  that	  an	  increase	  in	  the	  use	  of	  WCE	  for	  physiological	  studies	  will	  be	  seen.	  	  
	  
Other	  techniques	  	  
A	   wide	   range	   of	   interesting	   and	   increasingly	   sophisticated	   techniques	   has	   been	  developed	   to	   offer	   yet	   more	   information	   on	   the	   physiology	   of	   the	   small	   bowel.	  Ultrasound	  can	  be	  used	  to	  obtain	  visual	  data	  on	  segments	  of	  the	  small	  bowel	  and	  3D	  ultrasound	  of	  the	  intestine	  could	  be	  of	  interest	  the	  future[47].	  Gadolinium	  capsules	  in	  MR	  have	  been	  used	  to	  explore	  transit	  times	  through	  the	  small	  bowel	  but	  suffers	  the	   same	   problems	   observed	   in	   scintigraphy.	   However	   it	   may	   be	   coupled	   with	   a	  standard	  MR	  protocol	  to	  gain	  additional	  information[48].	  
Key	  point:	  Each	  technique	  has	  strengths	  and	  weaknesses	  but	  collectively	  represent	  a	  
push	   towards	  developing	  a	  better	  understanding	  of	   how	   small	   bowel	  motility	  works	  
through	   extraction	   of	   meaningful	   quantitative	   parameters	   to	   improve	   disease	  
diagnosis	  in	  the	  clinic.	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For	   the	   remainder	  of	   this	   introduction	  MR	  enterography	  will	   be	   considered	  along	  with	   the	   necessary	   post	   acquisition	   analysis	   required	   to	   derive	   quantitative	  information.	   This	   emerging	   field	   has	   offered	   some	   exciting	   new	   avenues	   of	  exploration	   over	   the	   last	   several	   years	   that	   address	   a	   number	   of	   the	   issues	   and	  limitations	  addressed	  above	  and	  introduce	  new	  opportunities	  for	  investigations	  into	  small	  bowel	  motility.	  	  
	  
Motility	  analysis	  using	  MRI	  	  
	  
Magnetic	   Resonance	   Imaging	   is	   perhaps	   the	   most	   advanced	   imaging	   tool	   at	   the	  clinicians’	   disposal.	   The	   technique	   uses	   a	   strong,	   uniform	  magnetic	   field	   to	   excite	  hydrogen	  atoms	  present	  in	  water	  and	  fat.	  By	  then	  applying	  an	  oscillating	  magnetic	  field	  at	  the	  appropriate	  resonant	  frequency,	  a	  radio	  frequency	  signal	  can	  be	  received	  when	   the	   excited	   protons	   return	   to	   equilibrium	   that	   together	   with	   gradient	  encoding	   allows	   the	   construction	   of	   the	   MRI	   image[49].	   The	   contrast	   between	  different	   tissues	   is	   determined	   by	   the	   rate	   at	   which	   excited	   atoms	   dephase	   and	  return	  to	  equilibrium,	  that	  in	  turn	  depends	  on	  their	  local	  chemical	  environment.	  It	  is	  MRI’s	   sensitivity	   to	   hydrogen	   that	   makes	   it	   an	   excellent	   modality	   to	   image	   soft	  tissue.	  In	  addition,	  the	  use	  of	  non-­‐ionising	  radiation	  makes	  it	  safe	  and	  well	  suited	  for	  the	   investigation	   of	   chronic	   conditions	   and	   those	   that	  manifest	   at	   a	   young	   age.	   In	  Crohn’s	  disease	   for	   example,	  MRI	   can	  deliver	  high-­‐resolution	   images	  of	   the	  bowel	  wall	   together	   with	   extra-­‐luminal	   changes	   taking	   place	   that	   are	   essential	   for	   the	  accurate	   grading	  of	  disease	   activity	   and	   timely	   administration	  of	  medical	   therapy.	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The	   ability	   of	   non-­‐invasive	   and	   safe	   tests	   to	   inform	   medical	   management	   is	  beneficial	   for	   the	  patient	   in	   that	   it	  helps	   to	  mitigate	  side	  effects	  and	   increase	  their	  return	   to	   health.	   It	   is	   further	   economically	   valuable	   where	   the	   use	   of	   expensive	  medications	  can	  be	  better	  targeted.	  As	  such,	  the	  role	  of	  MRI	  in	  Crohn’s	  disease	  and	  the	   high	   level	   of	   anatomical	   information	   it	   provides	   is	   now	   indicated	   by	  international	  consensus	  statements	  and	  the	  role	  of	  this	  modality	   is	  expanding[50],	  [51].	  Alongside	  the	  anatomical	   information	  there	  is	  emerging	  value	  in	  the	  capacity	  for	   functional	   imaging.	   Dynamic	   or	   ‘cine’	   imaging	   allows	   a	   uniquely	   physiological	  view	   of	   the	   bowel	   and	   is	   increasingly	   being	   used	   alongside	   structural	   imaging	   to	  investigate	   bowel	   pathology.	   This	   thesis	   explores	   the	   value	   of	   MR	   beyond	   its	  anatomical	  value	  looking	  specifically	  at	  the	  functional	  potential	  of	  this	  increasingly	  popular	  and	  available	  imaging	  modality.	  
	  
There	   are	   however	   a	   number	   of	   methodological	   considerations	   including	   subject	  preparation,	   scanner	  sequences	  and	   image	  processing	   that	  have	  a	   large	   impact	  on	  assertions	  made	  surrounding	  a	  physiological	  process	  such	  as	  motility.	  	  	  
	  
Subject	  preparation	  	  
All	   imaging	   strategies	   targeting	   the	   small	   bowel	   are	   dependent	   on	   adequate	  distension	   of	   the	   small	   intestine	   alongside	   sufficient	   luminal	   contrast	   so	   that	   the	  bowel	  wall	   can	   be	   suitably	   discriminated	   and	   the	   intra-­‐intestinal	   space	   observed.	  MR	  enterolysis,	  where	  liquid	  is	  rapidly	  injected	  directly	  into	  the	  intestine	  via	  naso-­‐
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duodenal	  catheter,	  was	  developed	  to	  ensure	  adequate	  distension	  along	  the	  length	  of	  the	   intestine.	  While	   enterolysis	   provided	   exceptional	   distension	   and	   contrast,	   the	  invasive	  nature	  of	  the	  procedure	  was	  less	  well	  tolerated	  by	  patients	  and	  more	  time	  consuming.	   	  Because	  of	  this,	   the	  oral	  administration	  of	  contrast,	  MR	  enterography,	  became	   popular.	   To	   this	   end	   the	   simplest	   contrast	   agent	   one	  might	   use	   is	   water	  yielding	   a	   bright	   signal	   on	   T2	   weighted	   imaging	   and	   dark	   on	   T1.	   However	  administration	  of	  water	  results	  in	  rapid	  absorption	  along	  the	  small	  bowel	  and	  poor,	  inconsistent	  bowel	  distension	  (Figure	  1.3).	  A	  solution	  to	  this	  problem	  is	  to	  mix	  the	  water	  with	   various	   additives	   to	   inhibit	   absorption	   and	   various	   formulations	   exist	  today	  with	  choice	  dictated	  by	  availability,	  patient	  compliance,	  cost	  and	  experience	  [52],	   [53].	   Two	   of	   the	   most	   popular	   preparations	   found	   in	   the	   literature	   are	   the	  mannitol	  solution	  and	  locust	  bean	  gum	  with	  mannitol	  solution.	  
	  
Figure	   1.3	   Small	   bowel	   prepared	   by	   MR	   enterography	   with	   water	   (a)	   and	   with	  
mannitol/	  Locust	  bean	  gum	  solution	  (b).	  	  	  
a)	   b)	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Mannitol	   is	  a	  carbohydrate	  classed	  as	  a	  sugar-­‐alcohol	  with	  its	  underlying	  chemical	  structure	  preventing	  intestinal	  absorption[54].	  Its	  inherent	  osmotic	  properties	  help	  reduce	  the	  amount	  of	  water	  reabsorbed	  along	  the	  gut	  and	  also	  add	  a	  slightly	  sweet	  taste	  that	  appears	  to	  improve	  the	  patient	  experience.	  Locust	  bean	  gum	  is	  extracted	  from	  the	  seeds	  of	  the	  Mediterranean	  Carob	  tree	  (Ceratonia	  siliqua)	  and	  is	  used	  in	  a	  range	   of	   foodstuffs	   principally	   as	   a	   thickening	   agent.	  Whilst	   on	   its	   own	   does	   not	  taste	   particularly	   pleasant,	   it	   may	   be	   sweetened	   but	   more	   importantly	   provide	  better	  bowel	  distension	  and	  fewer	  diarrhoeal	  instances	  when	  compared	  to	  mannitol	  alone[52].	  Additional	  paramagnetic	  compounds	  such	  as	  gadolinium-­‐based	  contrast	  agents	  might	  also	  be	  added	  to	  provide	  high	  luminal	  signal	  on	  T1-­‐weighted	  studies.	  However,	   oral	   gadolinium	   is	   expensive	   and	   together	   with	   the	   associated	   risk	   of	  toxicity	  represents	  an	  unnecessary	  further	  step	  towards	  imaging	  the	   lumen	  at	  this	  time.	  	  	  
	  
Key	  point:	  Oral	  contrast	  induces	  a	  stretch	  in	  the	  lumen	  that	  likely	  has	  a	  stimulatory	  
effect	  on	  motility	  characterised	  by	  strong	  ‘postprandial’	  segmental	  contractile	  activity.	  	  
	  
In	  the	  clinical	  setting	  a	  typical	  contrast	  solution	  would	  involve	  around	  2%	  mannitol	  in	  1000ml	  H2O	  and	  0.2%	  locust	  bean	  gum	  but	  may	  vary	  across	  institutions.	  A	  patient	  would	  be	  required	  to	  fast	  from	  solids	  for	  around	  4h	  prior	  to	  their	  scan,	  drinking	  the	  entirety	  of	  the	  contrast	  solution	  at	  regular	  intervals	  anywhere	  between	  30mins	  and	  3h	  before	  their	  scan	  until	  just	  before	  they	  enter	  the	  scanner.	  The	  amount	  drunk	  over	  time	  directly	  influences	  how	  much	  of	  the	  bowel	  becomes	  distended	  and	  can	  have	  an	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Scan	  sequences	  	  	  
Even	  at	  rest,	  the	  rhythmical	  contractile	  activity	  of	  the	  small	  intestine	  is	  sufficient	  to	  create	  motion	  artefacts	  on	  the	  majority	  of	  small	  bowel	  sequences	  used	  routinely	  in	  the	  clinic	   today.	  As	  a	  consequence,	  antispasmodic	  medication	   is	   routinely	  given	   to	  paralyse	  the	  bowel	  in	  an	  attempt	  to	  improve	  study	  quality.	  For	  obvious	  reasons	  this	  is	  not	  the	  case	  when	  performing	  small	  bowel	  motility	  studies	  where	  instead	  a	  high	  temporal	  resolution	  is	  used	  to	  mitigate	  and	  indeed	  capture	  the	  effects	  of	  peristaltic	  movement	  at	   the	  cost	  of	  spatial	  resolution.	  Fast	  scans	  such	  as	  T2-­‐weighted	  single-­‐shot	  fast-­‐spin	  echo	  (FSE)	  sequences	  allow	  planning	  of	  the	  dynamic	  sequence	  stacks	  in	  the	  coronal	  plane	  through	  the	  abdomen	  to	  cover	  the	  entire	  small	  bowel	  in	  a	  short	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time.	   It	   is	   essential	   to	   develop	   a	   rough	   understanding	   of	   the	   individual’s	   bowel	  anatomy	   as	   there	   is	   a	   large	   degree	   of	   heterogeneity	   between	   patients	   with	  landmarks,	  including	  the	  terminal	  ileum,	  potentially	  being	  lost	  between	  scans	  slices.	  A	   typical	   dynamic	   sequence	   for	   motility	   imaging	   is	   usually	   a	   fast	   T1-­‐weighted	  gradient	  echo	  or	   fast	  T2	  weighted	  single	   shot	   free	  precession	   (SSFP)	  or	  any	  other	  sequence	   with	   a	   acquisition	   time	   of	   less	   than	   1s	   which	   provides	   a	   satisfactory	  impression	  of	  small	  bowel	  peristalsis.	  The	  selected	  sequence	  is	  repeated	  every	  500-­‐1000ms	  to	  gather	  around	  20	  frames	  during	  a	  single	  breath	  hold	  with	  a	  1.5T	  scanner.	  A	   slice	   thickness	   of	   around	   10mm	   is	  most	   frequently	   used	   as	   this	   provides	   good	  bowel	  wall	  contrast	  and	  good	  spatial	  coverage	  of	  the	  small	  intestine.	  The	  number	  of	  dynamic	  sequences	  in	  a	  stack	  is	  invariably	  dependent	  on	  the	  patient	  size.	  If	  a	  patient	  is	   slim	   10	   slices	   should	   be	   sufficient,	   where	   the	   patient	   is	   morbidly	   obese	   the	  intestine	  may	  become	  sufficiently	  separated	  through	  the	  abdomen	  so	  that	  complete	  coverage	  would	  require	  in	  the	  region	  of	  25	  slices,	  although	  this	  is	  rarely	  performed.	  Potentially,	  the	  dynamic	  stacks	  can	  be	  collected	  in	  any	  plane	  however	  visual	  motility	  interpretation	  is	   less	  intuitive	  from	  the	  axial	  or	  sagittal	  planes.	  The	  total	  scan	  time	  allocated	  in	  most	  centres	  for	  dynamic	  acquisition	  is	  around	  10-­‐15	  minutes	  prior	  to	  spasmolytic	   administration	   and	   additional	   sequences	   diagnostic	   sequences	  (anatomical	  T2,	  diffusion,	  dynamic	  contrast	  enhancement	  etc.).	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Table	  1.2	  Summary	  of	  quantitative	  techniques	  to	  evaluate	  small	  bowel	  motility.	  	  
	  
Motility	  Metric	   Unit	   Description	   Strengths	   Weakness	  
Contraction	  
rate	  	  
Frequency	  (Hz)	  expressed	  as	  contractions	  per	  minute	  (CPM)	  
A	  diameter	  change	  of	  more	  than	  10%	  of	  the	  mean	  luminal	  diameter	  for	  the	  time	  series	  








mm	   Max	  diameter	  -­‐	  minimum	  diameter	   Rapid	  analysis,	  simple,	  describes	  bowel	  contractile	  potential	  




Unitless	   Amplitude/diameter	   Rapid	  analysis,	  simple,	  less	  susceptible	  to	  bias	  from	  large	  calibre	  bowel	  





Unitless	   Registration	  derived	  motility	  surrogate	  based	  on	  quantification	  of	  the	  fractional	  change	  in	  a	  pixels	  area	  summarised	  by	  the	  SD	  of	  its	  Jacobian	  determinant	  through	  time	  
Application	  in	  global	  and	  segmental	  analysis,	  rapid,	  powerful	  parametric	  analysis	  tool,	  validated	  prospectively	  
Complex	  calculation,	  unitless	  metric,	  surrogate	  measure	  
Image	  Tagging	  
	  
Hz	   Tagline	  voxel	  deformation	   High	  temporal	  resolution,	  suitable	  for	  global	  analysis	  
non-­‐specific	  measurement,	  un-­‐characterised	  physiological	  meaning	  
Chyme	  flow	  rate	  
measurement	  
Mm/min	   Flow	  velocity	  	   Direct	  physiological	  measure	   Uncharacterised	  relationship	  between	  segmental	  flow	  and	  peristalsis	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Temporal	  resolution	  	  	  
There	  has	  been	  a	  tradition	  of	  scanning	  the	  small	  bowel	  at	  a	  <1s	  temporal	  resolution	  and	   there	   is	   a	   certain	  wisdom	   for	   this	  where	   one’s	   analysis	   is	   dependent	   on	   real	  observations	  of	  the	  bowel	  (ie.	  diameter	  change	  of	  the	  luminal	  space	  over	  time)[14],	  [17],	  [55]–[59].	  Where	  possible,	  the	  maxim	  of	  ‘the	  faster	  the	  better’	  has	  been	  applied.	  However,	   certainly	   on	   the	   1.5T	   platforms,	   it	   has	   been	   difficult	   to	   improve	   on	   2	  images	  per	  second	  whilst	  retaining	  adequate	  spatial	  resolution.	  Segmental,	  diameter	  changes	  of	  the	  bowel	   lumen	  have	  proved	  the	  mainstay	  of	  quantitative	  MR	  motility	  measurement	  in	  the	  peer-­‐reviewed	  literature	  to	  date.	  However,	  with	  advanced	  post-­‐processing	  techniques	  being	  developed	  and	  increasing	  scanner	  field	  strength	  there	  has	   been	   a	   general	   move	   away	   from	   these	   direct	   measurements	   of	   local	   luminal	  calibre	   into	   more	   global	   parametric	   forms	   of	   analysis	   with	   temporal	   resolution	  being	  sacrificed	  for	  spatial	  resolution	  in	  terms	  of	  complete	  volume	  coverage.	  	  
	  
Scanning	  at	  different	  field	  strengths	  	  
A	  brief	  note	  on	  field	  strength.	  Scanning	  at	  1.5T	  allows	  the	  acquisition	  of	   images	  at	  sufficient	  spatial	  and	  temporal	  resolution	  to	  observe	  peristalsis	  in	  vivo.	  From	  these	  quantitative	  measurements	   can	   be	  made.	   The	   fundamental	   limitation	   at	   this	   field	  strength,	  and	  largely	  surpassed	  by	  scanning	  at	  3T,	   is	  the	  limitation	  of	  analysis	  to	  a	  single	  2D	  slice	  of	  bowel	   through	   time.	  At	  3T,	  using	  specialised	  sequences,	  one	  can	  acquire	  volumetric	  data	  in	  much	  the	  same	  way	  one	  might	  acquire	  single	  slice	  data	  at	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1.5T	  permitting	  analysis	  of	  the	  bowel	  as	  a	  system	  with	  temporal	  coherence	  between	  anatomical	  positions.	  
	  
MRI	  -­‐	  Motility	  quantitation	  	  Motility	  might	   be	   assessed	   through	   a	   number	   of	   approaches	   summarised	   in	   table	  1.2.	  One	  might	  simply	  ‘eyeball’	  the	  cine	  series	  and	  comment	  on	  the	  presence	  of	  static	  areas	   of	   the	   bowel	   (stricture	   etc).	   Beyond	   this,	   one	   might	   utilise	   a	   quantitative	  approach	  to	  count	   the	  number	  of	  contractions	   in	  a	  given	  section	  of	  bowel.	  Finally,	  more	  advanced	  registration	  and	  post-­‐processing	  techniques	  might	  be	  implemented	  to	  extract	   information	  based	  on	  deformation	   fields	  permitting	  observations	  across	  the	  bowel	  as	  a	  system.	  The	  implementation	  of	  quantitative	  metrics	  for	  small	  bowel	  motility	  observations	  will	  be	  the	  subject	  of	  this	  next	  section	  and	  these	  take	  a	  variety	  forms	   that	  move	   away	   from	   the	   limitations	   of	   subjective	   analysis.	   As	   this	   field	   is	  fairly	   new,	   some	   select	   publications	   have	   been	   used	   to	   explore	   the	  most	   popular	  techniques	  for	  motility	  analysis.	  	  	  
Physical	  measurement	  	  	  
By	   far	   the	   most	   common	   technique	   for	   motility	   analysis	   in	   the	   small	   bowel	   is	  through	  the	  use	  of	  manually	  adjusted	  ROIs,	  usually	  taking	  the	  form	  of	  a	  line	  drawn	  across	   the	   lumen	  perpendicular	   to	   the	   axis	   of	   the	  bowel	   in	   the	   coronal	  plane[60].	  The	   length	   of	   this	   line	   can	   be	   adjusted	   on	   each	   image	   and	   the	   series	   of	   lengths	  
	  	   46	  
	  
	  
	   	  
plotted	  against	  time	  to	  give	  a	  peristaltic	  wave.	  Where	  the	  subject	  is	  scanned	  in	  the	  sagittal	   plane,	   polygonal	   ROIs	   placed	   over	   the	   cross	   section	   of	   the	   bowel	   and	  adjusted	  also	  provide	  a	  good	  impression	  of	  peristaltic	  action[55].	  The	  reason	  for	  the	  popularity	  of	  this	  metric	  is	  due	  largely	  to	  the	  simplicity	  of	  analysis,	  together	  with	  the	  observation	   of	   a	   ‘real’	   process	   -­‐	   that	   is,	   a	   contraction	   in	   the	   bowel	   as	   opposed	   to	  abstract	  surrogates.	  There	  are	  two	  key	  limitations	  with	  this	  approach	  with	  the	  first	  being	  through	  plane	  motion	  and	  the	  second	  in	  its	  time	  consuming	  nature[60].	  
Key	  point:	  Direct	  measurement	  of	  bowel	  diameter	  is	  a	  simple	  and	  descriptive	  way	  of	   quantitatively	   evaluating	   bowel	   wall	   motion.	   It	   is	   the	   most	   commonly	   used	  motility	  metric	  reported	  in	  the	  literature.	  	  	  
Through	  plane	  motion	  occurs	  where	  an	  individual’s	  anatomy	  moves	  perpendicular	  to	   the	   imaging	   plane	   during	   acquisition	   caused	   largely,	   in	   MRE,	   by	   respiration	  removing	  a	  given	  bowel	  loop	  from	  the	  acquired	  image.	  In	  theory,	  one	  could	  move	  to	  a	  different	   slice	   to	  make	   the	  measurement.	  However,	   as	  most	  of	   these	   studies	  are	  performed	   at	   1.5T	   there	   is	   as	   much	   as	   a	   60s	   temporal	   gap	   between	   anatomical	  positions	  through	  the	  abdomen	  and	  thus	  temporal	  continuity	  with	  respect	  to	  small	  bowel	  physiology	  is	  lost.	  As	  a	  result	  a	  ‘good’	  bowel	  loop	  is	  subjectively	  picked	  that	  is	  well	  distended	  and	  present	   though	   the	   sequence.	  Even	   then,	   it	   is	   rare	   that	  a	  good	  sinusoidal	  curve	  is	  produced.	  Consequently	  peristalsis	  is	  rarely	  reported	  in	  terms	  of	  cycles	  per	  minute	  and	  many	  groups	  instead	  take	  the	  standard	  deviation	  of	  change	  in	  area	   size	   or	   line	   length	   over	   time	   and	   use	   this	   as	   their	  motility	  metric[60].	   Peak	  counting	   may	   be	   performed	   where	   the	   number	   of	   	   ‘peaks’	   in	   luminal	   diameter	  change	   is	   counted.	   There	   remains	   a	   great	   deal	   of	   ambiguity	   in	   how	   one	   might	  interpret	   such	   data,	   however,	   with	   a	   contraction	   generally	   considered	   to	   be	   a	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diameter	  change	  greater	  than	  10%	  of	  the	  mean	  luminal	  diameter	  through	  that	  time	  series	   [59]	   [61].	   	   The	   second	   limitation	   is	   the	   fairly	   common	   issue	   of	   labour	  intensiveness,	  where	  manual	  measurements	   need	   to	   be	  made,	   limiting	   the	   use	   of	  this	   technique	  exclusively	   to	   research.	   In	  an	  early	  paper	  by	  Froehlich	  et	  al	  70,000	  measurements	   were	   made	   in	   ten	   subjects	   with	   this	   level	   of	   user	   input	   being	  impractical	   in	  most	   scenarios	   [60].	   	   Since	   then,	   an	   automated	   technique	  has	   been	  developed	  and	  validated	  by	   this	  group	  however,	   the	   technical	  description	  of	   these	  has	   not	   yet	   been	   published[59].	   In	   spite	   of	   these	   limitations,	   the	   technique	   is	  popular	   in	   that	   it	   does	   not	   interfere	   with	   standard	   clinical	   work	   up,	   is	   more	  objective	   than	   visual	   assessment	   by	   the	   examining	   radiologist,	   and	   is	   more	  methodologically	   transparent	   in	   the	   sense	   that	   it	   is	   an	   automation	   of	   a	   task	   that	  could	  otherwise	  be	  performed	  manually.	  
	  
Flow	  rate	  measurement	  	  	  
Peristaltic	   contraction	   serves	   to	  mix	   and	   drive	   the	   food	   bolus	   through	   the	   bowel.	  Luminal	   transit	  may	   be	   used	   as	   a	   surrogate	   for	   the	   degree	   to	  which	   peristalsis	   is	  taking	  place	  and	  measurements	  of	  ‘flux’	  or	  flow	  of	  the	  intestinal	  contents	  through	  a	  segment	   of	   bowel	   can	   be	   quantified	   using	   phase-­‐contrast	   (PC)	   pulse	   sequences	  originally	   developed	   for	   angiographic	   techniques	   in	   large	   vessels[62].	   In	   their	  publication,	  Gutzeit	  et	  al.	  (2010)	  validated	  this	  approach	  in	  a	  synthetic	  phantom	  and	  applied	  it	  to	  10	  healthy	  volunteers	  with	  a	  modest	  400ml	  preparation	  of	  gadolinium	  spiked	  water	  preparation.	  Volunteers	  were	  scanned	  in	  the	  sagittal	  plane	  for	  phase	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contrast	  flow	  quantitation	  as	  well	  as	  traditional	  cine	  imaging	  for	  a	  period	  of	  30s	  in	  each	  case.	  The	  technique	  was	  found	  to	  be	  well	   tolerated	  in	  all	  volunteers	  however	  distension	  was	  poor,	   limiting	  the	  number	  of	  places	  an	  observation	  might	  be	  made.	  In	  spite	  of	  this,	  PC	  revealed	  rhythmical	  velocity	  changes	  within	  the	  lumen	  and	  this	  was	   also	   observed	  using	   a	  manually	   adjusted	  ROI	   at	   the	   same	   location,	  with	   area	  change	  being	  plotted	   instead	  of	  velocity	  over	   time.	   In	  both	   instances,	   velocity	  and	  area	   change	  were	  demonstrated	   to	  be	   suppressed	   following	   the	   administration	  of	  butylscopolamine	  bromide	  (Buscopan)	  suggesting	  both	  observations	  were	  linked	  to	  physiological	   activity	   related	   to	   peristalsis.	   The	   fact	   that	   chyme	   flow	   and	   radial	  contractions	   in	   the	   bowel	   appear	   linked,	   although	   sounding	   obvious,	   does	   not	  necessarily	   indicate	   a	   causal	   relationship	   -­‐	   the	   rigid	   acrylic	   phantom	   used	   in	   this	  publication	   was	   not	   exhibiting	   peristalsis	   for	   example.	   Upstream	   motile	   action	  would	   be	   sufficient	   to	   effect	   pulsatile	   movements	   of	   intestinal	   contents	   in	   the	  absence	  of	   local	  peristaltic	  action.	  However,	   the	   two	  appeared	   to	  correlate	  well	   in	  this	   publication.	   Despite	   this,	   sensitivity	   to	   Buscopan	   strongly	   supported	   the	  process	   of	   flow	   being	   related	   to	   peristaltic	   action	   and	   thus	   qualifies	   this	   as	   a	  surrogate	   for	   motility	   that	   further	   serves	   as	   a	   quantitative	   outcome.	   A	   further	  consideration	   for	   this	   technique	   is	   the	  neglect	   of	   segmental	   contraction	   to	   ‘churn’	  bowel	  contents	  that	  constitutes	  a	  proportion	  of	  total	  motile	  action,	  especially	  in	  the	  presence	  of	  a	  perceived	  meal.	  Again,	  although	  correlation	  with	  manually	  delineated	  area	   changes	   over	   time	   appears	   high,	   this	  may	   serve	   to	   confound	   an	   observation	  designed	  to	  detect	  net	  flow	  through	  a	  singular	  loop	  of	  bowel.	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Spin	  labelling	  	  In	  an	  n=1	  proof	  of	  concept	  study,	  Sprengers	  et	  al.	  used	  a	  motion	  coding	   technique	  also	   referred	   to	   as	   SPAMM	   (spatial	   modulation	   of	   the	   magnetization)	   originally	  developed	  for	  cardiac	  motion	  imaging	  to	  develop	  a	  technique	  to	  quantize	  intestinal	  motion[63],	   [64].	   In	  SPAMM,	  a	  short	  pre-­‐pulse	  sequence	  periodically	  saturates	   the	  magnetization	   that	  will	  eventually	  appear	  as	  a	   line	  or	   tag	  pattern	   in	   the	   image.	  As	  the	  tissue	  deforms,	  the	  tagged	  spins	  deform	  accordingly	  and	  this	  motion	  can	  then	  be	  analysed	   (often	   in	   the	   frequency	   domain).	   From	   here,	   assertions	   with	   respect	   to	  peristalsis	  might	  be	  made	  in	  a	  quantitative	  manner.	  
In	  this	  study,	  Sprengers	  et	  al.	  demonstrate	  that	  application	  of	   this	  technique	  could	  be	   expanded	  beyond	   cardiac	   imaging	   to	   the	   abdomen.	   The	   healthy	   volunteer	  was	  prepared	  with	  1000ml	  mannitol	  solution	  after	  fasting	  and	  scanned	  continuously	  for	  8	  minutes.	   Following	   a	   scout	   scan	   the	   tagged	   dynamic	   sequence	  was	   run	   (FOV	   =	  40x40x3.6cm)	  for	  two	  minutes	  before	  glucagon	  was	  injected	  to	  paralyse	  the	  bowel.	  By	   splitting	   the	   frequency	   spectra	   into	   discrete	   ranges,	   loosely	   representative	   of	  physiological	   motion	   (0.0-­‐0.2Hz	   =	   low,	   0.3	   -­‐	   0.5Hz	   =	   Breathing,	   0.6-­‐0.8Hz	   =	  Intermediate	  and	  1.0-­‐1.2Hz	  =	  cardiac),	  the	  spectral	  power	  was	  then	  assessed	  at	  the	  different	   frequencies	   to	   quantitatively	   describe	   on	   small	   bowel	   motility	   and	   the	  induced	   change	   following	   glucagon	   injection.	   Sprengers	   at	   al.	   postulated	   the	  frequency	  band	  between	  0.0-­‐0.2Hz	  corresponded	  to	  what	  one	  might	  expect	  in	  terms	  of	   contractile	   activity	   in	   the	   small	   bowel	   (8-­‐10	   contractions	   per	  minute	   based	   on	  previous	   studies	   using	   MRI	   and	   the	   existing	   physiology	   literature)[56],	   [60].	  Accordingly	   a	   linear	   reduction	   in	   spectral	   power	   was	   observed	   in	   this	   frequency	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band	  across	  the	  quadrants	  over	  the	  four	  time	  points	  (2,4,6	  and	  8	  minutes)	  following	  drug	  administration.	  	  
This	   is	   an	   interesting	   technique	   and	   good	   example	   of	   the	   varied	  ways	   one	  might	  extract	   metrics	   from	   magnetic	   resonance.	   However,	   there	   are	   a	   number	   of	  methodological	   and	   conceptual	   issues	   that	   are	   important	   to	   consider	   when	  analysing	   small	   bowel	   motility	   using	   this	   or	   similar	   techniques.	   Firstly,	   the	   tag	  pattern	   does	   not	   discriminate	   between	   structures	   in	   the	   abdomen	   (blood,	   bowel,	  intestinal	   contents,	   liver,	   muscle)	   making	   the	   technique	   non-­‐specific.	   As	   a	   result,	  analysis,	  as	  performed	  here,	  by	  quadrant	  leads	  to	  a	  grouping	  of	  low	  frequency,	  static	  structures	  in	  with	  the	  motile	  bowel.	  By	  then	  collapsing	  these	  frequencies	  together	  in	  a	  range	  between	  0	  and	  0.2Hz,	  the	  potential	  to	  negatively	  bias	  any	  observation	  made	  in	   a	   quadrant	   where	   significant	   proportion	   of	   the	   signal	   is	   derived	   from	   static	  structure.	  A	  clear	  partial	  resolution	  of	  this	  issue	  is	  through	  specific	  ROI	  placement,	  for	  example	  around	  the	  small	  intestine	  while	  (mostly)	  precluding	  fixed	  structures.	  	  
Key	   Point:	   Spin	   labelling	   offers	   a	   direct	  means	   of	   evaluating	  motion	   arising	   from	  global	   bowel	   motility	   with	   a	   high	   temporal	   resolution.	   Tagging	   is	   however	  nonspecific	   and	   the	   low	   anatomical	   resolution	   of	   anatomical	   structure	   makes	  further	  annotation	  difficult.	  
However,	   expanding	   on	   the	   theme	   of	   non-­‐specificity	   and	   focusing	   only	   on	   the	  intestine,	   the	   tag	   lines	   run	   through	   both	   the	   bowel	   wall	   and	   its	   contents	  indiscriminately.	  Therefore,	  deformation	  due	  to	  flow	  from	  the	  intestinal	  contents	  is	  inseparable	   from	   the	   contractile	   activity	   of	   the	   bowel	   wall	   as	   far	   as	   the	   tagged	  deformation	   is	   concerned	   and	   presumably	   spans	   a	   broad	   frequency	   bandwidth.	  Although	  flow	  and	  peristalsis	  are	  largely	  concomitant	  (as	  demonstrated	  by	  Gutzeit	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et	   al.)	   one	   can	  make,	   at	   best,	   limited	   inferences	   on	   one	   from	   the	   other,	   especially	  with	  respect	   to	  pathology	   in	   the	  bowel[62].	  This	   is	  an	   issue	  where,	   for	  example,	  a	  narrowed,	   stenotic	   section	   of	   bowel	   experiences	   flow	   due	   to	   upstream	   peristaltic	  effects	   but	   does	   not	   in	   itself	   peristalse	   as	   it	   is	   often	   seen	   in	   inflammatory	   bowel	  disease.	  	  
	  
This	   technique	   is	   nevertheless	   promising	   and	   offers	   a	   more	   direct,	   global	  impression	  of	  motion	  within	   the	  small	  bowel	  with	  a	  high	  temporal	  resolution	  that	  shows	  some	  sensitivity	  to	  pharmaceutical	  intervention.	  	  
	  
Registration	  	  
The	  final	  section	  of	  this	  chapter	  introduces	  image	  registration	  and	  provides	  a	  brief	  summary	   	  of	   	  how	   	   this	  approach	  can	   	  be	   	  applied	   	   to	   	  assist	   	   the	   	  quantitation	   	  of	  	  small	  	  bowel	  	  motility.	  	  This	  topic	  	  is	  the	  specific	  	  focus	  	  of	  	  the	  	  next	  	  chapter	  	  and	  	  the	  central	  tool	  used	  in	  experiments	  described	  in	  	  the	  	  remainder	  of	  the	  thesis.	  	  The	  key	  fundamental	  concepts	   that	  underpin	   image	  registration	  are	  addressed	  here	  with	  a	  view	   to	   providing	   a	   high-­‐level	   overview	   of	  what	   is,	   in	   itself,	   a	   vast	   area	   of	   active	  research.	   	  The	  book,	   ‘Medical	   Image	  Registration’	  by	  Hajnal,	  Hill	   and	  Hawkes	   [65]	  provides	   an	  excellent	   introduction	   to	   this	   topic	   for	   further	   reading.	   Further,	  more	  recent	  and	  comprehensive	  reviews	  can	  be	  found	  in[66]–[70].	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Registration	   algorithms	   are	   driven	   by	   pixel	   (or	   voxel)	   intensity	   or	   feature	  correspondence	  between	  images;	  in	  other	  words,	  corresponding	  intensity	  patterns	  or	   features	  (for	  example,	  anatomical	   features)	   in	  each	   input	   image	  are	  matched	  to	  bring	  the	  images	  into	  spatial	  alignment.	  So-­‐called	  image-­‐intensity-­‐based	  algorithms	  are	  widely-­‐used	   as	   they	  provide	   a	   general-­‐purpose	   solution	   for	  many	   registration	  problems	   where	   different	   images	   from	   different	   imaging	   modalities	   are	   to	   be	  registered.	   Such	   intensity-­‐based	   algorithms	   canonically	   contain	   three	   	   key	  	  elements:	   	  a	   	  similarity	  measure,	   	  a	   	   transformation	   	  model,	   	  and	   	  an	   	  optimization	  	  scheme.	   	   In	   the	   simplest	   case,	   when	   two	   images	   are	   registered,	   one	   image	   is	  commonly	   referred	   to	  as	   the	   ‘source’	   image,	  whereas	   the	  other	   is	   referred	   to	  as	   a	  ‘target’	   or	   ‘reference’	   image.	   The	   source	   image	   is	   then	   transformed	   by	   applying	   a	  mathematical	  transformation	  that	  displaces	  individual	  pixel	  (voxel)	  locations	  of	  the	  source	   image	   so	   that	   the	   resulting	   transformed	   source	   image	   is	   aligned	   with	   the	  target	   image.	  For	   the	  case	  where	   there	  are	  multiple	   input	   images,	  multiple	   source	  images	  may	  be	  registered	  to	  a	  single	  target.	  In	  recent	  years,	  however,	  a	  number	  of	  so-­‐called	  groupwise	  registration	  approaches	  have	  emerged	  which	  aim	  to	  determine	  anatomical	   correspondence	  within	  a	   set	  of	   images	   so	   that	   these	   can	  be	   registered	  together	  without	  the	  potential	  bias	  introduced	  by	  selecting	  any	  particular	  image	  as	  the	  target	   image.	  The	  similarity	   	  measure,	   	  as	   	  the	   	  name	  	  suggests,	   	   is	  a	  numerical	  metric	   that	  quantifies	   the	  alignment	   input	   	   images	  with	   the	  assumption	  that	   these	  images	   are	   aligned	   once	   the	   similarity	   measure	   reaches	   its	   maximum	   value	  (commonly	  referred	  to	  as	  the	  ‘global	  maximum’	  value).	   	  Notable	  examples	  	  include	  	  the	   	   sum	   	   of	   	   squares	   	   difference	   (found	   by	   subtracting	   overlapping	   pixel	   (voxel)	  intensity	   values	   of	   transformed	   input	   images	   to	   find	   the	   intensity	   difference	   and	  then	   	   summing	   the	  square	  of	   these	  values	   to	  arrive	  a	   single	  number),	   	   correlation	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coefficient,	   	   and	   so-­‐called	   information	   theoretic	   measures	   such	   as	   mutual	  	  information	  [71][72]	  and	  normalized	  	  mutual	  	  information[73],	  which	  are	  based	  on	  image	  entropy.	   	  Similarity	  measures	  vary	  in	  	  their	  	  complexity	  	  and	  	  computational	  	  requirements,	   which	   	   leads	   to	   variations	   	   in	   	   processing	   	   speed,	   in	   some	   cases	  leading	   to	   significant	   computational	   burden	   for	  more	   complicated	  measures.	   	   The	  choice	  of	  similarity	  measure	  needs	  to	  broadly	  suit	  the	  intended	  application	  and	  the	  nature	  of	  and	  variation	  between	  the	  input	  images.	  
The	  transformation	  model	  computes	  	  the	  	  displacement	  	  vector	  that	  transforms	  the	  co-­‐ordinates	  of	  each	  pixel	  (voxel)	  	  from	  	  the	  	  source	  	  image	  	  to	  	  the	  	  corresponding	  co-­‐ordinates	  	  in	  	  the	  	  target	  	  image.	  	  Common	  transformation	  models	  	  	  are	  rigid-­‐body	  transformations	   in	  which	   the	  entire	   image	   is	   translated	  and/or	  rotated,	   	  an	  affine,	  which	   combines	   a	   rigid-­‐body	   transformation	   with	   a	   sheer	   and	   scaling	  transformation,	  	  and	  	  nonrigid	  	  where	  	  each	  	  pixel	  	  undergoes	  	  a	  	  potentially	  	  unique	  	  displacement	  	  to	  	  its	  	  target	  	  such	  that	  	  the	  source	  	  image	  is	  warped	  to	  fit	  the	  target.	  The	  pixel	  (voxel)	  displacements	  across	  the	  image	  are	  collectively	  referred	  to	  as	  the	  deformation	   or	   displacement	   field.	   	   Constraining	   the	   	   transformation	   model	   	   is	  	  crucial	  	  to	  	  maintain	  	  biological	  	  plausibility	  	  in	  	  an	  	  algorithm;	  	  for	  	  example,	  	  one	  is	  	  measuring	  	  bowel	  	  wall	  	  motion,	  	  the	  	  contraction	  	  is	  	  unlikely	  	  to	  	  exceed	  	  2cm	  	  and	  	  one	  	  would	  therefore	  constrain	  	  the	  	  algorithm	  	  accordingly.	  Introducing	  constraints	  also	   prevent	   non-­‐physical	   aberrations	   such	   as	   image	   folding	   	   and	   	   tearing.	   The	  similarity	   measure	   and	   transformation	   model	   are	   linked	   by	   the	   optimization	  scheme,	   the	  goal	  of	  which	   is	   the	  numerical	  maximisation	  of	   the	  similarity	   function	  (or	   equivalently	   the	   minimisation	   of	   the	   inverse	   of	   the	   similarity	   function)	   that	  signifies	  the	  alignment	  of	  two	  images.	  Classical	  numerical	  optimisation	  schemes	  	  to	  
	  	   54	  
	  
	  
	   	  
perform	   this	   maximisation	   (minimisation)	   include	   	   gradient	   	   descent,	   	   conjugate	  	  gradient,	   	   and	   	  Gauss-­‐Newton	   schemes,	  but	  many	  others	  have	  been	  developed	   for	  particular	   image	   registration	   problems.	   Typically,	   the	   cost	   function	   –	   i.e.	   the	  function	   to	   be	   maximised/minimised	   –	   employed	   by	   the	   optimisation	   scheme	   is	  closely	   related	   to	   the	   similarity	   measure,	   but	   may	   be	   modified	   to	   incorporate	  constraints	   (for	   example,	   an	   increasing	   penalty	   for	   increasing	   displacements	   that	  would	   relate	   to	   physically	   implausible	   deformations)	   and/or	   mathematical	  regularisation	  to	  improve	  the	  stability	  of	  the	  optimisation	  scheme.	  
	  
The	  rationale	  for	  	  using	  	  image	  	  registration	  in	  this	  thesis	  lies	  in	  	  the	  	  availability	  	  of	  	  dynamic	   	  data	   	  sets	   	  acquired	   	  as	   	  part	   	  of	   	  clinical	   	  routine	   	  at	   	  University	   	  College	  	  Hospital	   	   without	   the	   need	   for	   	   new	   	   scanner	   	   hardware	   	   or	   	   protocol	   	   changes.	  	  Beyond	  	  this,	  	  a	  	  dual	  	  benefit	  	  with	  respect	  to	  analysis	  can	  be	  found	  in	  the	  generation	  of	  deformation	  fields	  to	  not	  	  only	  	  automatically	  	  propagate	  	  user	  	  placed	  	  ROIs	  	  but	  	  also	   	   to	   	   generate	   	   quantitative	   	   parametric	  maps	  which	   could	   serve	   as	   a	   further	  means	  of	  quantifying	  motility.	  
	  
The	  only	  paper	  published	  	  at	  	  present	  	  concerning	  	  the	  	  use	  	  of	  	  registration	  	  in	  	  small	  	  bowel	   	   motility	   	   analysis	   	   is	   	   that	   	   written	   	   by	   	   Odille	   	   et	   	   al.	   	   (2012),	   which	   is	  discussed	  in	  	  detail	  in	  the	  next	  chapter[57].	  When	  image	  registration	  is	  referred	  to	  in	  a	  more	  general	   sense,	   the	  desirable	  end	  point	   is	   a	   set	  of	  new	   images	  without	  a	  particular	   physical	   perturbation	   to	   permit	   faster	   	   or	   	   more	   	   accurate	   	   clinical	  	  measurements	  –	  a	  	  classic	  	  case	  	  being	  	  the	  	  removal	  	  of	  	  respiratory	  	  motion	  	  from	  	  a	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dynamic	   	   contrast	   	   enhanced	   	   MRI	   image	   	   series.	   	   Conversely,	   where	   one	   is	  	  interested	  	  in	  	  motion	  	  analysis,	  	  the	  	  registered	  images	  cease	  to	  be	  of	  interest	  with	  the	   emphasis	   now	   lying	   on	   the	   degree	   	   to	   which	   the	   original	   images	   had	   to	   be	  deformed	  to	  reach	  a	  given	  target	  image.	  	  
	  
Odille	  et	  al.	  applied	  an	  optical	  flow	  technique	  to	  small	  bowel	  dynamic	  image	  data	  to	  ‘correct’	   local	  deformation	  caused	  by	  peristalsis	  between	  consecutive	  MRI	  	  images.	  	  The	  accuracy	  	  of	  	  the	  	  registration	  	  was	  	  assessed	  	  by	  	  comparing	  	  an	  	  automatically	  	  propagated	  	  region	  	  of	  	  interest	  	  through	  	  the	  	  time	  	  series	  	  to	  	  a	  	  manually	  	  corrected	  gold	   standard,	   consisting	   of	   the	  mean	   score	   of	   two	   independent	   reviewers	   in	   	   10	  	  subjects.	   	   The	   high	   	   levels	   	   of	   	   agreement	   	   supported	   	   the	   	   accuracy	   	   of	   	   this	  	  registration	   	   approach	   	   and	   	   also	   	   provided	   	   a	   	   convenient	   	   way	   	   to	   	   perform	  	  frequency	  	  based	  	  segmental	  	  small	  	  bowel	  	  motility	  	  analysis	  	  in	  	  a	  	  timely	  	  fashion.	  	  Beyond	  this,	  	  direct	  analysis	  of	  the	  deformation	  field	  itself	  could	  be	  performed,	  and	  in	  this	  paper	   it	   	  was	   	  demonstrated	   	   that	   	  deformation-­‐field-­‐generated	   	  metrics	   	  of	  	  motility	   	   are	   potentially	   more	   powerful	   than	   physical	   measures	   when	   scoring	  intestinal	  motility	  	  compared	  with	  clinical	  grading.	  	  	  
	  
Key	   point:	   Image	   registration	   	   can	   	   be	   	   used	   	   to	   	   automatically	   quantify	   physical	  	  measurements	  	  of	  	  bowel	  	  motility	  	  and	  	  can	  	  provide	  	  parametric	  	  information	  	  based	  	  on	  	  analysis	  	  of	  	  the	  	  deformation	  fields.	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Conclusion	  
	  
Small	  bowel	  motility	  is	  an	  enigmatic	  and	  exciting	  area	  for	  research.	  Over	  the	  course	  of	   this	   introduction,	   it	   is	   clear	   that	   not	   only	   is	   there	   an	   array	   of	   investigational	  techniques	   at	   the	   researchers	   disposal,	   but	   excitingly,	   new	   and	   increasingly	  versatile	   imaging	   based	   techniques	   are	   being	   developed	   with	   the	   potential	   to	  explore	  as	  yet	  uncharted	  areas	  of	  this	  fundamental	  component	  of	  human	  physiology.	  In	  the	  next	  chapter,	  the	  use	  of	  image	  registration,	  introduced	  here,	  will	  be	  expanded	  and	  the	  initial	  validation	  work	  that	  took	  place	  presented.	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CHAPTER	   2:	   INTRODUCTION	   AND	   VALIDATION	   OF	  THE	   OPTIC	   FLOW	   REGISTRATION	   TECHNIQUE	   TO	  EVALUATE	  SMALL	  BOWEL	  MOTILITY	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Research	  Question:	  Can	  image	  post-­‐processing	  be	  used	  to	  objectively	  evaluate	  MRE-­‐derived	  small	  bowel	  motility	  data?	  	  
Rationale:	  Manual	   assessment	   of	   small	   bowel	   motility	   through	   manual	   adjustment	   of	   ROIs	  between	  time	  points	  in	  dynamic	  series	  is	  time-­‐consuming	  with	  the	  potential	  for	  user	  error.	  Although	  valuable	  as	  a	  research	  tool,	  an	  automated	  approach	  would	  broaden	  the	  appeal	  of	  the	  technique	  to	  a	  clinical	  audience	  where	  motility	  analysis	  might	  be	  used	   to	   objectively	   grade	   disease,	   measure	   response	   to	   medication	   or	   help	   in	  forming	  a	  diagnosis.	  	  
Hypotheses:	  1)	   Medical	   image	   registration	   can	   be	   used	   to	   automate	   ROI	   placement	   and	   2)	  provide	  surrogate	  measures	  of	  motility	  based	  on	  deformation	  fields.	  	  
Aim(s):	  i)	  Validate	  the	  accuracy	  of	  the	  optic-­‐flow	  image	  registration	  technique	  for	  correcting	  bowel	  wall	  movement.	  	  ii)	   Evaluate	   the	   ability	   of	   the	   optic-­‐flow	   technique	   to	   objectively	   grade	   clinical	  scoring	  of	  bowel	  motility.	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  to	  assess	  registration	  accuracy.	  	  	  
2.1	  Introduction	  	  
	  In	   the	   previous	   chapter	   key	   physiological	   themes	   were	   covered	   relating	   to	   small	  bowel	   physiology	   and	   how	   MR	   has	   been	   used	   to	   evaluate	   motility	   through	  evaluating	   the	   dynamic	   images	   as	   a	   ‘cine’	   loop.	   Beyond	   this,	   the	   quantitative	  assessment	  of	   lumen	  diameter	  or	  area	  change	  through	  time	  is	  possible	  but	   is	   time	  consuming	  where	   performed	  manually	   and	   impractical	   for	   clinical	   use.	   	   The	   final	  section	   of	   Chapter	   1	   introduced	  medical	   image	   registration	   as	   a	  method	   for	   both	  automating	  the	  analysis	  of	  small	  bowel	  motility	  data	  and	  also	  providing	  a	  number	  of	  additional	  methods,	  based	  on	  the	  analysis	  of	  deformation	  fields,	  to	  assess	  motility.	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In	  this	  chapter	  a	  nonrigid	  image	  registration	  technique	  developed	  by	  Odille	  et	  al.	  is	  validated	   to	   estimate	   2D	   time-­‐varying	   displacement	   fields	   in	   a	   time	   series	   of	  dynamic	  MRI	  images[57].	  However,	  nonrigid	  registration	  is	  technically	  challenging	  with	  the	  small	  bowel	  time	  series	  data	  presenting	  some	  particular	  difficulties:	  First,	  in	   addition	   to	   in-­‐plane	   local	   displacement	   cause	   by	   bowel	   wall	   motion,	   through-­‐plane	   motion	   is	   observed	   either	   from	  movement	   of	   the	   diaphragm	   or	   peristalsis	  itself	  contributing	  additional	  local	  intensity	  changes	  to	  the	  images.	  Second,	  another	  source	  of	   intensity	  changes	   in	   the	  bowel	  arises	   from	  the	   flow	  of	  chyme	  (intestinal	  contents)	  both	  within	  and	  through	  plane.	  This	  large	  variation	  in	  consecutive	  image	  intensities	  is	  often	  problematic	  for	  image	  registration	  algorithms	  because	  they	  can	  find	   it	   difficult	   to	  distinguish	   an	   apparent	   intensity	   change	  due	   structures	  moving	  from	   a	   change	   in	   the	   underlying	   intensity.	   Where	   the	   assumptions	   of	   the	   three	  cardinal	  similarity	  measures	  (sum	  of	  squared	  difference,	  correlation	  coefficient	  and	  normalised	  mutual	  information)	  are	  poorly	  satisfied	  or	  violated	  altogether	  resulting	  in	  poor	  image	  registration.	  	  A	   solution	   is	   presented	   in	   Odille	   et	   al.	   through	   jointly	   incorporating	   an	   explicit	  model	  of	   intensity	   change	   that	   is	  optimised	  simultaneously	  with	   the	  displacement	  field	  based	  on	  an	  assumption	  that	  local	   intensity	  changes	  between	  two	  images	  can	  be	  described	   locally	  by	  a	  smooth	   function.	  Simultaneous	  nonrigid	  registration	  and	  modelling	   of	   time	   intensity	   changes	   takes	   the	   form	   of	   a	   sequence	   of	   linear	   least-­‐squares	   problems	   which	   are	   easer	   to	   solve	   individually	   than	   the	   optimisation	   of	  generalised	   similarity	  measures	   and	   constitutes	   the	   novelty	   of	   this	   approach.	   The	  image	  registration	  produces	  a	  dense	  displacement	  field	  over	  the	  whole	  field	  of	  view	  that	   serves	   the	   dual	   purpose	   of	   generating	   parametric	  maps	   that	  may	   be	   further	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analysed	   to	  produce	   surrogate	  measures	  of	  motility	   and	   to	  propagate	  user-­‐placed	  ROIs	  through	  the	  time	  series.	  	  	  This	   chapter	   describes	   specifically	   the	   validation	   of	   the	   optic	   flow	   technique	  assessing	  both	  the	  1)	  accuracy	  and	  2)	  the	  ability	  of	  the	  registration	  derived	  metric	  to	  reflect	  a	  radiologist’s	  motility	  evaluation.	  An	  overview	  of	  the	  registration	  theory	  is	   provided	   with	   associated	   equations	   provided	   in	   Odille	   et	   al.	   alongside	   this	  validation[57].	  	  	  
2.2	  Methods	  
2.2.1	  Theory:	  Joint	  nonrigid	  registration	  and	  modelling	  of	  intensity	  
changes	  	  The	   goal	   of	   image	   registration	   is	   to	   place	   the	   same	   anatomy	   at	   the	   same	   image	  position	   in	   all	   frames	  within	   a	   series	   of	   images.	   	   After	   successful	   registration,	   the	  frames	   played	   as	   a	   movie	   should	   look	   static.	   To	   perform	   this	   re-­‐alignment	   of	  anatomical	  structures,	  a	  different	  deformation	  field	  is	  applied	  to	  each	  frame	  to	  warp	  it	  to	  a	  reference	  frame	  and	  subsequently	  these	  deformation	  fields	  are	  used	  here	  to	  quantify	  motility.	  	  	  	  As	   discussed	   in	   the	   previous	   chapter,	   registration	   algorithms	   have	   three	   basic	  components;	   the	   transformations	   that	   describe	   the	   deformation	   fields,	   the	   cost	  function	  that	  measures	  the	  similarity	  of	  the	  reference	  and	  warped	  frames,	  and	  the	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mechanism	   for	   optimising	   the	   deformation	   field.	   For	   small	   bowel	   motility,	   local	  nonrigid	   deformations	   (i.e.	   small	   anatomical	   changes	   in	   position	   caused	   by	   bowel	  contractility)	  needed	  to	  be	  permitted	  and	  so	  a	  parametric	  representation	  (e.g.	  using	  B-­‐splines)	  on	  the	  deformation	  was	  not	  used.	  The	  changes	  in	  deformation	  during	  the	  registration	   optimisation	   are	   driven	   by	   the	   local	   image	   intensity	   gradients	   in	   a	  similar	   way	   to	   the	   classic	   optic	   flow	   technique[74].	   By	   using	   a	   sum	   of	   squared	  difference	  cost	  function,	  these	  deformation	  changes	  can	  be	  computed	  directly	  from	  the	  image	  gradients.	  This	  provides	  for	  a	  rapid	  means	  to	  perform	  the	  optimisation	  of	  the	   deformation	   field	   and	   permits	   non-­‐linear	   deformations.	   A	   constraint	   on	   the	  deformation	  fields	  is	  added	  to	  prevent	  artificial	  collapse	  or	  tearing	  in	  the	  images.	  To	  cope	   with	   underlying	   intensity	   changes	   (rather	   than	   motion),	   Odille	   added	   an	  intensity	   change	  map	   that	   is	  also	  optimised	  by	   the	  algorithm.	  Although	  developed	  independently,	   it	   turned	   out	   this	   extension	   to	   the	   classic	   optic	   flow	   had	   been	  previously	  published[74].	  	  	  In	  common	  with	  most	  registration	  algorithms	  there	  are	  tuning	   parameters	   that	   require	   setting.	   These	   parameters	   were	   set	   based	   on	  observations	   from	   trial	   data	   but	   were	   not	   changed	   for	   any	   of	   the	   studies	   in	   this	  thesis.	  Also	  in	  common	  with	  other	  algorithms,	  visual	  inspection	  sometimes	  revealed	  some	  inaccuracies	  in	  the	  deformation	  fields.	  The	  purpose	  of	  this	  chapter	  was	  first	  to	  establish	   the	   extent	   of	   said	   errors	   in	   the	   registration	   result	   and	   secondly	   to	  demonstrate	  that	  the	  metrics	  derived	  from	  the	  deformation	  fields	  provide	  clinically	  meaningful	  and	  useful	  correlations.	  	  	  
2.2.2	  Patient	  population:	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Ten	   patients	   (7	   female,	  mean	   age	   31)	  with	   histopathologically	   confirmed	   Crohn’s	  disease	   were	   recruited	   from	   the	   hospital	   database	   for	   this	   study	   based	   on	   the	  assumption	   that	   such	  patients	  would	   exhibit	   greater	   variability	   in	   terms	  of	   bowel	  motility.	   Each	   subject	   underwent	   MRI	   enterography	   (MRE)	   with	   a	   view	   to	  evaluating	  disease	  recurrence	  and	  there	  were	  no	  specific	  exclusion	  criteria.	  	  
2.2.3	  MRI	  Protocol	  	  	  MRE	   was	   performed	   on	   a	   1.5T	   Siemens	   Avanto	   scanner	   (Siemens,	   Erlangen,	  Germany).	   All	   patients	   fasted	   for	   4h	   prior	   to	   the	   ingestion	   of	   1L	   of	   2%	  mannitol,	  0.2%	  locust	  bean	  gum	  oral	  solution	  drunk	  at	  regular	  intervals	  over	  40	  minutes	  prior	  to	   the	   scan.	   All	   patients	   lay	   prone	   in	   the	   scanner.	   No	   antispasmodic	   agents	  were	  administered	  until	  after	  the	  acquisition	  of	  the	  dynamic	  images.	  	  	  A	  balanced	  steady-­‐state	  free	  precession	  sequence	  was	  used	  for	  dynamic	  scanning	  of	  the	   small	   bowel	   with	   the	   following	   parameters:	   flip	   angle	   60,	   TR	   =	   3.8ms,	   TE	   =	  1.9ms,	  256x200	  matrix	   filling,	  zero-­‐filling	   to	  512x512,	  1x1mm	  in	  plane	  resolution,	  10mm	   slice	   thickness	   and	   0.8	   seconds	   temporal	   resolution.	   Between	   7	   and	   16	  dynamic	  sequences	  were	  acquired	  for	  each	  patient	  depending	  on	  the	  patients’	  body	  habitus.	   The	   slice	   position	   of	   each	   dynamic	   block	   was	   selected	   by	   the	   attending	  radiographer	   to	   cover	   the	   entirety	   of	   the	   small	   bowel.	   Each	   dynamic	   block	   was	  acquired	  on	  inspiration	  breath-­‐hold	  lasting	  around	  20	  seconds.	  	  	  
2.2.4	  Registration	  Implementation	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  Each	   patient’s	   dataset	   was	   downloaded	   and	   anonymised	   from	   the	   hospital	   PACS	  system	   (Agfa	   HealthCare,	  Middlesex,	   United	   Kingdom)	   before	   being	   loaded	   into	   a	  MATLAB	  (The	  MathWorks,	  Natick,	  MA)	  function,	  written	  by	  F.	  Odille	  to	  set	  several	  key	  parameters	  necessary	   for	   the	   registration.	  A	   reference	   image	   from	  within	   the	  time	  series	  was	  selected	  based	  on	  its	  closeness	  to	  the	  median	  image	  of	  the	  series	  as	  defined	  by	  the	  minimal	  Euclidian	  distance	  between	  images.	  	  All	  the	  other	  images	  are	  registered	   to	   this	   median	   image.	   Images	   were	   down	   sampled	   to	   256x256	   for	  registration	  as	   the	  previous	  zero-­‐filling	   to	  512x512	   is	  only	  useful	   for	  visualisation	  purposes.	   Zero-­‐filling	   was	   not	   used	   and	   no	   cropping	   of	   the	   original	   images	   took	  place.	   Registration	   was	   implemented	   in	   a	   multi-­‐resolution	   manner	   and	   the	  displacement	  fields	  and	  maps	  for	   intensity	  changes	  were	  initialised	  to	  zero	  for	  the	  first	  ‘course’	  scale	  of	  registration.	  A	  total	  of	  four	  scales	  were	  used	  corresponding	  to	  multi-­‐resolution	  factors	  1/8,	  1/4,	  1/2	  and	  1.	  Images	  were	  down-­‐sampled	  to	  each	  of	  these	   resolution	   levels	   after	   Gaussian	   filtering	   to	   avoid	   aliasing.	   After	   registration	  convergence	  had	  been	   reached	  at	   a	   given	   resolution	   level,	   the	  displacement	   fields	  are	   interpolated	   to	   the	   next	   (finer)	   resolution	   and	   the	   process	   is	   repeated	   until	  convergence	  at	  the	  final	  scale	  has	  been	  achieved.	  	  	  
2.2.5	  Assessment	  of	  registration	  accuracy	  	  A	  graphical	  user	  interface	  and	  region	  of	  interest	  (ROI)	  tools	  native	  to	  MATLAB	  were	  used	   to	   draw	   linear	   and	   polygonal	   regions	   of	   interest	   in	   the	   small	   bowel	   by	   two	  observers	  (Asia	  Ahmed	  2	  years	  experience	  and	  Alex	  Menys	  6	  months	  experience).	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Specific	  experience	  in	  ROI	  placement	  was	  gained	  by	  adjusting	  line	  and	  area	  ROIs	  in	  consensus	   under	   supervision	   of	   a	   consultant	   radiologist	   (Prof.	   S.	   A.	   Taylor).	   Lines	  were	  drawn	  perpendicular	  to	  the	  central	  axis	  of	  the	  bowel	  running	  lumen	  to	  lumen	  and	  polygons	  were	  placed	  where	  the	  bowel	  presented	  as	  an	  ellipse	  in	  cross	  section	  (Figure	   2.1).	   Users	   placed,	   in	   consensus,	   a	   set	   of	   5	   line	   and	   5	   polygon	   ROIs	   at	  random	  positions	  on	  the	  median	  registration	  reference	  images	  (each	  median	  image	  represented	  a	  different	  anatomical	  position	  in	  the	  coronal	  plane)	  in	  each	  of	  the	  10	  patient	  data	   sets.	  All	  ROIs	  were	  propagated	  by	   the	   registration	  deformation	   fields	  through	   the	   time	   series.	   In	   theory,	   the	   length	   of	   the	   line	   ROIs	   and	   area	   of	   the	  polygonal	   ROIs	   would	   change	   according	   to	   the	   dynamic	   movement	   of	   the	   small	  bowel.	  Each	  of	  the	  two	  observers,	  independently,	  proceeded	  to	  manually	  adjust	  the	  line	   length	   and	   polygon	   areas	   for	   each	   time	   point.	   Modification	   was	   allowed	   by	  dragging	  the	  ends	  of	  the	  line	  or	  the	  vertices	  of	  the	  polygon	  ROIs	  to	  a	  new	  position	  believed	  to	  be	  better	  representative	  of	  the	  bowel	  wall	  location.	  	  	  
	  
Figure	  2.1.	  Figure	  2.1.	  Region	  of	  interest	  (ROI)	  placement	  in	  the	  small	  bowel.	  A	  linear	  
region	  of	   interest	  running	  to	  the	  interior	  of	  the	  bowel	  wall,	  across	  the	  central	  axis	  of	  
the	  bowel	   (a)	  and	  a	  polygonal	  region	  of	   interest	  with	  a	  spline	   fit	  where	   the	  bowel	   is	  
seen	   in	   longitudinal	   cross	   section	   (b).	   In	   both	   cases,	   ROI’s	   were	   placed	   around	   the	  
outer-­‐lumen	  boundary,	  in	  the	  bowel	  wall.	  
A)	   B)	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The	   average	   of	   the	   two	   observers	   ROI	   lengths	   and	   areas	  was	   used	   to	   construct	   a	  ground-­‐truth	  score	  for	  each	  ROI	  position.	  To	  assess	  the	  accuracy	  of	  the	  registration	  this	  ground	  truth	  was	  compared	  to	  the	  automatically	  propagated	  registration	  result.	  	  	  
2.2.6	  Assessment	  of	  automated	  motility	  quantitation	  	  	  The	   application	   of	   the	   registration	   deformation	   fields	   to	   generate	   quantitative	  measures	   describing	   motility	   was	   assessed	   by	   comparing	   a	   set	   of	   metrics	   to	   a	  subjective	   gold-­‐standard	   constituting	   the	   consensus	   evaluation	   by	   two	   consultant	  Radiologists	   (6	   and	   5	   years	   in	   Magnetic	   Resonance	   Enterography).	   Five	   Crohn’s	  Disease	   patient	   data	   sets	   were	   used	   with	   a	   total	   of	   83	   ROIs	   (39	   linear	   and	   44	  polygonal).	   The	   radiologists	   subjectively	   graded	   the	   bowel	  motility	   at	   each	   of	   the	  ROIs	  on	  a	  four-­‐point	  scale	  from	  1	  (normal)	  to	  4	  (static).	  Scores	  2	  and	  3	  represented	  bowel	   that	   was	   peristalsing	  more	   slowly	   than	   normal	   bowel	   and	   bowel	   that	   was	  essentially	   static	   with	   some	   movement	   respectively.	   This	   grading	   scale	   was	  developed	   especially	   for	   this	   study	   in	   the	   absence	   of	   previous,	   validated	  methodology.	  	  This	  study	  used	   four	  quantitative	  methods	   to	  assess	   the	  motility	  at	  each	  of	   the	  83	  ROIs	  consisting	  of	  standard	  deviation	  of	   length/area	  change,	  standard	  deviation	  of	  the	  Jacobian	  determinant,	  standard	  deviation	  of	  the	  intensity	  change	  and	  combined	  measure	   of	   the	   Jacobian	   determinant	   and	   intensity	   change.	   An	   overview	   of	   the	  selected	  metrics	  is	  presented	  in	  Table	  2.1.	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Line	   and	   area	   change	   (σLine/Area)	  metrics	   are	   commonly	   used	   in	   the	   literature	   and	  detailed	  in	  the	  previous	  chapter[56],	  [59],	  [76],	  [77].	  Their	  use	  here	  represents	  the	  role	  the	  algorithm	  can	  play	  in	  acquiring	  ‘real’	  measurements	  expressed	  in	  distance	  as	  opposed	  to	  abstract	  surrogate	  metrics.	  The	  standard	  deviation	  of	  area	  and	  length	  is	   taken	   to	   summarise	   these	   data	   and	   expected	   to	   increase	  where	  motion	   arising	  from	  peristalsis	  is	  large.	  	  	  
Metric	  name	   Symbol	   Measure	   Measure	  summary	  Line/Area	  SD	   σLine/Area	   distance	  (mm)	   Standard	  Deviation	  Line/Area	  Jacobian	   σJ	   fractional	  change	  in	  area	   Standard	  Deviation	  Line/Area	  Intensity	   σC	   intensity	   Standard	  Deviation	  Line/Area	  combined	   σJC	   fractional	  change	  in	  area	  and	  intensity	   Standard	  Deviation	  	  
Table	  2.1.	  Summary	  table	  of	  the	  four	  proposed	  metrics	  to	  evaluate	  motility	  	  The	  standard	  deviation	  of	  the	  Jacobian	  determinant	  (σJ)	  was	  used	  as	  a	  quantitative	  metric.	  In	  theory,	  the	  Jacobian	  determinant	  should	  be	  robust	  to	  rigid	  movement	  as	  seen	  in	  liver	  that	  should	  produce	  a	  score	  of	  1	  (Figure	  2.2).	  Conversely,	  deformations	  that	   represent	   either	   a	   fractional	   increase	   or	   decrease	   in	   area	   should	   produce	   a	  score	  either	  smaller	  or	  greater	  than	  1.	  We	  would	  expect	  to	  see	  such	  a	  process	  in	  the	  local	   deformation	   fields	   generated	   during	   the	   registration	   of	   small	   bowel	  motility	  data.	  An	  illustrative	  example	  and	  additional	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A)	   B)	  









	   Stretch	  ___	  Translate	  	  ___	  
Figure	  2.2	  –	  Figure	  text	  over	  page	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Figure	  2.2	  The	  effect	  of	   image	  stretch	  and	  translation	  on	  the	   Jacobian	  determinant.	  
For	  illustrative	  purposes,	  two	  types	  of	  transformations	  were	  applied	  to	  a	  target	  image	  
and	   the	   Jacobian	   for	   each	   pixel	   calculated.	   The	   first	   was	   an	   iterative	   stretch	  
transformation	  repeated	  for	  20	  time	  points	  beginning	  with	  A	  and	  ending	  with	  B.	  The	  
Second	  transformation	  was	  a	  translation,	  repeated	  again	  from	  20	  time	  points	  from	  C	  
to	   D.	   These	   images	   were	   registered	   using	   the	   optic	   flow	   code	   and	   a	   series	   of	  
deformation	   fields	   produced	   which	   were	   assessed	   by	   taking	   a	   fixed	   pixels	   value	  
through	  time	  and	  plotting	  its	  Jacobian	  (E).	  	  	  For	  both	  the	  stretch	  and	  translate	  series,	  
the	   Jacobian	  was	  1	   for	   the	   reference	   image	  confirming	   there	  was	  no	  change	   in	  area	  
taking	   place.	   For	   the	   stretch	   images,	   the	   Jacobian	   value	   decreases	   as	   compression	  
occurs	  in	  the	  image	  away	  from	  the	  reference	  image	  and	  an	  increase	  in	  the	  Jacobian	  as	  
the	  image	  stretches	  away	  from	  the	  reference.	  Where	  the	  image	  is	  translated	  in	  a	  rigid	  
fashion	  a	  value	  of	  approximately	  1	  is	  maintained	  throughout	  the	  time	  series.	  Broadly	  
this	   demonstrates	   the	   Jacobian	  measure	   is	   representative	   of	   fractional	   area	   change	  
but	   not	   rigid-­‐motion	   and	   should	   therefore	   be	   valuable	   in	   interrogating	   bowel	   wall	  
motion.	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explanation	  is	  provided	  in	  Figure	  2.2.	  The	  standard	  deviation	  is	  used	  to	  summarise	  the	  Jacobian	  score	  through	  time	  producing	  a	  SD	  Jacobian	  motility	  map	  with	  0	  where	  no	  motion	  is	  present	  and	  increasing	  where	  nonrigid	  deformation	  is	  present	  (Figure	  2.2).	  	  	  To	  expand	  on	  this	  further	  as	  this	  metric	   is	  central	  to	  this	  thesis,	   imagine	  the	  mean	  Jacobian	  was	  taken	  (instead	  of	  the	  standard	  deviation),	  where	  symmetrical	  changes	  took	  place	   in	  bowel	  wall	  motion	   (as	   is	   likely	  due	   to	   the	  cyclical	   contraction	  of	   the	  bowel)	  there	  would	  be	  little	  ‘net’	  change	  in	  area	  with	  a	  fractional	  increase	  followed	  by	  a	  proportional	  fractional	  decrease.	  The	  Jacobian	  in	  this	   instance	  of	  symmetrical	  increase/decrease,	   regardless	   of	   its	   magnitude	   would	   have	   a	   value	   close	   to	   1,	  suggestive	  of	  no	  motility.	  By	  taking	  the	  SD	  instead,	  1	  standard	  deviation	  (±67.5%)	  is	  observed	  from	  the	  mean	  Jacobian	  value	  with	  a	  larger	  standard	  deviation	  describing	  greater	  variation	  in	  area	  increase/decrease	  from	  1	  in	  the	  time	  series.	  For	  example,	  a	  0.34AU	   score	  would	   suggest	   that	   ±67.5%	  of	   that	   pixels	   area	   change	   through	   time	  will	  be	  within	  ±0.34AU	  from	  1.	  The	  lower	  the	  area	  change	  through	  time,	  the	  smaller	  the	   SD	   Jacobian	   value.	   The	   SD	   Jacobian	   metric	   is	   therefore	   a	   summary	   measure,	  blind	  to	  the	  number	  of	  time	  points,	  with	  dimensionless	  units.	  	  A	  measure	   to	   represent	   intensity	   change	   (σC)	  was	   investigated	   as	   flow,	   caused	  by	  the	   movement	   of	   intestinal	   contents	   (chyme)	   is	   postulated	   to	   correlate	   with	  peristaltic	  activity.	  An	  intensity	  map	  was	  generated	  by	  taking	  the	  standard	  deviation	  of	   the	   intensity	   field,	  generated	  from	  the	  registration	  with	  the	  score	  being	  directly	  related	  to	  the	  variation	  in	  intensity	  through	  time	  (Figure	  2.3).	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A	   final	   parametric	   map	   was	   generated	   by	   multiplying	   the	   SD	   Jacobian	   and	   SD	  Intensity	   maps	   (σJC)	   to	   capture	   changes	   from	   both	   deformation	   and	   intensity	  through	  time	  (Figure	  2.3).	  	  
	  
Figure	  2.3.	  Parametric	  motility	  map	  overview.	  The	  reference	  frame	  from	  an	  individual	  
(raw)	  with	  the	  three	  parametric	  motility	  map	  overlays	  (red=	  high	  motility	  and	  blue	  =	  
low	   motility).	   Small	   intestine	   outlined	   in	   red	   with	   key	   anatomy	   labelled	   in	   top-­‐left	  
‘Raw’	   image.	   	   All	   three	  maps	   appear	   similar	  with	   structures	   including	   the	   liver	   and	  
colon	   attracting	   low	   motility	   scores	   although	   differences	   can	   be	   seen	   in	   the	   maps	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2.2.7	  Statistical	  analysis	  	  Accuracy	   of	   the	   registration	   was	   assessed	   by	   comparing	   the	   ground-­‐truth	   ROI	  length	  and	  areas,	  produced	  by	   the	  observers,	   to	   the	  algorithm-­‐propagated	   lengths	  and	  areas.	  Bland-­‐Altman	   limits	  of	   agreement	  were	  used	   to	  assess	  agreement	  both	  between	   observers	   and	   between	   ground	   truth	   and	   the	   registration	   algorithm.	  Evaluation	  of	  the	  quantitative	  assessment	  of	  motility	  was	  performed	  using	  ANOVA	  to	   detect	   significant	   differences	   between	   mean	   of	   metrics	   according	   to	   the	   4	  categories	  of	  bowel	  motility	  assigned	  by	  the	  radiologists	   	  (significance	  at	  P	  <	  0.05)	  with	   Tukey-­‐Kramer	   post-­‐hoc	   testing	   to	   categorise	   groups.	   Pearson’s	   correlation	  coefficient	  was	  additionally	  calculated	  to	  further	  characterise	  the	  metrics.	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2.3	  Results	  
2.3.1	  Inter-­‐reader	  agreement	  	  The	   ground-­‐truth	  was	   calculated	   by	   averaging	   the	   two	   observers	   line	   length	   and	  polygon	  area	  measurements.	  Analysis	  of	  line	  length	  ROIs	  with	  Bland	  Altman	  Limits	  of	   Agreement	   revealed	   a	   mean	   difference	   between	   readers	   linear	   ROI	  measurements	   of	   0.2mm	  with	   a	   range	   of	   observed	   values	   between	   6	   and	   25mm.	  95%	  LoA	  were	  ±2.3mm	  (Figure	  2.4a).	  Similar	  analysis	  of	  polygon	  areas	  between	  the	  two	   readers	   demonstrated	   a	   mean	   difference	   between	   readers	   of	   5mm2	   with	   a	  range	  of	  observed	  values	  between	  70	  and	  780mm2	  95%	  LoA	  were	  ±46mm2	  (Figure	  2.4b).	  	  
Figure	   2.4.	   Bland-­‐Altman	   Limits	   of	   Agreement	   between	   observers	   for	   line	   (A)	   and	  
polygon	  (B)	  	  ROIs.	  	  	  







) A)	   B)	  Observer	  1/Observer	  2	  lines	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2.3.2	  Assessment	  of	  registration	  accuracy	  	  	  Comparing	  ground-­‐truth	  to	  registration	  propagated	  line	  length	  ROIs	  demonstrated	  a	  mean	   difference	   of	   0.5mm	   across	   the	   range	   of	   values	   5	   to	   25mm	   (Figure	   2.5a).	  95%	  LoA	  was	  ±	  2mm.	  Analysis	  of	  polygon	  ROIs	  showed	  a	  mean	  difference	  between	  the	  algorithm	  and	  ground	  truth	  of	  5mm2	  with	  a	  range	  of	  observed	  values	  between	  70	  and	  705mm2	  95%	  LoA	  were	  ±20mm2	  (Figure	  2.5b).	  	  
	  
Figure	  2.5.	  Bland-­‐Altman	  Limits	  of	  Agreement	  between	  ground-­‐truth	  and	  algorithm	  
propagated	  line	  (A)	  and	  polygon	  (B)	  ROIs.	  	  
2.3.3	  Assessment	  of	  automated	  motility	  quantitation	  	  	  A	  total	  of	  83	  line	  (39)	  and	  polygon	  (44)	  radiologist	  drawn	  observations	  were	  made	  to	   which	   the	   metrics	   were	   compared.	   Correlation	   between	   motility	   metrics	   and	  clinical	   grading	   are	   summarised	   in	   table	   2.2	   and	   in	   Figure	   2.6	   with	   each	   metric	  demonstrating	  a	  strong	  negative	  correlation	  that	  was	  statistically	  significant.	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Table	   2.2	   Pearson	   correlation	   coefficients	   and	   ANOVA	   test	   statistics	   for	   the	  






ANOVA	  (Line)	   ANOVA	  (Polygon)	  
	  
	  
R	  (P-­‐Value)	   R	  (P-­‐Value)	  
F	   Statistic/P	  
value	  
F	  Statistic/P	  value	  
σLine/Area	   -­‐0.70	  (<0.001)	   -­‐0.57(<0.001)	   3.2	  (<0.033)	   7.1	  (<0.001)	  
σJ	   -­‐0.78	  (<0.001)	   -­‐0.83(<0.001)	   23.8	  (<0.001)	   35	  (<0.001)	  
σC	   -­‐0.71(<0.001)	   -­‐0.55	  (<0.001)	   12.5	  (<0.001)	   8.3	  (<0.001)	  
σJC	   -­‐0.74(<0.001)	   -­‐0.50	  (<0.001)	   15	  (<0.001)	   5.5	  (0.003)	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Figure	  2.6.	  Boxplots	  for	  SD	  Jacobian	  (σJ)	  Line	  and	  polygon	  motility	  metrics	  across	  the	  










Clinical	  grading	  score	   Clinical	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  score	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   Motion	  Index	   Group	  	  Tested	  	   Sig	  diff	  groups	  Line	   Poly	  
σline	  /	  σpolygon	  	  
1	   2,3,4	   3,4	  2	   1,3	   n	  3	   1	   1	  4	   1,2	   1	  
σJ	  
1	   2,3,4	   2,3,4	  2	   1,4	   1,4	  3	   1,4	   1,4	  4	   1,2,3	   1,2,3	  
σC	  
1	   3,4	   4	  2	   1	   1	  3	   1	   1	  4	   1,2	   1,2	  
σJC	  
1	   2,3,4	   4	  2	   1,2	   n	  3	   1	   n	  4	   1,2	   1,2	  	  
	  
Table	   2.3	   Tukey-­‐Kramer	   post-­‐hoc	   testing	   of	   motility	   metrics.	   This	   test	   helps	   to	  
demonstrate	  which	  groups	  are	  significantly	  different	  within	  line	  and	  polygon	  ROIs.	  The	  
numbers	  in	  significant	  groups	  represent	  which	  groups	  are	  significantly	  different	  from	  
each	  other.	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  Post-­‐hoc	   analysis	   to	   identify	   which	   groups	   could	   be	   separated	   using	   objective	  scoring	   and	   in	   all	   cases,	   the	   intermediate	   motility	   (groups	   2	   and	   3)	   appeared	  challenging	  with	  data	  summarised	  in	  table	  2.3.	  Broadly	  the	  SD	  Jacobian	  was	  capable	  of	   stratifying	   the	   greatest	   number	   of	   groups	   although	   all	   metrics	   struggled	   to	  differentiate	  intermediate	  motility	  scores.	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2.4	  Discussion	  
	  The	   purpose	   of	   this	   chapter	   has	   been	   to	   introduce	   the	   optic	   flow	   registration	  algorithm,	   demonstrate	   its	   accuracy	   and	   finally	   present	   an	   explanation	   and	  justification	  for	  how	  small	  bowel	  motility	  might	  be	  objectively	  evaluated.	  	  	  In	  this	  study,	  the	  manual	  ground	  truth	  was	  the	  mean	  of	  two	  observers	  corrected	  line	  lengths	   or	   polygon	   areas.	   Bland-­‐Altman	   (BA)	   Limits	   of	   Agreement	   (LoA)	   was	  employed	   to	   estimate	   the	   mean	   difference	   between	   the	   observers	   for	   both	   ROI	  types.	   BA	   LoA	   can	   be	   used	   to	   estimate	   the	   between	   (inter)-­‐reader	   variation,	   an	  essential	  component	  of	  assessing	  the	  quality	  of	  our	  ground-­‐truth.	  In	  this	  study	  95%	  of	  the	  estimated	  inter-­‐reader	  variation	  was	  expected	  to	  fall	  within	  ±1.5mm	  in	  lines	  or	  ±15mm2	  in	  polygon	  range.	  The	  question	  then	  becomes,	   is	   this	   level	  of	  variation	  acceptable	   between	   readers?	   To	   answer	   this,	   variance	   within	   the	   context	   of	   the	  range	  of	  values	  observed	  in	  the	  study	  was	  examined	  which,	  for	  lines,	  was	  17mm	  and	  polygons	  700mm2.	  For	  both	  ROI	  types,	   the	   level	  of	   inter-­‐reader	  variation	   is	  nearly	  an	  order	  of	  magnitude	  smaller	  than	  the	  range	  of	  observed	  values,	  meaning	  variation	  between	  readers	  will	  be	  likely	  to	  have	  little	  effect	  on	  the	  measurement	  and	  confirms	  the	  suitability	  of	  this	  ground	  truth	  for	  comparative	  purposes.	  	  	  	  	  Confidence	  in	  the	  gold	  standard	  allowed	  its	  comparison	  to	  the	  algorithm	  propagated	  ROIs.	   When	   observing	   the	   algorithm	   propagated	   ROI,	   it	   appears	   ‘to	   “track”	   the	  bowel	  wall.	  This	  is	  the	  result	  of	  the	  registration	  finding	  the	  true	  deformation	  field	  of	  the	   bowel	   with	   the	   algorithm	   making	   no	   differentiation	   between	   abdominal	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structures.	  The	  ROI	  position,	  determined	  by	  the	  deformation	  field,	  was	  analysed	  in	  terms	  of	  length	  or	  area	  and	  compared	  to	  the	  ground	  truth.	  Again	  using	  BA	  LoA,	  both	  ROI	   types	   demonstrated	   a	   small	   mean	   difference	   of	   0.5mm	   and	   2mm2	   for	   the	  respective	   ROI	   types,	   effectively	   at	   the	   resolution	   of	   the	   images	   themselves	   at	  1x1mm.	   Examining	   once	  more	   the	   interplay	  within	  measures	  with	   respect	   to	   the	  range	  of	  the	  data,	  a	  negligible	  variance	  is	  seen	  between	  the	  techniques	  in	  relation	  to	  the	   range	  of	   values	  measured.	  Approximately	  5x	   and	  12x	   the	   amount	  of	   variation	  occurred	   across	   the	   cohort	   compared	   to	   within	   the	   observations	   for	   line	   and	  polygon	  ROIs	  respectively.	  Thus	  it	  can	  be	  reasonably	  concluded	  from	  these	  data	  that	  the	  registration	  algorithm	  is	  capable	  of	  accurately	  correcting	  the	  time-­‐series	  data.	  	  	  There	   are	   nevertheless	   some	   limitations	   here	  with	   the	   first	   being	   that	   line	   length	  alone	   is	   not	   a	   sufficient	   indicator	   of	   registration	   accuracy.	   Where	   respiration	   or	  through	  plane	  motion	  removes	  a	  loop	  of	  bowel	  from	  the	  image,	  the	  algorithm	  might	  translocate	   the	   ROI	   to	   a	   adjacent	   bowel	   loop	   for	   example	   maintaining	   a	   similar	  length	  but	  being	  fundamentally	  wrong	  in	  terms	  of	  its	  location.	  Using	  a	  breath-­‐hold	  protocol	   helped	   to	   mitigate	   this	   as	   a	   problem.	   Here	   the	   ability	   to	   automatically	  propagate	  a	  ROI	  faithfully	  is	  not	  just	  a	  useful	  tool	  to	  evaluate	  registration	  accuracy	  but	   can	  be	  used	  as	  a	  primary	  endpoint	   for	  quantitative	   investigation	  of	   the	  bowel	  and,	  even	  now,	  the	  most	  common	  metric	  used	  takes	  less	  than	  a	  second	  with	  the	  help	  of	  the	  registration	  code[16],	  [56],	  [76]–[78].	  	  	  When	  comparing	  the	  algorithm	  to	  subjective	  radiologist	  assessment	  of	  motility,	  the	  parametric	   motility	   metrics	   performed	   well,	   each	   providing	   a	   novel	   approach	   to	  quantitatively	   evaluate	  motility.	   	   The	  best	  performing	  metric	  was	   the	   SD	   Jacobian	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that	  produced	  a	  high	  correlation	  coefficient	  against	  clinical	  grading	  and	  an	  ability	  to	  categorise	   motility	   into	   groups.	   Importantly,	   this	   metric	   exclusively	   assesses	  deformation	   as	   opposed	   to	   intensity	   change	   that	   represents	   a	   key	   physiological	  point	  of	  consideration.	  Following	  MRE	  preparation,	  the	  lumen	  of	  the	  bowel	  is	  filled	  with	  fluid	  yielding	  a	  bright	  signal;	  this	  signal	  produces	  a	  high	  signal	  intensity	  that	  in	  turn	   leads	   to	  a	  high	   intensity	  metric	  score.	   In	  many	  cases,	   this	   filling	  of	   the	  bowel	  lumen	  will	  trigger	  type	  2	  contractile	  actions	  and	  so	  will	  undoubtedly	  correlate	  with	  motility.	   Where	   the	   bowel	   is	   collapsed	   however,	   peristalsis	   can	   and	   often	   does	  continue	  which	  is	  poorly	  reflected	  in	  an	  intensity	  driven	  metric	  but	  representative	  of	  important	  physiological	  activity.	  This	  bias	  of	  the	  metric	  towards	  filling	  with	  oral	  preparation	  may	  mitigate	  the	  usefulness	  of	  the	  technique	  especially	  where	  patients	  cannot	   tolerate	   large	   volumes	   of	   liquid.	   An	   additional	   consideration	   is	   the	  generalizability	   of	   the	   finding	   where	   different	   clinical	   protocols	   might	   provide	  different	  contrast	  (eg.	  sequence	  variations)	  that	  would	  need	  to	  be	  first	  corrected	  for	  motility	   quantitation[62].	   A	   partial	   solution	   provided	   here	   was	   to	   combine	   the	  intensity	  map	  with	   the	  deformation	  map	   to	  produce	   an	   additional	  motility	  metric	  and	  this	  indeed	  correlated	  well	  with	  clinical	  grading	  (Table	  2.2).	  However,	  until	  the	  relationship	  between	  intestinal	  content	  and	  motility	  is	  better	  resolved,	  the	  inclusion	  of	   intensity	   in	   a	   metric	   to	   describe	   motility	   is	   a	   potential	   source	   of	   error	   to	   an	  already	  complex	  method	  of	  analysis.	  One	  key	  limitation	  in	  this	  part	  of	  the	  study	  was	  the	  gold	   standard	  grading.	  A	   semi-­‐quantitative	  4-­‐point	   scale	  was	  used	  here	   in	   the	  absence	  of	  a	  validated	  method	  for	  objectively	  evaluating	  dynamic	  MRE	  data.	  Despite	  the	  experience	  of	  the	  examining	  radiologists,	  this	  grading	  remained	  subjective	  and	  therefore	  subject	   to	  bias.	   It	  was	  exceptionally	  difficult	   to	   identify	  category	  2	  and	  3	  motility	   scores	   consistently	   and	   in	   many	   ways	   demonstrates	   the	   purpose	   and	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necessity	   of	   this	   research.	   When	   grouping	   category	   2	   and	   3	   together,	   the	  intermediate	  motility	  could	  be	  resolved	  by	  several	  of	  the	  metrics	  but	  this	  might	  be	  too	   stringent	   a	   test	   for	   the	   radiologist	   and	   should	   not	   necessarily	   be	   seen	   as	   a	  limitation	   of	   the	   registration.	   	   In	   practice,	   radiologists	   will	   simply	   state	   whether	  peristalsis	   is	   present	   or	   not	   rather	   than	   commenting	   on	   the	   rate	   of	   contractile	  activity	  and	  so	  there	  is	  certainly	  room	  for	  the	  development	  of	  a	  more	  robust	  gold-­‐standard.	  	  	  A	   second	   limitation	  of	   all	   of	   these	  metrics	   lay	   in	   the	   fact	   that	   they	  did	  not	  have	   a	  temporal	   component	   as	   the	   SD	   of	   deformation	   or	   intensity	   variation	   over	   the	  number	   of	   time	   points	  was	   taken.	   The	   larger	   the	   SD	   Jacobian	   the	  more	   fractional	  area	  change	  there	  is	  and	  hence	  more	  elastic	  movement	  of	  the	  pixels.	  The	  implication	  being	  that	  if	  one	  were	  to	  increase	  the	  number	  of	  time	  points,	  it	  would	  increase	  the	  ‘height’	  of	   the	  histogram	  without	   changing	  overall	   spread	  of	  values.	   In	   the	   case	  of	  breath-­‐hold	  studies	  running	  over	  20s	  this	  is	  acceptable	  and	  even	  advantageous	  as	  a	  step	  to	  standardise	  the	  data.	  However	  the	  potential	  problem	  arises	  when	  the	  bowel	  is	   examined	   from	   a	   physiological	   perspective.	   The	   bowel,	   as	   discussed	   in	   the	  previous	  chapter,	  is	  a	  heterogeneous	  organ	  with	  varied	  contraction	  cycles	  and	  quite	  a	   unique	   behaviour	   in	   response	   to	   various	   stimuli.	   The	   SD	   Jacobian	   measure	   in	  effect	  removes	  much	  of	   this	   information	  and	  undoubtedly,	  when	  moving	  to	   longer	  time	  series	  may	  conceal	  otherwise	  valuable	  data	  contained	  within	  the	  time	  series.	  A	  solution	   might	   be	   found	   in	   the	   first	   instance	   by,	   instead	   of	   taking	   the	   standard	  deviation	  through	  time,	  recording	  a	  cumulative	  score	  per	  minute	  to	  give	  the	  metric	  a	  temporal	  component,	  bringing	   it	   in	   line	  with	  other	  metrics	   including	   ‘contractions	  per	  minute’	  of	  diameter	  and	  making	   the	  metric	  more	  accessible	   for	  research	  uses.	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Beyond	   this,	   the	   texture	  and	  heterogeneity	  of	   the	  values	  beneath	  an	  ROI	  might	  be	  investigated	   with	   scores	   using	   kurtosis	   and	   other	   forms	   of	   histogram	   analysis	  potentially	  representing	  an	  exciting	  new	  area	  of	  research.	  	  	  
Summary	  	  
	  This	  chapter	  has	  introduced	  the	  core	  technology	  that	  underpins	  this	  PhD	  and	  some	  of	  the	  key	  methodological	  concepts	  that	  run	  throughout	  this	  thesis.	  In	  the	  next	  two	  chapters	   the	   registration	   algorithm	   is	   applied	   in	   two	   proof-­‐of-­‐concept	   studies	   to	  demonstrate	  both	  the	  role	  of	  registration	  in	  motility	  analysis	  and	  also	  the	  power	  of	  MRI	  to	  gain	  insight	  into	  an	  extremely	  challenging	  aspect	  of	  human	  physiology.	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SECTION	   B:	   RETROSPECTIVE	   INVESTIGATION	   OF	  SMALL	   BOWEL	   MOTILITY	   CHANGES	   IN	   CROHN’S	  DISEASE	  	  
	  
Section	   B	   explores	   the	   practical	   application	   of	   quantitative	   motility	   analysis	   in	  patient	   datasets.	   The	   Centre	   for	   Medical	   Imaging	   was	   granted	   ethics	   for	   the	  retrospectively	   use	   of	   clinical	   small	   bowel	   imaging	   data	   the	   University	   College	  Hospital	   providing	   a	   large	   cohort	   of	   over	   1300	   patient	   scans	   with	   dynamic	   MRI	  imaging.	  Most	  patients	  were	  referred	   for	  known	  or	  suspected	  Crohn’s	  disease	  and	  this	   provided	   the	   starting	   point	   for	   clinical	   investigations	   detailed	   in	   this	   thesis.	  Application	   of	   the	   registration	   algorithm	   to	   a	   cohort	   of	   28	   Crohn’s	   Disease	   (CD)	  patients	   is	   described	   in	  Chapter	   3	   where	   the	   relationship	   between	   inflammation	  and	  motility	  at	   the	   terminal	   ileum	   is	  explored.	  The	  hypothesis	  being	   tested	   is	   that	  motility	  is	  affected	  by	  the	  level	  of	  inflammation	  (ie	  the	  more	  the	  bowel	  is	  inflamed,	  the	   lower	   the	   motility).	   The	   inflammatory	   process	   that	   characterises	   Crohn’s	  disease	   often	   leads	   to	   a	   narrowing	   of	   the	   bowel	   lumen	   and	   in	   severe	   cases	   may	  severely	  restrict	  or	  completely	  obstruct	   the	  passage	  of	  contents	  along	  the	  GI	   tract.	  This	  functional	  obstruction	  leads	  to	  dilatation	  of	  the	  bowel	  immediately	  upstream	  of	  the	  obstructed	  bowel	  and	  is	  extremely	  common	  in	  Crohn’s	  disease,	  but	  data	  relating	  to	   the	   functional	   motility	   changes	   are	   poorly	   represented	   in	   the	   literature	   and	  remain	  largely	  anecdotal.	   	  In	  Chapter	  4,	  data	  is	  presented	  investigating	  stricturing	  disease	  in	  81	  CD	  patients	  where	  it	  is	  hypothesised	  that	  that	  quantitative	  changes	  in	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motility	  occur	  both	  at	  the	  site	  of	  the	  stricture	  and	  in	  the	  preceding	  dilated	  bowel	  in	  relation	  to	  the	  magnitude	  of	  the	  calibre	  change.	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CHAPTER	   3:	   QUANTITATIVE	   ASSESSMENT	   OF	  TERMINAL	   ILEAL	   MOTILITY	   IN	   CROHN’S	   DISEASE	  PATIENTS	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Research	  Question:	  What	  is	  the	  relationship	  between	  small	  bowel	  motility	  and	  inflammatory	  activity	  at	  the	  terminal	  ileum	  in	  Crohn’s	  disease	  (CD)	  patients?	  	  	  
	  
Rationale:	  Inflammatory	  activity	  in	  Crohn’s	  diseases	  leads	  to	  thickening	  of	  the	  bowel	  wall	  and	  an	  array	  of	  discrete	  structural	  changes	  in	  bowel	  appearance.	  Contrast	  enhancement,	  mural	   thickening	   and	   T2	   signal	   have	   all	   been	   correlated	   with	   an	   increased	  inflammatory	  score	  assessed	  through	  biopsy	  and	  serve	  as	  a	  non-­‐invasive	  means	  of	  grading	   CD.	   Additional	   features	   predictive	   of	   inflammatory	   activity	   would	   be	  valuable	  in	  the	  clinic	  to	  inform	  therapeutic	  intervention.	  	  
	  
Hypothesis:	  A	   decrease	   in	   small	   bowel	   motility	   correlates	   with	   an	   increase	   in	   inflammatory	  activity	  at	  the	  terminal	  ileum	  in	  CD	  patients.	  	  
	  
Aim(s):	  i)	  Correlate	  small	  bowel	  motility	  against	  a	  histopathological	  (eAIS)	  reference	  at	  the	  terminal	  ileum.	  	  ii)	  Correlate	  motility	  against	  anatomical	  MRI	  markers	  of	  inflammation	  and	  establish	  whether	  motility	  might	  serve	  as	  an	  independent	  predictor	  of	  inflammation.	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3.1	  Introduction	  
	  Crohn’s	  disease	   is	  a	  chronic,	   relapsing	   inflammatory	  bowel	  disease	  predominantly	  affecting	   the	  gastrointestinal	   tract.	  Patients	   typically	  present	  with	  abdominal	  pain,	  diarrhoea	   and	   symptoms	   suggestive	   of	   bowel	   obstruction.	   Across	   Western	  countries,	   the	  prevalence	  of	  Crohn’s	  disease	  (CD)	  is	   increasing	  with	  approximately	  157/100,000	   diagnosed	   with	   CD	   in	   the	   UK[79].	   Despite	   it’s	   high	   prevalence,	   the	  aetiology	  of	  the	  disease	  is	  poorly	  defined	  with	  numerous	  genetic	  and	  environmental	  factors	  being	  postulated.	  Familial	  aggregation	  has	  been	  described	  for	  over	  70	  years	  with	  twin	  concordance	  studies	  across	  Northern	  European	  countries	  demonstrating	  a	  clear	  genetic	  component	  to	  the	  disease[80].	  Genome	  wide	  association	  studies	  have	  identified	  70	  susceptibility	  loci	  for	  CD	  across	  17	  chromosomes,	  although	  none	  have	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revealed	  a	  ‘smoking	  gun’	  from	  a	  genetic	  perspective[81]–[83].	  These	  investigations	  have	   however	   uncovered	   important	   clues	   as	   to	   the	   implicated	   pathways,	   the	  majority	  of	  which	  suggest	  an	  aberrant	  intestinal	  immune	  system[84]–[87].	  Despite	  a	  growing	   understanding	   of	   the	   genetic	   basis	   for	   the	   disease,	   this	   component	   still	  explains	  only	  20%	  of	  the	  heritability	  of	  the	  disease	  with	  much	  of	  the	  research	  in	  this	  area	  now	  focusing	  on	  epigenetic	  and	  environmental	  factors[88],	  [89].	  	  	  	  The	  significance	  of	  environmental	   factors	   is	   illustrated	  by	  the	   increasing	   incidence	  in	  previously	   less	  affected	  ethnic	  groups	  after	  moving	   to	  high	   incidence	  areas[89].	  Myriad	   studies	   have	   investigated	   the	   effects	   of	   air	   pollution,	   sedentary	   lifestyle,	  Western	  diet	  for	  example.	  Smoking	  in	  particular	  has	  compelling	  evidence	  linking	  it	  to	  CD	  severity.	  	  [90]–[94].	  	  CD	  frequently	  occurs	  after	  infections	  gastroenteritis	  and	  the	   search	   for	   a	   causative	   infectious	   agent	   has	  been	   sought	  with	   several	   adhesive	  bacterial	   types	  being	  proposed	   candidates	   although	   little	   compelling	  evidence	  has	  been	  provided	  thus	  far	  for	  a	  single	  microbial	  origin[95].	  	  	  Despite	   the	   severity	   of	   this	   disease,	   those	   diagnosed	   with	   Crohn’s	   have	   only	   a	  slightly	  reduced	  life	  expectancy	  even	  though	  50%	  of	  patients	  require	  surgery	  within	  10	   years	   of	   their	   diagnosis[96],	   [97].	   Current	   treatment	   of	   CD	   aims	   to	   achieve	  sustained	  remission	  with	  the	  goal	  of	  disrupting	  the	  destructive	  course	  of	  the	  disease	  that	  would	  otherwise	  lead	  to	  intestinal	  failure	  and	  associated	  complications[98].	  	  A	  growing	  number	  of	  increasingly	  expensive	  therapeutic	  agents	  are	  now	  available	  for	  the	  management	  of	  patient	  symptoms	  with	   fast	  acting	  steroids	  or	  anti-­‐TNF	  agents	  routinely	   used	   to	   provide	   rapid	   symptom	   relief	   [50].	   Rational	   use	   of	  immunosuppressive	  therapies	  in	  Crohn’s	  disease	  relies	  on	  accurate	  identification	  of	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those	  patients	  with	  acute	  inflammation	  –	  so-­‐called	  “active	  disease”	  –	  who	  are	  most	  likely	   to	   respond	   to	   the	   treatment.	   Assessing	   disease	   activity	   is	   difficult	   and	   a	  number	   of	   approaches	   are	   employed,	   ranging	   from	   clinical	   assessments	   based	   on	  patient	   symptomatology	   (such	   as	   the	   Crohn’s	   disease	   activity	   index	   and	   Harvey	  Bradshaw	  index),	  biochemical	  markers	  such	  as	  ESR,	  CRP	  and	  stool	  calprotectin,	  and	  endoscopic	  and	  histopathological	  grading[50],	  [98].	  	  	  	  Advances	   in	   medical	   imaging,	   initially	   using	   CT,	   have	   facilitated	   high	   resolution	  cross	   sectional	   imaging	  of	   the	  bowel	  wall	   to	  evaluate	   intra	  and	   importantly	  extra-­‐luminal	   disease	   activity[99]–[103].	   More	   recently	   Magnetic	   Resonance	  Enterography	   (MRE)	   has	   further	   added	   to	   the	   diagnostic	   toolset	   available	   in	   the	  modern	  clinic	  with	  the	  additional	  advantage	  over	  CT	  of	  not	  using	  ionising	  radiation.	  MRI	   is	   increasingly	   used	   in	   the	   diagnosis	   of	   CD	   to	   assess	   disease	   activity	   and	  objectively	   inform	   therapeutic	   strategies.	   Features	   of	   inflammatory	   disease	  including	   increased	   bowel	  wall	   T2	   signal,	   bowel	  wall	   thickness	   and	   enhancement	  have	   been	   strongly	   correlated	   with	   disease	   activity	   on	   endoscopy	   and	  histopathology	  and	  increasingly	  present	  a	  safe	  and	  non-­‐invasive	  method	  of	  grading	  and	   observing	   disease[104]–[109].	   Beyond	   imaging,	   a	   diagnosis	   of	   CD	   of	   course	  includes	  patient	  history	  and	  objective	  data	  from	  a	  range	  of	  blood,	  histopathological,	  endoscopic	   and	   imaging	   investigations	   with	   no	   single	   test,	   at	   present,	   being	  sufficient	   to	  make	   a	   diagnosis	   in	   isolation.	   However,	   some	   investigations	   such	   as	  MRI	   have	   the	   capability	   to	   offer	   multiple	   insights	   on	   disease	   physiology	   beyond	  structural	   changes	   in	   the	   bowel	   non-­‐invasively	   and	   without	   the	   use	   of	   ionising	  radiation.	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One	  might	  reasonably	  assume	  that	  motility	  will	  be	  reduced	  in	  Crohn’s	  disease	  based	  on	  the	  appearance	  of	   the	  bowel	  wall	  alone.	  Surgical	  resection	  of	  severely	  diseased	  bowel	   reveals	   marked	   hypertrophy	   of	   the	   wall	   and	   this	   is	   routinely	   described	  clinically	  based	  on	  cross	  sectional	  imaging	  (Figure	  3.1	  A-­‐D)[105]–[107],	  [109].	  This	  thickening	  is	  likely	  to	  have	  a	  marked	  impact	  on	  the	  ability	  of	  the	  bowel	  to	  contract	  with	   both	   inflammatory	   and	   fibrotic	   infiltrate	   likely	   playing	   a	   role.	   Fibrosis	  undoubtedly	   has	   a	   direct	   and	   irreversible	   impact	   on	   motility,	   quite	   literally	  stiffening	  the	  wall	  such	  that	  any	  contractile	  potential	  is	  lost	  (Figure	  3.1	  E&F).	  More	  complex	   is	   the	   effect	   of	   inflammation	   with	   both	   a	   direct	   impact	   of	   swelling	   and	  oedema	  impairing	  contraction	  but	  also	  the	  potential	  for	  indirect,	  cytokine	  mediated	  suppression	   of	   motility[110]–[113].	   	   Although	   anecdotal	   evidence	   and	   a	   single	  preliminary	   study	   have	   suggested	  motility	   is	   altered	   in	   active	   CD,	   there	   were	   no	  quantitative	  investigations	  at	  the	  time	  of	  this	  work	  to	  draw	  a	  relationship	  between	  specifically	   inflammatory	   activity	   and	   motility[14].	   In	   this	   chapter	   it	   was	  hypothesised	  that	  motility	  will	  be	  negatively	  impacted	  by	  inflammation.	  However,	  of	  further	  interest	  will	  be	  the	  correlation	  with	  routine	  anatomical	  markers	  of	  activity	  such	  as	  bowel	  wall	  thickness	  with	  which	  motility	  is	  potentially	  inseparably	  related.	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  Figure	  3.1	  Anatomical	  overview	  of	  changes	  in	  small	  bowel	  structure	  in	  CD.	  Axial	  MRE	  
slices	  of	  four	  progressively	  thickened	  (A-­‐D)	  small	  bowel	  loops.	  Bowel	  wall	  thickness	  has	  
been	   negatively	   correlated	   with	   both	   luminal	   and	   trans-­‐luminal	   histopathological	  
markers	  of	   inflammation	   [95].	  E	   shows	  a	   resected	  bowel	   loop	  with	  extensive	   fibrotic	  
process	   (red	   bracket)	   and	   haematoxylin-­‐eosin	   staining	   F.	   Such	   extensive	   fibrotic	  
changes	   are	   likely	   to	   irreversibly	   induce	   motility	   changes	   in	   bowel	   wall	   (E	   &	   F	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3.2	  Materials	  and	  methods	  
3.2.1	  Patient	  cohort	  	  A	   review	   of	   the	   UCLH	   institutional	   database	   (2008–2011)	   was	   undertaken	   to	  identify	   patients	   fulfilling	   the	   study	   eligibility	   criteria	   of	   (i)	   prior	   histologically	  proven	   diagnosis	   of	   Crohn’s	   disease,	   (ii)	   undergoing	   clinically	   indicated	   disease	  assessment	  with	  MRE	  (including	  cine	  MRI	  motility	  sequences	  –	  see	  below)	  and	  (iii)	  endoscopic	  terminal	  ileal	  biopsy	  within	  4	  weeks	  of	  MRI.	  	  	  Twenty-­‐eight	  patients	   (mean	  age	  34	  range	  16–71,	  18	   female,	  10	  male)	   fulfilled	  all	  eligibility	   criteria.	   The	   demographics	   of	   this	   cohort	   are	   represented	   in	   Table	   3.1.	  	  Most	   (n=18)	   had	   ileocolonic	   disease.	   	   	   The	   median	   time	   between	   MRE	   and	  endoscopy	  was	  4	  days	  (range	  0-­‐30),	  and	  in	  25	  of	  the	  cohort,	  the	  time	  difference	  was	  15	  days	  or	   less	  seven	  of	   the	  cohort	  had	  undergone	  terminal	   ileal	  resection	  and	  21	  had	  no	  previous	  surgical	  intervention	  (table	  3.1).	  	  	  
3.2.2	  MRI	  Protocol	  	  Patients	  underwent	  the	  same	  MR	  protocol	  for	  the	  coronal	  motility	  sequences	  as	  per	  chapter	   2.2	   using	   the	   same	   1.5T	   Siemens	   MRI	   scanner.	   Following	   dynamic	   data	  acquisition,	   20	  mg	  of	   IV	   spasmolytic	   (Buscopan,	  Boehringer	   Ingelheim,	   Ingelheim,	  Germany)	  was	   administered	   and	   the	   routine	   clinical	   protocol	   was	   run	   to	   acquire	  anatomical	  images	  including:	  axial	  and	  coronal	  fat/non-­‐fat-­‐saturated	  HASTE	  images.	  Coronal	  volumetric	  interpolated	  breath-­‐hold	  examination	  (VIBE)	  acquisitions	  were	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performed	   at	   30	   and	   70	   s	   post-­‐injection	   of	   10	   mL	   gadopentetate	   dimeglumine	  (Magnevist,	  Berlex	  Laboratories,	  Montville,	  NJ,	  USA).	  Detailed	  parameters	  of	  all	  MR	  sequences	  are	  provided	  in	  Table	  3.2.	  	  	  
Parameter	   Number	  of	  Patients	  
Disease	  Duration	   	  Less	  than	  1	  year	   8	  Between	  1	  and	  5	   4	  Between	  5	  and	  10	  years	   5	  Over	  10	  years	   6	  
	  
Disease	  Distribution	   	  Colonic	   2	  Ilecolic	   13	  Isolated	  Terminal	  ileum	   5	  Small	  bowel	  beyond	  terminal	  ileum	   3	  
	  
Current	  Immunosuppressive	  
medication	   	  none	   2	  1	  agent	   13	  2	  agents	   8	  
	  
Surgical	  History	   	  No	  previous	  surgery	   17	  One	  Operation	   5	  Two	  previous	  operations	   1	  	   	  
Table	   3.1.	   Patient	   demographics	   illustrating	   the	   distribution	   of	   disease	   duration	   and	  
location,	  medication	  status	  and	  surgical	  history	  of	  the	  recruited	  cohort.	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   Coronal	  balanced	  SSFP	   Coronal/	  axial	  HASTE	   Coronal/	  axial	  TrueFISP	   Coronal	  Baseline	  VIBE	   Coronal	  30s	  and	  70s	  VIBE	  Field	   of	   view	  (mm)	   Variable	   Variable	   Variable	   Variable	   Variable	  NO.	  Slices	   20	   20/26	   25/34	   48	   48	  Stacks	   6-­‐16	   1/4	   1/2	   1	   1	  TR	  (ms)	   3.85	   1200/800	   4/4.2	   17.2	   7.2	  TE	  (ms)	   1.93	   86/86	   1.7/2.1	   2.4	   2.4	  Image	  matrix	   256	  x	  184	   256x195	   256	  x	  205	   256	  x	  135	   256	  x	  135	  Slice	  thickness	  (mm)	   10	   4/4	   4/4	   3	   3	  Slice	  gap	   <	  10	   5.2/5.4	   5.2/5.4	   0	   0	  Averages	   1	   1	   1	   1	   1	  Turbo	  factor	   	   195	   -­‐	   -­‐	   -­‐	  iPAT	   	   Grappa	  x2	   n/a	   n/a	   n/a	  Flip	  Angle	   61	   50	   46	   10	   10	  	  
	  
3.2.3	  Motility	  assessment	  	  	  Anonymised	   datasets	   were	   downloaded	   from	   the	   hospital	   PACS	   system	   and	  processed	   with	   the	   optical	   flow	   registration	   software	   detailed	   in	   the	   previous	  chapter	   section	   2.2.4.	   For	   this	   study,	   the	   standard	   deviation	   of	   the	   Jacobian	   (SD	  Jacobian)	   determinant	   was	   used	   as	   a	   surrogate	   for	   motility	   as	   this	   was	   most	  strongly	   correlated	   with	   clinical	   grading	   of	   motility	   as	   detailed	   in	   the	   previous	  chapter	  validating	  the	  registration	  software	  (see	  2.3.3).	  In	  summary,	  the	  SD	  Jacobian	  
Table	   3.2	   MR	   protocol	   sequence	   parameters	   using	   a	   1.5T	   Siemens	   Avanto	   scanner	  (Siemens,	  Erlangen,	  Germany)	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metric	   evaluates	   the	   fractional	   change	   in	  area	  produced	  by	   the	  deformation	   fields	  generated	  by	  registration	  of	  the	  time	  series	  images.	  	  	  
	  
Figure	  3.2	  ROI	  Placement	  at	  the	  Terminal	  Ileum.	  a)	  A	  single	  image	  from	  a	  dynamic	  set	  
of	  20	  with	  a	  ROI	  placed	  on	  a	  diseased	   terminal	   Ileum.	  Red	  arrow	  points	   to	  diseased,	  
thickened	   terminal	   ilem.	   b)	   Summary	   image	   of	   the	   dynamic	   sequence	   with	   a	   the	  
Jacobian	  standard	  deviation	  parametric	  map	  overlay	  demonstrating	  areas	  associated	  
with	  larger	  degrees	  of	  motion	  (red)	  and	  decreased	  motion	  (blue).	  Motion	  is	  assessed	  by	  
assigning	  each	  pixel	  in	  the	  image	  with	  an	  associated	  displacement	  value,	  expressed	  as	  
the	  standard	  deviation	  of	  its	  Jacobian.	  c)	  Magnified	  view	  of	  the	  terminal	  ileum	  where	  a	  
user	  defined	  ROI	  produces	   the	  mean	  value	   for	   the	  pixel	  displacement	  within	   the	  ROI	  
and	  hence	  the	  motility	  value.	  	  A	  single	  observer	  (Prof	  Stuart	  Taylor),	  who	  was	  blinded	  to	  all	  clinical	  data,	  manually	  drew	  a	  polygonal	  ROI	  within	  the	   last	  3	  cm	  of	  the	  terminal	   ileum	  within	  a	  frame	  of	  the	  cine	  stack	  best	  depicting	  this	  section	  of	  small	  bowel	  and	  the	  motility	  score	  (SD	  Jac)	  recorded	  (Fig.	  3.2).	  	  	  
A)	   B)	   C)	  
	  	   97	  
	  
	  
	   	  
3.2.4	  Anatomical	  MRI	  grading	  of	  disease	  activity	  	  Two	   consultant	   radiologists	   (Dr	   S.	   Punwani	   and	   Prof.	   SA	   Taylor)	   reviewed	   all	   28	  datasets	   using	   a	   picture	   archiving	   and	   communication	   system	   (PACS)	   viewing	  system,	   unaware	   of	   the	  motility	   scores	   or	   clinical	   information.	   	   In	   particular	   they	  reviewed	   all	  MRI	   sequences	   acquired	   (Table	   3.3)	   but	   specifically	   not	   the	  motility	  sequences.	  In	  consensus	  the	  radiologists	  applied	  a	  qualitative	  score	  of	  MRI	  disease	  activity	  to	  the	  last	  3	  cm	  of	  terminal	  ileum	  based	  on	  that	  described	  by	  Steward	  et	  al	  (Table	  3.3)[107].	  In	  this	  work	  qualitative	  scoring	  (0–3)	  of	  mural	  thickness,	  mural	  T2	  signal,	  mural	  enhancement	  and	  perimural	  T2	  signal	  were	  all	  correlated	  with	  disease	  activity	  based	  on	  a	  transmural	  histopathological	  reference.	  The	  sum	  of	  the	  scores	  of	  these	  four	  parameters	  for	  each	  patient	  constituted	  the	  anatomical	  MR	  activity	  index	  (aMRI).	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Table	  3.3	  MRE	  anatomical	  activity	  grading	  algorithm	  based	  on	  Steward	  et	  el12	  
	  
	   	  
Score	   0	   1	   2	   3	  
Mural	  
thickness	  
1-­‐3mm	   >3-­‐5mm	   >5-­‐7mm	   >7mm	  
Mural	  T2	  
Signal	  
Equivalent	  to	  normal	  bowel	  wall	   Minor	  increase	  in	  signal-­‐bowel	  wall	  appears	  dark	  grey	  on	  fat	  saturated	  images	  
Signal-­‐bowel	  wall	  appears	  light	  grey	  on	  fat	  saturated	  images	  
Signal-­‐bowel	  wall	  contains	  areas	  of	  white	  high	  signal	  approaching	  that	  of	  luminal	  content	  
Perimural	  	  
T2	  signal	  
Equivalent	  to	  normal	  mesentery	   Increase	  in	  mesenteric	  signal	  but	  no	  fluid	   Small	  fluid	  rim	  (≤2mm)	   Larger	  fluid	  filled	  rim	  (>2mm)	  
Enhancem
-­‐ent	  
Equivalent	  to	  normal	  bowel	  wall	   Minor	  enhancement-­‐	  bowel	  wall	  signal	  greater	  than	  normal	  small	  bowel	  but	  significantly	  less	  than	  nearby	  vascular	  structures	  
Moderate	  enhancement-­‐	  bowel	  wall	  signal	  increased	  by	  somewhat	  less	  than	  nearby	  vascular	  structures	  
Marked	  enhancement	  -­‐	  bowel	  wall	  signal	  approaches	  that	  of	  nearby	  vascular	  structures	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3.2.5	  Histopathological	  reference	  	  In	  each	  patient	   the	   terminal	   ileal	  biopsy	  obtained	  during	  colonoscopy	  was	  stained	  with	   haematoxylin-­‐eosin	   and	   reviewed	   in	   consensus	   by	   two	   experienced	  pathologists	   (Dr.	   M.	   Rodriguez-­‐Justo	   &	   Prof.	   Marco	   Novelli,	   3	   and	   10	   years’	  experience	  respectively),	  who	  were	  unaware	  of	  clinical	  details	  or	  MRI	  findings.	  The	  histopathologists	   applied	   an	   endoscopic	   biopsy	   acute	   inflammatory	   score	   (eAIS)	  based	   on	   the	   typical	   morphological	   features	   of	   Crohn’s	   disease	   described	   in	  guidelines	  published	  by	  the	  European	  Crohn’s	  and	  Colitis	  Organization[51],	  and	  first	  proposed	  by	  Steward	  et	  al[107].	  The	  numerical	  system	  includes	  variables	  associated	  with	   epithelial	   damage	   and	   neutrophilic	   infiltration	   (i.e.	   epithelial	   damage,	  architectural	  changes,	  epithelial	  neutrophils	  and	  lamina	  propria,	  erosion/ulceration,	  and	   presence	   of	   granulomas;	   Table	   3.4).	   At	   least	   three	   samples	   of	   terminal	   ileum	  biopsy	  were	  collected	  for	  each	  patient	  and	  the	  highest	  score	  for	  each	  was	  used	  for	  that	  patient,	  in	  accordance	  with	  the	  standard	  procedure	  at	  UCLH.	  	  
Histological	  variable	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  Grade	  Erosion	  or	  ulceration	   0	  =	  No,	  1	  =	  Yes	  Polymorphs	  in	  the	  lamina	  propria	  	   0	  =	  No,	  1	  =	  Yes	  Cryptitis	   0	  =	  No,	  1	  =	  Yes	  Crypt	  and	  abscess	  formation	   0	  =	  No,	  1	  =	  Yes	  Inflammatory	  exudates	   0	  =	  No,	  1	  =	  Yes	  Granulomas	   0	  =	  No,	  1	  =	  Yes	  
	  
Table	  3.4	  Histopathology	  grading	  scheme	  for	  eAIS	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3.2.6	  Statistical	  analysis	  	  The	  Shapiro–Wilk	  test	  (α	  =	  0.5)	  was	  used	  to	  examine	  whether	  motility,	  anatomical	  MR	  activity	  index	  and	  histopathological	  grading	  were	  normally	  distributed.	  	  Patients	   were	   also	   divided	   into	   those	   with	   histopathological	   evidence	   of	  inflammation	   on	   terminal	   ileal	   biopsy	   (eAIS	   ≥1)	   and	   those	  without	   (eAIS=0).	   The	  motility	  index	  was	  compared	  between	  the	  two	  groups	  using	  the	  Wilcoxon	  rank	  sum	  test.	  	  	  The	   association	   (if	   any)	   between	   the	   derived	   MRI	   motility	   index	   and	   the	  histopathological	   eAIS	   score,	   and	   was	   assessed	   by	   Spearman’s	   rank	   correlation.	  Spearman’s	   rank	  was	   also	   used	   to	   assess	   the	   strength	   of	   association	   between	   the	  anatomical	  MRI	  grading	  of	  activity	  and	  both	  the	  eAIS	  score	  and	  motility	  index.	  	  	  A	   linear	   regression	   model	   was	   built	   to	   test	   if	   the	   addition	   of	   motility	   beyond	  anatomical	   MR	   grading	   could	   improve	   the	   prediction	   of	   inflammation.	   The	   first	  stage	   of	   the	   data	   analysis	   examined	   the	   ability	   of	   the	   anatomical	   MRI	   grade	   to	  predict	   inflammation	   in	   a	   univariate	   analysis.	   In	   the	   second	   stage	   of	   analysis,	   the	  benefit	  of	   including	  a	  motility	  score	  with	  the	  anatomical	  MRI	  grade	  was	  examined.	  Statistical	  significance	  was	  assessed	  at	  P	  <	  0.05.	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3.3	  Results	  
3.3.1	  Motility	  score	  and	  histopathological	  correlation	  	  Across	  the	  28	  patients,	  the	  mean	  motility	  score	  was	  0.27	  (range	  0.06–0.55)	  and	  the	  mean	   histopathology	   score	   (eAIS)	   was	   1.5	   (range	   0–5).	   One	   of	   the	   cohort	   had	  dilatation	  of	  the	  terminal	  ileum.	  
	  
Figure	   3.3	   Boxplot	   of	   inflamed	   and	   non-­‐inflamed	   study	   subjects	   assessed	   by	   eAIS	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(eAIS	   ≥	   1;	  n	   =	   16,	  mean	   0.19,	   range	   0.06	   to	   0.44;	  P	  =	   0.002;	   T-­‐stat	   3.4	   [df27];	   CI,	  0.07–0.28;	  Fig.	  3.3).	  	  There	   was	   a	   significant	   negative	   correlation	   between	   the	   motility	   index	   and	  histopathological	   grading	   of	   activity	   (eAIS;	   Rho	   =	   -­‐0.52,	   P	   =	   0.005;	   Fig.	   3.4).	   This	  correlation	   remained	   when	   subjects	   with	   a	   history	   of	   surgical	   resection	   were	  excluded	  (n	  =	  21,	  Rho	  -­‐0.49,	  P	  =	  0.002).	  	  
	  
	  
Figure	  3.4	  Scatter	  plot	  of	  histopathological	  activity	  score	  (eAIS)	  of	  inflammation	  and	  
motility	  score	  Jacobian	  SD.	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3.3.2	  Anatomical	  MRI	  grade	  and	  Histopathological	  Reference	  	  The	   mean	   anatomical	   MRI	   grade	   (sum	   of	   T2	   signal,	   mural	   thickness,	   mural	  enhancement	  and	  perimural	  oedema	  scores)	  was	  3.8	  (range	  0	  to	  10).	  There	  was	  a	  statistically	   significant	   positive	   correlation	   between	   anatomical	   MRI	   grade	   and	  histopathology	  (eAIS)	  score	  (Rho	  =	  0.67,	  P	  <0.001).	  	  
3.3.3	  Motility	  score	  and	  Anatomical	  MRI	  grade	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Table	  3.5	  Spearman’s	  Rank	  correlation	  between	  anatomical	  MR	  parameters	  and	  SD	  
Jacobian	  motility	  score.	  
	  	   	  
	   Rho	   p	  Mural	  thickness	   -­‐0.52	   0.005	  T2	  Signal	   -­‐0.69	   0.002	  
Perimural	  signal	   -­‐0.45	   0.016	  Enhancement	  	   -­‐0.67	   <0.001	  Total	  anatomical	  MRI	  grade	   -­‐0.7	   <0.001	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3.4	  Discussion	  	  
	  The	   evidence	   to	   support	   the	   use	   of	  medical	   imaging	   to	   predict	   disease	   activity	   in	  Crohn’s	   disease	   is	   increasingly	   apparent.	  Whilst	   there	   remains	   some	   debate	   as	   to	  which	   technique	   and	   parameters	   are	   optimal,	   the	   role	   of	   MRI	   in	   this	   context	   is	  expanding.	  The	  potential	  of	  motility	  assessment	   to	  aid	   the	  classification	  of	  disease	  activity	  over	  conventional	  MRI	  parameters	  has	  however	  received	  little	  attention.	  	  	  Chapter	  2	  presented	  the	  validation	  of	  a	  registration-­‐based	  method	  for	  quantitatively	  evaluating	  motility,	  and	  here	  applied	   it	   in	  a	  clinical	  cohort	   to	   investigate	  a	  disease	  process	   that	   is	   very	   likely	   to	   influence	   small	   bowel	   motility.	   	   A	   statistically	  significant	   negative	   correlation	   between	   objectively	   measured	   terminal	   ileal	  motility	  and	  an	  independent	  histopathological	  score	  of	  disease	  activity	  was	  found.	  	  	  It	   is	   acknowledged	   that	   the	  histopathological	   standard	  of	   reference	  utilised	   in	   the	  current	   study	   was	   based	   on	   an	   endoscopic	   biopsy	   which	   by	   definition	   cannot	  encompass	   the	   entire	   thickness	   of	   the	   bowel	   wall.	   However	   the	   eAIS	   score	   did	  include	   factors	   known	   to	   be	   indicative	   of	   inflammatory	   activity.	   Furthermore,	  histopathological	  grading	  of	  biopsies	   is	  a	   recognised	  reference	   for	  Crohn’s	  disease	  activity	  and	  has	  continued	  to	  appear	  as	  the	  gold-­‐standard	  in	  numerous	  studies[51].	  It	   is	   very	   likely	   that	   inflammatory	   activity	   on	   biopsy	   is	   closely	   correlated	   with	  activity	  throughout	  the	  bowel	  wall.	  Indeed	  Steward	  et	  al.	  found	  that	  an	  MRI	  model	  of	  activity	   derived	   using	   transmural	   histopathological	   sections	   from	   surgical	  specimens	  could	  equally	  predict	  the	  eAIS	  score	  based	  on	  endoscopic	  biopsy	  [107].	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  In	   this	  study	  motility	  was	  also	  correlated	  with	   independently	  assessed	  anatomical	  MRI	  grading	  of	  activity	  using	  mural	  thickness,	  T2	  signal,	  contrast	  enhancement	  and	  perimural	   oedema.	   This	   anatomical	   scoring	   system	   has	   been	   proposed	   and	  validated	   previously	   by	   Steward	   et	   al.	   study[107].	   Using	   regression	   modelling,	  although	  the	  predictive	  ability	  of	   the	  anatomical	  MRI	  grading	  for	  histopathological	  inflammation	  was	   confirmed,	   the	   strength	  of	   this	  prediction	  was	  not	   improved	  by	  adding	   the	   motility	   index.	   This	   suggests	   that	   motility	   itself	   may	   not	   be	   an	  independent	   marker	   of	   activity	   beyond	   existing	   anatomical	   parameters.	   Indeed	  there	  was	   a	   very	   strong	   negative	   correlation	   between	  motility	   and	  wall	   thickness	  alone.	  It	  appears	  intuitive	  that	  diseased	  bowel	  wall	  thickness	  and	  motility	  should	  be	  inversely	   correlated	   but	   this	   relationship	   could	   be	   exploited	   when	   looking	   for	  reversible	   versus	   irreversible	   changes	   following	   treatment	   in	   future	   studies.	   It	   is	  unclear	   for	   example	   if	   as	   wall	   thickness	   reduces,	   motility	   recovers	   although	   this	  reversibility	  could	  be	  an	  important	  parameter	  for	  differentiating	  inflammatory	  from	  fibrotic	  disease	  where	  the	  latter	  is	  irreversible.	  	  Data	  presented	  in	  the	  next	  chapter	  (chapter	  4)	  begins	  to	  explore	  this	  concept	  in	  a	  study	  of	  patients	  with	  Crohn’s	  disease	  related	  strictures.	  	  As	   described	   in	   Chapter	   1,	   small	   bowel	   motility	   is	   a	   complex	   and	   only	   partly	  understood	   process	   even	   in	   healthy	   individuals.	   Although	   the	   motility	   index	   was	  significantly	   different	   between	   those	   with	   and	   those	   without	   histopathological	  inflammation,	  there	  was	  clearly	  an	  overlap	  and	  a	  relatively	  wide	  range	  of	  motility	  in	  “normal”	  (eg.	  no	  inflammation)	  individuals.	  Although	  the	  routine	  UCLH	  clinical	  MRE	  protocol	   kept	   the	   period	   of	   starvation	   and	   composition	   of	   the	   oral	   contrast	   agent	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constant	   in	  all	  subjects,	  other	   factors	   that	  may	   influence	  motility	  such	  as	  smoking,	  caffeine	  intake,	  time	  of	  day	  and	  hormonal	  fluctuation	  associated	  with	  the	  menstrual	  cycle	   were	   not	   controlled	   for[114],	   [115].	   In	   disease	   states,	   and	   particularly	   in	  Crohn’s	   disease,	   additional	   factors	   over	   and	   above	   acute	   inflammation	  may	   affect	  motility,	   including	  drug	  regimens,	  disease	  duration,	   location,	  coexistence	  of	  colitis,	  previous	   surgery	   and	   mural	   fibrosis.	   Such	   parameters	   require	   detailed	  consideration	   in	   prospective	   studies.	   The	   study	   population	   was	   relatively	  heterogeneous	   although	   perhaps	   this	   is	   a	   strength	   as	   the	   data	   may	   be	   more	  generalisable.	  However,	  equally	  it	  means	  that	  the	  various	  parameters	  that	  may	  have	  confounded	  the	  analysis	  were	  fully	  controlled	  for	  and	  may	  be	  responsible	  for	  some	  of	  the	  outlying	  data	  points.	  	  Of	  note,	  the	  statistically	  significant	  correlations	  between	  motility	   and	  eAIS	  were	  preserved	  when	  7	  patients	  with	  prior	   ileal	   resection	  were	  excluded.	   	   Perhaps	   of	   most	   interest	   is	   the	   effect	   of	   fibrosis	   –	   intuitively,	   fibrotic	  bowel	  will	  peristalse	  differently	  from	  normal	  bowel	  and	  the	  additional	  contribution	  of	  acute	  inflammation	  is	  unknown.	  It	  would	  seem	  reasonable	  to	  further	  hypothesise	  that	   both	   inactive,	   fibrotic	   disease	   and	   acutely	   inflamed	   bowel	   would	   decrease	  motility	  and	  both	  would	  attract	  very	  different	  eAIS	  scores,	  and	  this	  could	  certainly	  explain	  why	  such	  variation	  was	  observed	  within	  the	  ‘no	  inflammation’	  participants	  in	   out	   cohort.	   Conversely,	   two	   of	   the	   patients	   recorded	   high	   motility	   and	  inflammatory	   scores	   which	   might	   perhaps	   be	   explained	   by	   acute	   mucosal	  inflammation	   at	   the	   TI.	   Alternatively,	   motility	   might	   be	   more	   variable	   than	   first	  assumed	  and	   indeed	   this	  will	   form	   the	   subject	  of	   chapter	  5.	  Nevertheless,	   fibrosis	  and	  acute	  inflammation	  usually	  co-­‐exist	  in	  Crohn’s	  disease,	  with	  one	  predominating	  over	   the	   other	   making	   any	   assertions	   with	   respect	   to	   the	   fibrotic	   nature	   of	   the	  bowel	  difficult	  to	  demonstrate	  empirically	  [116].	  Whether	  it	  will	  ever	  be	  possible	  to	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use	   motility	   to	   differentiate	   between	   fibrosis	   and	   acute	   inflammation	   remains	  speculative.	   Certainly	   it	   is	   plausible	   that	   upon	   follow	  up,	   a	   patient,	   after	   receiving	  anti-­‐inflammatory	  treatment,	  might	  demonstrate	  a	  change	  in	  motility	  at	  the	  site	  of	  their	  lesion	  which	  could	  in	  turn	  be	  used	  to	  estimate	  their	  fibrotic	  load.	  Although	  in	  our	  cohort	  only	  one	  of	  the	  terminal	  ileum	  segments	  was	  dilated,	  it	  seems	  likely	  that	  bowel	  dilatation,	   for	  example	  upstream	  of	  a	  stricture,	  could	   influence	  motility	  and	  indeed	  this	  will	  be	  investigated	  more	  thoroughly	  in	  the	  next	  chapter.	  	  	  This	   study	  does	  have	   limitations.	  Using	  only	  he	  highest	  biopsy	  score	   to	  assign	   the	  per	  patient	  eAIS	  score,	  although	  standard	  practice	  at	  UCLH,	  could	  have	  introduced	  sampling	   bias.	   However	   the	   alternative	   of	   using	   an	   average	   of	   all	   biopsy	   scores	  could	  have	  skewed	  the	  data,	  for	  example	  if	  there	  was	  a	  large	  number	  of	  near	  normal	  biopsies	  in	  an	  otherwise	  highly	  inflamed	  segment.	  An	  endoscopic	  severity	  score	  was	  not	  included	  here	  although	  it	  might	  have	  been	  useful.	  However	  scoring	  systems	  are	  rarely	   used	   in	   routine	   clinical	   practice	   and	   the	   cohort	   was	   retrospective.	   A	  prospective	   study	   design	   would	   have	   been	   preferable,	   although	   because	   of	   the	  invasiveness	   and	   risks	   of	   colonoscopy,	   even	   prospective	   studies	   will	   likely	   be	  limited	  to	  including	  only	  those	  undergoing	  colonoscopy	  for	  clinical	  indications,	  and	  thus	  will	   also	   be	   open	   to	   similar	   spectrum	  bias.	   As	  with	   all	   studies	   attempting	   to	  validate	  MR	  markers	  of	  disease	  activity	  against	  endoscopic	  or	  histological	  standards	  of	   reference,	   it	   was	   not	   possible	   to	   be	   certain	   the	   endoscopic	   biopsy	   site	   exactly	  matched	   the	   site	   from	   which	   imaging	   scores	   were	   obtained.	   This	   was	   partially	  mitigated	  by	  using	  the	  last	  3	  cm	  of	  terminal	  ileum.	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Summary	  
	  This	  chapter	  detailed	  the	   first	  application	  of	  a	  post-­‐processing	  technique	  to	  assess	  motility	   in	   a	   clinical	   cohort.	   The	   results	   showed	   that	  motility	   could	  be	  used	   as	   an	  independent	  quantitative	  marker	  of	   inflammatory	  diseases	  activity	   and	   correlated	  with	   existing,	   well	   validated	   measures.	   In	   the	   next	   chapter,	   Crohn’s	   disease	   will	  remain	   the	   subject	   of	   interest	   but	   this	   time,	   exploring	   a	   long	   held	   but	   largely	   un-­‐investigated	  feature	  of	  the	  diseases,	  strictures,	  and	  the	  functional	  changes	  that	  take	  place	  in	  relation	  to	  this	  process.	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CHAPTER	  4:	  SMALL	  BOWEL	  STRICTURES	  IN	  CROHN’S	  DISEASE:	   A	   QUANTITATIVE	   INVESTIGATION	   OF	  INTESTINAL	  MOTILITY	  USING	  MR	  ENTEROGRAPHY.	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Research	  Question:	  How	  do	  Crohn’s	  disease	  strictures	  influence	  small	  bowel	  motility?	  
Rationale:	  It	  is	  anecdotally	  well	  known	  that	  stricturing	  disease	  has	  an	  adverse	  effect	  on	  small	  bowel	  motility	   both	   at	   the	   site	   of	   the	   stricture	   as	  well	   as	   in	   the	   proximal	   dilated	  bowel.	   Although	   several	   investigations	   have	   demonstrated	   motility	   changes	   in	  animal	  models,	  there	  is	  little	  to	  no	  quantitative	  data	  to	  explore	  this	  process	  either	  in	  humans	  or	  in	  Crohn’s	  disease.	  It	  is	  furthermore	  unknown	  whether	  motility	  changes	  in	  the	  case	  of	  the	  pre-­‐stricture	  bowel	  are	  reversible	  following	  treatment	  that	  in	  turn	  has	  an	  impact	  on	  surgical	  management	  of	  the	  disease.	  	  
Hypothesis:	  A	  negative	  correlation	  exists	  between	  the	  calibre	  of	   the	  pre-­‐stenotic	  bowel	  and	   its	  motility	  but	  this	  is	  reversible	  where	  the	  obstruction	  is	  treated.	  	  
Aim(s):	  i)	  Quantitate	   small	   bowel	  motility	   in	  patients	  with	   stricturing	  CD	  both	  within	   and	  upstream	  of	  the	  obstructive	  lesion.	  	  ii)	   Investigate	   changes	   in	   pre-­‐stricture	  motility	   between	   scans	  where	   a	   follow	   up	  investigation	  is	  available.	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4.1	  Introduction	  
	   	  The	   previous	   chapter	   described	   and	   investigated	   the	   inflammatory	   process	   that	  takes	  place	  in	  Crohn’s	  disease.	  In	  many	  cases	  this	  process	  leads	  to	  progressive	  wall	  thickening	   and	   narrowing	   of	   the	   bowel	   lumen	   resulting	   in	   stricturing	   disease.	  Inflammatory	   strictures	   can	   themselves	   cause	   obstruction	   of	   the	   bowel.	  Furthermore,	   following	   repeat	   flares	   of	   the	   disease,	   the	   bowel	   wall	   may	   become	  fibrotic	   and	   permanently	   thickened,	   gradually	   occluding	   bowel	   lumen.	   In	   many	  cases,	   the	  bowel	  becomes	   chronically	   obstructed	  due	   to	   the	   irreversible	  nature	  of	  the	   fibrotic	   stricture,	   which	   is	   one	   of	   the	   leading	   causes	   for	   surgical	   intervention	  including	  resection	  and	  balloon	  dilatation	  (carried	  out	  in	  over	  80%	  of	  patients	  with	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long	   term	   Crohn’s	   disease)	   [97].	   Obstructed	   patients	   will	   often	   present	   clinically	  with	  severe	  abdominal	  pain	  and	  vomiting	  and	  radiological	  imaging	  will	  reveal	  often	  striking	  dilatation	  in	  a	  region	  of	  bowel	  (Figure	  4.1)	  upstream	  of	  a	  stricture	  caused	  by	   the	   functional	   hold-­‐up	   of	   intestinal	   contents.	   Most	   small	   bowel	   strictures	   are	  beyond	  the	  reach	  of	  the	  endoscope	  and	  therefore	  imaging	  is	  pivotal	  to	  diagnosis	  and	  long-­‐term	  assessment.	   	  	  
Figure	   4.1	  Depiction	  of	  a	   small	  bowel	   stricture	   imaged	  with	  a	  T2	  weighted	   (A)	  and	  
post-­‐contrast	  THRIVE	  (B)	  sequences.	  A	  narrowing	  of	  the	  bowel	   lumen	  can	  be	  seen	  in	  
both	  images	  characterised	  by	  a	  thickening	  of	  the	  bowel	  wall	  (red	  arrow).	  The	  proximal	  
dilation	   is	   characteristic	   of	   such	   luminal	   narrowing	   and	  while	   the	   bowel	   wall	   itself	  
remains	  ‘normal’	  (green	  arrow)	  the	  calibre	  of	  the	  bowel	  increases	  to	  many	  times	  that	  







A)	   B)	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follow-­‐through,	  where	  contrast	  is	  ingested	  to	  view	  the	  bowel	  lumen,	  abnormalities	  in	  how	  the	  bowel	  peristalsis	  related	  to	  strictures	  has	  been	  described,	  although	  little	  in	   the	  way	  of	   published	  data	   exists	   on	   the	   topic	   [117].	  Anecdotally,	   the	   thickened	  strictured	   bowel	   was	   found	   to	   be	   hypo-­‐peristaltic,	   but	   pre-­‐stricture	   the	   (often)	  dilated	   bowel	   demonstrated	   variable	   altered	   motility	   being	   either	   greater	   or	  reduced	   compared	   to	   adjacent	   normal	   bowel[117].	   	   This	   perception	   has	   been	  further	   reinforced	   by	   pre-­‐clinical	   studies	   in	   animals	   which	   have	   quantitatively	  demonstrated	  in	  both	  transient	  and	  longer-­‐term	  changes	  in	  motility(Prihoda,	  Flatt,	  &	   Summers,	   1984).	   Prihoda	  demonstrated	   in	   a	   canine	  model	   an	   acute	   increase	   in	  proximal	   small	   bowel	   motility	   when	   an	   obstruction	   was	   induced	   by	   inflating	   an	  intraluminal	   balloon,	   with	   an	   associated	   decrease	   in	   distal	   motility[118].	  Quantitative	  studies	  in	  humans	  have	  however	  remained	  essentially	  absent	  from	  the	  literature	   for	   a	   number	   of	   reasons.	   Barium	   follow	   though,	   whilst	   an	   excellent	  technique	   for	   viewing	   the	   bowel	   lumen,	   is	   difficult	   to	   quantitate	   with	   a	   further	  reliance	  on	  ionising	  radiation	  that	  has	  increasingly	  mitigated	  its	  use	  in	  the	  modern	  clinic[51],	   [120].	  Traditional	  methods	   for	  evaluating	  motility	   including	  manometry	  are	  contraindicated	  due	  to	  the	  presence	  of	  obstruction	  and	  thus	  the	  investigation	  of	  this	  aspect	  of	  CD	  has	  remained	  largely	  neglected.	  	  	  This	  chapter	  investigates	  the	  functional	  dynamic	  motility	  data	  from	  a	  cohort	  of	  CD	  patients	   with	   sticturing	   disease	   and	   specifically	   to	   evaluate	   motility	   alteration	   in	  obstructed	   bowel.	   In	   the	   previous	   chapter,	   the	   data	   suggests	   that	   motility	   was	  inversely	   correlated	   with	   bowel	   wall	   thickness	   and	   therefore	   it	   is	   reasonable	   to	  hypothesise	   that	   the	   thickened	   bowel	   in	   strictures	   will	   almost	   certainly	   also	   be	  hypo-­‐motile.	  	  Of	  greater	  interest	  however	  is	  what	  happens	  immediately	  upstream	  of	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strictures	  in	  the	  dilated	  pre-­‐stenotic	  bowel	  and	  in	  regions	  of	  anatomically	   ‘normal’	  bowel	  to	  look	  for	  the	  first	  time	  at	  using	  MRI	  to	  investigate	  the	  impact	  of	  stricturing	  Crohns	  on	  small	  bowel	  motility.	  This	  retrospective	  investigation	  again	  had	  access	  to	  UCLH’s	   small	   bowel	   MR	   database	   and	   therefore	   also	   had	   the	   opportunity	   to	  investigate	   instances	   where	   patients	   returned	   to	   the	   clinic	   for	   follow-­‐up	   scans.	  Additionally,	   the	  opportunity	   to	   investigate	   temporal	  changes	  between	   individuals	  undergoing	  small	  bowel	  enterography	  was	  exploited.	  	  	  
4.2	  Methods	  
Patient	  cohort	  
	  A	  primary	  review	  of	  UCLH	  database	  (2008–2012)	  was	  undertaken	  to	  identify	  a	  list	  of	  patients	  fulfilling	  the	  study	  eligibility	  criteria	  of:	   i)	  previous	  clinical	  diagnosis	  of	  Crohn’s	  disease,	   ii)	  undergoing	  MR	  enterography	   (MRE)	  as	  part	  of	   routine	  clinical	  practice,	   including	   motility	   sequences	   (see	   below)	   and	   iii)	   the	   term	   ‘stricture’	  reported	  by	  the	  reviewing	  radiologist	  at	  the	  time	  of	  scan.	  	  The	  MRE	  examinations	  from	  350	  identified	  patients	  were	  reviewed	  by	  a	  radiologist	  with	  4	  years	  experience	  of	  reporting	  MRE	  (Dr	  Emma	  Helbren)	  to	  identify	  those	  with	  a	  true	  small	  bowel	  stricture.	  For	  the	  purposes	  of	  the	  current	  study,	  a	  stricture	  was	  defined	   as	   a	   focal	   reduction	   in	   small	   bowel	   luminal	   calibre	  with	   associated	  bowel	  wall	   thickening	   and	   an	   appreciable	   increase	   in	  diameter	   of	   the	   calibre	  of	   the	  pre-­‐
	  	   116	   	  
	   	  
stricture	  bowel	  compared	  to	  normal	  bowel	  diameter.	  This	  review	  identified	  a	  cohort	  of	  130	  potentially	  eligible	  patients.	  	  A	  further	  25	  were	  excluded	  where	  the	  dynamic	  sequence	  did	  not	  adequately	  include	  the	  stricture	  site,	  or	  the	  breath-­‐hold	  was	  inadequate	  for	  the	  assessment	  of	  stricture	  motility.	  Finally	  a	   further	  14	  were	  excluded	  after	  review	  of	  clinical	   records	   if	   they	  were	   taking	   medication	   known	   to	   affect	   bowel	   motility	   (notably	   corticosteroids,	  butylscopolamine	   and	   opioids).	   The	   final	   cohort	   consisted	   of	   91	   patients	   (median	  age	  36,	  range	  18	  to	  88,	  37	  male).	  The	  median	  disease	  duration	  was	  11	  years	  (range	  0	   to	  42),	  40	  had	  undergone	  surgical	   resection;	  72	  where	  on	  one	  or	  more	  disease-­‐specific	  medication.	  The	  specifics	  of	  these	  data	  are	  summarised	  in	  Table	  4.1.	  	  	  Forty-­‐one	  of	  the	  91	  patients	  had	  2	  or	  more	  MRE	  examinations	  during	  the	  period	  of	  data	  collection.	  Where	  patients	  had	  undergone	  multiple	  MRE	  examinations	  over	  the	  time	  period	  the	  examination	  that	  best-­‐displayed	  stricture	  on	  the	  motility	  sequences	  was	  used	  for	  the	  primary	  analysis.	  However,	  MRE	  from	  chronologically	  later	  scans	  in	   the	  same	  patient	  were	  analysed	   if	   the	  same	  stricture	  could	  be	   identified	  on	   the	  follow	  up	  MRE	  (eg	  had	  not	  been	  surgically	  removed	  or	  inadequately	  covered	  by	  the	  motility	  sequence).	  Overall,	  the	  follow-­‐up	  MRE	  was	  analysed	  in	  a	  total	  of	  21	  patients	  (median	  age	  34,	  9	  male).	  The	  mean	  between	  the	   initial	  and	  follow	  up	  scan	  was	  14	  months.	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Parameter	   Number	  of	  Patients	  
Disease	  Diagnosis	   	  	  Less	  than	  1	  year	   12	  Between	  1	  and	  5	  years	   10	  Between	  5	  and	  10	  years	   18	  Over	  10	  years	   51	  
Medication	  at	  time	  of	  scan	   	  	  None	   22	  1	  agent	   31	  2-­‐4	  agents	   21	  more	  than	  4	  agents	   17	  
Surgical	  history	   	  	  No	  surgical	  history	   52	  1	  operation	   26	  2	  Operation	   13	  
Disease	  Distribution	   	  	  Ileo-­‐colonic	  (2)	   55	  Ileal(3)	   33	  Other	  small	  bowel(4)	   1	  	   	  	   	  	  
Table	  4.1	  Patient	  demographics	  for	  primary	  cohort	  of	  91	  subjects.	  	  	  
MRI	  Protocol	  
	  During	   the	   4	   year	   time	   period,	   UCLH	   introduced	   a	   3T	   MRI	   system	   alongside	   its	  existing	  1.5T	  MRI	  scanner.	  Consequently,	  of	  the	  91-­‐subject	  cohort,	  84	  were	  imaged	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on	   a	   1.5T	   MRI	   (Siemens	   Avanto	   system	   (Siemens,	   Erlangen,	   Germany)),	   and	   7	  patients	   on	   a	   Philips	   Achieva	   3T	   MRI	   scanner	   (Philips	   Healthcare,	   Netherlands).	  Patients	  were	  prepared	  using	  the	  same	  protocol	  across	  both	  scanners	  as	  per	  chapter	  2.2.2.	   The	   dynamic	   sequences	   acquired	   at	   3T	   used	   the	   following	   parameters	   flip	  angle	  45,	  TR	  =	  1.96ms,	  TE	  =	  0.98ms,	  200x167	  matrix	  filling,	  zero-­‐filling	  to	  512x512,	  1x1mm	  in	  plane	  resolution,	  10mm	  slice	  thickness	  and	  1	  second	  temporal	  resolution.	  
	  
Motility	  assessment	  	  	  All	   images	  were	  registered	  as	  per	  chapter	  2.2.4	  with	  the	  standard	  deviation	  of	   the	  Jacobian	  determinant,	   averaged	  under	   a	  ROI	   again	  used	   as	   the	  motility	  metric	   for	  this	  study.	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Figure	   4.2	   A)	   ROI	   placement	   in	   the	   normal,	   unaffected	   pre-­‐stricture	   bowel	   (green	  
line),	  in	  the	  pre-­‐stricture,	  dilated	  bowel	  (yellow	  line)	  and	  at	  the	  stricture	  (red	  line).	  All	  
ROIs	  were	   placed	   serosa	   to	   serosa	   as	   opposed	   to	   lumen	   to	   lumen	   in	   contrast	   to	   the	  
other	   chapters	   where	   line	   ROIs	   were	   placed	   within	   the	   bowel	   wall.	   B)	   The	  motility	  
score	   for	   each	   ROI	   was	   calculated	   by	   sampling	   the	   corresponding	   parametric	   SD	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A	  single	  observer	  (radiologist	  with	  5	  years	  experience	  of	  MRE	  E.	  Herlbren)	  placed	  a	  total	  of	  three	  regions	  of	  interest	  (ROIs)	  in	  order	  to	  quantify	  motility	  and	  small	  bowel	  diameter	   using	   the	   motility	   analysis	   software.	   All	   ROIs	   were	   linear	   and	   drawn	  perpendicular	  to	  the	  central	  axis	  of	  the	  bowel	  from	  serosa	  to	  serosa	  on	  the	  coronal	  image.	   Specifically,	   serosa-­‐serosa	   measurements	   were	   made	   as	   this	   made	  annotation	   of	   strictured	   bowel	   (where	   no	   lumen	   is	   present)	   possible	   and	  measurements	  methodologically	  consistent	  across	  the	  three	  ROIs.	  This	  differs	  from	  chapter	  2	  where	  line	  ROIs	  were	  placed	  lumen	  to	  lumen	  in	  morphologically	  normal	  bowel.	   The	   first	   region	   of	   interest	   was	   placed	   in	   a	   normal	   segment	   of	   bowel,	  proximal	  to	  the	  stricture	  and	  in	  the	  same	  anatomical	  region	  (eg.	  where	  the	  stricture	  was	  in	  the	  ileum)	  as	  the	  normal	  reference	  bowel	  was	  also	  drawn	  in	  the	  ileum.	  The	  second	   ROI	   was	   drawn	   across	   the	   immediate	   pre-­‐stricture	   bowel	   at	   the	   point	   of	  maximum	  dilatation	  across	   the	  cine-­‐loop.	  The	   third	  ROI	  was	  placed	  halfway	  along	  the	   total	   length	   of	   the	   strictured	   bowel	   (Figure	   4.2	   A).	   ROIs	   were	   automatically	  propagated	  through	  the	  20	  frame	  time	  series	  by	  the	  software	  algorithm.	  	  	  From	  each	  ROI,	  two	  numerical	  metrics	  were	  derived:	  	   1. Motility	   score	   in	   arbitrary	   units	   describing	   the	   motility	   of	   the	   underlying	  bowel	  beneath	  the	  region	  of	  interest	  (standard	  deviation	  of	  the	  determinant	  of	   the	   pixel’s	   Jacobian	   and	   expressed	   as,	   a	   motility	   score	   (SD	   Jacobian)	  (Figure	  4.2B).	  	  2. The	  maximum	  diameter	  of	  the	  bowel	  based	  on	  the	  length	  of	  the	  ROI.	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Patients	  with	  follow	  up	  scans	  
	  Where	   individuals	   had	   a	   follow	   up	  MRE	   fulfilling	   the	   eligibility	   criteria	   described	  above,	  the	  datasets	  were	  arranged	  into	  chronological	  order	  and	  ROIs	  duplicated	  as	  described	  above	  so	  that	  the	  same	  sections	  of	  bowel	  were	  examined	  across	  the	  two	  time	  points.	  	  Side	  by	  side	  comparison	  of	  all	  sequences	  from	  the	  initial	  and	  follow	  up	  MRI	  were	  utilised	  by	  the	  observer	  to	  facilitate	  this	  matching	  of	  ROI	  placement.	  	  
Statistical	  analysis	  	  The	   Shapiro-­‐Wilk	   test	   (α	   =	   0.5)	   was	   used	   to	   examine	   whether	   motility,	   and	  diameters	  adhered	  to	  a	  Gaussian	  distribution.	  Where	  non-­‐normality	  was	  observed,	  data	  was	  log-­‐transformed	  or	  non-­‐parametric	  tests	  were	  used.	  	  Quantitative	   differences	   in	   bowel	   diameter	   was	   assessed	   using	   repeat	   measures	  analysis	   of	   variance	   (ANOVA)	   with	   Tukey-­‐Kramer	   post-­‐hoc	   analysis	   as	   was	   the	  difference	  in	  bowel	  motility	  across	  the	  three	  locations	  with	  significance	  measured	  at	  P<0.05).	  	  	  Motility	  scores	  across	  the	  demographics	  (including	  disease	  duration,	  medication	  use	  and	   surgical	   history)	   were	   assessed	   for	   normality	   and	   evaluated	   using	   Kruskal	  Wallis	  testing.	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Relationships	  between	  the	  diameter	  and	  motility	  of	  the	  normal	  bowel,	  pre-­‐stricture	  dilatation	  and	  stricture	   itself	  was	  examined	  using	  Pearson’s	  correlation	  coefficient	  at	  a	  significance	  of	  P<0.05.	  	  	  For	   patients	   with	   follow	   up	   studies,	   the	   percentage	   change	   in	   motility	   and	  percentage	  change	  in	  diameter	  of	  the	  dilated	  bowel	  were	  calculated.	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4.3	  Results	  
4.3.1	   Size	   and	  motility	   differences	   across	   the	   stricture,	   dilatation	  
and	  normal	  bowel	  
	  The	  mean	   diameter	   of	   normal	   bowel,	   pre-­‐stricture	   dilation	   and	   stricture	   site	  was	  20mm	   (range	   12	   to	   38mm),	   30mm	   (range	   14	   to	   104mm)	   and	   15mm	   (range	   5	   to	  34mm)	  respectively.	  Analysis	  with	  repeat	  measures	  ANOVA	  revealed	  an	  F-­‐statistic	  of	  112.91	  with	  P<0.001.	  Post	  hoc	  analysis	  suggested	  the	  mean	  diameter	  of	  the	  pre-­‐stricture	  bowel	  was	  significantly	  different	  to	  that	  of	  the	  normal	  and	  strictured	  bowel	  in	  this	  cohort	  (Figure	  4.3A).	  	  
	  Mean	  small	  bowel	  motility	   in	   the	  normal	  bowel	  was	  0.43A.U	   (range	  0.17	   to	  0.75),	  mean	   pre-­‐stricture	   bowel	   motility	   was	   0.28A.U	   (range	   0.3	   to	   0.95A.U)	   and	  mean	  stricture	  motility	  was	  0.15A.U	  (range	  0.02	  to	  0.71).	  Analysis	  with	  repeat	  measures	  ANOVA	  revealed	  an	  F-­‐statistic	  of	  101.6	  with	  P<0.0001.	  Post	  hoc	  analysis	  suggested	  mean	  motility	  in	  the	  three	  regions	  of	  bowel	  were	  statistically	  significantly	  different.	  	  
	  Motility	  scores	  across	  the	  cohort	  were	  stratified	  by	  disease	  duration,	  drug	  regimen	  and	   surgical	  history	   (grouped	  as	  per	   table	  4.1)	   and	  analysed	  using	  Kruskal-­‐Wallis	  testing	   after	   failing	   Shapiro-­‐Wilk	   test	   (α	   =	   0.5)	   normality	   test.	   No	   significant	  differences	  were	   found	  when	   stratifying	   the	   cohort	   into	   groups	   based	   on	   disease	  duration,	  medication	  or	  surgical	  history	  for	  motility	  score	  at	  the	  three	  bowel	  regions	  (Table	  4.3).	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Figure	  4.3.	  A)	  The	  serosa-­‐serosa	  diameter	  (mm)	  for	  the	  91	  subjects	  small	  bowel	  loops	  
across	   the	  normal,	  pre-­‐stricture	  and	  strictured	  bowel.	  B)	  Motility	   scores	  at	   the	   same	  
locations.	   Black	   box	   represents	   inter-­‐quartile	   range,	   red	   horizontal	   lines	   show	   data	  
median	  and	  dotted	  lines	  show	  data	  min/max	  limits.	  
	   	  Kruskal-­‐Wallis	  P	  value	  
Motility	  (AU)	   Normal	   Dilated	   Stricture	  
Disease	  
Duration	   0.71	   0.6	   0.46	  
Medication	   0.18	   0.51	   0.95	  
Surgical	  History	   0.32	   0.96	   0.62	  
	  
Table	   4.2.	   Patient	   motility	   stratified	   by	   demographics.	   Values	   represent	   P	   vale	   of	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4.3.2	  Relationship	  between	  pre-­‐stricture	  small	  bowel	  diameter	  and	  
motility	  	  
	  There	   was	   a	   strong	   negative	   correlation	   between	   pre-­‐stricture	   small	   bowel	  diameter	   size	   and	   motility	   with	   a	   Pearson’s	   correlation	   coefficient	   at	   -­‐0.47,	   P	   =	  <0.001.	  Raw	  data	  was	  non-­‐normal	  (α	  >0.05)	  and	  a	  log-­‐transformation	  was	  applied	  to	  normalise	  the	  distribution	  (i.e.	  make	  the	  data	  normally	  distributed)	  to	  make	  use	  of	  the	  more	  powerful	  parametric	  test.	  Thus	   in	  general	  the	  more	  dilated	  the	  bowel,	  the	  lower	  its	  motility	  (Figure	  4.4).	  A	  significant	  relationship	  was	  also	  found	  between	  stricture	   diameter	   and	   motility	   (R	   =	   -­‐0.42,	   P<0.001).	   No	   significant	   relationships	  were	  found	  within	  the	  normal	  bowel	  between	  motility	  and	  diameter.	  
Figure	  4.4	  A	  negative	  correlation	  was	  observed	  between	  normalised	  log-­‐
transformed	  pre-­‐stricture	  bowel	  diameter	  and	  motility	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4.3.3	  Changes	  in	  motility	  over	  time	  	  
	  21	  subjects	  underwent	  two	  scans	  (mean	  scan	  time	  between	  scans	  14	  months	  (range	  4	   to	   26	   months)).	   The	   mean	   percentage	   change	   in	   pre-­‐stricture	   bowel	   diameter	  across	   this	   cohort	   showed	   a	   decrease	   of	   7.8%	   (range	   -­‐56.6%	   to	   +62.5%)	   with	   a	  mean	   percentage	   motility	   change	   of	   -­‐58%	   (range	   -­‐625.0%	   to	   88.7%).	   There	   was	  again	   a	   negative	   correlation	   between	   the	   percentage	   change	   in	   diameter	   and	  motility	   (Spearman’s	   Rho	   coefficient	   of	   -­‐0.6,	   P	   =	   0.007).	   This	   suggests	   that	   as	   the	  pre-­‐stricture	  bowel	  diameter	  decreases,	  motility	  increases	  and	  vice	  versa	  suggesting	  reversibility.	  	  Analysis	  of	  the	  normal	  segment	  of	  bowel	  over	  the	  two	  time	  points	  as	  a	  comparison	  demonstrated	   a	   much	   smaller	   mean	   change	   and	   range	   in	   diameter	   change	  compared	   to	   the	   pre-­‐stricture	   bowel	   (mean	   decrease	   in	  motility	   of	   3.3%	   (range	   -­‐14.7%	  to	  +13.6%)	  (Figure	  4.5	  –	  green	  vs.	  red	  dots).	  Similarly	  the	  mean	  and	  range	  of	  motility	  change	  was	  smaller	  than	  in	  the	  pre-­‐stricture	  bowel	  (mean	  motility	  change	  11%	  (range	   -­‐47.2%	   to	  36.8%)	   (Figure	  4.5	  –	   green	  dots).	  There	  was	  no	   significant	  correlation	  between	  percentage	   change	   in	  diameter	   and	  motility	   in	   normal	   bowel	  (Spearman’s	  Rho	  of	  0.08	  P	  =	  0.94).	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Figure	   4.5	   Percentage	   change	   in	   motility	   plotted	   against	   percentage	   change	   in	  
diameter	  for	  normal	  bowel	  (green)	  and	  pre-­‐stricture	  bowel	  (red)	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4.4	  Discussion	  
	  The	  observation	  that	  intestinal	  obstruction	  leads	  to	  changes	  in	  contractile	  activity	  is	  well	  known.	  The	  vast	  majority	  of	  research	  into	  the	  effects	  of	  obstruction	  on	  bowel	  function	  has	  been	  conducted	   in	  animal	  models	  with	  relatively	   little	  data	   in	  patient	  cohorts,	   particularly	   those	   with	   Crohn’s	   disease	   related	   strictures.	   To	   our	  knowledge,	  this	  was	  the	  first	  study	  to	  systematically	  quantify	  regional	  small	  bowel	  motility	  using	  MRE	  in	  patients	  with	  stricturing	  Crohn’s	  disease.	  	  Data	   presented	   in	   this	   study	   suggested	   that	   motility	   within	   a	   stricture	   is	  significantly	   decreased	   in	   comparison	   to	   normal	   and	   the	   immediate	   pre-­‐stricture	  bowel.	  Crohn’s	  disease	  results	  in	  inflammatory	  and	  fibrotic	  infiltrate	  causing	  bowel	  wall	  thickening	  and	  it	  is	  intuitive	  that	  this	  should	  reduce	  local	  peristaltic	  activity	  and	  indeed	  evidence	  was	  presented	  in	  the	  previous	  chapter	  to	  support	  this	  (table	  3.5).	  Perhaps	   of	   more	   interest	   are	   the	   observations	   made	   on	   the	   pre-­‐stricture	   bowel.	  Such	  bowel	   is	   theoretically	  not	  directly	   involved	  with	   the	  Crohn’s	  disease,	  yet	  any	  disturbance	   in	   motility	   will	   add	   to	   the	   patient	   symptom	   load,	   and	   potentially	  influence	   the	   size	   of	   surgical	   resection	   if	   performed[50],	   [51].	   Here	   it	   was	  demonstrated	   that	   pre-­‐stricture	   small	   bowel	   has	   reduced	   motility	   compared	   to	  normal	   bowel	   and	   that	   this	   reduction	   is	   inversely	   correlated	   to	   its	   diameter	   for	  example	   the	  more	   dilated	   the	   bowel,	   the	   lower	   its	   contractibility.	   This	   raises	   the	  concept	   of	   bowel	   “failure”,	   where	   obstructed	   bowel	   undergoes	   compensatory	  dilation,	  which	  then	  produces	  ineffective	  and	  reduced	  motility	   if	   the	  obstruction	  is	  not	  relieved.	  A	  crucial	  question	  is	  whether	  this	  change	  is	  reversible?	  In	  the	  present	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cohort	   evidence	   was	   found	   supporting	   the	   potential	   reversibility	   of	   this	  phenomenon.	   In	   the	  21	  patients	  with	   follow	  up	  examinations,	   the	  diameter	  of	   the	  pre-­‐stricture	   bowel	   changed,	   and,	   importantly,	   as	   the	   bowel	   diameter	   reduced,	  motility	  increased.	  	  	  These	  data	  may	  have	  a	  physiological	  explanation	  based	  on	  the	  current	  literature.	  In	  a	   canine	   model	   Prihoda	   et	   al.	   induced	   acute	   small	   bowel	   obstruction[118]	   and	  observed	   an	   acute	   surge	   in	   intestinal	   motility	   in	   the	   immediate	   proximal	   bowel	  following	  balloon	  obstruction,	  followed	  by	  a	  decrease	  and	  stasis	  in	  the	  longer	  term.	  This	   reduction	   of	   motility	   mirrors	   our	   observations.	   However,	   stricture-­‐related	  obstruction	  in	  CD	  is	  an	  insidious	  process	  and	  a	  transient	  surge	  in	  motility	  is	  unlikely	  to	  be	  observed	  by	  chance	  in	  clinical	  practice.	  Thus,	  Prihoda’s	  observations	  could	  not	  be	   reproduced	   here.	   Shi	   et	   al.	   reported	   induction	   of	   COX-­‐2	   in	   response	   to	   stretch	  receptor	   activation	   in	   rats	   and	   that	   this	   acts	   as	   a	   direct	   inhibitor	   of	   bowel	  motility[113].	  This	  stretch-­‐receptor-­‐induced	  arbitration	  of	  motility	  could	  potentially	  serve	  as	  a	  protective	  measure	  where	  an	  obstruction	  is	  encountered,	  i.e.	  to	  decrease	  peristalsis	   in	   response	   to	   an	   obstruction	   rather	   than	   increasing	   pressure	   to	   the	  point	  that	  a	  rupture	  in	  the	  bowel	  wall	  might	  occur.	  It	  also	  could	  explain	  our	  finding	  that	   as	  pre-­‐stricture	  diameter	  decreases,	  motility	   increases.	  This	  dynamism	   in	   the	  motility	   at	   the	   pre-­‐obstructive	   bowel	   in	   relation	   to	   calibre	   may	   be	   of	   wider	  importance	   within	   the	   surgical	   setting.	   For	   example,	   dilated	   bowel	   resected	   at	  surgery	   due	   to	   presumed	   loss	   of	   function,	  may	   in	   fact	   be	   salvageable.	   Potentially	  valuable	  future	  studies	  might	  be	  conducted	  investigating	  this	  reversibility	  following	  therapeutic	  intervention	  using	  motility	  as	  a	  biomarker	  of	  response.	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The	  study	  does	  have	  limitations.	  By	  definition,	  the	  cohort	  likely	  included	  a	  range	  of	  inflammatory	   and	   fibrotic	   strictures	   and	   without	   histopathological	   correlation	   it	  was	  not	  possible	  to	  further	  investigate	  how	  the	  stricture	  type	  influences	  our	  motility	  changes.	   It	   does	   however	   raise	   the	   intriguing	   possibility	   that	   disease	   response	   to	  medication	   can	   be	   monitored	   by	   quantitative	   MRI	   motility	   measurements	   rather	  than	  subjective	  patient	   symptomatology.	   	  A	   range	  of	  disease	  chronicity,	   as	  well	   as	  patients	   with	   and	   without	   a	   surgical	   history,	   were	   included	   in	   this	   study,	  complicating	   the	   interpretation	  of	   the	   results.	  However,	   age,	  medications,	   surgical	  history	   and	   disease	   duration	   had	   a	   negligible	   effect	   on	   the	   results.	   Clearly,	  prospective	  studies	  are	  now	   indicated	   to	   investigate	   the	  use	  of	  MRI	   to	  predict	   the	  natural	   history	   of	   Crohn’s	   strictures	   and	   to	   evaluate	   follow	   up	   following	  medical	  interventions	   in	   comparison	   to	   conventional,	   endoscopic	   clinical	   and	   biological	  markers.	  The	  length	  of	  the	  stricture	  was	  not	  assessed	  in	  this	  study	  as	  the	  spatial	  and	  temporal	  gaps	  between	  the	  motility	  data	  sets	  made	  meaningful	  analysis	  of	  the	  data	  difficult	   especially	  where	   the	   stricture	   ran	   perpendicular	   to	   the	   imaging	   plane.	   In	  future	  studies,	  the	  length	  of	  the	  stricture	  and	  its	  global	  motility	  might	  be	  of	  further	  interest	   especially	   in	   conjunction	   alongside	   the	   concept	   of	   disease	   reversibility	   to	  allow	  more	  conservative	  and	  targeted	  resection	  of	  bowel.	   In	   this	  study,	  ROIs	  were	  placed	   serosa-­‐serosa	   across	   the	   three	   regions	   of	   bowel	   mainly	   to	   standardise	  measurements	  at	  the	  stricture,	  where	  the	  lumen	  could	  often	  not	  be	  seen.	  In	  practice,	  it	  was	  difficult	   to	  measure	   the	  bowel	   serosa	  of	   the	  morphologically	  normal	  bowel	  with	   high	   accuracy	   due	   to	   the	   difficulty	   of	   distinguishing	   the	   boundaries	   of	   the	  bowel	  wall	  (often	  1-­‐2	  pixels	  in	  thickness)	  due	  to	  the	  limited	  spatial	  resolution	  of	  the	  MR	   images.	  A	   final	  methodological	  point	   that	   is	  of	  key	   importance	   to	   this	   thesis	   is	  the	  identification	  of	  a	   ‘normal’	   loop	  of	  small	  bowel;	  several	  studies	  have	  suggested	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indirect	  effects	  of	  an	  inflammatory	  state	  on	  bowel	  motility	  and	  it	  would	  be	  naïve	  to	  assume	   anatomically	   normal	   bowel	   on	   MRI	   is	   entirely	   comparable	   to	   healthy	  controls.	   However,	   a	   clear	  mechanism	  with	   robust	   empirical	   evidence	   in	   humans	  has	  yet	  to	  appear	  in	  the	  literature	  [121].	  	  	  	  
Summary	  
	  The	  data	  presented	  in	  this	  chapter	  demonstrates	  clear	  differences	  between	  normal,	  strictured	   and	   pre-­‐stricture	   bowel	   in	   Crohn’s	   disease.	   Motility	   reduces	   with	  increasing	   small	   bowel	   dilatation	   but	   this	   process	   seems	   potentially	   reversible	   in	  some.	   As	   touched	   on	   in	   this	   chapter,	   one	   of	   the	   crucial	   issues	   that	   have	   made	  interpretation	   of	   the	   clinical	   findings	   challenging	   thus	   far	   is	   the	   absence	   of	   well-­‐characterised	  healthy	  individuals	  to	  which	  disease	  states	  can	  be	  compared.	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SECTION	   C:	   IDENTIFYING	   AND	   ADDRESSING	  LIMITATIONS	   IN	   SMALL	   BOWEL	   MOTILITY	  ASSESSMENT	  WITH	  MRE.	  	  
	  Section	   B	   demonstrated	   the	  way	   in	  which	   registration	   derived	  measures	   of	   small	  bowel	   motility	   could	   be	   used	   to	   investigate	   dysmotility	   in	   Crohn’s	   disease,	   a	  condition	  often	  characterised	  by	  a	  morphological	  change	  in	  the	  bowel	  wall	  anatomy	  driven	   by	   an	   inflammatory	   process.	   Importantly,	   this	   structural	   change	   is	  identifiable	  on	  imaging	  and	  the	  lesion	  was	  used	  in	  Chapters	  3	  and	  4	  to	  inform	  ROI	  based	   analysis.	   From	   a	   broader	   clinical	   perspective,	   many	   of	   the	   conditions	   that	  would	  potentially	  benefit	   from	  a	  diagnostic	   technique	   to	   evaluate	  motility	   are	  not	  defined	  by	  a	  discrete	  segmental	  abnormality,	  but	  rather	  affect	  global	  bowel	  motility	  as	   a	   whole.	   Indeed,	   a	   range	   of	   neuropathic	   and	   myopathic	   diseases	   (e.g.	  Parkinson’s),	   as	   well	   as	   idiopathic	   conditions	   such	   as	   irritable	   bowel	   syndrome	  (IBS),	   have	   apparently	   structurally	   normal	   bowel	   but	   are	   also	   likely	   to	   exhibit	  aberrant	  motility	  underlying	  at	  least	  some	  of	  their	  clinical	  manifestations.	  Following	  ethical	   approval	   for	   prospective	   investigation	   into	   healthy	   individuals,	   Section	   C	  aims	   to	   build	   on	   the	   previous	   chapters	   and	   investigate	   the	   concept	   of	   ‘normal	  motility’	   in	   healthy,	   well-­‐controlled	   subjects.	   Chapter	   5	   specifically	   addresses	  limitations	  in	  segmental	  forms	  of	  motility	  analysis	  with	  the	  central	  hypothesis	  being	  that	  variability,	  even	  within	  a	  healthy	  subject,	  is	  too	  high	  to	  allow	  inferences	  from	  a	  single	   bowel	   segment	   to	   be	  made	   in	   the	   absence	   of	   a	   discreet	   lesion.	   Chapter	   6	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introduces	   and	  details	   the	   validation	  of	   a	   novel,	   global	  method	   for	   the	   analysis	   of	  small	  bowel	  motility.	  By	  assessing	  global	  over	  segmental	  motility,	  it	  is	  hypothesised	  that	  inter-­‐scan	  variability	  within	  individuals	  is	  reduced	  and	  that	  this	  approach	  can	  be	  used	  to	  more	  robustly	  detect	  changes	  in	  motility	  following	  the	  administration	  of	  motility	  altering	  drugs	  against	  placebo.	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Research	  Question:	  What	  are	   the	  potential	  methodological	   issues	  arising	   from	  segmental	   (local	  bowel	  loop)	  ROI	  placement	  in	  small	  bowel	  motility	  analysis?	  	  
Rationale:	  Analysis	   of	   ‘cine’	   MRI	   using	   segmental	   ROIs	   has	   become	   increasingly	   popular	   for	  investigating	   bowel	   motility	   with	   a	   growing	   number	   of	   techniques	   now	   using	  metrics	  such	  as	   ‘contractions	  per	  minute’	   to	  describe	  small	  bowel	  motility	   in	  both	  health	  and	  disease.	  However,	  small	  bowel	  motility	  variation	  in	  normal	  subjects	  both	  within	   and	   between	   scans	   remains	   poorly	   described	   creating	   an	   important	  methodological	   consideration	   for	   quantitative	   investigation	   using	   gerneralsiations	  from	  segmental	  analysis	  as	  a	  study	  outcome.	  	  	  
Hypothesis:	  Small	  bowel	  motility	   is	  sufficiently	  heterogeneous	   in	  healthy	  subjects	  both	  within-­‐scan	  and	  between-­‐scan	  that	  segmental	  ROI,	  driven	  observations	  are	  not	  suitable	  in	  the	  absence	  of	  an	  overt	  lesion	  or	  anatomical	  landmark.	  	  	  
Aim(s):	  i)	  Examine	  intra-­‐scan	  variability	  of	  small	  bowel	  motility	  in	  healthy	  subjects	  ii)	  Examine	  inter-­‐scan	  variability	  of	  small	  bowel	  motility	  in	  healthy	  subjects	  iii)	  Compare	  two	  validated	  segmental	  motility	  metrics	  (Jacobian	  SD	  and	  CPM).	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5.1	  Introduction	  
	  Section	  B	  presented	  data	  exploring	  motility	  changes	   in	   the	  small	  bowel	  at	   specific	  locations	  along	  the	  bowel,	  the	  TI	  in	  Chapter	  3	  and	  surrounding	  a	  stricture	  in	  chapter	  4.	  This	  segmental	  form	  of	  analysis	  has	  become	  popular	  with	  other	  research	  groups	  with	   various	   examples	   of	   quantitative	   assessment	   of	   dynamic	   sets	   in	   a	   range	   of	  conditions,	   most	   notably	   inflammatory	   bowel	   disease	   and	   enteric	   dysmotility	  syndromes[15],	  [16],	  [76],	  [78],	  [121],	  [122].	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Despite	  a	  growing	  literature,	  consensus	  has	  yet	  to	  be	  reached	  or	  even	  suggested	  as	  to	  the	  best	  method	  of	  quantitatively	  analysing	  small	  bowel	  data	  and	  indeed	  a	  range	  of	   motility	   metrics	   are	   proposed	   summarised	   in	   table	   1.2	   [15],	   [16],	   [56]–[59],	  [123].	  The	  most	  commonly	  used	  metric	  is	  the	  change	  in	  luminal	  diameter	  at	  a	  fixed	  position	  through	  the	  time	  series.	  By	  plotting	  diameter	  against	  time,	  a	  characteristic	  curve	   can	   be	   produced	   with	   the	   number	   of	   contractions	   expressed	   per	   minute	  (CPM)	  giving	  an	  intuitive	  and	  broadly	  accepted	  metric	  for	  small	  bowel	  motility[15],	  [16],	   [56],	   [59],	   [76],	   [78],	   [121],	   [124].	   Indeed,	   several	   studies	   (including	   those	  detailed	  in	  section	  B)	  have	  reported	  a	  relationship	  between	  CPM	  and	  dysmotility	  in	  disease,	   either	   compared	   to	   a	   histopathological	   standard	   or	   ‘normal’	   reference	  bowel	  loops	  [15],	  [16],	  [58],	  [76].	  An	  array	  of	  additional	  metrics	  derived	  both	  from	  bowel	   diameter	   measures	   and	   more	   abstract	   processing	   techniques	   have	   further	  been	  implemented	  with	  varying	  degrees	  of	  effectiveness	  in	  disease	  and	  health	  [15],	  [55],	  [57],	  [64],	  [76],	  [121],	  [123].	  	  	  Although	   intuitively	  attractive,	   the	   robustness	  of	   assessing	  overall	   enteric	  motility	  using	  only	  an	   isolated	   loop	  of	  bowel	  has	  received	  relatively	   little	  attention	   to	  date	  irrespective	   of	   the	   precise	   metric	   applied.	   It	   is	   unclear	   how	   representative	   the	  selected	   bowel	   loops	   are	   of	   overall	   small	   bowel	   motility	   and	   if	   normal	   motility	  intrinsically	  differs	  between	  bowel	  segments,	  for	  example	  between	  the	  jejunum	  and	  ileum.	   Furthermore,	   the	   repeatability	   of	   single	   loop	   metrics,	   even	   in	   normal	  individuals,	  is	  not	  well	  described,	  knowledge	  of	  which	  is	  vital	  if	  segmental	  analysis	  are	   to	   be	   used	   to	   diagnose,	   guide	   treatment	   and	   monitor	   enteric	   pathology	   and	  make	  inferences	  on	  disease.	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The	  purpose	  of	  this	  study	  is	  to	  explore	  segmental	  variation	  in	  small	  bowel	  motility	  in	  healthy	  volunteers	  measured	  using	  two	  commonly	  reported	  small	  bowel	  metrics	  (Contractions	   per	   minute	   and	   Jacobian	   Standard	   Deviation	   (SD))	   looking	   at	   1)	  within	   scan	   motility	   variation	   between	   different	   segments,	   2)	   between	   scan	  variation	  (repeatability)	  across	  two	  time	  points.	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5.2	  Methods	  
5.2.1	  Patients	  	  20	  healthy	  volunteers	  (mean	  age	  28,	  range	  22	  to	  48,	  14	  Male)	  were	  recruited	  over	  an	   18-­‐month	   period.	   Each	   subject	   underwent	   a	   specific	   small	   bowel	   motility	  protocol.	   Inclusion	  criteria	   included	  ability	   to	  give	   informed	  consent,	  non-­‐smokers	  and	   abstinence	   from	   caffeinated	   and	   alcoholic	   drinks	   on	   the	   day	   of	   the	   scan.	  Exclusion	   criteria	   were	   any	   known	   chronic	   intestinal	   disease,	   any	   long–term	  medication	  excluding	   the	  oral	  contraceptive,	  self	   reported	  GI	  symptoms	  or	  history	  of	   GI	   surgery.	   Volunteers	   were	   recruited	   prospectively	   by	   advertisement	   and	  interview.	  	  	  
5.2.2	  Protocol	  	  Volunteers	  fasted	  for	  4h	  prior	  to	  ingesting	  1L	  of	  2%	  mannitol	  solution	  over	  the	  50	  minutes	  prior	  to	  the	  MRI	  scan.	  Locust	  bean	  gum	  was	  not	  used	   in	  this	  study	  nor	   in	  clinical	   practice	   at	   3T	   following	   a	   change	   in	   UCLH	   MRE	   protocols	   with	   no	  appreciable	  difference	  seen	   in	  scan	  quality,	  an	   improvement	   in	  patient	  acceptance	  and	  an	  operational	  cost	  saving.	  Subjects	   ingested	  the	  mannitol	  at	  regular	   intervals	  such	   that	   the	   last	   of	   the	   solution	  was	   consumed	   immediately	   before	   entering	   the	  scanner	  room.	  Subjects	  lay	  in	  the	  prone	  position	  and	  were	  scanned	  using	  a	  Philips	  Achieva	  3T	  Multi-­‐transmit	  MRI	  scanner	  (Philips	  Healthcare,	  Netherlands)	  using	  the	  manufacturer’s	  torso	  coil	  (XL-­‐TORSO).	  	  Each	  subject	  underwent	  planning	  sequences	  followed	   by	   a	   multi-­‐slice	   balanced	   turbo	   field	   echo	   (BTFE)	   motility	   sequence	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(coronal,	  2.5x2.5x5mm	  voxel	  size,	  FOV	  420x420x30mm,	  FA	  20	  degrees,	  TE=1.85ms,	  TR=3.7ms	  dual	  channel	  RF	  transmit	  with	  adaptive	  RF	  shimming),	  no	  slice	  gap	  with	  6	  slices	  in	  a	  volume.	  Each	  3cm	  block	  volume	  was	  acquired	  during	  a	  20	  second	  breath	  hold	  with	  temporal	  resolution	  of	  1	  volume	  per	  second	  (20	  time	  points	  acquired	  per	  breath-­‐hold).	   Blocks	   were	   acquired	   sequentially	   through	   the	   abdomen	   during	  repeat	  breath-­‐holds	  to	  cover	  the	  whole	  small	  bowel	  volume.	  The	  author	  selected	  the	  volume	  that	  best	  displayed	  the	  terminal	  ileum	  and	  data	  acquisition	  was	  extended	  to	  a	  1-­‐minute	  period	  of	  free	  breathing.	  The	  total	  scan	  duration	  was	  20	  mins	  with	  other	  anatomical	  and	  motility	  scans	  performed	  detailed	  in	  chapter	  6.2.	  	  	  	  
Figure	   5.1	  Positions	  of	   the	   four	  ROIs	   in	  quadrants	  1-­‐4	  with	   the	  TI	   in	  Q3	  along	  with	  
time	  series	  plots	  of	  line	  lengths	  for	  the	  respective	  quadrants	  	  	  Each	  volunteer	  underwent	  a	  second	  MR	  examination	  after	  a	  mean	  gap	  of	  4	  weeks	  (range	  2	  to	  7)	  using	  an	  identical	  preparation	  and	  MRI	  protocol.	  	  The	  time	  of	  day	  at	  
Q3	  
Q1	   Q2	  
Q4	  
Q1	   Q2	  
Q3	   Q4	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which	   time	   the	   second	   scan	  was	   undertaken	  was	  within	   1	   hour	   of	   the	   first	   in	   all	  cases.	  	  	  	  	  
5.2.3	  ROI	  placement	  	  The	  coronal	  cine	  blocks	  were	  divided	  into	  4	  quadrants	  (upper	  right	  (Q1),	  upper	  left	  (Q2),	  lower	  right	  (Q3),	  lower	  left	  (Q4)	  by	  placing	  2	  intersecting	  lines	  located	  at	  the	  mid	  point	  in	  the	  x	  and	  y	  direction	  respectively-­‐Figure	  5.1).	  	  	  
Figure	  5.2	  Repeat	  scans	  across	  two	  time	  points	  (A	  &	  B)	  with	  ROIs	   in	  each	  quadrant	  
indicated	   by	   red	   lines.	   Anatomical	   markers	   including	   the	   ileo-­‐caecal	   valve,	  
duodenojejunal	  flexure	  were	  used	  to	  aid	  ROI	  duplication.	  	  
	  
A)	   B)	  
Q1	   Q2	  
Q3	   Q4	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A	  radiologist	  with	  5	  years’	  experience	  of	  MR	  enterography	  (Dr.	  A.	  Plumb)	  reviewed	  all	  the	  cine	  blocks	  encompassing	  the	  small	  bowel	  volume	  and	  chose	  the	  single	  best	  block	  which	  included	  the	  terminal	  ileum	  in	  Q3,	  but	  also	  ensured	  a	  small	  bowel	  loop	  in	   the	   remaining	   3	   quadrants	   could	   be	   followed	   in	   its	   entirety	   throughout	   the	   20	  second	  time	  series	  (ie	  the	  loop	  was	  well	  distended	  and	  remained	  in	  plane	  on	  at	  least	  one	  of	   6	   slices	  within	   in	   the	  block).	   	   For	   each	   subject,	   the	   observer	   then	  placed	   a	  linear	  ROI	  across	  the	  bowel	  lumen,	  from	  serosa	  to	  serosa	  in	  a	  well-­‐distended	  loop	  in	  each	  of	  the	  4	  quadrants	  on	  the	  most	  appropriate	  slice	  in	  the	  block	  (Figure	  5.1).	  The	  Q3	   ROI	  was	   specifically	   placed	  within	   the	   last	   5cm	   of	   the	   terminal	   ileum	   (Figure	  5.1).	   	   The	   ROI	   was	   automatically	   propagated	   using	   the	   registration	   deformation	  fields	   across	   the	   20-­‐second	   time	   series.	   The	   observer	   then	  manually	   adjusted	   the	  length	  and	  exact	  position	  of	  each	  copied	  ROI	  to	  ensure	  it	  closely	  followed	  the	  lumen	  of	  the	  bowel	  loop	  over	  the	  20	  seconds	  of	  data	  acquisition.	  The	  process	  was	  repeated	  in	  the	  free	  breathing	  data	  with	  ROIs	  in	  each	  quadrant	  as	  described	  previously.	  	  The	   whole	   process	   was	   repeated	   for	   the	   second	   scan	   for	   each	   volunteer.	   The	  position	  of	  each	  of	  the	  4	  ROIs	  was	  replicated	  as	  far	  as	  possible	  by	  the	  observer	  (Dr.	  A	  Plumb)	  using	  knowledge	  of	  the	  location	  in	  the	  z-­‐axis	  of	  the	  first	  block	  together	  with	  visible	  anatomical	  landmarks	  (eg	  ileo-­‐caecal	  valve,	  DJ	  flexure	  etc)	  	  (Figure	  5.2)	  	  
5.2.4	  Motility	  analysis	  
	  
Contraction	  per	  minute	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The	   line	   length	   of	   each	   ROI	   was	   plotted	   against	   time	   to	   create	   a	   motility	   curve	  (Figure	  5.1).	  The	  mean	  ROI	  length	  was	  calculated	  and	  <	  10%	  mean	  length	  horizontal	  lines	  were	   indicated	  on	   the	  motility	   curve	  and	   small	  bowel	   contractions	  manually	  counted	  by	  the	  author.	  	  A	  small	  bowel	  contraction	  was	  recorded	  where	  there	  was	  a	  decrease	   in	   luminal	  diameter	  greater	  than	  10%	  of	  the	  mean	  small	  bowel	  diameter	  for	   the	   given	   time	   series[77].	   The	   contraction	   rate	  was	   expressed	   in	   contractions	  per	  minute	   (CPM)	   (scaled	   appropriately	   for	   the	   20	   second	   BH	   data).	   An	   example	  time	   series	   plot	   for	   each	   quadrant	   is	   provided	   in	   Figure	   5.1.	   Contractions	   were	  rounded	  to	  the	  nearest	  integer.	  	  
	  
Registration	  derived	  motility	  score	  
Again	  the	  SD	  Jacobian	  score	  was	  used	  as	  per	  chapter	  2.2.4	  
	  
Statistical	  analysis	  All	   data	   was	   assessed	   for	   normality	   using	   Shapiro-­‐Wilk	   testing	   (alpha	   P<0.5).	  	  Correlation	   between	   the	   two	   motility	   metrics	   was	   assessed	   using	   Pearson’s	  correlation	  in	  breath-­‐hold	  and	  free-­‐breathing	  data.	  	  The	  level	  of	  agreement	  between	  the	   two	   motility	   metrics	   in	   each	   of	   the	   four	   quadrants	   within	   a	   single	   scan	   was	  assessed	  using	  intra-­‐class	  correlation.	  	  For	   assessment	   of	   intra-­‐subject	   repeatability	   across	   the	   two	   scan	   times,	   the	   CPM	  and	  Jacobian	  SD	  for	  all	  4	  ROIs	  were	  assessed	  with	  Bland-­‐Altman	  limits	  of	  agreement	  adjusted	   for	   multiple	   observations	   per	   individual[125].	   This	   was	   performed	   for	  breath-­‐hold	  data	  and	  then	  repeated	  for	  the	  free	  breathing	  data.	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  All	  data	  collection	  and	  statistical	  analysis	  was	  performed	  using	  MATLAB.	  
5.3	  Results	  
	  All	  subjects	  achieved	  adequate	  distension	  of	  the	  small	  bowel	  to	  allow	  ROI	  placement	  in	  each	  of	  the	  4	  quadrants	  for	  both	  scans.	  	  	  
5.3.1	  Correlation	  between	  motility	  metrics	  
	  CPM	  and	   the	   Jacobian	  SD	  motility	  metric	  showed	  moderate	  positive	  correlation	   in	  both	   breath-­‐hold	   (Pearson	   R	   	   =	   0.42,	   p	   <0.001,	   Figure	   5.3A)	   and	   during	   free-­‐breathing	  	  	  (Pearson	  R	  =	  0.58,	  p	  <0.001,	  Figure	  5.3B).	  	  	  
	  
Figure	   5.3	   Correlation	   between	   contraction	   rate	   and	   SD	   Jacobian	  metric	   in	   breath	  
hold	  A)	  and	  free	  breathing	  B).	  
A)	   B)	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5.3.2	  Within-­‐scan	   intra-­‐subject	  variation	  between	  different	  bowel	  
segments	  	  
	  	  	  
BREATH	  HOLD	  
	  
FREE	  BREATHING	  	  	   Contractions	  Per	  Minute	  (CPM)	  
	  
	  	   Contractions	  Per	  Minute	  (CPM)	  	  	   Mean	   Range	   SD	  
	  
	  	   Mean	   Range	   SD	  Q1	   6	   0	  to	  15	   1	  
	  
Q1	   6	   1	  to	  13	   3	  Q2	   5	   0	  to	  12	   1	  
	  
Q2	   6	   1	  to	  11	   2	  Q3	  (TI)	   3	   0	  to	  9	   2	  
	  
Q3	  (TI)	   6	   0	  to	  10	   3	  Q4	   6	   0	  to	  12	   1	  
	  
Q4	   6	   1	  to	  10	   3	  
	   	   	   	   	   	   	   	   	  
	   	   	   	   	   	   	   	   	  
	   	   	   	   	   	   	   	   	  BREATH	  HOLD	  
	  
FREE	  BREATHING	  	  	   Motility	  AU	  (Jacobian	  SD)	  	  
	  
	  	   Motility	  AU	  (Jacobian	  SD)	  	  	  	   Mean	   Range	   SD	  
	  
	  	   Mean	   Range	   SD	  Q1	   0.29	   0.09	  to	  0.66	   0.1	  
	  
Q1	   0.38	   0.13	  to	  0.53	   0.1	  Q2	   0.32	   0.20	  to	  0.53	   0.15	  
	  
Q2	   0.37	   0.24	  to	  0.62	   0.1	  Q3	  (TI)	   0.21	   0.05	  to	  0.51	   0.12	  
	  
Q3	  (TI)	   0.29	   0.15	  to	  0.49	   0.1	  Q4	   0.27	   0.06	  to	  0.47	   0.1	  
	  
Q4	   0.37	   0.18	  to	  0.63	   0.13	  
	  
	  
Table	   5.1	   Summary	   data	   for	   intra-­‐scan	   variation	   across	   breath	   hold	   and	   free	  
breathing	  protocols	  (left	  and	  right)	  using	  the	  two	  metrics	  (top	  =	  contractions,	  bottom	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Breath	  hold	  results:	  The	   CPM	   and	   Jacobian	   SD	  mean,	   range	   and	   standard	   deviation	   for	   each	   of	   the	   4	  quadrants	  is	  summarised	  in	  table	  1.	  	  Assessment	  with	  intra-­‐class	  correlation	  in	  	  
	  
Figure	   5.4	  Raw	  data	  plots	   for	   each	   subject	  where	   ‘purple	   circles’	   represent	  Q1,	   ‘red	  
stars’	  Q2,	  ‘black	  diamonds’	  Q3	  (TI)	  and	  ‘blue	  squares’	  Q4.	  Contraction	  rates	  in	  breath-­‐
hold	  and	  free-­‐breathing	  are	  shown	  in	  A	  &	  B	  with	  respective	  plots	  for	  Jacobian	  SD	  in	  C	  
&	  D.	  	  	  breath	   hold	   data	   demonstrated	   an	   R-­‐coefficient	   of	   0.06,	   p	   =	   0.1.	   Individual	   data	  points	  for	  each	  subject	  are	  presented	  in	  Figure	  5.4A	  &	  C.	  Similar	  assessment	  of	  the	  
A)	   B)	  
C)	   D)	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SD	  Jacobian	  motility	  metric	  demonstrated	  a	  significant	  but	  weak	  ICC	  R-­‐coefficient	  	  =	  0.2,	   p	   =	   0.027	   (Figure	   5.4C).	   These	   data	   broadly	   suggests	   high	   variation	   in	   both	  contraction	  rate	  and	  motility	  score	  between	  quadrants	  in	  the	  same	  individual.	  	  	  For	  example	  the	  CPM	  variation	  within	  volunteer	  13	  was	  0	  CPM	  in	  Q2	  and	  12CPM	  in	  C4	  while	  the	  total	  range	  across	  the	  cohort	  in	  CPM	  was	  0	  to	  15CPM.	  Similarly	  for	  the	  Jacobian	  SD	  metric,	  subject	  2	  had	  motility	  values	  in	  Q2	  of	  0.15AU	  and	  0.55AU	  in	  Q1	  while	  the	  range	  across	  the	  cohort	  was	  0.05	  to	  0.66.	  	  	  
Free	  breathing	  results	  The	  mean,	  range	  and	  standard	  deviation	  of	  each	  quadrants	  contraction	  rate	  over	  the	  60s	  free	  breathing	  period	  is	  summarised	  in	  table	  1.	  	  Individual	  data	  points	  for	  each	  subject	  are	  presented	  in	  Figure	  5.4	  (B&D).	  	  In	  general	   the	  magnitude	  of	  CPM	  was	  similar	   to	   that	  acquired	  during	  a	  20	  second	  breath-­‐hold	  (table	  1),	  although	  the	  variation	  within	  individuals	  was	  reduced	  (Figure	  5.4	   B&D).	   	   Notably	   with	   the	   intra-­‐class	   correlation	   demonstrated	   a	   marginally	  increased	  and	  significant	  R-­‐coefficient	  of	  -­‐0.26,	  p	  =	  0.05.	  	  The	  result	  for	  the	  Jacobian	  motility	  metric	  remained	  similar	  with	  a	  weakly	  significant	  R	  co-­‐efficient	  of	  0.19,	  p	  =	  0.03.	   In	   the	   breath	   hold	   data,	   there	   was	   high	   variation	   between	   quadrants	   in	  individual	  volunteers.	  For	  example	  subject	  one	  had	  Q3	  and	  Q4	  motility	  of	  0.13	  and	  0.58AU	  while	   the	  max	  and	  min	  motility	  across	   the	  cohort	   ranged	  between	  0.13	   to	  0.62AU.	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5.3.3	  Within-­‐subject	  repeatability	  between	  different	  time	  points	  
	  
Breath	  hold	  results	  Across	   all	   ROIs	   in	   all	   subjects,	   the	  mean	   CPM	   at	   time	   point	   1	  was	   6	   contractions	  (range	  0	  to	  15)	  and	  mean	  CPM	  at	  time	  point	  2	  was	  6	  contractions	  (range	  0	  to	  13).	  Bland-­‐Altman	   limits	   of	   agreement	   for	   repeat	   measures	   demonstrated	   a	   mean	  difference	  of	  0	  contractions	  with	  a	  LoA	  of	  ±	  8	  contractions	  (Figure	  5.5a)	  suggesting	  relatively	  poor	  repeatability	  of	  CPM	  across	  time	  for	  matched	  segments.	  	  Using	  the	  Jacobian	  SD	  metric,	  mean	  motility	  score	  at	  time	  point	  1	  was	  0.28AU	  (range	  0.05	  to	  0.66)	  and	  mean	  motility	  at	  time	  point	  2	  was	  0.26AU	  contractions	  (range	  0.07	  to	   0.63).	   Bland-­‐Altman	   limits	   of	   agreement	   for	   repeat	   measures	   demonstrated	   a	  mean	  difference	  of	  0.01	  contractions	  with	  a	  LoA	  of	  ±	  0.32	  contractions	  (Figure	  5.5c)	  suggesting	  again	  a	  large	  source	  of	  intra-­‐subject	  variability.	  
	  
Free	  breathing	  results	  Mean	  contraction	  number	  at	   time	  point	  1	  was	  6	   contractions	   (range	  0	   to	  13)	   and	  mean	  contraction	  at	  time	  point	  2	  was	  6	  contractions	  (range	  0	  to	  11).	  Bland-­‐Altman	  limits	   of	   agreement	   for	   repeat	   measures	   demonstrated	   a	   mean	   difference	   of	   1	  contraction	  with	  a	  LoA	  of	  ±6	  contractions.	  (Figure	  5.5b),	  suggesting	  relatively	  poor	  repeatability	  of	  CPM	  across	  time.	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Using	   the	   Jacobian	   (SD)	   metric,	   mean	  motility	   score	   at	   time	   point	   1	   was	   0.35AU	  (range	   0.05	   to	   0.63AU)	   and	   mean	   CPM	   at	   time	   point	   2	   was	   0.34AU	   contractions	  (range	   0.13	   to	   0.69AU).	   Bland-­‐Altman	   limits	   of	   agreement	   for	   repeat	   measures	  demonstrated	   a	   mean	   difference	   of	   0.01	   AU	   with	   a	   LoA	   of	   ±	   0.32	   contractions	  (Figure	  5.5d)	  suggesting	  a	  large	  source	  of	  intra-­‐subject	  variability.	  	  
	  
Figure	  5.5	  Bland-­‐Altman	  limits	  of	  agreement	  (LoA)	  adjusted	  for	  repeat	  observations	  
per	   individual,	   for	   contraction	   rate	   in	   breath-­‐hold	   and	   free	   breathing	   (A	   &	   B).	  
Respective	  motility	  scores	  with	  Jacobian	  SD	  metric	  (C	  &	  D).	  	  
A)	   B)	  
C)	   D)	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5.4	  Discussion	  
	  The	  purpose	  of	  this	  chapter	  was	  to	  examine	  the	  variation	  of	  segmental	  small	  bowel	  motility	  in	  a	  cohort	  of	  20,	  well-­‐controlled,	  healthy	  volunteers.	  These	  data	  show	  that	  large	  variation	  in	  segmental	  motility	  within	  the	  same	  individual	  was	  demonstrated	  both	  at	  different	  small	  bowel	   locations	  and	  at	  the	  same	  location	  at	  different	  times.	  	  This	   raises	   important	   methodological	   limitations	   when	   performing	   segmental	  analysis	  of	  bowel	  motility,	  regardless	  of	  the	  metric	  used.	  	  Through	   employing	   both	   breath-­‐hold	   and	   free-­‐breathing	   protocols	   this	  investigation	  replicates	   the	  majority	  of	  study	  protocols	  described	   in	   the	   literature.	  	  Intuitively	   it	  might	  be	  presumed	   that	   free-­‐breathing	  data	   is	  better	   suited	   for	  CPM	  analysis	   as	   the	   longer	   period	   of	   data	   collection	  makes	   it	  more	   robust	   to	   potential	  transient	  surges	   in	  contractile	  activity[6],	   [34].	   Indeed	   there	  was	  evidence	   for	   this	  with	  longer	  acquisition	  times	  where	  there	  was	  decreased	  intra-­‐subject	  variance	  and	  an	   increased	   ICC.	   Nevertheless,	   even	   with	   60	   seconds	   of	   free	   breathing	   there	  remained	   large	   variation	   in	   the	   segmental	  motility	   across	   small	   bowel	   quadrants	  and	  between	  different	  scan	  times.	  	  	  With	   FB	   appearing	   superior	   for	   the	   CPM	   metric,	   BH	   studies	   might	   appear	  redundant.	  However	  there	  are	  several	  potential	  advantages.	  First,	  a	  20s	  breath	  hold	  is	   rapid	   and,	   if	   the	   aim	   is	   to	   sample	   the	   whole	   small	   bowel	   volume	   (requiring	  multiple	  acquisitions),	  a	  smaller	  scan	  time	  is	  preferable,	  particularly	  if	  implemented	  in	   clinical	   practice.	   Again	   from	   a	   practical	   perspective,	   the	   breath-­‐hold	   protocol	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reduces	  the	  data	  volume	  generated	  and	  allows	  more	  feasible	  analysis	  with	  manual	  quantitation	  or	  post-­‐processing.	  Furthermore,	  the	  anterior-­‐	  posterior	  displacement	  caused	  by	  the	  respiratory	  cycle	  can	  “remove”	  sampled	  small	  bowel	  loops	  for	  periods	  within	   the	   time	   series.	   Breath-­‐holds	   reduce/eliminate	   displacement	   caused	   by	  respiration	  which	  ensures	  any	  bowel	   loop	  can	  be	  sampled	  and	  not	   just	   those	  well	  seen	   throughout	   the	   time	   period,	   which	   may	   reduce	   sampling	   bias.	   Many	   MRI	  motility	  metrics	  have	  been	  developed	  to	  work	  over	   these	  shorter	   time	  periods	   for	  example	   contraction	   amplitude	   where	   only	   a	   single,	   well	   formed	   contraction	   is	  sampled	  independent	  of	  time	  assuming	  the	  scan	  is	  long	  enough	  to	  fully	  resolve	  one	  contraction	   [55],	   [76],	   [121].	  This	   study	  saw	  a	  negligible	   reduction	   in	  variance	   for	  the	  Jacobian	  SD	  metric	  between	  BH	  and	  FB	  protocols.	  For	  longer	  time	  periods,	  the	  Jacobian	  metric	  could	  be	  standardised,	  as	  the	  Contraction	  rate	  has	  been,	  to	  a	  period	  of	  one	  minute	  for	  example	  and	  is	  likely	  to	  represent	  the	  direction	  of	  future	  work.	  	  	  This	   study	   further	  aimed	   to	  examine	   the	   range	  of	  within-­‐subject	  motility	  during	  a	  single	  scan	  by	  placing	  a	  series	  of	  ROIs,	  one	  in	  each	  quadrant.	  The	  data	  showed	  that	  there	   was	   in	   fact	   large	   variation	  within	   the	   different	   segments	   of	   bowel.	   Further	  examination	   of	   the	   data	   graphically	   and	   visually	   confirmed	   the	   apparent	  heterogeneity	   of	   contractions	   through	   the	   bowel,	   raising	   an	   important	   point	   for	  further	  consideration.	   In	   several	   recent	   studies,	   subjective	   selection	  of	  bowel	   loop	  based	  on	  good	  distension	  has	  been	  performed	  and	  assumed	  to	  be	  representative	  of	  global	  motility,	   for	  example	  higher	  motility	   in	   this	   loop	  being	  attributed	   to	  a	  non-­‐diseased	   state[76],	   [78],	   [121].	   Across	   both	   BH	   and	   FB	   the	   results	   suggested	   that	  many	   of	   the	   subjects	   possessed	   both	   relatively	   ‘hypo-­‐motile’	   and	   ‘hyper-­‐motile’	  segments	   based	   on	   both	   their	   CPM	   and	   Jacobian	   SD	   scores.	   This	   within-­‐subject	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heterogeneity	   presents	   a	   serious	   challenge	   to	   the	   persevering	   notions	   of	  hyper/hypo	  motile	  bowel	  derived	  from	  an	  analysis	  of	  limited	  small	  bowel	  loops.	  The	  fact	   that	   both	  metrics	   provided	   comparable	   ICC	   scores	   and	   spread	   of	   data	   values	  implies	   this	   reflects	   genuine	   physiological	   variability	   and	   is	   not	   particular	   to	   any	  specific	  metric.	  These	  results	  might	  further	  explain	  why	  relatively	  low	  motility	  was	  seen	  in	  CD	  patients	  in	  chapter	  3	  with	  no	  evidence	  of	  inflammatory	  activity.	  Although	  principally	  descriptive,	  these	  results	  may	  serve	  a	  role	  in	  determining	  study	  power	  in	  future	  investigations	  examining	  segmental	  dysmotility	  in	  health	  and	  disease.	  	  	  The	  final	  result	  presented	  in	  this	  study	  describes	  poor	  intra-­‐subject	  repeatability	  of	  the	  CPM	  and	  Jacobian	  SD	  metrics	  at	  time	  points	  on	  average	  4	  weeks	  apart.	  This	  held	  true	  for	  both	  breath-­‐hold	  and	  free-­‐breathing	  datasets.	  Indeed	  intra-­‐subject	  variation	  over	   time	   appeared	   similar	   in	  magnitude	   to	  between	   subject-­‐variation	   for	   several	  participants	   in	   the	   cohort.	   The	   study	   cohort	   was	   standardised	   for	   a	   number	   of	  factors	   that	   might	   affect	   small	   bowel	   motility	   with	   particular	   attention	   paid	   to	  preparation	  with	  oral	  contrast	  agent,	  caffeine	  and	  nicotine	   intake,	   time	  of	  day	  and	  ingestion	   of	  medication.	   One	   of	   the	   principal	   influencing	   factors	   for	   the	   variation	  might	   be	   variation	   in	   ROI	   placement	   between	   scans.	   Although	   care	   was	   taken	   to	  duplicate	  precisely	   the	  ROI	  position	  across	   the	  quadrants	   it	  was	   in	   fact	  difficult	   in	  the	   absence	   of	   in-­‐situ	  markers,	   to	   be	   certain	   of	   the	   exact	   location	   of	   the	   previous	  ROI.	  In	  this	  respect	  it	  was	  ensured	  that	  one	  ROI	  for	  each	  scan	  was	  placed	  within	  5cm	  of	   the	   terminal	   ileum	   where	   a	   high	   degree	   of	   certainty	   could	   be	   achieved	   with	  respect	  to	  the	  re-­‐positioning	  of	  the	  ROI	  later	  on.	  Even	  then,	  at	  the	  TI	  high	  variation	  was	   again	   observed	   between	   scans	   both	   during	   breath-­‐hold	   and	   free-­‐breathing	  across	  the	  two	  metrics.	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  With	  respect	  to	  limitations,	  60	  seconds	  of	  free	  breathing	  might	  still	  be	  argued	  to	  be	  too	   short	   a	   time	   to	   evaluate	  motility	  with	   respect	   to	   contractions	  per	  minute	   and	  extended	   free-­‐breathing	   studies	   should	   be	   conducted	   to	   evaluate	   the	   impact	   on	  repeatability	   and	   reproducibility	   of	   analysis.	   Another	   limitation	   lies	   in	   the	  assessment	   of	   only	   two	  metrics	   in	   this	   study	  with	   still	   no	   clear	   consensus	   for	   the	  usage	   of	   certain	   metrics,	   including	   mean-­‐diameter	   and	   contraction	   amplitude,	  established.	   	  Additionally,	  the	  cohort	  described	  in	  this	  study	  is	  relatively	  small	  and	  homogeneous	   in	   terms	   of	   age.	   A	   larger	   sample	   size	   would	   assist	   in	   the	   better	  characterisation	  of	  motility	  in	  healthy	  subjects	  using	  MRI.	   	  In	  this	  study,	  we	  used	  a	  3T	  MRI	  machine	  that	  provided	  a	  significant	  advantage	  over	  1.5T	  scanners	  in	  terms	  of	   spatial	   and	   temporal	   resolution.	   The	   registration	   algorithm	   is	   nevertheless	  designed	   for	   2D	   time	   series	   and	   therefore	   can	   still	   be	   performed	   at	   lower	   field	  strength	  so	   long	  as	   images	  of	  sufficient	  spatial	   resolution	  are	  obtained.	  The	  added	  value	   of	   volumetric	   sequences	  was	   convenient	   for	   this	   study	   as	   it	   allowed	   better	  bowel	  loop	  matching	  but	  remain	  of	  indeterminate	  value	  in	  wider	  practice.	  	  	  Whether	   or	   not	   segmental	  metrics	   are	   useful	   for	   the	   investigation	   of	   small	   bowel	  motility	   is	   unclear.	   Undoubtedly,	   where	   ROI	   placement	   can	   be	   guided	   by	   the	  existence	  of	  pathology	  (such	  as	  a	  stricture),	  segmental	  methods	  of	  analysis	  are	  valid	  and,	   as	   scanner	  hardware	   and	   software	   improves,	   this	   form	  of	   analysis	  will	   likely	  become	   increasingly	   valuable	   for	   the	   investigation	   of	   diseases	   affecting	   specific	  bowel	  segments.	  However,	  due	  to	  the	  apparent	  heterogeneity	  within	  normal	  bowel,	  great	  caution	  must	  be	  placed	  on	  inferences	  based	  on	  analysing	  subjectively	  placed	  segmental	  ROIs.	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Summary	  
	  MRI	  quantified	  normal	  segmental	  small	  bowel	  motility	  demonstrates	  wide	  variation	  across	   different	   locations	   within	   the	   small	   bowel,	   and	   in	   the	   same	   location	   at	  different	   time	   points.	   	   This	   presents	   an	   important	   limitation	   in	   the	   application	   of	  segmental	  analysis	  in	  the	  investigation	  of	  global	  dysmotility.	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Research	  Question:	  Can	   global	   small	   bowel	   assessment	   be	   used	   to	   provide	   robust,	   repeatable	   and	  sensitive	  measures	  of	  small	  bowel	  motility?	  
Rationale:	  The	   data	   in	   chapter	   5	   demonstrated	   the	   high	   variability	   in	   ROI	   based	   analysis	   of	  bowel	   loops	  regardless	  of	   the	  metric	  used	   largely	  due	  to	  the	  complexity	  of	   the	  gut	  and	   absence	   of	   anatomical	   landmarks	   to	   inform	   ROI	   placement.	   Diseases	   that	  feature	  dysmotility	  (Parkinson’s,	  diabetes,	  scleroderma,	  amyloidosis,	  IBS	  etc)	  often	  feature	  an	  anatomically	  normal	  bowel	  making	  segmental	  forms	  of	  analysis	  difficult	  to	   use	   in	   an	   unbiased	   fashion.	   The	   deformation	   fields	   generated	   through	   image	  registration	  have	   thus	   far	  been	  explored	  segmentally	  however	   this	  method	  can	  be	  expanded	  by	  placing	   larger	  ROIs	   to	  segment	   the	  entire	  small	  bowel,	  averaging	   the	  motility	  score	  to	  create	  a	  global	  metric	  describing	  motility.	  	  
Hypotheses:	  Global	  small	  bowel	  motility	  analysis	  can	  be	  used	  to	  provide	  quantitative	  measures	  of	  motility	  that	  are	  1)	  repeatable	  and	  2)	  sensitive	  to	  pharmacological	  stimuli.	  	  
Aim(s):	  i)	  Demonstrate	  global	  measures	  of	  SBM	  are	  reproducible	  between	  observers.	  	  ii)	   Global	  measures	   demonstrate	   good	   intra-­‐subject	   repeatability	   across	   two	   time	  points.	  	  iii)	   Demonstrate	   sensitivity	   of	   global	   measures	   to	   the	   drug	   provocation	   against	  placebo.	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6.1	  Introduction	  
	  Section	  B	  explored	  the	  practical	  application	  of	  image	  registration	  to	  quantify	  motion	  at	   fixed	   points	   along	   the	   bowel.	   This	   ‘segmental’	   form	   of	   analysis	   is	   useful	   for	  interrogating	  a	  specific	  pathology	  at	  a	  definable	  position	  and	  valuable	   for	  deriving	  real,	   physiological	   information	   in	   terms	   of	   contraction	   rates	   or	   amplitude	   to	  evaluate	   local	   motility.	   However,	   data	   from	   the	   previous	   chapter,	   demonstrated	  large	  variability	   in	  motility	  of	   anatomically	  normal	   small	  bowel	   scans	  making	   this	  selection	   of	   ‘healthy’	   bowel	   loops	   a	   key	   a	   major	   source	   of	   potential	   observer	   &	  conformation	  bias.	   Importantly	   from	  a	  clinical	  perspective,	  many	  of	   the	  conditions	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that	  would	  potentially	  benefit	   from	  a	  diagnostic	   technique	  to	  evaluate	  motility	  are	  not	   defined	   by	   focal	   enteric	   abnormality	   such	   as	   strictures.	   Neuropathic	   and	  myopathic	  diseases	  (e.g.	  Parkinson’s,	  diabetes,	  scleroderma,	  amyloidosis)	  as	  well	  as	  idiopathic	   conditions	   (IBS)	   have	   anatomically	   normal	   bowels	   making	   segmental	  forms	  of	  analysis	  likely	  limited	  in	  such	  disorders	  [24],	  [29]–[32].	  	  	  This	  chapter	  specifically	  focuses	  on	  the	  development	  of	  a	  quantitative	  technique	  to	  evaluate	  global	  small	  bowel	  motility	  with	  a	  view	  to	  the	  clinical	  investigation	  of	  pan-­‐gut	  dysmotility	  disorders.	   Chapter	  2	   introduced	   the	   analysis	   of	  deformation	   fields	  can	  be	  used	  to	  produce	  parametric	  motility	  maps	  that	  were	  used	  in	  chapters	  3	  &	  4	  to	   investigate	   individual	  bowel	   loops	  of	   interest.	  Here,	   this	  concept	   is	  expanded	  to	  delineate	   the	  whole	   small	   bowel	   and	   taking	   the	   average	   of	   the	   SD	   Jacobian	   score	  under	   the	   ROI(s).	   This	   study	   will	   also	   test	   the	   hypothesis	   that	   inter	   reader	  agreement	  will	  deteriorate	  when	  tasked	  with	  delineating	   the	  whole	  bowel	  volume	  when	  compared	  to	  interrogating	  a	  discrete	  loop	  only	  [59].	  	  The	  use	  of	  deformation	  fields	  as	  a	  surrogate	  for	  motility	  represents	  a	  novel	  method	  for	  describing	  bowel	  motion	  and	  as	  such,	  a	  direct	  comparison	  to	  a	  gold-­‐standard	  is	  very	   challenging.	   Manometry	   looks	   only	   at	   small	   regions	   of	   the	   bowel	   and	  scinitgiraphy	  examines	  transit	  time	  only	  as	  a	  surrogate	  for	  motility.	  A	  study	  protocol	  that	   could	   investigate	   the	   key	   attributes	   of	   the	   proposed	   method	   including	  sensitivity	   to	   pharmacological	   stimuli	   reproducibility	   and	   inter-­‐observer	  reproducibility	  of	  metrics	  was	  implemented.	  This	  study	  took	  the	  form	  of	  a	  placebo-­‐controlled	   crossover	   investigation	   in	   healthy	   individuals.	   The	   use	   of	   a	   crossover	  study	   allowed	   the	   examination	   of	   the	   magnitude	   of	   within-­‐subject	   variation	   in	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motility,	   one	   of	   the	   central	   tenets	   of	   a	   robust	   technique.	   Where	   all	   controllable	  environmental	   factors	  are	  maintained,	  a	  healthy	   individuals	  physiology	  be	   it	  heart	  rate,	  blood	  pressure	  or,	  in	  this	  case,	  bowel	  motility	  should	  stay	  the	  same.	  The	  study	  format	  also	  allowed	  administration	  of	  placebo-­‐controlled	  pro-­‐kinetic	  (neostigmine)	  and	   spasmolytic	   (butyscopolamine)	   agents	   to	   evaluate	   the	   techniques	   ability	   to	  quantitatively	  evaluate	  the	  effect	  of	  known	  motility	  influencing	  agents[126].	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6.2	  Materials	  and	  Methods	  	  
6.2.1	  Volunteer	  selection	  	  This	  study	  used	  the	  same	  healthy	  control	  cohort	  described	  in	  chapter	  5.2.1.	  Patients	  in	  the	  neostigmine	  arm	  of	  the	  study	  were	  checked	  for	  contraindications	  to	  the	  drug	  including	  asthma	  and	  cardiac	  history.	  	  
6.2.2	  Summary	  of	  Study	  design	  	  The	  design	  was	  a	  randomised	  subject	  and	  reader	  blinded,	  placebo-­‐controlled,	  cross-­‐over	   study	   that	   investigated,	  1)	   intra-­‐subject	   repeatability	  of	  motility	  measures	   in	  visits	   separated	   by	   a	   mean	   of	   four	   weeks	   (described	   in	   chapter	   5.2.1)	   and,	   2)	  sensitivity	   of	   the	   technique	   to	   pharmacologically	   induced	   changes	   in	   small	   bowel	  motility.	   Two	   parallel	   arms	   were	   conducted.	   In	   the	   first	   arm,	   volunteers	   were	  randomised	   between	   IV	   placebo	   and	   IV	   butylscopolamine	   (inhibitor	   of	   bowel	  motility).	   In	  the	  second	  arm,	  volunteers	  were	  randomised	  between	  IV	  placebo	  and	  IV	  neostigmine	   (pro-­‐kinetic	   agent).	   	  Drug/placebo	  order	  was	  given	  according	   to	   a	  randomisation	  block	  generated	  by	  the	  author.	  	  	  
6.2.3	  Sample	  size	  and	  power	  calculation	  	  A	   sample	   size	   calculation	   was	   performed	   based	   on	   examining	   the	   agreement	  between	   repeated	   measurements	   of	   baseline	   small	   bowel	   motility.	   Preliminary	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motility	  measurements	  on	  four	  patients	  undergoing	  MRE,	  as	  part	  of	  routine	  clinical	  care	   at	   our	   institution,	   were	   used	   to	   develop	   an	   understanding	   of	   the	   expected	  variation	   (Appendix	   2.1).	   It	   was	   postulated	   that	   baseline	   resting	   bowel	   motility	  should	   not	   vary	   by	   more	   than	   20%	   between	   MRI	   visits	   and	   that	   the	   difference	  between	  measurements	  would	  have	  a	  standard	  deviation	  of	  10%.	  	  A	  sample	  size	  of	  20	  volunteers	  was	  required	  to	  estimate	  subject	  variance	  to	  within	  7.5%	  of	  the	  true	  population	  value.	  	  	  In	  3	  patients,	  again	  with	  normal	  MRE	  findings,	  repeat	  motility	  scans	  before	  and	  after	  butylscopolamine	   revealed	   a	   mean	   decrease	   of	   50%	   in	   small	   bowel	   motility	  (Appendix	  2.2).	   	  From	  this,	   it	  was	  determined	  a	  sample	  size	  of	  11	  volunteers	  gave	  90%	   power	   at	   alpha	   0.05	   to	   detect	   a	   10%	   change	   in	   motility	   following	   drug	  administration,	   assuming	   a	   within-­‐subject	   standard	   deviation	   of	   10%,	   would	   be	  sufficient	  for	  this	  study.	  	  	  
6.2.4	  MR	  Protocol	  	  	  All	   subjects	   were	   prepared	   as	   per	   chapter	   5.2.	   For	   the	   purposes	   of	   drug	  administration,	  an	   intravenous	  cannula	  (22G,	   Introcan	  Safety,	  Braun)	  was	   inserted	  into	   an	   antecubital	   vein	   by	   the	   attending	   radiographer	   approximately	   15	  minutes	  before	  the	  scan	  start	  time.	  	  	  The	   motility	   scan	   protocol	   was	   designed	   to	   “cine	   capture”	   small	   bowel	   motility	  during	  a	  20	  second	  breath	  hold	  (temporal	  resolution	  1	  volume	  per	  second)	  and	  to	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encompass	   the	  majority	  of	   the	   small	  bowel	  volume	  within	   this	   single	  breath	  hold.	  Specifically,	  a	  3D	  Balanced	  Turbo	  Field	  Echo	  (BTFE)	  sequence	  was	  used	  to	  acquire,	  every	  second,	  a	  15cm	  (15	  x	  1cm	  slices)	  coronal	  volume	  through	  the	  abdomen	  and	  pelvis,	  repeated	  for	  20	  seconds	  (2.5x2.5x10mm	  voxel	  size,	  FOV	  420x420mm,	  FA	  20,	  TE=1.7ms,	   TR=3.5ms,	   SENSE	   (3LR,	   1.5AP),	   no	   slice	   gap,	   dual	   channel	  RF	   transmit	  with	   adaptive	   RF	   shimming).	   The	   cranio-­‐caudal	   location	   of	   the	   15cm	   volume	  acquisition	   was	   selected	   by	   the	   author	   using	   the	   sagittal,	   coronal	   and	   transverse	  axial	  planner	  scans	  to	  best	  cover	  small	  bowel	  volume.	  The	  most	  anterior	  portion	  of	  the	   block	   was	   positioned	   along	   the	   abdominal	   musculature	   on	   the	   sagittal	   view.	  Note,	  this	  sequence	  is	  different	  to	  that	  used	  in	  5.2.2.	  	  	  
6.2.5	  Drug	  administration	  	  Following	   acquisition	   of	   the	   baseline	   motility	   scan,	   volunteers	   in	   the	  Butylscopolamine	  arm	  (n=10)	  randomly	  received	  an	  IV	  10ml	  bolus	  of	  saline	  or	  10ml	  bolus	   of	   Butylscopolamine	   (containing	   a	   20mg	   dose,	   Boehringer,	   Ingelheim,	  administered	   by	   attending	   radiographer)	   through	   their	   venous	   catheter.	   An	  identical	   procedure	   was	   followed	   for	   those	   in	   the	   Neostigmine	   arm	   (n=11),	   with	  volunteer	   randomised	  between	  a	  10ml	   saline	  bolus	  or	  10ml	  bolus	  of	  Neostigmine	  (containing	   0.5mg	   Neostigmine	   Methylsulphate,	   Mercury	   Pharma,	   UK).	   Within	   2	  minutes	  of	  administration	  of	  the	  placebo	  or	  active	  drug,	  the	  cine	  motility	  sequence	  was	  repeated	  as	  described	  above.	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Figure	   6.1	   ROI	   placement	   and	  motility	   score	   extraction.	   	   A)	   The	  motility	   sequence	  
captures	  a	  15-­‐slice	  volume	  (six	  slices	  shown	  here)	  at	  a	  1	  second	  per	  volume	  temporal	  
resolution.	   This	   is	   repeated	   for	   20s	   in	   a	   breath	   hold.	   The	   small	   bowel	   is	   initially	  
manually	   segmented.	   B)	   Visualisation	   of	   the	   deformation	   field,	   produced	   by	   the	  
registration	   algorithm,	   as	   a	   deformation	   grid.	   As	   an	   illustration,	   where	   greater	  
movement	  of	  the	  underlying	  small	  bowel	  takes	  place,	  greater	  distortion	  occurs	  in	  the	  
grid.	   C)	   Analyses	   of	   the	   per-­‐pixel	   deformation	   grid	   as	   a	   parametric	   map	   with	   the	  
motility	  score,	  extracted	  as	  the	  mean	  pixel	  (SD	  Jacobian)	  value	  under	  the	  ROI.	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Each	  volunteer	  then	  re-­‐attended	  for	  a	  second	  MRI	  scan	  after	  a	  mean	  gap	  of	  4	  weeks	  (range	  2	  weeks	  to	  7	  weeks),	  no	  individual’s	  scan	  start	  time	  varied	  by	  more	  than	  1h	  between	  the	  two	  visits.	  Volunteers	  were	  prepared	  and	  examined	  in	  exactly	  the	  same	  way	  as	  previously	  except	  that	  the	  IV	  injection	  was	  crossed-­‐over	  so	  that	  placebo	  was	  given	  when	  they	  had	  previously	  received	  the	  drug	  and	  vice-­‐versa.	  	  
6.2.7	  ROI	  placement	  	  Two	   radiologists	   (Drs	   A.	   Plumb	   and	   A.	   Ahmed,	   each	  with	   a	  minimum	   four	   year’s	  experience	   of	   small	   bowel	   MRI)	   independently	   placed	   regions	   of	   interest	   (ROIs)	  around	   the	   small	   bowel	   included	   in	   each	   coronal	   slice	   over	   the	   15-­‐slice	   volume,	  using	  a	  MATLAB	  GUI.	  The	  author	   randomised	  presentation	  of	   the	  data	   sets	   to	   the	  readers,	   both	   between	   individual	   volunteer	   visits,	   and	   between	   baseline	  measurement	  and	  post	  drug/placebo	  measurement.	  	  	  The	   two	   radiologists	   drew	   a	   large	   region	   of	   interest	   on	   each	   coronal	   slice	   to	  encompass	  as	  much	  of	  the	  visualised	  small	  bowel	  volume	  as	  possible	  (Figure	  6.1A).	  	  Solid	  organs	  and	  the	  colon	  and	  stomach	  were	  excluded	  as	  were	  major	  blood	  vessels.	  Mesenteric	   structures	   between	   bowel	   loops,	   where	   present,	   were	   excluded	   also.	  Where	  necessary,	  more	  than	  one	  ROI	  was	  placed	  per	  slice	  to	  ensure	  the	  whole	  small	  bowel	  was	   included	   (Figure	  6.1).	   	   For	   each	  anatomical	   slice	  position,	   the	  ROI	  was	  automatically	   propagated	   through	   the	   20-­‐second	   time	   series	   by	   the	   software	  without	   the	  need	   for	   further	   adjustment.	  ROI	  placement	  was	   repeated	   for	   each	  of	  the	   15	   coronal	   slices	   where	   bowel	   was	   visualised.	   The	   motility	   score	   (AU)	   was	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derived	   and	   recorded	   for	   each	  ROI,	   and	   represented	   the	  mean	   of	   all	   the	   included	  pixels	   within	   the	   ROI	   (as	   this	   quantity	   is	   a	   mean	   over	   the	   ROI,	   it	   is	   relatively	  independent	   of	   ROI	   size).	   A	   global	   AU	   score	   of	   motility	   across	   the	   small	   bowel	  volume	  was	  then	  calculated	  by	  averaging	  all	  ROIs.	  	  	  
6.2.8	  Statistical	  analysis	  
	  Shapiro-­‐Wilk	  testing	  was	  used	  to	  determine	  normality	  of	  data	  for	  each	  stage	  of	  the	  analysis.	   Agreement	   between	   the	   two	   radiologists	   for	   measurement	   of	   volunteer	  mean	  motility	  score	  across	  all	  datasets	  was	  evaluated	  using	  the	  Bland-­‐Altman	  (BA)	  limits	   of	   agreement	   and	   intra-­‐class	   correlation.	   As	   multiple	   measurements	   were	  made	   in	   the	   same	   individual,	   limits	   of	   agreement	   were	   adjusted	   to	   take	   into	  consideration	   multiple	   within-­‐subject	   observations(1).	   The	   mean	   of	   the	   two	  readers’	   score	  was	   thereafter	   used	   as	   the	   ‘ground	   truth’	   global	  motility	   value	   for	  each	  individual	  volunteer	  scan.	  	  	  Intra-­‐subject	  agreement	  between	  baseline	  motility	  measurements	  was	  determined	  by	   calculating	   the	  mean	   difference	   and	   BA	   limits	   of	   agreement[125].	   The	  within-­‐subject	   coefficient	   of	   variation	   (wCV)	   was	   also	   calculated:	   wCV	   is	   computed	   via	  dividing	   within	   subject	   standard	   deviation	   (from	   one-­‐way	   ANOVA)	   by	   the	   group	  mean,	  multiplied	  by	  100.	  This	  gives	  a	  percentage	  that	  reflects	  repeatability,	  smaller	  scores	  reflecting	  greater	  repeatability.	  	  	  For	  each	  volunteer,	  the	  mean	  AU	  following	  active	  drug	  and	  placebo	  was	  compared	  using	  a	  paired	  t-­‐test.	  Baseline	  motility	  was	  compared	  to	  that	   following	  placebo	  for	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each	  volunteer	  using	  a	  paired	  t-­‐test	  to	  investigate	  any	  “placebo”	  response	  change	  in	  motility.	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6.3	  Results	  
6.3.1	  Inter-­‐observer	  agreement	  
	  Inter-­‐observer	   agreement	  was	   assessed	   in	   the	   neostigmine	   and	  Butylscopolamine	  group	   separately	  with	   four	  motility	   scores	  made	  per	  volunteer	   (two	  baseline,	   one	  post	   drug	   and	   one	   post	   placebo).	   In	   the	   Butylscopolamine	   group,	   the	   mean	  difference	   for	   the	  motility	   AU	   between	   the	   2	   observers	  was	   -­‐0.005	  with	   adjusted	  LoA	  ±0.02	  across	  motility	  AU	  ranging	  from	  0.06	  to	  0.395AU	  (Figure	  6.2A).	  The	  intra-­‐class	  correlation	  coefficient	  was	  0.98.	  The	  mean	  difference	  in	  the	  motility	  score	  (AU)	  between	  the	  two	  observers	  in	  the	  neostigmine	  group	  was	  -­‐0.005AU	  and	  the	  BA	  95%	  adjusted	  limits	  of	  agreement	  (LoA)	  were	  ±0.02	  across	  a	  range	  of	  values	  from	  0.245	  to	  0.435	  (Figure	  6.2B).	  	  
	  
Figure.	   6.2	   Bland-­‐Altman	   limits	   of	   agreement	   between	   observer	   1	   and	   observer	   2	  
motility	  scores	  in	  the	  Butylscopolamine	  (A)	  and	  Neostigmine	  (B)	  groups.	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6.3.2	  Intra-­‐subject	  variability	  	  One	   of	   the	   21	   volunteers	   (in	   the	   Butylscopolamine	   arm)	   failed	   to	   perform	   an	  adequate	   breath	   hold	   after	   drug	   administration	   affecting	   the	   motility	   score	  interpretation,	  and	  was	  excluded	  from	  the	  analysis.	  	  	  Baseline	   motility	   scores	   from	   the	   first	   scan	   attendance	   (mean	   score	   0.34,	   range	  0.28-­‐0.39)	  and	  second	  scan	  attendance	  (mean	  score	  0.34,	  range	  0.30-­‐0.40)	  is	  shown	  in	  6.3A.	  The	  mean	  difference	  between	  scans	  was	  0.0025AU	  with	  BA	  95%	  limits	  of	  agreement	   at	   ±0.044	   (Figure	   6.3B).	   Plotting	   the	   observed	   difference	   against	   the	  observation	  means	  revealed	  no	  trends,	  signifying	  measurement	  error	  was	  unlikely	  related	  to	  motility	  AU	  value.	  Within	  subject	  coefficient	  of	  variation	  was	  calculated	  at	  4.9%.	  	  
6.3.3	  Motility	  changes	  following	  Neostigmine	  	  
	  11	   subjects	   (9	   male,	   mean	   age	   27.6y)	   received	   Neostigmine	   and	   saline	   placebo	  (Figure	   6.4A).	   The	   mean	   motility	   following	   the	   administration	   of	   placebo	   was	  0.32AU	   (range	   0.25	   to	   0.35)	   and	   Neostigmine	   was	   0.39AU	   (0.32	   to	   0.44)	   with	   a	  mean	  group	  difference	  of	  0.07	  (95%	  CI	  =	  0.038	  to	  0.098,	  p	  <	  0.001)	  representing	  a	  22%	   increase	   in	   small	   bowel	   motility.	   Ten	   of	   11	   subjects	   showed	   an	   increase	   in	  motility	  after	  blinded	  Neostigmine	  administration.	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Figure	  6.3	  Baseline	  variability	  across	  two	  time	  points.	  A)	  Line	  plots	  for	  each	  of	  the	  20	  
volunteers	   showing	  global	  motility	  at	  baseline	  scan	  1	  and	  baseline	  scan	  2.	  B)	  Bland-­‐
Altman	   limits	   of	   agreement	   between	   baseline	   scans.	   Stars	   represent	   co-­‐incidental	  
observations,	  dots	  single	  observations.	  	  
6.3.4	  Motility	  changes	  following	  Butylscopolamine	  	  Nine	   subjects	   (4	   male,	   average	   age	   31.5y)	   were	   analysed	   (Fig.	   6.4B).	   The	   mean	  motility	   scores	   following	   administration	   of	   placebo	   and	   Butylscopolamine	   were	  0.30AU	  (0.20-­‐0.39)	  and	  0.13AU	  (0.06-­‐0.34)	  respectively,	  with	  a	  mean	  difference	  of	  0.17	   (95%	   CI	   from	   0.10	   to	   0.23,	   P	   <0.001)	   and	   representing	   a	   57%	   decrease	   in	  motility.	   All	   individuals	   showed	   a	   reduction	   in	   motility	   with	   blinded	  butylscopolamine	  administration.	  
A)	   B)	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Figure	  6.4	  Response	  to	  drug	  provocation.	  A)	  Line	  plot	  showing	  the	  change	  in	  motility	  
for	  11	  volunteers	  on	  Neostigmine	  arm	  of	  the	  trial	  and	  B)	   for	  the	  9	  volunteers	  on	  the	  
Butylscopolamine	  against	  placebo.	  	  
6.2.5	   Changes	   in	   small	   bowel	   motility	   from	   baseline	   following	  
placebo	  
	  Across	   the	   20	   volunteers	   mean	   baseline	   motility	   was	   0.33	   AU	   (0.26-­‐0.40)	   and	  following	  placebo	  decreased	   to	   0.30AU	   (0.19	   to	   0.39)	  with	   a	  mean	  difference	   of	   -­‐0.03	   AU	   (95%	   CI	   0.01	   to	   0.04),	   P=0.002.	   A	   significant	   increase	   in	   mean	   global	  motility	  persisted	  [0.39	  (0.32	  to	  0.44)]	  following	  Neostigmine	  even	  when	  compared	  to	   the	  pre-­‐neostigmine	  baseline	  scan	   [0.34AU	  (0.28	   to	  0.37)]	   for	   those	   individuals	  on	  that	  arm,	  mean	  difference	  +0.04AU	  (95%	  CI	  0.02	  to	  0.07	  p	  =	  0.0026).	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6.4	  Discussion	  
	  This	   study	   showed	   that	   a	   registration	   derived	   imaging	   surrogate	   for	   global	   small	  bowel	  motility	  based	  on	  MRI	  is	  both	  repeatable	  in	  normal	  subjects	  and	  sensitive	  to	  changes	   induced	   by	  medication	   that	   exerts	   known	  pharmacological	   effects	   on	   gut	  function.	  	  Assessment	   of	  within-­‐subject	   repeatability	   using	  Bland-­‐Altman	  plot	   demonstrated	  good	   within-­‐subject	   repeatability	   between	   time	   points	   with	   the	   mean	   difference	  between	   scans	   close	   to	   zero	   with	   narrow	   limits	   of	   agreement.	   Similarly,	   the	  coefficient	   of	   variation	   was	   low,	   at	   less	   than	   5%,	   suggesting	   low	   intra-­‐subject	  variation	   and	   simple	   subjective	   evaluation	   of	   the	   line	   plots	   revealed	   consistent	  motility	   scores	   for	   most	   participants	   across	   the	   two	   scan	   dates.	   Given	   the	   many	  factors	   that	   influence	   small	   bowel	   function,	   it	   was	   reassuring	   that	   similarity	  between	   subjects	   scanned	   at	   least	   2	   weeks	   apart	   could	   be	   seen	   using	   the	  standardised	   acquisition	  methodology	   and	   software.	   Standardising	   the	   acquisition	  methodology	   and	   software	   were	   likely	   key	   to	   this,	   with	   confounding	   factors	  including	   dietary	   (fasted	   state,	   limiting	   caffeine	   and	   nicotine	   intake)	   and	   diurnal	  ones	  (same	  afternoon	  time	  slot)	  well	  controlled	  here.	  A	  uniform	  oral	  preparation	  of	  mannitol	  was	  also	  used,	  both	  to	  control	  oral	  intake	  and	  to	  distend	  the	  small	  bowel	  in	  a	  predictable	   fashion.	  The	  technique	  was	  well	   tolerated,	  and	   is	  practical	   in	  clinical	  practice.	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Variation	   in	   baseline	   motility	   for	   three	   of	   the	   volunteers	   was	   relatively	   large	  compared	   to	   the	   rest	   of	   the	   cohort.	   One	   of	   these	   volunteers	   failed	   to	   perform	   an	  adequate	  breath	  hold	   and	  was	   excluded	   from	   the	   analysis	  presented.	   In	   the	  other	  two	  volunteers	  there	  was	  an	  apparent	  difference	  in	  mannitol	  distribution	  between	  the	   two	   scan	   attendances,	  with	   selective	   retention	  of	   contrast	  within	   the	   stomach	  (with	   an	   associated	   higher	   motility	   score,	   Figure	   6.5).	   This	   could	   be	   related	   to	  difference	  in	  gastric	  emptying	  times	  between	  the	  two	  visits,	  or	  on	  differing	  ingestion	  rates.	  Volunteers	  were	  instructed	  to	  ingest	  the	  contrast	  steadily	  over	  the	  50	  minutes	  before	   the	   scan	   but	   this	  may	   need	   to	   be	   standardised	  more	   thoroughly	   in	   future	  investigations.	  	  	  An	   interesting	  observation	  was	   that	  of	   a	   small	  but	   significant	  decrease	   in	  motility	  following	   administration	   of	   the	   saline	   placebo.	   Assuming	   this	   observation	  generalises	  from	  our	  relatively	  small	  cohort,	  it	  is	  possible	  that	  slowing	  was	  related	  to	  a	  combination	  of	  the	  volunteers’	  anticipation	  of	  receiving	  the	  injection,	  increasing	  familiarity	   to	   lying	   in	   the	   scanner	   or	   to	   the	   mannitol	   moving	   though	   the	   bowel.	  	  Alternatively,	   the	   placebo	   (saline)	   might	   precipitate	   a	   genuine	   parasympathetic	  response	   in	   small	   bowel	   motility	   and	   be,	   in	   itself,	   a	   method	   for	   provoking	   the	  autonomic	  nervous	   system	  with	  a	  potential	   value	   in	   function	   testing	   in	  a	   range	  of	  conditions	   featuring	   autonomic/enteric	   dysfunction.	   In	   any	   case,	   it	   should	   be	  considered	   in	   the	   design	   of	   future	   studies	   and	   a	   placebo	   should	   be	   used	   when	  investigating	   the	   effects	   of	   motility	   altering	   drugs	   using	   MR	   based	   techniques	   or	  where	  repeat	  measurements	  are	  made	  during	  a	  single	  scanning	  session.	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Figure	   6.5	   Two	   volunteers	   (A	   &	   B)	   with	   higher	   score	   variability	   between	   baseline	  
scans	   and	   large	   differences	   in	   mannitol	   distribution	   through	   the	   bowel	   (stomach	  
indicated	   with	   green	   arrow).	   Lower	   scores	   were	   observed	   where	   there	   was	   a	   low	  
stomach	  content	  of	  mannitol	  (A1	  &	  B1)	  compared	  to	  high	  mannitol	  content	  (A2	  &	  B2).	  	  The	   second	   aim	   of	   the	   study	   was	   to	   test	   the	   ability	   to	   detect	   changes	   in	   bowel	  motility	   induced	   by	   medication	   with	   known	   pharmacological	   effects	   on	   bowel	  function.	  Butylscopolamine	  relaxes	  enteric	  smooth	  muscle	  due	  to	  its	  antagonism	  of	  muscarinic	   receptors	   –	   it	   is	   routinely	   used	   in	   clinical	   practice	   to	   improve	   image	  quality	   during	   abdominal	   MRI.	   Gutzeit	   et	   al	   used	   segmental	   quantification	   of	  
	  	   174	   	  
	   	  
motility	   to	   show	   at	   least	   a	   50%	   decrease	   in	   segmental	   bowel	   motility	   following	  40mg	   in	   six	   volunteers.	   A	   single	   well-­‐displayed	   loop	   of	   small	   bowel	   was	   used	   to	  quantify	  motility	  by	  measuring	  cross	  sectional	  area	  change	  over	  time.	  In	  this	  study,	  20mg	   produced	   a	   strong	   and	   predictable	   anti-­‐kinetic	   effect,	   reducing	   motility	   by	  approximately	  56%.	  This	  is	  comparable	  to	  the	  effects	  described	  by	  Gutzeit,	  although	  my	   assessment	   reflected	  motility	   across	   the	  whole	   small	   bowel	   volume	   against	   a	  placebo	  control.	  	  	  Neostigmine	   was	   used	   to	   provoke	   motility,	   which,	   although	   not	   usually	  administered	   within	   the	   MRI	   scanning	   environment,	   has	   a	   demonstrated	  stimulatory	  effect	  in	  vivo	  (2-­‐5).	  Although	  2mg	  has	  previously	  been	  shown	  to	  exert	  a	  prokinetic	   effect	   in	   chronic	   intestinal	   pseudo-­‐obstruction,	   the	   chance	   of	   adverse	  effects	  were	  minimised	  by	  administering	   just	  0.5mg	  concordant	  with	   that	  used	  by	  Serrea	   et	   al.	   	   (2,	   6).	   At	   this	   dose	   a	   significant,	   detectible	   change	   in	   motility	   was	  observed	   with	   a	   22%	   increase	   compared	   to	   placebo.	   The	   stimulatory	   effect	  remained	  significant	  even	  when	  compared	   to	  baseline.	  Detection	  of	   such	  a	  change	  with	   a	   relatively	   small	   dose	   of	   Neostigmine	   suggests	   it	   could	   form	   a	   sensitive	  biomarker,	   although	   translation	   into	   clinical	   practice	   may	   need	   a	   larger	   dose	   to	  detect	  an	  abnormal	  or	  attenuated	  response	   in	  disease	  states.	  An	  interesting	  future	  research	  objective	  could	  be	  to	  develop	  alternative	  ways	  of	  provoking	  bowel	  motility.	  In	  this	  study,	  although	  no	  adverse	  events	  were	  seen	  in	  response	  to	  either	  drug,	  the	  safety	   requirements	   to	   administer	   neostigmine	   required	   a	   detailed	   history	   check	  and	  scan	  attendance	  by	  a	  gastroenterologist	  making	  this	  potentially	  challenging	  as	  part	   of	   clinical	   routine.	   In	   cardiac	   MR,	   numerous	   physical	   and	   pharmacological	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protocols	  have	  been	  developed	  and	  this	  might	  constitute	  an	  exciting	  future	  research	  project.	  	  A	   limitation	   is	   the	  movement	   of	   a	   bowel	   loops	   in	   the	   through-­‐slice	   direction	   (i.e.	  perpendicular	   to	   the	   imaging	   plane).	   The	   technique	   is	   relatively	   robust	   to	   this	  process	  because	  it	  is	  performed	  in	  breath	  hold	  using	  a	  1cm	  slice	  thickness	  with	  no	  slice	   gaps.	   Thus,	   bowel	   that	   transition	   between	   slices	   produces	   deformation	   field	  changes	   in	   each	   slice	   and	   these	   contribute	   to	   the	   score	   for	   the	   volume.	   A	   further	  limitation	  of	  the	  approach	  is	  the	  time	  required	  for	  analysis.	  Drawing	  the	  ROIs	  is	  time	  consuming,	   taking	   at	   least	   5mins	   per	   volume	   cumulatively	   up	   45	   minutes	   per	  patient	  when	  anatomy	  was	  complex.	  Variation	  due	  to	  differences	  in	  ROI	  placement	  may	   be	   another	   disadvantage,	   but	   in	   the	   study	   the	   two	   independent	   assessors	  showed	   narrow	   limits	   of	   agreement	   and	   a	   mean	   difference	   of	   just	   0.005AU.	   An	  additional	  limitation	  of	  the	  work	  relates	  to	  the	  fact	  that	  our	  study	  population	  were	  young,	   but	   there	   is	   no	   specific	   reason	   to	   expect	   that	   different	   results	   would	   be	  obtained	  in	  a	  more	  senior	  cohort	  adhering	  to	  the	  same	  protocol.	  	  The	   registration	   algorithm	   and	   analysis	   generated	   a	   unitless	   global	  motility	   score	  that	   served	   as	   a	   surrogate	   for	   small	   bowel	   motility.	   As	   seen	   in	   chapter	   2,	   the	  algorithm	  is	  “blind”	   to	   the	  source	  of	  physical	  deformation	   in	   the	  region	  of	   interest	  and	  careful	  segmentation	  helped	  exclude	  motion	  from	  other	  moving	  structures	  such	  as	  the	  aorta.	  The	  requirement	  for	  a	  20s	  breath-­‐hold	  acquisition	  protocol	  represents	  an	  additional	  limitation	  in	  this	  experiment.	  A	  breath-­‐hold	  protocol	  was	  nevertheless	  used	   principally	   due	   to	   the	   registration	   algorithm	   being	   unable	   to	   separate	  respiratory	  motion	  from	  that	  of	  the	  bowel	  wall	  with	  the	  potential	  to	  bias	  the	  motility	  
	  	   176	   	  
	   	  
score.	   This	   reliance	   on	   breath-­‐hold	   data	   might	   prove	   to	   be	   problematic	   where	  patients	  are	  unable	  to	  hold	  their	  breath	  or	  where	  longer	  time	  series	  are	  required	  to	  evaluate	  the	  varied	  facets	  of	  small	  bowel	  motility	  and	  indeed	  this	  will	  be	  explored	  in	  the	  next	  section.	  	  	  
Summary	  
	  In	   conclusion,	   registration	   quantified	   global	   small	   bowel	   motility	   captured	   using	  MRI	   in	   human	   volunteers	   shows	   good	   repeatability	   and	   can	   detect	   changes	   in	  motility	  induced	  by	  pharmacological	   intervention.	  In	  the	  next	  chapter,	  the	  reliance	  on	  breath-­‐hold	  protocols	  is	  addressed	  with	  a	  view	  to	  increasing	  the	  generalisability	  of	  this	  technique	  both	  to	  the	  small	  bowel	  and	  beyond.	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SECTION	   D:	   IMPLEMENTING	   NEW	   TECHNIQUES	   FOR	  SMALL	  BOWEL	  MOTILITY	  ASSESSMENT	  IN	  THE	  CLINIC	  	  
	  Section	  B	  presented	  data	  demonstrating	  a	  clear	  application	  for	  quantitative	  motility	  analysis	  using	  MRE	  and	  post	  processing.	  In	  Section	  C,	  limitations	  were	  highlighted	  in	  segmental	  methods	  of	  analysis	  along	  with	  a	  solution	  in	  the	  form	  of	  global	  analysis	  -­‐	  all	   of	   which	   was	   conducted	   in	   healthy	   well-­‐controlled	   volunteers.	   The	   subject	   of	  
Section	  D	   is	  a	   further	  extension	  to	  the	   image	  post-­‐processing	  to	  maximise	  clinical	  viability	   and	   explore	   the	   role	   of	   global	  motility	   in	   the	   assessment	   of	  motility	   in	   a	  prospective	   disease	   cohort.	   The	   healthy	   subjects	   used	   in	   section	   C	   tolerated	   the	  protocol	  well	  and	  were	  able	  to	  perform	  the	  breath-­‐hold	  required	  for	  global	  analysis.	  However,	  a	  practical	   limitation	  exists	  here	  where	  often	  severely	  ill	  patients	  cannot	  comply	  with	  this	  requirement	  potentially	  impacting	  on	  clinical	  value.	  	  Further,	  from	  a	   physiological	   perspective,	   many	   of	   the	   slower	   contractile	   actions	   in	   the	   small	  bowel,	  of	  interest	  to	  a	  clinical	  diagnosis,	  take	  place	  over	  minutes,	  clearly	  outside	  the	  scope	  of	  a	  breath-­‐hold	  protocol.	  	  	  In	  chapter	  7,	  a	  technique	  called	  Dual	  Registration	  of	  abdominal	  motion	  is	  validated	  in	  free-­‐breathing	  data	  sets	  as	  an	  additional	  means	  of	  investigating	  dynamic	  series	  in	  both	  small	  bowel	  and	  colonic	  datasets.	  Finally	  in	  Chapter	  8	  the	  global	  technique	  is	  applied	   to	   a	   cohort	   of	   Chronic	   Intestinal	   Pesudo-­‐Obstruction	   patients,	   a	   cohort	  characterised	  by	  dilated	  bowel	  and	   reduced	  motility.	  This	  patient	   cohort	  provides	  an	  ideal	  substrate	  for	  this	  work	  as	  a	  reduction	  in	  motility	  has	  been	  previously	  been	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demonstrated	   allowing	   here	   the	   demonstration	   of	   this	   techniques	   clinical	  applicability.	   Novel	   information	   will	   be	   further	   added	   to	   this	   area	   of	   research	  through	  administering	  neostigmine	  against	  placebo	  control	  to	  see	  what,	  if	  any,	  affect	  it	   has	   on	   small	   bowel	   motility,	   using	   the	   healthy	   cohort	   from	   chapter	   5	   as	   a	  comparison.	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CHAPTER	   7:	   DUAL	   REGISTRATION	   OF	   ABDOMINAL	  
MOTION	   TO	   QUANTIFY	   BOWEL	   MOTILITY	   IN	   FREE-­‐
BREATHING	  DATA	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Research	  Question:	  Can	   a	   pre-­‐registration	   respiratory	   motion	   correction	   step	   be	   used	   to	   extend	   the	  application	  of	  the	  optic-­‐flow	  technique	  to	  free	  breathing	  bowel	  motility	  data?	  	  	  	  
Rationale:	  A	  range	  of	  contractile	  actions	  take	  place	  in	  the	  bowel	  beyond	  local	  segmentation.	  In	  the	   colon	   especially,	   a	   single	   contraction	  might	   take	   place	   every	   several	   minutes	  making	   breath-­‐hold	   protocols	   unsuitable	   for	   the	   investigation	   of	   these	   studies.	   In	  addition,	  many	  patients	  are	  not	  capable	  of	  performing	  a	  breath-­‐hold	  and	  therefore	  overcoming	  the	  reliance	  on	  this	  protocol	  would	  represent	  an	  important	  advance	  for	  clinical	  application.	  	  	  
Hypothesis:	  Respiratory	  motion	  correction	  can	  be	  used	  prior	  to	  motility	  assessment	  to	  broaden	  the	  application	  of	  the	  optic-­‐flow	  registration	  technique	  in	  FB	  data.	  	  	  
Aim(s):	  i)	  Demonstrate	   registration	  accuracy	  against	  gold-­‐standard	   in	  FB	  small	  bowel	  and	  colon	  data.	  	  	  ii)	  Demonstrate	  comparability	  of	  parametric	  maps	  in	  BH	  and	  FB	  corrected	  data	  sets.	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7.1	  Introduction	  
	  This	   thesis	   has	   so	   far	   explored	   image	   registration	   as	   a	   means	   of	   generating	  surrogate	  measures	  of	  bowel	  motility.	  In	  each	  of	  the	  studies	  presented,	  the	  data	  has	  been	  acquired	  in	  breath	  hold	  principally	  to	  remove	  the	  affects	  of	  respiratory	  motion	  that	   would	   otherwise	   bias	  motility	   quantitation.	   Although	   the	   results	   have	   so	   far	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supported	  optic-­‐flow	  accuracy	  in	  correcting	   local	  deformation,	   it	   is	  of	  course	  blind	  to	  the	  source	  of	  deformation	  with	  organs	  such	  as	  the	  liver	  attracting	  a	  motility	  score.	  Optic-­‐flows	   restriction	   to	   breath-­‐hold	   limits	   application	   for	   important	   groups	   of	  pathological	   conditions	   where	   aberrant	   small	   bowel	   motility	   patterns	   take	   place	  over	  minutes	  or	  conditions	  which	  predominantly	  affect	  the	  colon	  where	  the	  period	  between	  peristaltic	  waves	  is	  longer	  than	  a	  breath	  hold	  duration.	  	  	  The	  purpose	  of	  this	  chapter	  is	  to	  explore	  a	  pre-­‐processing	  step	  to	  remove	  the	  effects	  of	  respiratory	  motion	  from	  the	  data	  before	  performing	  registration	  with	  optic-­‐flow.	  Although	   there	   are	   several	   potential	   methods	   to	   do	   this,	   the	   Centre	   for	   Medical	  Imaging	  at	  the	  time,	  exploring	  a	  new	  technique	  called	  Robust	  Principle	  Component	  Analysis	   (RPCA)	   that	   provided	   some	   interesting	   possibilities	   with	   respect	   to	   the	  processing	   time	   series	   data[127].	   RPCA	   is	   a	   modification	   of	   the	   widely	   used	  statistical	   procedure	   Principle	   Component	   Analysis	   (PCA)	   that	   addresses	   PCAs	  limitations	  with	  respect	   to	  grossly	  corrupted	  data.	  RPCA	   is	  a	   fascinating	  statistical	  tool	   and	   while	   an	   in	   depth	   discussion	   is	   outside	   the	   scope	   of	   this	   chapter,	   an	  introduction	   will	   be	   made	   here	   to	   illustrate	   how	   this	   chapter	   arrived	   at	   the	  technique	  as	  a	  means	  of	  differentially	  correcting	  respiratory	  motion.	  	  	  	  Let	  M	   be	   a	  matrix	  with	   each	   column	   constituting	   all	   the	   pixels	   from	   a	   2D	  matrix	  representing	  a	  single	  time-­‐point	  of	  a	  dynamic	  series.	  RPCA	  splits	  M	  into	  a	  low-­‐rank	  matrix	   (L)	   and	   a	   corresponding	   sparse	  matrix	   (S)	  with	   the	   sum	   of	   L	   and	   S	   being	  equal	  to	  the	  original	  matrix	  M.	  A	  regularization	  parameter	  lambda	  (λ)	  controls	  the	  weighting	  of	  the	  perturbation	  in	  the	  observed	  ‘corrupted’	  data	  and,	  in	  effect,	  serves	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as	  a	  trade-­‐off	  between	  the	  L	  and	  S	  components.	  For	  high	  lambda	  values	  all	  data	  will	  appear	  in	  L	  and	  conversely	  for	  low	  lambda	  values	  data	  will	  appear	  in	  S	  (Figure	  7.1).	  
	  
Figure	   7.1	   A	   corrupted	   matrix	   (M)	   is	   separated	   into	   low	   rank	   (L)	   and	   sparse	   (S)	  
components	  through	  selection	  of	  a	  suitable	  trade-­‐off	  parameter	  called	  lambda	  (λ).	  	  
	  The	   RPCA	   technique	   finds	   applications	   across	   computer	   science	   and	   one	   of	   best	  examples	  can	  be	  seen	  in	  CCTV	  footage	  of	  people	  standing	  in	  a	  foyer	  (Figure	  7.2A-­‐C).	  The	  decomposition	  of	  the	  time	  series	  results	  in	  the	  static	  features	  of	  the	  room	  (floor,	  desk	  etc)	  appearing	  in	  the	  low-­‐rank	  matrix	  and	  the	  people	  (dynamic	  content)	  in	  the	  sparse.	  This	  technique	  originally	  presented	  itself	  as	  a	  potential	  method	  to	  quantify	  bowel	   motility	   and	   application	   of	   the	   code	   to	   the	   motility	   series	   provided	   an	  interesting	   result,	   isolating	  bowel	  motility	   (sparse)	   from	   the	  static	   structure	   (low-­‐rank)	   after	   some	   empiric	   tuning	   of	   lambda	   (figure	   7.2D-­‐I).	   A	   more	   in	   depth	  investigation	   of	   this	   premise	   formed	   the	   MSc	   project	   for	   Pauline	   Ferry	   and	   an	  abstract	  can	  be	  found	  in	  the	  Appendix	  3.	  	  Although	  an	  interesting	  project,	  a	  number	  of	  limitations	  existed	  over	  its	  applicability	  as	   a	   competing	   technique	   to	   optic	   flow[57].	   First	   it	   did	   not	   provide	   deformation	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fields	   and	   so	   the	   ability	   to	   propagate	   ROIs	   through	   time	   series	   is	   lost.	   Second,	  although	   the	   motility	   maps	   RPCA	   produced	   looked	   reasonable	   and	   indeed	  corresponded	   to	   optic-­‐flow	   driven	  metrics,	   it	  was	   unclear	   as	   to	   exactly	  what	  was	  driving	   high	   motility	   scores	   (e.g.	   bowel	   wall	   motion,	   intensity	   from	   chime	   flow,	  some	   combination).	   Additionally,	   RPCA	   was	   not	   as	   sensitive	   to	   drug-­‐induced	  motility	   changes	  when	   compared	   to	   the	   Jacobian	   SD	   score	   and	   for	   these	   reasons,	  RPCA	   as	   a	  motility	   surrogate,	  was	   abandoned.	  While	  RPCA	  did	   not	   appear	   to	   add	  particular	  value	   for	  direct	  motility	  quantitation,	   it	  played	  a	  central	   role	   in	  another	  project	   taking	   place	   in	   the	   department	   at	   that	   time.	   Valentin	  Hamy	  used	  RPCA	   in	  combination	  with	   registration	   to	   address	   the	   problem	  of	   spatial	  misalignments	   in	  dynamic	   contrast	   enhanced	   (DCE)	   time	   series.	  Hamy’s	   assumption	  was	   that	  RPCA	  could	   be	   used	   to	   separate	   low-­‐rank	   motion	   components	   from	   sparse	   contrast	  enhancement	  within	   an	   iterative	   framework	   to	   allow	   progressive	   re-­‐alignment	   of	  the	  imaged	  features[128].	  One	  of	  the	  key	  challenges	  for	  registration	  of	  DCE	  data	  is	  the	  dual	  effect	  of	  continual	  intensity	  change	  with	  motion	  from	  respiration.	  Without	  intensity	  changes	  in	  the	  data,	  the	  residual	  complexity	  algorithm	  could	  be	  applied	  to	  much	  greater	  effect	  with	  the	  resultant	  deformation	  fields	  finally	  being	  then	  used	  to	  correct	   the	   original	   time	   series	   data.	   This	   technique	  was	   robust	   and	  worked	  well	  across	  organs	  in	  a	  number	  of	  different	  DCE	  data	  series	  and	  was	  named	  Robust	  Data	  Decomposition	  Registration	  (RDDR)[128].	  	  It	  is	  hypothesised	  in	  this	  study	  that	  this	  technique	  could	  be	  extended	  to	  correct	  the	  respiratory	  motion	   in	   dynamic	   small	   bowel	  motility	   data,	  which	  unlike	  peristalsis	  was	  fairly	  periodic.	  	  In	  this	  schema,	  the	  intensity	  changes	  filling	  sparse	  matrix	  would	  be	   replaced	   the	   local	   deformation	   caused	   by	   the	   small	   bowel	  motility.	   As	   before,	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respiratory	   motion	   appearing	   in	   the	   low	   rank	   could	   be	   registered	   to	   correct	   the	  original	   data.	   The	   corrected	   RDDR	   could	   then	   be	   registered	   with	   optic-­‐flow	  algorithm	   as	   per	   chapter	   2.2.4	   to	   finally	   correct	   local	   deformation	   caused	   by	  peristalsis	  and	  from	  this,	  generate	  the	  motility	  maps.	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Figure	   7.2	   Three	   examples	   of	   RPCA	   decomposition	   with	   each	   image	  
representing	  a	  single	  time	  point	  from	  a	  dynamic	  series.	  A	  is	  the	  original	  Candes	  
(2009)	   CCTV	   footage	   with	   the	   low	   rank	   (B)	   static	   and	   sparse	   (C)	   dynamic	  
components	  separated	  by	  a	  variable	  lambda.	  D	  and	  G	  represent	  dynamic	  series	  
of	   the	   small	   bowel	   and	   colon	   respectively.	   Low	   rank	   components	   from	  
decomposition	  are	   shown	   in	  E	  and	  H	  with	   the	   sparse	  motility	  data	   in	  F	  and	   I.	  
These	  motility	  maps	  can	  be	  analysed	  in	  the	  same	  way	  as	  the	  SD	  Jacobian	  maps	  
seen	  throughout	  this	  thesis,	  providing	  an	  alternate	  surrogate	  for	  motility.	  	  	  	  
M	  (Sample	  time-­‐series)	   L	  (Low-­‐rank)	   S	  (Sparse)	  
A)	   B)	   C)	  
D)	   E)	   F)	  
G)	   H)	   I)	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7.2	  Methods	  
7.2.1	  Dual	  Registration	  of	  Abdominal	  Motion	  	  
Robust	  Data	  Decomposition	  Registration.	  Our	   aim	   was	   to	   use	   Robust	   Data	   Decomposition	   Registration	   (RDDR)	   as	   a	   pre-­‐processing	  step	  to	  register	  and	  remove	  the	  respiratory	  component	  of	  motion,	  whilst	  preserving	  peristaltic	  motion	  in	  the	  data.	  This	  method	  uses	  RPCA	  to	  decompose	  the	  cine	   data	   into	   low	   rank	   (L)	   and	   sparse	   (S)	   components	   [127].	   The	   low-­‐rank	  component	   tends	   to	  contain	   the	  slowly	  varying	  respiratory	  motion	  and	   the	  sparse	  component	  the	  local	  rapid	  changes	  due	  to	  peristalsis.	  This	  decomposition	  does	  not	  perfectly	  separate	  the	  two	  physiological	  motions	  and	  to	  remove	  only	  the	  respiratory	  motion,	   RDDR	   applies	   an	   iterative	   registration	   scheme.	   Within	   RDDR,	   RPCA	  performs	  the	  decomposition	  in	  (1):	  	   minimize   L ∗   +   λ S !	  subject  to    L+ S = M	   (1)	  where	  ||. ||∗  and	  ||. ||𝟏  respectively	   represent	   the	   nuclear	   norm	   (i.e.	   the	   sum	   of	   the	  matrix	  singular	  values)	  and	  the	   l1-­‐norm	  (i.e.	   the	  sum	  of	   the	  absolute	  values	  of	   the	  matrix	   elements).	   M,	   L,	   and	   S	   respectively	   correspond	   to	   the	   input	   data,	   the	   low	  rank,	   and	   the	   sparse	   component.	   The	   parameter	   lambda	   (λ)	   appearing	   in	   (1)	   is	   a	  trade-­‐off	   parameter	   that	   determines	   the	   relative	   amount	   of	   information	   in	   L	   or	  S[127].	   For	   the	   purpose	   of	   separating	   and	   correcting	   respiratory	   motion	   from	  peristaltic	  motion,	  lambda	  is	  varied	  in	  an	  iterative	  scheme	  that	  includes	  successive	  registrations	   of	   the	   low	   rank	   frames	   as	   shown	   in	   Figure	   7.3.	   For	   lower	   values	   of	  lambda,	  only	  elements	  of	  respiratory	  motion	  appear	  in	  L.	  As	  lambda	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respiratory	  motion	  is	  present	  and	  peristalsis	  gradually	  appears	  as	  shown	  in	  Figure	  7.3.	   At	   each	   iteration,	   the	   frames	   contained	   in	   the	   low-­‐rank	   component	   are	   all	  registered	   to	   the	   frame	   that	   minimizes	   the	   difference	   to	   the	   pixelwise	   statistical	  median	  over	   time.	  The	  resulting	  deformation	   fields	  are	  applied	   to	   the	   initial	   time-­‐series	  so	  that	  a	  part	  of	  the	  motion	  can	  be	  removed.	  This	  process	  (decomposition	  +	  registration)	   is	   repeated	   for	   increasing	   values	   of	   the	   trade-­‐off	   parameter.	   The	  deformation	  fields	  generated	  at	  each	  registration	  stage	  are	  added	  to	  a	  single	  global	  deformation	   field	   applied	   to	   the	   initial	   time	   series	   after	   the	   last	   iteration	   to	   avoid	  loss	  of	  information	  caused	  by	  multiple	  resampling.	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Figure	   7.3	   Flow	   chart	   illustrating	   the	   process	   of	   DRAM.	   The	   parameter	   lambda	   is	  
gradually	   increased	   in	   RDDR	   to	   let	   more	   information	   appear	   in	   the	   Low	   rank	  
component	  over	  iterations.	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The	   registration	   steps	  within	   RDDR	   use	   the	   residual	   complexity	   similarity	  metric	  [129]	   and	   transformation	   fields	   are	   described	   using	   B-­‐spline	   based	   free	   form	  deformations.	  The	  2D	  control	  point	  grid	  used	  here	  has	  a	  relatively	  large	  spacing	  (10	  pixels)	  aimed	  at	  capturing	  the	  large-­‐scale	  deformations	  due	  to	  respiratory	  motion.	  	  
	  
Figure	  7.4	  Effect	  of	   increasing	   lambda	  on	  RPCA	   low	  rank	  component	   in	  an	  example	  
data	  set.	  Time	  cuts	  for	  the	  original	  time	  series	  and	  various	  low	  rank	  components	  are	  
shown.	   The	   location	   of	   these	   time	   cuts	   is	   indicated	   by	   a	   white	   dashed	   line	   in	   the	  
anatomical	  reference.	  	  
RPCA	  settings	  The	  starting	  value	  of	  lambda	  is	  chosen	  such	  that	  the	  rank	  of	  L	  in	  the	  first	  iteration	  of	  RDDR	  is	  the	  number	  of	  time	  frames	  divided	  by	  four.	  This	  initial	  value	  of	  lambda	  was	  empirically	  found	  to	  be	  high	  enough	  to	  include	  some	  elements	  of	  respiratory	  motion	  in	  L	  and	   low	  enough	  to	  keep	  peristalsis	   in	   the	  sparse	  component	   [128].	  For	   lower	  values	   of	   lambda,	   respiratory	   motion	   might	   entirely	   appear	   in	   the	   sparse	  component	   making	   the	   first	   iteration	   useless.	   The	   starting	   value	   of	   lambda	   is	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logarithmically	  incremented	  in	  subsequent	  iterations	  similar	  to	  the	  original	  version	  of	  the	  algorithm.	  The	  same	  settings	  were	  used	  for	  all	  the	  datasets	  (both	  small	  bowel	  and	  colon)	  analysed	  in	  this	  study.	  	  This	  stopping	  criterion	   is	  designed	  so	   that	  no	  peristalsis	  appears	   in	   the	  registered	  low	  rank	  components.	  A	   threshold	  on	   the	   sparsity	  of	   the	  RPCA	  sparse	   component	  was	  used	  to	   terminate	  the	   iterations.	  Given	  the	  pseudo-­‐periodical	  characteristic	  of	  respiratory	  motion	  and	  peristalsis,	   the	  optimum	  threshold	   for	   lambda	  was	  chosen	  using	  an	  analysis	  of	   test	  data	   in	   the	   frequency	  domain,	   inspired	  by	  previous	  work	  from	  Sprengers	  et.al.	  [130].	  The	  frequency	  of	  peristalsis	  is	  expected	  to	  be	  the	  same	  in	   both	   breath	   hold	   and	   free	   breathing.	   Thus	   the	   difference	   between	   breath-­‐hold	  and	  free	  breathing	  data	  in	  the	  Fourier	  domain	  should	  show	  only	  the	  contribution	  of	  respiratory	  motion.	   Such	   a	   difference	   is	   used	   as	   an	   indicator	   of	   the	   effect	   of	   each	  iteration	   in	   RDDR.	   Spectral	   powers	   were	   computed	   by	   summing	   the	   Fourier	  transform	  of	   time-­‐intensity	  variations	   for	  every	  pixel	  over	   the	  entire	   field	  of	  view.	  Figure	  7.4	  presents	   the	  evolution	  of	   the	   spectral	  power	  difference	  with	   respect	   to	  the	   sparsity	   of	   RPCA	   sparse	   component.	   A	   minimum	   difference	   appears	   clearly	  when	  the	  sparsity	  is	  equal	  to	  20%.	  The	  stopping	  criterion	  for	  RDDR	  is	  then	  chosen	  to	  be	  when	  the	  sparsity	  of	  S	  falls	  below	  a	  threshold	  of	  20%	  (as	  indicated	  in	  Figure	  7.5).	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Figure	   7.5	   Spectral	   analysis	   of	   a	   subject	   for	   tuning	   of	   RDDR	   stopping	   criterion.	  
Spectral	   differences	   between	   gradually	   corrected	   data	   and	   breath-­‐hold	   are	  
progressively	  reduced	  until	  a	  minimum	  is	  reached.	  The	  sparsity	  of	  S	  at	  that	  minimum	  
value	  (20%)	  is	  chosen	  as	   lower	  threshold	  to	  stop	  the	  iterative	  registration	  and	  avoid	  
deterioration	  of	  the	  information	  on	  motility.	  
	  
Motility	  Quantification	  Optic	   flow	  was	   applied	   to	   the	   RDDR	   corrected	   data	   as	   per	   chapter	   2.2.4	   without	  additional	  adjustments.	  	  
	  
7.2.2	  Study	  Overview	  	  In	  this	  study	  motility	  is	  quantified	  in	  dynamic	  small	  bowel	  and	  colonic	  data	  with	  the	  OF	  registration	  algorithm.	  The	  purpose	  of	   this	  study	  was	   to	  evaluate	   the	  ability	  of	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the	  pre-­‐processing	  registration	  step,	  RDDR,	  to	  correct	  free	  breathing	  motion	  before	  OF	   processing.	   Two	  main	   results	   are	   provided	   that	   focus	   on	   1)	   the	   ability	   of	   OF-­‐alone	  and	  DRAM	  to	   faithfully	  propagate	  a	   line	  ROI	  (i.e.	  a	  1D	   line	  drawn	  across	  the	  bowel	   lumen,	   perpendicular	   to	   the	   central	   axis	   of	   the	   bowel)	   through	   processed	  small	   bowel	   and	   colonic	   time	   series	   data	   using	   the	   average	   of	   two	   independent	  manually	  propagated	  ROIs	  as	  a	  gold	  standard.	  2)	  Free	  breathing	  parametric	  motility	  maps	   in	   small	   bowel	   data	   sets	   registered	  with	   OF-­‐alone	   and	   DRAM,	   using	   breath	  hold	  OF	  data	  as	  a	  gold	  standard.	  A	  summary	  is	  provided	  in	  Figure	  7.6.	  	  	  
	  
	  
Figure	   7.6	   DRAM	   Study	   overview.	   1)	   Setting	   of	   DRAM	   parameters.	   2)	   Registration	  
accuracy	   of	   the	   two	  methods	   was	   investigated	   by	   comparing	   the	   ability	   of	   the	   two	  
algorithms	   to	   propagate	   a	   ROI	   against	   a	   manually	   adjusted	   ‘gold-­‐standard.’	   3)	  
Registration	  accuracy	  was	  assessed	  as	  per	  (2)	  in	  the	  colonic	  data	  sets.	  4)	  Parametric	  
motility	  maps	  derived	  from	  free	  breathing	  data	  sets	  were	  compared	  to	  a	  breath-­‐hold	  
pseudo	  ground-­‐truth.	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7.2.3	  Subject	  population	  	  Two	  data	  sources	  were	  used	  for	  the	  validation	  of	  this	  technique.	  The	  first	  was	  from	  the	  prospective	  study	  of	  small	  bowel	  motility	  in	  20	  volunteers,	  and	  the	  second	  in	  a	  study	  of	  colonic	  motility	  in	  6	  volunteers	  provided	  by	  Nottingham	  University.	  	  	  
Small	  bowel	  The	  same	  20	  healthy	  subjects	  were	  used	  as	  described	  in	  Chapter	  5.2.1.	  	  	  
Colon	  Colon	   data	   sets	   for	   6	   healthy	   volunteers	   were	   used	   in	   this	   study	   with	   subject	  demographics	  as	  follows,	  mean	  age	  27,	  range	  19-­‐43	  years,	  1	  Male.	  	  Volunteers	  were	  included	  in	  the	  study	  where	  they	  were	  able	  to	  give	  informed	  written	  consent,	  were	  non-­‐smokers	  and	  had	  abstained	   from	  alcohol	   for	  24	  hours	  prior	   to	   the	   study	  day.	  	  Volunteers	  were	  excluded	  if	  they	  had	  any	  history	  of	  serious	  acute	  or	  chronic	  illness,	  especially	  gastro-­‐intestinal,	  if	  they	  regularly	  used	  medication	  which	  interfered	  with	  GI	  function	  or	  had	  previous	  GI	  surgery	  (excluding	  appendectomy).	  	  Volunteers	  were	  recruited	  prospectively	  by	  advertisement.	  MRI	  protocol	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7.2.4	  Scan	  Protocol	  	  
Small	  bowel	  	  Volunteers	   were	   prepared	   and	   scanned	   as	   per	   chapter	   5	   using	   the	   6-­‐slice	   BTFE	  sequence,	  with	   the	  key	  difference	  between	   this	   study	  being	   that	   both	  breath-­‐hold	  and	  free-­‐breathing	  series	  were	  collected.	  	  	  The	  motility	  sequence	  was	  run	   first	  on	   inspiration	  breath-­‐hold	  to	  collect	  a	   total	  of	  20	  images	  of	  the	  same	  anatomical	  slice.	  This	  process	  was	  repeated	  following	  a	  10	  s	  recovery	  period	  with	  the	  subject	  this	  time	  instructed	  to	  ‘gently	  free-­‐breathe’	  whilst	  a	  total	  of	  60	  images	  were	  acquired	  in	  the	  same	  anatomical	  position	  unchanged	  from	  the	  breath-­‐hold	  scan.	  	  
Colon	  The	  volunteers	   arrived	   after	   an	  overnight	   fast.	   Scans	  were	   carried	  out	   at	   baseline	  and	  at	  hourly	  intervals	  following	  consumption	  of	  either	  1	  L	  or	  2	  L	  Polyethlene	  glycol	  (PEG)	  formulation.	  A	  total	  of	  9	  data	  sets	  from	  6	  subjects	  are	  included	  in	  this	  work	  to	  highlight	   differing	   amounts	   of	   colonic	   motility	   and	   breathing	   effects,	   selected	  subjectively	  based	  on	  visual	  inspection	  of	  the	  time	  series	  by	  the	  study	  scientist	  (Dr.	  Caroline	   Hoad).	   All	   volunteers	   underwent	   a	   baseline	   scan	   and	   then	   hourly	   scans	  after	   ingestion	  of	  PEG.	   	  The	  data	   in	   this	  study	  comprises	  of	  2	  baseline	  scans	  and	  7	  scans	  at	  various	  time	  points	  post	  ingestion.	  	  Subjects	  lay	  in	  the	  supine	  position	  and	  were	  scanned	  using	  a	  Philips	  Achieva	  1.5	  T	  MRI	  scanner	  using	  the	  XL-­‐Torso	  receiver	  coil.	  
	  	   196	   	  
	   	  
	  The	  colon	  motility	  scan	  consisted	  of	  a	  single	  slice	  BTFE	  sequence	  positioned	  in	  the	  sagittal	   plane	   through	   the	   ascending	   colon	   (sagittal	   plane,	   voxel	   size	   	   1.5x1.5x15	  mm3,	   FOV	   330x228x15	   mm3,	   FA	   70	   degrees,	   TE=1.5	   ms,	   TR=3.0	   ms).	   	   Temporal	  resolution	  was	  1	  slice	  per	  second	  and	  scans	  were	  acquired	  during	   two	  minutes	  of	  thoracic	  free	  breathing	  (example	  time	  point	  in	  7.2G).	  	  
7.2.5	  Assessment	  of	  the	  effect	  of	  registration	  	  The	   effect	   of	   respiratory	   motion	   correction	   using	   RDDR	   was	   assessed	   by	  investigating	  the	  fidelity	  of	  the	  optic	  flow	  algorithm	  to	  propagate	  a	  line	  ROI	  through	  the	  1)	  small	  bowel	  and	  2)	  colon	  free-­‐breathing	  time	  series	  data.	  	  	  	  
Small	  bowel	  One	   gastroenterology	   research	   fellow	   and	   one	   research	   scientist	   (Dr.	   Jessica	  Makanyanga	  -­‐	  3	  years	  experience	  MRE,	  the	  author	  -­‐	  3	  years	  experience	  small	  bowel	  MR)	  identified,	  in	  consensus,	  a	  small	  bowel	  loop	  in	  the	  upper	  left	  quadrant	  of	  each	  subject,	   which	   remained	   visible	   through	   the	   time	   series	   (i.e.	   did	   not	  move	   out	   of	  plane).	  	  
	  
Colon	  This	   process	  was	   repeated	   in	   the	   colon	   data	   sets,	  where	   the	   same	   two	   observers	  placed	  in	  consensus	  two	  line	  ROIs	  in	  the	  ascending	  portion	  of	  the	  colon.	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In	  both	  types	  of	  data,	  the	  line	  ROIs	  were	  automatically	  propagated	  through	  the	  time	  series	  by	  both	  OF	  alone	  and	  the	  OF	  component	  of	  DRAM	  based	  on	  the	  registration	  deformation	   fields,	   and	   the	   results	   saved.	   The	   ROI	   was	   then	   manually	   corrected	  independently	  by	  both	  JM	  and	  AM	  for	  each	  time	  point.	  Agreement	  between	  readers	  was	   assessed	   using	   Bland-­‐Altman	   limits	   of	   agreement	   and	   Intra-­‐class	   correlation.	  The	  manually	  corrected	  line	  ROIs	  for	  the	  two	  observers	  were	  averaged	  for	  each	  time	  point	  and	  used	  to	  create	  a	  ground	  truth	  for	  each	  data	  set.	  	  	  Accuracy	  of	  the	  OF-­‐alone	  and	  DRAM	  algorithms	  to	  the	  ground	  truth	  was	  compared	  by:	  1)	  assessing	  change	  in	  line	  length	  over	  time	  between	  the	  manually	  corrected	  and	  automatically	   propagated	   ROIs	   using	   Bland-­‐Altman	   limits	   of	   agreement	   (LoA).	   2)	  Assessing	   the	   variance	   of	   the	   displacement	   of	   ROIs	   by	   computing	   the	   target	  registration	   error	   (TRE)	   i.e.	   the	   distance	   between	   each	   line	   end-­‐point	   of	   the	  manually	   corrected	  and	  automatically	  propagated	  ROIs.	  A	   threshold	   for	  TREs	  was	  set	  to	  1e-­‐3	  mm.	  Errors	  below	  this	  value	  were	  considered	  as	  zero.	  	  
Validation	  of	  motility	  scoring	  	  The	   global	   small	   bowel	   ROI	   was	   placed	   by	   the	   author	   and	   Dr.	   J	   Makanyanga	   in	  consensus	   for	   each	   subject:	   1)	   the	   breath-­‐hold	   registered	   with	   OF	   2)	   the	   free	  breathing	  registered	  with	  DRAM	  data	  sets;	  and	  3)	  the	  free-­‐breathing	  registered	  with	  OF-­‐alone.	   The	   20	   s	   BH	   data	   (i.e.	   without	   respiratory	  motion)	   served	   as	   a	   ground	  truth.	  For	  each	  data	  series,	  the	  parametric	  SD	  Jacobian	  motility	  map	  was	  calculated.	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7.3	  Results	  
7.3.1	  Registration	  assessment	  	  Example	  images	  of	  time	  cuts	  obtained	  after	  registration	  are	  shown	  in	  Figure	  7.7.	  The	  time	  cut	  representation	  shows	  correction	  of	  breathing	  motion	  after	  RDDR	  with	  little	  apparent	  effect	  on	  peristaltic	  motion.	  	  
	  
Figure	   7.7	   Time-­‐cut	   representations	   illustrating	   organ	   motion	   before	   and	   after	  
registration	   of	   images	   from	   a	   dynamic	   MR	   time-­‐series	   obtained	   on	   a	   healthy	  
volunteer:	   (a)	  A	   coronal	  MR	   scan	  at	  a	  particular	   time-­‐point	  within	   the	  dynamic	  MR	  
series.	  The	  spatial	  location	  of	  the	  time	  cuts,	  shown	  in	  (b),	  (c)	  and	  (d),	  is	  indicated	  by	  a	  
white	  dashed	  line,	  with	  different	  organs	  labelled.	  Each	  time-­‐cut	  image	  represents	  the	  
image	   intensities	  along	   this	   line	  as	  a	   function	  of	   time	  (horizontal	  axis).	   (b)	  Time-­‐cut	  
image	   before	   registration	   with	   RDDR.	   (c)	   Time-­‐cut	   image	   before	   registration	   	   with	  	  
RDDR.	  (d)	  Time-­‐cut	  image	  based	  on	  breath-­‐hold	  data	  for	  	  comparison;	  	  note	  	  that	  	  the	  	  
time-­‐cut	   	   series	   	   is	   	   smaller	   	  due	   	   to	   	   the	   	   fewer	  number	  of	  available	   time	  points	   (20	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respiratory	  	  motion	  at	  	  the	  	  interface	  	  between	  	  the	  	  stomach	  	  and	  	  liver,	  indicated	  by	  
arrow	  	  1,	  are	  accurately	  corrected	  by	  RDDR,	  whilst	  small	  bowel	  motility	  information,	  
indicated	  by	  arrow	  2,	  is	  preserved.	  
	  
Small	  bowel	  In	   the	  small	  bowel,	   two	  observers	  manually	  propagated	  a	   linear	  region	  of	   interest	  through	   60	   time	   points	   in	   each	   of	   the	   20	   subjects.	   Inter-­‐reader	   variability	   was	  assessed	   through	   Bland-­‐Altman	   LoA	   and	   intra-­‐class	   correlation	   (ICC).	   For	   the	  manually	   corrected	  OF-­‐alone	   data,	  mean	   difference	   between	   readers	  was	   0.4	  mm	  (95%	  LoA	  ±7.3	  mm).	  ICC	  was	  0.85.	  For	  the	  manually	  corrected	  DRAM	  data	  the	  mean	  difference	  between	  readers	  was	  0.54	  mm,	  LoA	  ±3.4	  mm.	  ICC	  was	  0.96.	  	  The	   BA	   analysis	   of	   line	   length	   ROIs	   in	   OF-­‐alone	   registered	   and	   DRAM	   registered	  data	  with	   the	  manual	  measurements	   (mean	  of	   two	  observers)	   is	   shown	   in	   Figure	  7.8a	   and	   7.8b.	   For	   the	  OF-­‐alone	   registered	   data	   the	  mean	   difference	   between	   the	  manually	  corrected	  and	  automatically	  propagated	  ROIs	  was	  -­‐	  2.0	  mm	  (95%	  LoA	  ±9	  mm).	  For	  the	  DRAM	  processed	  images	  mean	  difference	  was	  -­‐0.48	  mm	  (95%	  LoA	  ±	  4.15	  mm).	  	  Target	  Registration	  Errors	  were	  below	   the	   threshold	   in	  49%	  of	   the	  cases	  with	  OF	  only	   and	   in	   70%	   of	   the	   cases	   after	   pre-­‐processing	  with	   RDDR.	   For	   nonzero	   TREs	  (Figure	  7.8c),	  OF-­‐alone	  yielded	  a	  median	  error	  of	  0.5	  mm	  (IQR	  2.27	  mm)	  and	  DRAM	  yielded	  a	  median	  error	  of	  0.05	  mm	  (IQR	  0.1	  mm).	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Figure	   7.8	   Bland	   Altman	   limits	   of	   agreement	   for	   line	   ROIs	   in	   small	   bowel	   data	  
registered	  with	  OF	  against	  manually	  corrected	  ground	  truth	  (A)	  and	  data	  registered	  
with	  DRAM	  against	  manually	  corrected	  ground	  truth	  (B).	  Target	  registration	  error	  in	  
DRAM	  and	  OF	  alone	  (C).	  	  
Colon	  Inter-­‐reader	  variability	   in	   the	  colon	  was	  examined	   in	  exactly	   the	  same	  way	  as	   the	  small	   bowel	   result.	   For	   the	   manually	   corrected	   OF-­‐alone	   data,	   mean	   difference	  between	   readers	  was	  0.2mm	  (95%	  LoA	  ±1.1mm).	   ICC	  was	  0.98.	  For	   the	  manually	  corrected	   DRAM	   data	   the	   mean	   difference	   between	   readers	   was	   0.28mm,	   LoA	  ±1.7mm.	  ICC	  was	  0.99.	  	  
	  	   201	   	  
	   	  
The	   BA	   analysis	   of	   line	   length	   ROIs	   in	   OF-­‐alone	   registered	   and	   DRAM	   registered	  data	  with	   the	  manual	  measurements	   (mean	  of	   two	  observers)	   is	   shown	   in	   Figure	  7.9a	   and	   7.9b.	   For	   the	  OF-­‐alone	   registered	   data	   the	  mean	   difference	   between	   the	  manually	   corrected	   and	   automatically	   propagated	   ROIs	   was	   -­‐1.25	  mm	   (95%	   LoA	  ±7.57	  mm).	  For	  the	  DRAM	  processed	  images	  mean	  difference	  was	  -­‐0.13	  mm	  (95%	  LoA	  ±	  1.96	  mm).	  	  	  Target	  Registration	  Errors	  were	  below	  the	  threshold	  in	  37%	  of	  the	  cases	  with	  OF-­‐alone	  and	   in	  70%	  of	   the	  cases	  after	  pre-­‐processing	  with	  RDDR.	  For	  nonzero	  TREs	  (Figure	  7.9c),	  OF	  alone	  yielded	  a	  median	  error	  of	  4.9	  mm	  (IQR	  8	  mm)	  and	  DRAM	  yielded	  a	  median	  error	  of	  2.2	  mm	  (IQR	  2.1	  mm).	  
	  
Figure	   7.9.	   Bland	   Altman	   limits	   of	   agreement	   for	   line	   ROIs	   in	   colon	   data	   registered	  
with	  OF	  against	  manually	  corrected	  ground	  truth	  (A)	  and	  data	  registered	  with	  DRAM	  
against	  manually	  corrected	  ground	  truth	  (B).	  Target	  registration	  error	  in	  DRAM	  and	  
OF	  alone	  (C).	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  An	  example	  plot	  of	   the	   line	   lengths	   through	   time,	  propagated	  by	  OF	  and	  DRAM,	   is	  shown	  in	  Figure	  7.10.	  
	  
Figure	  7.10	  Sagittal	  view	  of	  the	  ascending	  colon	  with	  line	  ROI	  across	  colon	  diameter	  
(a).	   	   Line	   ROI	   propagated	   in	   data	   registered	  with	   OF	   (b)	   and	   DRAM	   (c).	   Both	   ROIs	  
remained	   manually	   unadjusted.	   Blue	   line	   represents	   mean	   line	   length,	   black	   lines	  
represent	  ±5%	  and	  red	  lines	  show	  ±10%	  of	  mean	  diameter.	  
	  
7.3.2	  Validation	  of	  motility	  scoring	  	  	  The	  mean	   global	  motility	   score	   	  within	   the	  manually	   placed	  ROIs	   for	   the	  BH	  data	  sets	  across	  the	  cohort	  was	  0.340	  (range	  0.181	  to	  0.422).	  	  Mean	  global	  motility	  score	  for	   DRAM	   registered	   data	   was	   0.335	   (range	   0.189	   to	   0.430)	   and	   OF	   alone	   free-­‐
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breathing	   data	   sets	  was	   0.365	   (range	   0.268	   to	   0.458).	   	   Subjective	   visualisation	   of	  motility	  colormaps	  is	  shown	  in	  Figure	  7.11	  with	  data	  summarised	  in	  Figure	  7.12.	  
	  	  
Figure	  7.11	  Parametric	  motility	  maps	  in	  BH	  and	  FB	  data.	  AU	  denotes	  absolute	  units,	  
normalised	   between	   0	   and	   1.	   Example	   data	  with	   contoured	   small	   bowel	   region	   and	  
motility	  maps	  for	  breath-­‐hold	  ground	  truth	  (a,	  d),	  DRAM	  (FB)	  (b,	  e)	  and	  free	  breathing	  
optical	  flow	  registration	  alone	  (c,	  f)	  respectively.	  Respiratory	  motion	  compensation	  is	  
visible	   as	   reduced	   motility	   in	   the	   transverse	   colon	   closest	   to	   the	   diaphragm	   and	  
systemically	   over	   the	   small	   bowel.	   The	   effect	   of	   RDDR	   is	   less	   apparent	   in	   the	   lower	  
bowel	   further	   from	   the	   diaphragm	   where	   the	   effects	   of	   free	   breathing	   are	   less	  
pronounced.	  Motility	  map	  shows	  black	  as	  lower	  motility	  and	  white	  as	  higher.	  
0	  AU	  	  
1	  AU	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Figure	   7.12	   Box	   plots	   for	   OF	   derived	  motility	   scores	   in	   the	   20	   subjects	   with	   range	  
(dotted	   line),	   interquartile	   range	   (box)	   and	  median	   (red	   horizontal	   line)	   for	   Breath	  
hold	   optic	   flow	   registered	   data	   (BH	  OF),	   free	   breathing	  DRAM	   (DRAM	  FB)	   and	   free	  








	  	   205	   	  
	   	  
7.4	  Discussion	  
	  This	  chapter	  aimed	  to	  validate	  a	  two-­‐stage	  technique	  that	  first	  corrects	  respiratory	  motion	   before	   applying	   an	   existing	   OF	   method	   to	   register	   local	   deformation	  generated	   by	   peristalsis.	   Such	   an	   approach	   would	   allow	   rapid	   and	   robust	   data	  analysis	  from	  longer	  datasets	  acquired	  in	  free	  breathing.	  	  	  Within	  the	  scheme	  parameters	  were	  selected	  empirically	  once,	  with	  the	  same	  values	  used	  thereafter	   for	  all	  datasets	  providing	  results	  that	  appear	  generalisable	  to	  both	  the	  colon	  and	  small	  bowel.	  An	   iterative	  scheme	  was	  used	  within	  RDDR	  to	   remove	  the	   respiratory	   component	   of	  motion.	   However,	   there	  was	   the	   potential	   of	   losing	  physiological	   information	   related	   to	   peristalsis	   by	   over-­‐estimating	   lambda	   in	   this	  iterative	   process.	   This	   risk	   was	   reduced	   by	  modifying	   the	   original	   version	   of	   the	  algorithm	  to	  impose	  a	  specific	  stopping	  criterion.	  To	  evaluate	  the	  effect	  of	  this,	  the	  motility	  metric	  was	   compared	   between	   the	   pseudo-­‐ground	   truth	   breath-­‐hold	   and	  the	   free	   breathing	   DRAM	   data	   over	   global	   small	   bowel	   ROIs.	   The	   analysis	  	  demonstrated	  comparable	  results	  using	  free	  breathing	  DRAM	  data	  and	  the	  pseudo-­‐ground	   truth	   of	   the	   BH.	   Specifically	   the	   breath-­‐hold	   OF	   registration	   gave	  comparable	  global	  scores	  to	  DRAM	  and	  a	  positive	  bias	  in	  OF-­‐alone	  registered	  global	  motility	   scores	   in	   free	   breathing	   datasets	   was	   observed.	   This	   supports	   the	  conclusion	  that	  DRAM	  removes	  respiratory	  motion	  whilst	  leaving	  peristaltic	  motion	  largely	  intact.	  The	  breath-­‐hold	  data	  was	  not	  a	  perfect	  ground	  truth	  as	  the	  data	  was	  temporally	  separated	  from	  the	  subsequent	  free	  breathing	  data	  collection.	  	  However	  the	   30s	   time	   difference	   from	   the	   commencement	   of	   the	   breath-­‐hold	   to	   the	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commencement	   of	   the	   free-­‐breathing	   series	   is	   unlikely	   to	   impact	   significantly	   on	  bowel	  motion	  especially	  when	  assessed	  in	  a	  global	  manner.	  	  	  The	  accuracy	  of	   the	   registration	   technique	  was	   assessed	  by	   comparing	  algorithm-­‐propagated	  ROIs	  through	  the	  time	  series	  data	  and	  comparing	  their	  size	  and	  position	  to	   a	   manually	   adjusted	   ground	   truth.	   Assessment	   of	   the	   DRAM	   corrected	   data	  demonstrated	   greater	   registration	   accuracy	   with	   a	   mean	   error	   comparable	   to	  previous	   values	   from	   breath-­‐hold	   data	   by	   Odille	   and	   Bikelhaupt	   [57],	   [59].	   The	  DRAM	   data	   did	   however	   show	   a	   slightly	   larger	   variance	   in	   the	   BA	   LoA	   when	  compared	   to	   the	   original	   Odille	   data	   using	   breath-­‐hold	   data.	   This	   is	   likely	   due	   to	  several	  factors,	  principally	  the	  choice	  of	  ROI	  position	  which	  in	  the	  current	  study	  was	  the	   upper	   left	   quadrant	   (i.e.	   proximal	   bowel	   close	   to	   the	   diaphragm)	   with	   the	  specific	   intention	   of	   challenging	   the	   capabilities	   of	   the	   respective	   algorithms	  with	  the	  effects	  of	  respiration.	  Assessment	  of	   the	  displacement	  distance	  of	   the	  adjusted	  ROIs	   compared	   to	   the	  manual	   gold	   standard	  was	   performed	   to	   identify	  ROIs	   that	  may	  have	  been	  mis-­‐registered	   to	  adjacent	  bowel	   loops.	  This	  comparison	   is	  a	  good	  test	   for	  registration,	  as	   it	   is	  based	  directly	  on	  displacements	  reflecting	  registration	  accuracy	   and	   has	   not	   previously	   been	   performed	   in	   other	   small	   bowel	   motility	  validation	  studies.	  On	  average,	   less	  manual	  correction	  was	  necessary	   in	  the	  DRAM	  data	  and	  when	  ROIs	  were	  adjusted.	  The	  median	  distance	  and	  variance	  was	  several	  times	  lower	  than	  that	  without	  RDDR	  pre-­‐processing.	  By	  collectively	  assessing	  these	  two	  components	  of	  registration	  fidelity	  in	  a	  challenging	  region	  of	  bowel,	  both	  DRAM	  and	   OF	   algorithms	  were	   subjected	   to	   a	   robust	   test	   and	   in	   both	   cases	   DRAM	  was	  found	   to	   perform	   better	   in	   comparison	   to	   the	   ground	   truth	   and	   comparable	   to	  existing	  literature	  values	  derived	  using	  BH	  OF.	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  An	   important	   component	   of	   the	   investigation	   was	   the	   application	   of	   the	  methodology	  to	  colonic	  data	  sets.	  Physiologically,	  the	  colon	  is	  quite	  different	  to	  the	  small	  bowel	  with	  a	  less	  frequent	  contraction	  rate	  [131].	  Using	  the	  same	  parameters	  employed	  for	  the	  small	  bowel	  registration	  the	  data	  demonstrated	  again	  that	  DRAM	  performed	  well,	   largely	  correcting	   the	  effects	  of	   free	  breathing	  and	  permitting	   the	  accurate	  registration	  of	  colon	  wall	  deformation.	  Automated	  propagation	  of	  a	  linear	  ROI	   through	   the	   time	   series	  was	   possible	  with	   seemingly	   accurate	   assessment	   of	  contraction	  compared	  to	  our	  ground	  truth	  with	  manual	  adjustment.	  Due	  to	  the	  slow	  contraction	   rate	   of	   the	   colon,	   this	   increase	   in	   registration	   fidelity	   is	   important,	   as	  manual	   measurements	   are	   exceptionally	   time	   consuming	   and	   not	   practicable	   in	  clinical	  practice.	  In	  this	  study	  the	  technique	  was	  applied	  to	  two	  colonic	  regions	  per	  data	  set	  in	  a	  total	  of	  nine	  data	  sets,	  which	  is	  relatively	  small.	  Furthermore,	  with	  only	  two	   contractions	   expected	   to	   occur	   over	   the	   two	  minute	   scan,	   future	  work	  might	  extend	  the	  data	  acquisition	  time	  to	  around	  10	  minutes	  to	  more	  fully	  explore	  colonic	  physiology	  with	  MR.	  However	  the	  aim	  in	  this	  preliminary	  work	  was	  to	  demonstrate	  the	  broad	  applicability	  of	  the	  unaltered	  DRAM	  technique	  to	  the	  colon,	  an	  organ	  with	  different	  physiological	  characteristics	  to	  the	  small	  bowel	  and	  using	  data	  acquired	  at	  a	  different	  MRI	  field	  strength	  and	  over	  a	  different	  number	  of	  time	  frames.	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Summary	  
	  This	   chapter	   validated	   a	   new	   post-­‐processing	   methodology	   for	   extracting	  quantitative	   metrics	   to	   assess	   small	   bowel	   and	   colonic	   motility	   during	   free-­‐breathing.	   Improvement	  was	  demonstrated	  both	   in	  segmental	  and	  global	  analyses	  when	   using	   DRAM	   that	   has	   gone	   on	   to	   be	   used	   for	   evaluation	   of	   data	   at	   the	  University	   of	   Nottingham	   and	   largely	   broadens	   the	   applicability	   of	   optic	   flow	   to	  other	  areas	  of	  the	  GI	  tract.	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CHAPTER	   8:	   GLOBAL	   SMALL	   BOWEL	   MOTILITY	   IN	  CHRONIC	   INTESTINAL	   PSEUDO-­‐OBSTRUCTION	  ASSESSED	  USING	  MRE	  AND	  IMAGE	  POST-­‐PROCESSING	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Research	  Question:	  Can	   global	   small	   bowel	   motility	   analysis	   be	   used	   to	   quantitatively	   demonstrate	  physiological	   differences	   between	   healthy	   controls	   and	   Chronic	   Intestinal	   Pseudo	  Obstruction?	  	  
Rationale:	  CIPO	   patients	   are	   broadly	   acknowledged	   as	   having	   altered,	   decreased	   bowel	  motility	  and	  a	  number	  of	   research	  studies	  have	   found	  neuropathic	  and	  myopathic	  origins	   for	   this	   disease	   that	   both	   result	   in	   decreased	   intestinal	   motility.	   By	  quantifying	   altered	   motility	   in	   this	   cohort	   against	   controls,	   this	   study	   aims	   to	  provide	   additional	   confirmatory	   evidence	   for	   its	   sensitivity	   and	   more	   broadly	  applicability	  in	  a	  clinical	  cohort	  within	  the	  hospital	  setting.	  	  
	  
Hypothesis:	  CIPO	  patients	  will	  have	  a	  lower	  motility	  score	  at	  baseline	  compared	  to	  controls	  and	  an	  altered	  response	  to	  neostigmine.	  
	  
Aim(s):	  i)	  Compare	  baseline	  motility	  in	  CIPO	  and	  controls.	  	  ii)	  Compare	  CIPO	  and	  control	  response	  to	  IV	  neostigmine	  versus	  placebo.	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  Pseudo-­‐Obstruction	  and	  controls:	  A	  Preliminary	  Study.	  2114,	  ISMRM.	  	  	  
8.1	  Introduction	  
	  Chronic	  Intestinal	  Pseudo-­‐Obstruction	  is	  a	  rare	  but	  severe	  disease	  characterised	  by	  the	   failure	   of	   the	   intestinal	   tract	   to	   propel	   its	   contents,	   clinically	   mimicking	  mechanical	  intestinal	  obstruction	  (Figure	  8.1).	  CIPO	  represents	  an	  important	  cause	  of	   intestinal	   failure	   in	   both	   paediatric	   (15%)	   and	   adult	   (20%)	   patients.	   Sufferers	  typically	   have	   a	  marked,	   chronic	   decrease	   in	   the	   quality	   of	   life	   through	   disabling	  digestive	  symptoms	  (nausea,	  diarrhoea,	  pain	  etc.)	  and	  malnutrition	  through	  loss	  of	  functional	   capacity[24],	   [132]–[134].	   Therapy	   is	   difficult	   and	   often	   provides	  unsatisfactory	   results.	   Patients	   invariably	   require	   nutritional	   support,	  pharmacological	   treatment	   targeted	  at	   symptom	  relief	  and	   in	  some	  cases	  undergo	  multiple	  ineffective	  surgical	  interventions	  for	  misdiagnosed	  mechanical	  obstruction.	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Figure	   8.1	  An	  example	  BTFE	  coronal	   slice	   from	  a	  CIPO	   (A)	  and	  healthy	   (B)	   subject.	  
Note	  the	  extensive	  bowel	  loop	  dilatation	  in	  A.	  	  CIPO	   can	   be	   primary	   or	   arise	   secondary	   to	   a	   range	   of	   diseases	   that	   affect	   the	  intrinsic	   and	   extrinsic	   GI	   tract	   nerve	   supply;	   some	  may	   be	   central	   (Parkinson’s),	  peripheral	  (diabetic	  neuropathy,	  scleroderma)	  or	  the	  result	  of	  an	  infective	  episode	  (Chagas	  disease)	  summarised	  in	  Table	  8.1.	  Primary	  forms	  of	  the	  disease	  are	  poorly	  understood	   although	   a	   number	   of	   gene	   loci	   have	   been	   identified	   implicating	  connective	  tissue	  deregulation[135],	  [136].	  The	  secondary,	  myopathic	  classification	  of	  the	  disease	  is	  generally	  considered	  more	  insidious	  and	  confirmable	  only	  through	  biopsy	   of	   the	   affected	   bowel.	   A	   controlled	  multi-­‐centre	   study	   suggested	   an	   alpha-­‐actin	  deficit	  in	  the	  smooth	  muscle	  of	  the	  bowel	  might	  be	  responsible	  for	  the	  loss	  of	  function	  [23].	  Myopathic	  CIPO	  generally	  attracts	  a	  worsened	  prognosis	  due	  to	  a	  lack	  of	  therapeutic	  targets[24].	  	  	  
A)	   B)	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Diseases	  of	  the	  central,	  autonomic	  and	  enteric	  nervous	  system	  
Stroke,	  Parkinson’s,	  encephalitis,	  calcification	  of	  basal	  ganglia,	  orthostatic	  hypotension,	  Von	  Recklinghausen,	  Hirschsprungs	  
Immune-­‐mediated	  and	  collagen	  disease	   Scleroderma,	  amyloidosis	  Ehlers-­‐Danlos,	  LES,	  Malignancy	  Endocrine	  and	  metabolic	  diseases	   Diabetes,	  hypothyroidism,	  hypoparathyroidism,	  pheochromocytoma	  Other	   Radiation	  enteritis,	  clonidine,	  phenothiazines,	  antidepressants,	  antiparkinsonians,	  chemotherapy,	  bronchodilators,	  anthraquinones,	  jejunal	  diverticulosis,	  Chagas	  disease.	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discussion	   took	   place	   around	   disorders	   of	   dysmotility	   with	   gastroenterologists	  specialising	   in	  neurogastroenterology	   and	   reviewed	   the	   literature	   for	   quantitative	  information	  pertaining	   to	   low	  motility	   in	  disease.	  A	   range	  of	   candidate	   conditions	  including	   general	   ‘dysmotility,’	   IBS-­‐C,	   Parkinson’s,	   amyloidosis,	   diabetes	   and	   all	  featured	   as	   candidate	   conditions	   for	   the	   first	   proof	   of	   principal	   study	   based	   on	  speculated	   dysmotility	   as	   assessed	   by	   transit	   studies	   or	   other	   indirect	   measures.	  However	  none	  appeared	  to	  have	  the	  same	  body	  of	  evidence	  that	  exists	  for	  CIPO.	  	  	  This	   study	   hypothesises	   that	   CIPO	   patients	   display	   reduced	   bowel	   motility	  compared	   to	   that	   of	   controls	   and	   is	   accepted	   a	   priori	   that	   quantitative	  demonstration	   of	   this	   will	   not	   represent	   a	   novel	   finding.	   It	   will	   however	  demonstrate	  a	  clinical	  application	  of	  the	  MRI	  technique	  within	  the	  hospital	  setting	  and	   provide	   important	   confirmatory	   evidence	   for	   the	   MRI	   motility	   assessment	  paradigm.	   Of	   a	   more	   broad	   scientific	   interest	   is	   the	   administration	   of	   0.5mg	  neostigmine	   against	   placebo	   control	   to	   investigate	   the	   effects	   of	   an	  anticholinesterase	   inhibitor	   on	  motility.	   Neostigmine	   is	  well	   recognised	   to	   relieve	  patient	  symptoms	  in	  CIPO,	  likely	  due	  to	  its	  direct	  action	  on	  the	  gut	  smooth	  muscle	  and	   it	   is	   further	   hypothesised	   here	   that	   a	   response	   will	   be	   seen	   in	   cases	   of	  neuropathic	  CIPO	  but	  that	  the	  response	  may	  be	  different	  to	  that	  of	  healthy	  controls	  [25]–[27].	  	  	  
8.2	  Methods	  	  
	  
8.2.1	  Summary	  of	  Study	  design	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  This	   prospective	   study	   took	   the	   form	   of	   patient	   and	   reader	   blinded	   placebo-­‐controlled	  cross-­‐over	  study	   in	  both	  CIPO	  patients	  and	  healthy	  controls.	  This	  study	  investigated	  small	  bowel	  motility	  differences	  at	  baseline	  between	  CIPO	  and	  controls	  and	  in	  response	  to	  0.5mg	  IV	  neostigmine.	  Drug	  placebo	  was	  administered	  according	  to	  a	  randomisation	  block	  generated	  by	  the	  author.	  	  	  
8.2.2	  Healthy	  control	  selection	  	  The	   same	   11	   healthy	   subjects	   who	   received	   neostigmine/placebo	   previously	  described	  in	  chapter	  6.2.3	  were	  used	  again	  in	  this	  study.	  	  	  
8.2.3	  CIPO	  patient	  selection	  	  7	   CIPO	  patients	   (4	  male,	  mean	   age	   57,	   range	   35	   to	   90)	  were	   identified	   through	   a	  specialist	   GI	   clinic.	   All	   patients	   had	   a	   prior	   diagnosis	   of	   CIPO	   and	   visibly	   dilated	  small	  bowel	  loops	  consistent	  with	  CIPO.	  Full	  patient	  demographics	  are	  presented	  in	  table	  8.2	  –	  In	  summary,	  four	  of	  the	  cohort	  had	  a	  primary	  diagnosis	  of	  CIPO,	  two	  of	  the	   cohort	   were	   receiving	   nutritional	   support	   through	   TPN.	   Two	   patients	   had	   a	  stoma	   and	   two	   had	   undergone	   previous	   surgery.	   All	   patients	   stopped	   taking	   any	  medication	   that	   might	   influence	   motility	   including	   antiemetics,	   opioids,	   anti-­‐diarrhoeals,	  SSRIs	  for	  example,	  for	  one	  week	  prior	  to	  their	  scan.	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Treatment	   Primary/	  
secondary	  
TPN	   Surgery	  
CIPO-­‐01	   70	   F	   2	   Scleroderma	   prokinetiks/	  antibiotics	   Secondary	  (Scleroderma)	   N	   N	  CIPO-­‐02	   35	   M	   2	   Dysmotility	   prokinetics	   Primary	   N	   Y	  (Colonic)	  CIPO-­‐03	   54	   M	   19	   Scleroderma	   Cardiac	  for	  AF,	  antibiotics	   Secondary	  (Scleroderma)	   Y	   N	  CIPO-­‐04	   68	   F	   19	   Dysmotility	   antibiotics	   Primary	  (Constipation)	   N	   N	  CIPO-­‐05	   90	   M	   8	   Visceral	  myopathy,	   omeprazole,	  losartan	   Primary	   N	   N	  CIPO-­‐06	   48	   F	   19	   Scleroderma	   antibiotics,	   Secondary	  (Scleroderma)	   Y	   N	  CIPO-­‐07	   36	   M	   7	   Dysmotility	   motility	   Primary	   N	   Y	  (Colonic)	  	  
Table	  8.2	  CIPO	  patient	  demographics	  
	  
8.2.4	  MRI	  Protocol	  	  The	   previous	   cohort	   of	   healthy	   subjects	   used	   in	   the	   neostigmine	   arm	   of	   the	  validation	   study	   described	   in	   6.2.5	   are	   again	   used	   here	   as	   controls.	   The	   CIPO	  patients	  underwent	  the	  exact	  same	  preparation.	  Two	  of	  the	  CIPO	  participants	  were	  unable	   to	   finish	   the	  mannitol	  drink	  and	   the	   total	   volume	   consumed	  was	   recorded	  and	   the	   same	  volume	  presented	   to	   them	  at	   follow	  up	   to	  ensure	   comparability.	  All	  CIPO	   patients	   abstained	   from	  motility	   influencing	  medication	   for	   1	  week	   prior	   to	  their	  first	  scan	  appointment.	  	  	  	  
8.2.5	  Drug	  Administration	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Neostimgine	   was	   administered	   as	   previously	   described	   in	   chapter	   6.2.5.	   Each	  subject	  then	  re-­‐attended	  for	  a	  second	  MRI	  scan	  after	  a	  mean	  gap	  of	  3	  weeks	  (range	  2	  days	   to	  7	  weeks),	  no	   individual’s	  scan	  start	   time	  varied	  by	  more	   than	  1h	  between	  the	   two	   visits.	   Subjects	  were	   prepared	   and	   examined	   in	   exactly	   the	   same	  way	   as	  previously	  except	  that	  the	  IV	  injection	  was	  crossed-­‐over	  so	  that	  placebo	  was	  given	  when	   they	   had	   previously	   received	   the	   drug	   and	   vice-­‐versa.	   For	   the	   two	   patients	  who	  could	  not	  complete	  the	  whole	  mannitol	  volume	  the	  first	  time,	  the	  same	  volume	  as	  preciously	  consumed	  was	  provided	  at	  the	  second	  visit.	  	  	  
8.2.6	  ROI	  placement	  	  The	   author	   randomised	   the	   presentation	   of	   the	   data	   sets	   to	   the	   reader.	   A	   single	  consultant	   radiologist	   (Dr.	   A	   Plumb,	   6	   years	   experience)	   placed	   ROIs	   around	   the	  small	  bowel	  in	  each	  coronal	  slice	  where	  it	  was	  present	  as	  per	  figure	  6.1.	  	  
	  
8.2.8	  Statistical	  Analysis	  	  	  Normality	  was	  assessed	  in	  all	  data	  series	  using	  Shapiro-­‐Wilk	  testing	  (alpha	  0.05).	  	   1. Baseline	  variation	   in	   global	   small	   bowel	  motility	  was	  assessed	   in	  CIPO	  and	  healthy	  controls	  using	  Bland-­‐Altman	  Limits	  of	  agreement.	  2. The	   mean	   baseline	   global	   motility	   score	   for	   each	   study	   participant	   was	  calculated	  and	  the	  CIPO	  and	  control	  group	  compared	  using	  T-­‐testing.	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3. The	   difference	   between	   neostigmine	   and	   placebo	   induced	   motility	   was	  calculated	   and	   tested	   for	   significance	   across	   both	   cohorts	   using	   paired	   T-­‐testing.	  4. The	   percentage	   difference	   neostigmine	   and	   placebo	   induced	  motility	   from	  their	  respective	  baseline	  was	  calculated	  and	  compared	  across	  the	  cohorts	  ie.	  Neostigmine	  (CIPO)	  versus	  Neostigmine	  (Control)	  and	  Placebo	  (CIPO)	  versus	  Placebo	  (Control)	  and	  tested	  using	  T-­‐test.	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8.3	  Results	  
	  
8.3.1	  Baseline	  variation	  	  Across	   the	   CIPO	   cohort,	  mean	   baseline	  motility	   at	   the	   first	   attendance	  was	   0.2AU	  (range	   0.12	   to	   0.3)	   and	   at	   the	   second	   was	   0.21	   (range	   0.16	   to	   0.29).	   The	   mean	  difference	  between	   scans	  was	   -­‐0.019AU	  with	  BA	   limits	  of	   agreement	   at	  ±0.061AU	  (figure	   8.2A).	   In	   the	   control	   cohort	  mean	   baseline	  motility	   at	   the	   first	   attendance	  was	  0.34	  (range	  0.275	  to	  0.37)	  and	  with	  a	  mean	  score	  at	  the	  second	  of	  0.34	  (range	  0.315	  to	  0.38).	  The	  mean	  difference	  between	  the	  cohort	  was	  	  0	  units	  with	  BA	  limits	  of	  agreement	  at	  ±0.042	  (figure	  8.2B).	  	  	  
	  
Figure	   8.2	   Bland	   Altman	   Limits	   of	   Agreement	   for	   CIPO	   patients	   (A)	   and	   healthy	  
controls	  (B)	  of	  global	  small	  bowel	  motility	  between	  visits.	  	  	  
A)	   B)	   Healthy	  controls	  (baseline	  1	  and	  baseline	  2)	  CIPO	  	  (Baseline	  1	  and	  Baseline	  2)	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8.3.2	  Difference	  in	  baseline	  motility	  between	  groups	  	  The	  median	   baseline	   global	  motility	   score	   across	   the	   two	   scan	   visits	   for	   the	   CIPO	  cohort	   was	   0.2AU	   (range	   0.14	   to	   0.295)	   and	   for	   the	   control	   subjects	   it	   was	   0.34	  (range	   0.28	   to	   0.375)	   (Figure	   8.3).	   There	   was	   a	   statistically	   significant	   mean	  difference	  between	  groups	  of	  0.14AU,	  P	  =	  <0.001	  (CI	  0.09	  to	  0.18).	  The	  two	  lowest	  scores	  in	  the	  CIPO	  cohort	  were	  attracted	  by	  patients	  with	  an	  underlying	  diagnosis	  of	  scleroderma.	  	  
Figure	   8.3	   Mean	   baseline	   global	  motility	   scores	   across	   the	   two	   visits	   for	   CIPO	   and	  
control	  subjects.	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0.16	  to	  0.42)	  and	  placebo	  was	  0.20AU	  (range	  0.14	  to	  0.31).	  There	  was	  a	  statistically	  significant	  mean	  difference	  of	  0.07AU	  between	  neostigmine	  and	  placebo,	  P	  =	  0.013	  (CI	  0.02	  to	  0.11)	  (Figure	  8.4A).	  	  In	   the	   healthy	   controls,	   mean	   global	   motility	   following	   neostigmine	   was	   0.39AU	  (range	  0.32	  to	  0.44)	  and	  placebo	  was	  0.32AU	  (range	  0.25	  and	  0.35).	  	  As	  reported	  in	  chapter	  6	  section	  5.2.3,	  there	  was	  a	  statistically	  significant	  mean	  difference	  between	  mean	  motility	   after	   neostigmine	   and	   placebo	   of	   0.07AU,	   P	   =	   0.005	   (CI	   =	   0.038	   to	  0.100)	  (Figure	  8.4B).	  
	  
Figure	   8.4	  Placebo	  versus	  Neostigmine	   line	  plots	   for	  CIPO	  patients	   (A)	  and	  controls	  
(B).	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8.3.4	  Relative	  response	  to	  Neostigmine	  challenge	  	  	  The	  relative	  percentage	  change	  in	  motility	  following	  neostigmine	  and	  placebo	  from	  the	  respective	  baseline	  is	  presented	  in	  Figure	  8.5.	   	  This	  additional	  comparison	  was	  performed	   to	   explore	  differences	   in	  motility	   response	   in	  CIPO	  and	   controls.	   	   Such	  subtle	   response	   variation	   could	   be	   potentially	   concealed	   by	   large	   baseline	  variability	  across	  the	  two	  time	  points.	  	  Comparison	  of	  percentage	  change	  in	  motility	  following	  neostigmine/placebo	  against	  baseline	   demonstrated	   a	   significant	   difference	   between	   CIPO	   (mean	   percent	  increase	   38	   percent,	   (range	   4.5	   to	   60)	   and	   controls	   (mean	   percent	   increase	   13.5,	  range	  0	  to	  39)	  of	  24.6	  percent,	  P	  =	  0.0015	  (CI	  10.9	  to	  38.2).	  	  There	  was	  however	  no	  statistically	   significant	   difference	   in	   response	   compared	   to	   baseline	   following	  administration	  of	  placebo	  (P	  =	  0.89).	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Figure	  8.5	  The	  percentage	  change	  from	  the	  respective	  baseline	  for	  neostigmine	  (black	  
dotted)	  and	  placebo	  (white	  dotted)	  for	  CIPO	  (A)	  and	  control	  (B).	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8.4	  Discussion	  
	  Data	  collected	  for	  this	  chapter	  confirms	  proof	  of	  concept	  for	  motility	  analysis	  using	  image	   registration	   in	  a	   clinical	   cohort	  demonstrating	  a	  difference	  both	   in	  baseline	  motility	  against	  controls	  and	  also	  response	  to	  the	  pro-­‐kinetic	  agent	  neostigmine.	  	  	  In	  chapter	  6,	  good	  repeatability	  between	  scans	  was	  demonstrated	  for	  healthy,	  well	  controlled	  volunteers.	  In	  this	  study,	  the	  data	  again	  showed	  reasonable	  repeatability	  although	  the	  LoA	  were	  larger	  at	  ±0.061	  in	  the	  CIPO	  cohort	  compared	  to	  the	  controls	  where	   the	   LoA	   ±0.042.	   The	   LoA	  were	   partly	   exaggerated	   by	   the	   small	   number	   of	  subjects	  but	  nevertheless,	  it	  was	  perhaps	  unexpected	  that	  this	  variability	  should	  be	  higher	   as	   each	   patient	   had	   established	   chronic	   disease	   and	   the	   time	   interval	  between	   scan	   dates	   was	   small.	   Although	   the	   CIPO	   cohort	   was	   well	   controlled	   in	  terms	  of	  medication	   and	  preparation	   it	   is	   likely	   that	   the	  underlying	  disease	   could	  lead	   to	   more	   irregular	   bowel	   contractility	   and	   indeed	   these	   patients	   anecdotally	  reported	  a	  large	  variation	  in	  the	  bowel	  symptoms.	  Two	  of	  the	  patients	  struggled	  to	  consume	  the	  entirety	  of	  the	  1L	  Manitol	  solution	  which	  may	  have	  influenced	  bowel	  motility.	   	   However,	   the	   volume	   consumed	   in	   the	   follow	   up	   visit	   was	   carefully	  matched	  and	  their	  motility	  scores	  did	  not	  appear	  to	  be	  outliers.	  	  	  It	   is	  broadly	  understood	  that	  small	  bowel	  motility	  in	  CIPO	  is	  reduced	  and	  this	  was	  investigated	  here	  by	  comparing	  the	  average	  small	  bowel	  score	  for	  each	  visit	  in	  the	  CIPO	   and	   control	   cohorts	   [24],	   [132].	   There	   was	   a	   large,	   statistically	   significant	  difference	   between	   group	   means	   with	   only	   a	   marginal	   overlap	   between	   cohorts	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confirming	  the	  hypothesis	  that	  motility	   is	   lower	   in	  this	  disease.	  This	  result	   further	  agrees	   with	   other	   research	   using	   segmental	   methods	   of	   small	   bowel	   motility	  quantification	  of	  MRI	  published	  recently	  by	  Ohkubo	  et	  al	   [76].	   Interestingly,	   there	  was	   however	   higher	   variance	   in	   motility	   across	   the	   CIPO	   cohort	   with	   the	   three	  patients	   who	   had	   an	   underlying	   diagnosis	   of	   scleroderma	   attracting	   the	   lowest	  motility	  scores.	  	  	  As	   presented	   in	   chapter	   6.3.3,	   a	   statistically	   significant	   increase	   in	   motility	   was	  observed	  in	  healthy	  controls	  following	  neostigmine	  compared	  to	  placebo.	  This	  study	  demonstrates	   that	  a	   significant	  difference	   is	  also	  observable	   in	   the	  CIPO	  cohort	   in	  response	   to	   the	   same	   dose	   of	   neostigmine,	   although	   again	   a	   larger	   variance	   was	  observed	   in	   the	   response	   with	   three	   patients	   in	   particular	   (two	   of	   whom	   had	  scleroderma)	   demonstrating	   only	   a	   marginal	   increase	   in	   motility.	   Due	   to	   the	  relatively	  high	  variability	  in	  baseline	  motility	  seen	  in	  7.3.1	  it	  was	  decided	  to	  further	  investigate	  the	  relative	  response	  to	  neostigmine	  and	  placebo.	  The	  reason	  being	  that	  where	  a	  patient	  recorded	  a	  baseline	  motility	  for	  scan	  1	  of	  0.32AU	  followed	  by	  0.35	  following	   neostigmine	   and	   then	   a	   baseline	   score	   at	   scan	   2	   of	   0.37	   and	   placebo	  change	   at	   0.36	   –	   the	   large	   difference	   in	   baseline	   would	   conceal	   the	   proceeding	  positive	   and	   negative	   changes	   from	   neostigmine	   and	   placebo.	   By	   examining	   the	  percentage	  change	   from	  baseline,	   it	  was	  possible	   to	   remove	  some	  of	   the	  potential	  bias	   introduced	   by	   physiological	   resting	   variability.	   In	   both	   the	   CIPO	   and	   control	  cohorts	   a	   positive	   response	   to	   neostigmine	   could	   be	   observed	   which	   was	   in	   fact	  significantly	  greater	  in	  the	  CIPO	  cohort.	  There	  was	  no	  significant	  difference	  between	  cohorts	   following	   placebo	   challenge	   supporting	   this	   observation	   as	   a	   real	  phenomenon.	  	  A	  response	  to	  neostigmine	  raises	  an	  interesting	  clinical	  consideration	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in	   that	   it	   signifies	   that,	   in-­‐spite	   of	   an	   overall	   decreases	  motility,	   the	   potential	   for	  contractile	   actions	   is	   still	   present.	   Neostigmine	   is	   a	   powerful	   acetycolinesterase	  inhibitor	  that	  acts	  at	  the	  level	  of	  the	  smooth	  muscle	  and	  is	  a	  well	  established	  method	  for	   symptom	   relief	   [25]–[27].	   One	  might	   reasonably	   hypothesise	   that	   none	   of	   the	  above	  cohort	  have	  a	  myopathic	  form	  of	  the	  disease.	  	  	  One	  of	  the	  main	  limitations	  of	  this	  study	  is	  the	  relatively	  small	  number	  of	  controls	  and	   in	  particular	  CIPO	  patients.	   Further	   complicating	   this	   problem	   is	   that	   CIPO	   is	  often	   a	   secondary	   process	   to	   a	   range	   of	   other	   diseases.	   Three	   of	   our	   cohort	   had	  scleroderma	   with	   the	   remaining	   4	   having	   a	   range	   of	   poorly	   characterised	  dysmotilities	   precipitating	   their	   CIPO	   diagnosis.	   The	   heterogeneity	   of	   the	   cohort	  makes	   the	   findings	   difficult	   to	   generalise,	   although	   valuable	   for	   hypothesis	  generation.	  One	  of	   the	  main	  challenges	   faced	   in	   this	  study	  was	  recruitment	  where	  even	   at	   a	   leading	   neurophysiology	   centre,	   the	   number	   of	   patients	   with	   CIPO	   and	  eligible	   for	   study	  participation,	  were	   low	   (1	  patient	  per	  3	  months).	  An	   interesting	  addition	   to	   this	   or	   future	   studies	  would	   be	   biopsy	   information	   on	   the	  myopathic	  versus	  neuropathic	   forms	  of	  CIPO	  where	  one	  might	  anticipate	  an	  altered	  response	  to	  neostigmine	  or	  other	  pro-­‐kinetic	  agents.	  A	  further	  limitation	  is	  the	  difference	  in	  age	   between	   controls	   (who	  were	  mainly	   young)	   and	   patients	  whose	   ages	   ranged	  between	  35	  and	  90.	  	  Many	  factors	  that	  are	  believed	  to	  influence	  motility	  were	  well	  controlled	   including	   time	  of	  day,	  bowel	  preparation,	   fasting,	   caffeine	   intake	  etc.	   In	  particular	   patients	   temporarily	   stopped	   motility	   altering	   medications	   (including	  painkillers,	   laxatives,	  SSRIs	  etc)	  7	  days	  before	  their	  scan	  that	  was	  greater	  than	  any	  of	   the	   medication	   half-­‐lives.	   In	   an	   attempt	   to	   minimise	   the	   patient	   time	   off	  medication	  the	  minimum	  follow-­‐up	  time	  between	  scans	  was	  decreased	  to	  2	  days.	  All	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of	   the	   healthy	   controls	   had	   a	  minimum	   delay	   between	   scans	   of	   2	   weeks	   and	   the	  difference	  in	  time	  between	  scans	  might	  impact	  on	  baseline	  repeatability.	  However,	  as	  the	  healthy	  subjects	  displayed	  a	  lower	  intra-­‐scan	  variability	  this	  was	  unlikely	  to	  be	  of	  importance	  in	  this	  study.	  	  	  The	  main	  purpose	  of	  this	  investigation	  was	  to	  demonstrate	  proof	  of	  concept	  for	  an	  MRI	   with	   post-­‐processing	   technique	   to	   evaluate	   motility	   in	   a	   clinical	   cohort.	  Although	  feasibility	  was	  demonstrated	  in	  healthy	  controls,	  this	  is	  the	  first	  time	  that	  a	   prospective	   investigation	   has	   been	   carried	   out	   in	   a	   patient	   group	   using	   this	  technique.	   CIPO	   were	   used	   as	   a	   target	   group	   for	   this	   study	   as	   they	   are	   widely	  recognised	  by	  the	  neurogastroenterology	  community	  as	  having	  low	  motility	  with	  a	  visible	  and	  clearly	  identifiable	  phenotype	  characterised	  by	  the	  bowel	  dilatation[24],	  [133].	  The	  mean	  baseline	  motility	  of	   the	  CIPO	  cohort	  was	  greater	   than	   that	  of	   the	  healthy	  controls	  presented	  in	  chapter	  6.3.4	  who	  received	  Buscopan	  (0.13AU).	  This	  suggests	   that	   even	   though	  CIPO	  baseline	  motility	  was	   low,	   it	  was	   still	  higher	   than	  healthy	   controls	   receiving	   a	   spasmolytic.	   This	   result	   is	   interesting	   in	   that	   it	  highlights	   the	   potential	   value	   of	   this	   technique	   in	   quantify	   relatively	   small	  differences	   in	  motility.	  One	  might	   imagine	  an	  application	  for	  assessing	  the	  efficacy	  of	  a	  drug	  that	  acts	  on	  the	  smooth	  muscle	  might	  help	  differentiate	  between	  the	  forms	  of	  the	  disease	  potentially	  avoiding	  the	  need	  for	  biopsy.	  Whether	  this	  is	  useful	  in	  the	  diagnosis	  and	  management	  of	  CIPO	  remains	  the	  subject	  of	  future	  work.	  Conversely,	  the	  technique	  might	  be	  extremely	  useful	  for	  other	  diseases	  of	  suspected	  dysmotility	  including	   IBS	   of	  whom	   a	   subselection	  may	   have	   a	   genuine,	  mechanical	   dysmotile	  component.	   From	   a	   practical	   perspective,	   all	   patients	   conformed	   to	   the	   protocol	  which	  took	  30min	  of	  scanner	  time	  (half	  that	  of	  a	  routine	  MRE	  investigation	  as	  well	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as	  being	  non-­‐invasive	  and	  widely	  available	  and	  compatible	  with	  most	  clinical	  MRI	  scanners).	  No	  adverse	  events	  were	  encountered	  in	  response	  to	  the	  administration	  of	  neostigmine.	  	  Not	   addressed	   in	   this	   study	   is	   assessment	   of	   the	   free-­‐breathing	   data	   or	   colonic	  motility.	  Chapter	  7	   introduced	  the	  DRAM	  technique	  to	  evaluate	   longer	  time	  series.	  	  However	  it	  was	  not	  used	  here	  for	  reasons	  of	  consistency	  with	  normal	  control	  data	  presented	   in	  chapter	  5.	   	   It	  will	  be	   interesting	   to	  see	  whether	   intra-­‐scan	  variability	  decreases	  when	  extended	  time	  series	  are	  used.	  Due	  to	  its	  superficial,	  distal	  location,	  the	  colon	  has	  been	  more	   thoroughly	   investigated	   in	   terms	  of	  motility	   in	  CIPO	  and	  again,	   using	   DRAM,	   there	   is	   the	   potential	   to	   perform	   detailed	   assessment	   of	   the	  colon	  in	  addition	  to	  small	  bowel.	  	  
Summary	  
	  This	   chapter	   has	   explored	   the	   clinical	   applicability	   of	   small	   bowel	   motility	  assessment	  with	  MRI.	  A	  number	  of	  new	  projects	  and	  research	  questions	  exist	  from	  these	   data	   alone	   and	   over	   the	   course	   of	   this	   PhD,	   a	   number	   of	   exciting	   new	  opportunities	  for	  in	  vivo	  motility	  assessment	  have	  arisen.	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SECTION	   E:	   CONCLUSIONS,	   FUTURE	   WORK	   AND	  EXPLOITATION	  	  	  
	  Section	   E	   concludes	   this	   thesis	   with	   Chapter	   9	   summarising	   the	   key	   findings	  providing	  a	  more	  personal	  reflection	  on	  the	  results	  and	  their	  broader	  interpretation	  within	   the	   context	   of	   the	   recent	   literature.	   In	   the	   futures	   section	   of	   this	   chapter,	  some	  of	  the	  important	  but	  less	  tangible	  challenges	  emerging	  from	  the	  work	  will	  be	  discussed,	   specifically	   regarding	   how	   the	   validated	   technology	   might	   be	   used	   to	  further	  research	  outside	  of	  the	  Centre	  for	  Medical	  Imaging	  and	  ultimately	  translate	  into	  the	  clinic.	  	  	  By	  way	  of	  a	  follow	  on	  to	  the	  core	  themes	  of	  Chapter	  9,	  Appendix	  4	  deviates	  from	  the	  science	  altogether	  and	   focuses	  on	   the	  business	  and	  commercialisation	  potential	  of	  the	   research.	   This	   section	   may	   be	   of	   interest	   to	   readers	   with	   a	   commercial	  background,	  those	  looking	  to	  develop	  their	  technology	  beyond	  the	  research	  setting	  or	   perhaps	   those	   yet	   to	   start	   a	   translational	   project,	   who	   are	   trying	   to	   better	  determine	  their	  research	  question.	  	   	  
	  	   230	   	  
	   	  
CHAPTER	   9:	   DISCUSSION	   OF	   RESULTS	   AND	   FUTURE	  PERSPECTIVES	  
Discussion	  of	  results	  
In	  this	  final	  section	  I	  conclude	  the	  thesis	  by	  discussing	  the	  research	  questions	  asked	  at	  the	  beginning	  of	  each	  chapter	  and	  presenting	  my	  perspective	  of	  the	  future	  of	  this	  research.	  I	  will	  also	  move	  into	  the	  first	  person	  to	  hopefully	  inject	  some	  interest	  into	  what	   is	   a	   somewhat	   subjective	   reflection	   of	   the	   key	   findings	   emerging	   from	   this	  project.	  Each	  of	  the	  following	  sections	  is	  presented	  as	  the	  original	  research	  question	  running	  from	  chapters	  2	  to	  8	  followed	  by	  a	  response	  written	  within	  the	  context	  of	  the	  thesis	  findings	  as	  a	  whole.	  	  Can	  image	  post-­‐processing	  be	  used	  to	  objectively	  evaluate	  MRE	  derived	  small	  bowel	  motility	  data?	  	  	  	  In	   this	   Chapter,	   I	   detailed	   the	   validation	   process	   for	   the	   registration	   algorithm	  developed	   by	   Freddy	   Odille	   to	   analyse	   dynamic	   time-­‐series	   MRI	   data.	   For	   a	   long	  time,	  image	  registration	  has	  been	  an	  extremely	  popular	  topic	  of	  research	  in	  medical	  imaging	   with	   numerous	   applications	   in	   oncology	   and	   neurology,	   for	   example	  measuring	   the	   change	   in	   size	   of	   various	   structures.	  Application	   to	   the	  bowel	  was,	  however,	  novel	  and	  an	  excellent	  demonstration	  of	  collaborative	  research,	  matching	  a	  clinical	  problem	  with	  a	  latent	  technical	  solution.	  The	  opportunity	  was	  also	  timely	  given	  the	  increasing	  implementation	  of	  Magnetic	  Resonance	  Enterography	  at	  UCLH	  as	  a	  routine	  diagnostic	  technique	  for	  evaluating	  Crohn’s	  disease,	  thereby	  providing	  a	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large	   amount	   of	   data	   including	   dynamic	   motility	   series.	   Chapter	   1	   provided	   the	  background	  to	  the	  thesis	  and	  stressed	  the	  major	  opportunities	  to	  researchers	  in	  this	  field.	   	   In	   Chapter	   2	   my	   validation	   experiments	   demonstrated	   that	   the	   algorithm	  could	  accurately	  propagate	  a	  user	  placed	  ROI	  through	  a	  time	  series,	  demonstrating	  that	  the	  local	  deformation	  caused	  by	  bowel	  wall	  movement	  was	  corrected	  well.	  This	  allowed	  a	  significant	  practical	  step	  in	  terms	  of	  ROI	  propagation	  (e.g.	  minimising	  the	  labour	  intensity	  of	  plotting	  of	  lumen	  diameter	  over	  time)	  but	  also	  a	  new	  possibility	  in	   the	   form	   of	   surrogate	   measures	   for	   motility	   based	   on	   the	   deformation	   fields	  themselves.	   This	   concept	   indeed	   proved	   to	   be	   a	   powerful	  measure	   to	   summarise	  motility	   both	   segmentally	   and	   ultimately	   globally,	   being	   sensitive	   to	  pharmacologically	   induced	   changes	   in	   motility	   and	   demonstrating	   good	   intra-­‐subject	   repeatability.	   An	   ongoing	   challenge	   has	   however	   been	   the	  meaning	   of	   the	  selected	   metric,	   the	   standard	   deviation	   of	   the	   Jacobian	   determinant	   and	   other	  surrogate	  measures	  of	  motility.	  This	  has	  been	  especially	  pertinent	  when	  presenting	  research	   data	   to	   clinically	   focused	   audiences.	   The	   notion	   of	   deformation	   fields	  quantified	  in	  this	  way	  seems	  detached	  from	  the	  underlying	  physiological	  processes	  and	  therefore	  troubling	  to	  many	  interested	  in	  the	  nature	  of	  the	  physiological	  action.	  Potential	  solutions	  exist	  in	  the	  form	  of	  providing	  entirely	  new	  metrics,	  for	  example	  pixel	  movement	   in	  space	  (mm)	  per	  unit	  of	   time	  (min)	  which	  would	  perhaps	  more	  directly	  present	  the	  data	  from	  the	  registration	  process	  and	  be	  broadly	  transferable	  should	  new	  registration	  schema	  be	  presented.	  As	  was	  demonstrated	   in	  Chapter	  2,	  several	   other	   candidate	   metrics	   were	   developed	   alongside	   the	   SD	   Jacobian	   and	  hundreds	  more	  exist	  that	  might	  be	  of	  value.	  However,	  the	  SD	  Jacobian	  measure	  was	  used	  throughout	  this	  PhD	  first	  because	  it	  correlated	  best	  against	  radiologist	  grading	  and	  secondly	  for	  the	  boarder	  reason	  establishing	  a	  consistent,	  if	  somewhat	  abstract,	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measurement	   in	   the	   published	   literature.	   A	   temptation	   is	   to	   measure	   an	  experimental	   finding	   using	   a	   range	   of	  motility	  metrics	   to	   see	  which	   produces	   the	  best	   result	   against	   the	   hypothesis.	   Indeed	   we	   have	   seen	   this	   in	   other	   studies,	  described	   in	   chapter	   1,	   where	   contraction	   rate,	   max	   diameter	   and	   diameter	  standard	  deviation	  are	  all	  used	   to	  measure	  bowel	  motility	   in	   the	  same	  paper.	  The	  implication	   of	   using	   multiple	   measures	   being	   a	   higher	   chance	   of	   a	   type	   1	   (false	  positive)	  error	  being	  observed	  and	  published	  where	  a	  spurious	  correlation	  or	  result	  is	  found.	  It	  has	  been	  my	  goal	  to	  provide	  consistency	  and	  transparency	  in	  my	  results	  and	   this	   has	   prohibited	  my	   developing	   and	   implementing	   additional	  measures	   of	  motility.	  In	  future	  work,	  I	  hope	  to	  go	  back	  and	  re-­‐validate	  a	  range	  of	  metrics	  based	  on	   feedback	   from	   the	   community	   and	   a	   better	   understanding	   of	   GI	   physiology	  however	  such	  research	  was	  outside	  the	  scope	  of	  this	  PhD	  thesis.	  	  	  	  	  What	  is	  the	  relationship	  between	  small	  bowel	  motility	  and	  inflammatory	  activity	  at	  the	  terminal	  ileum	  in	  Crohn’s	  disease	  patients?	  	  	  	  Bowel	  wall	  thickness	  has	  long	  been	  associated	  with	  inflammatory	  activity	  in	  CD	  and	  it	  remains	  intuitive	  that	  as	  the	  bowel	  becomes	  thickened,	  the	  ability	  of	  the	  bowel	  to	  contract	  decreases.	  The	  hypothesis	  in	  chapter	  3	  may	  appear	  in	  retrospect	  relatively	  obvious.	   However	   it	   was	   unclear	   if	   there	   was	   any	   relationship	   between	   actual	  inflammatory	  activity	  and	  motility,	  not	  just	  with	  wall	  thickness	  per	  se.	  Furthermore	  at	   the	   time,	   only	   one	   small,	   qualitative	   paper	   using	  motility	   to	   assist	   with	   lesion	  detection	  in	  CD	  had	  been	  published[14].	  Within	  the	  broader	  context	  of	  the	  field,	  new	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biomarkers	   for	   inflammation	   including	   diffusion,	   enhancement,	   magnetization	  transfer	  etc.,	  were	  all	  being	  explored	  to	  try	  and	  more	  accurately	  categorise	  disease	  using	  MRE	   [104],	   [107],	   [109],	   [140]–[142].	   	  Quantified	  motility	  was	   therefore	   an	  obvious	   target	   to	   explore	   with	   the	   validated	   technique.	   Motility	   was	   in	   fact	  negatively	   correlated	   with	   inflammatory	   activity	   and,	   based	   on	   the	   regression	  analysis	   presented,	   performed	   approximately	   as	   well	   as	   the	   other	   MR	   based	  features.	  One	   interesting	  observation	   from	  our	  data	  was	   the	   large	  number	  of	  non-­‐inflamed	   subjects	  with	   “low”	  motility.	   Following	   the	  publication	  of	   this	   study	  and,	  while	   presenting	   the	   results	   at	   conferences,	   many	   postulated	   or	   at	   least	   found	   it	  feasible	   that	   the	   motility	   was	   influenced	   by	   humoral	   factors	   mediated	   by	  inflammation[110]–[113],	   [121][16],	   [121][16],	   [121][16],	   [121][16],	   [120][16],	  [119][16],	  [118][16],.	  That	  is	  to	  say,	  as	  yet	  unknown	  factors	  were	  introducing	  high	  variation	   into	   histopathologically	   un-­‐inflamed	   subjects	   to	   indirectly	   suppress	  motility.	   	   At	   this	   time,	   there	  were	   no	   reference	   ranges	   for	  MRE	   assessed	   healthy	  small	  bowel	  motility	  so	  it	  was	  difficult	  to	  comment	  either	  way.	  	  	  How	  do	  Crohn’s	  disease	  strictures	  influence	  small	  bowel	  motility?	  	  Chapter	  4	  investigated	  the	  impact	  of	  stricturing	  CD	  on	  small	  bowel	  motility,	  and	  this	  time	   I	   expanded	   the	   analysis	   to	   the	   stricture	   itself,	   the	   upstream	   dilation	   and	   a	  morphologically	   and	   functionally	   normal	   reference	   loop	   of	   bowel.	   Robust	  differences	  were	   demonstrated	   between	   the	   thickened	   bowel	   at	   the	   stricture	   and	  the	  normal	  bowel	   confirming	   the	  observations	  described	   in	   chapter	  3	  –	   thickened	  bowel	  does	  not	  peristalse.	   Less	  variation	  was	   seen	   this	   time	   in	   the	  motility	  of	   the	  normal	   reference	   loops,	   likely	   because	  we	   specifically	   selected	   a	   bowel	   loop	   that	  
	  	   234	   	  
	   	  
was	  visibility	  peristalsing.	  This	  study	  demonstrated	  that	  the	  dilated	  bowel	  appeared	  to	   lose	   its	   capacity	   to	   contract	   as	   its	   calibre	   increased.	   Interestingly	   however	   the	  data	   suggested	   that	   the	   phenomena	   might	   be	   reversible	   with	   time.	   	   Although	  retrospective,	  the	  large	  number	  of	  subjects	  in	  this	  study,	  together	  with	  consistency	  of	   the	   findings	   with	   previous	   animal	   data,	   helped	   demonstrate	   the	   potential	   of	  quantified	  motility	  analysis	  to	  be	  a	  useful	  surrogate	  of	  bowel	  dynamics	  in	  health	  and	  disease.	  Poor	  motility	  in	  dilated	  bowel	  upstream	  of	  a	  stricture	  is	  well	  recognised	  by	  radiologists	  and	  surgeons	  in	  clinical	  practice,	  yet	  the	  literature	  is	  surprisingly	  sparse	  of	   any	   direct	   support	   for	   the	   widely	   held	   notions	   regarding	   motility	   dynamics	  around	  a	  stricture[118].	  It	  was	  therefore	  an	  altogether	  satisfying	  study	  to	  complete,	  not	   least	   on	   account	   of	   the	   huge	   amount	   of	   work	   Emma	   Helbren	   and	   I	   had	   to	  perform	  (examining	  virtually	  every	  MRE	  scan	  at	  UCLH	  over	  a	  three-­‐year	  period)	  but	  quantitation	  was	  provided	  essentially	  for	  the	  first	  time	  	  to	  support	  a	  well	  described	  clinical	  phenomena.	  	  	  What	   are	   the	  potential	  methodological	   issues	  arising	   from	  segmental	   (local	  bowel	  loop)	  ROI	  placement	  in	  small	  bowel	  motility	  analysis?	  	  While	   the	   retrospective	   studies	   in	   Section	   B	   were	   conducted,	   I	   recruited	   and	  scanned	   a	   cohort	   of	   20	   healthy	   subjects	   with	   a	   view	   to	   developing	   a	   better	  understanding	   of	   normality	   of	   bowel	   motility.	   Chapter	   5	   was	   a	   descriptive	   study	  that	  presents	   in	   as	  unbiased-­‐a-­‐fashion	   as	  possible,	   healthy	   reference	   ranges	  using	  the	  two	  techniques	  commonly	  used	  to	  investigate	  motility,	  contractions	  per	  minute	  and	  our	  SD	  Jacobian	  metric[12],	  [16],	  [76]–[78].	  A	  systematic	  approach	  was	  adopted	  to	  look	  at	  intra-­‐scan	  variability	  (i.e.	  between	  bowel	  segments)	  and	  variability	  at	  two	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time	   points	   in	   our	   healthy	   subjects	   across	   both	   breath-­‐hold	   and	   free-­‐breathing	  protocols.	   While	   this	   study	   is	   perhaps	   heavy	   on	   data,	   it	   is	   important	   for	   several	  reasons.	   First,	   it	   showed	   that	   intra-­‐scan	   variability,	   that	   is	   variability	   within	  someone’s	   own	   bowel	   segments,	   is	   surprisingly	   high	   and	   almost	   as	   high	   as	   the	  variability	  across	  the	  study	  population	  as	  a	  whole.	  The	  majority	  of	  the	  subjects	  had	  at	  least	  one	  ‘hypo-­‐motile’	  bowel	  loop,	  with	  motility	  comfortably	  within	  the	  range	  of	  the	  most	   ‘inflamed	   subjects’	   identified	   in	   chapter	   3,	   regardless	   of	   the	  metric	   used	  (also	   see	   Cullmann	   et	   al.,	   2013;).	   Second,	   the	   variability	   observed	   in	   inter-­‐scan	  reproducibility	   of	   the	  metrics	  was	   even	   higher.	   Even	  where	   the	   TI	  was	   used	   as	   a	  landmark	  and	  relatively	  high	  certainty	  could	  be	  achieved	  in	  accurate	  ROI	  placement	  across	  the	  scans,	  variability	  was	  very	  high.	  In	  this	  study	  I	  endeavoured	  to	  make	  it	  a	  fair	   reflection	  of	   the	  methodologies	  used	  both	  by	  us	   and	  by	   the	  other	   groups	   and	  was	   somewhat	   surprised	   by	   just	   how	   variable	   the	   data	  was	   despite	   the	   stringent	  study	  control	   and	  also	  by	   the	   relatively	  poor	   correlation	  between	   the	  SD	   Jacobian	  and	  CPM	  metrics.	  Although	  the	  paper	  was	  eventually	  published	   in	  BJR,	   it	  was	   first	  rejected	   by	   Radiology	   with	   almost	   no	   criticism	   other	   than,	   it	   not	   being	   directly	  relevant	  to	  a	  general	  radiological	  journal	  and	  then	  by	  NGM	  where	  they	  felt	  that	  such	  heterogeneity	   was	   “obvious”.	   Despite	   the	   latter	   comment,	   it	   had	   not	   prevented	   a	  rush	   of	   papers	   being	   published	   in	   2013	   using	   segmental	   methodologies	   to	   make	  assertions	  regarding	  motility	  using	  MRE	  based	  approaches	  and	  a	  collective	   lack	  of	  appreciation	  in	  the	  methodological	  pitfalls	  in	  this	  type	  of	  quantitative	  research[16],	  [76],	  [78],	  [121].	  	  	  Can	   global	   small	   bowel	   assessment	   be	   used	   to	   provide	   robust,	   repeatable	   and	  sensitive	  measures	  of	  small	  bowel	  motility?	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  Global	  motility	  assessment	  based	  on	   the	  evaluation	  of	  SD	   Jacobian	  score	  averaged	  across	  the	  entire	  bowel	  was	  an	  significant	  underlying	  concept	  behind	  my	  PhD	  and	  thus	   data	   presented	   	   present	   in	   Chapter	   6	   was	   a	   major	   advance	   over	   segmental	  analysis.	   Many	   of	   the	   conditions	   that	   originally	   interested	   me	   in	   this	   form	   of	  research,	   including	   IBS,	   Parkinson’s,	   Diabetes	   etc	   require	   a	   global	   method	   to	  evaluate	   motility.	   Despite	   severe	   gastrointestinal	   symptoms,	   there	   is	   often	   no	  causative	  lesion	  found	  and	  patients	  appear	  “radiologically	  normal”.	  It	  is	  in	  this	  form	  of	  global	  assessment	  that	  the	  registration	  technique	  was	  able	  to	  truly	  demonstrate	  its	   value	   allowing	   largely	   unbiased	   evaluation	   of	   the	   whole	   abdominal	   gut	   as	   a	  system.	  The	  one	  problem	  from	  a	  scientific	  point	  of	  view	  was	  the	  lack	  of	  any	  kind	  of	  gold	   standard;	   manometry	   is	   invasive	   and	   provides	   segmental	   data	   only,	   whilst	  scintigraphy	   looks	   at	   transit,	   not	   bowel	   wall	   motion.	   I	   attempted	   to	   address	   the	  issue	  of	  technique	  validation	  by	  performing	  a	  blinded,	  placebo	  controlled	  cross-­‐over	  study	   enabling	   the	   evaluation	   of	   both	   technique	   sensitivity	   to	   drugs	   with	   known	  pharmacological	  effects,	  	  and	  intra-­‐subject	  repeatability.	  I	  demonstrated	  high	  inter-­‐observer	   agreement	   between	   two	   radiologists	   who	   individually	   segmented	   the	  bowel	   for	   analysis..	   Quantified	   motility	   also	   demonstrated	   good	   intra-­‐subject	  repeatability	   over	   two	   time	   points,	   superior	   than	   that	   demonstrated	   using	  segmental	  analysis,	  likely	  helped	  by	  removing	  any	  variability	  in	  ROI	  placement	  and	  negating	   intersegment	   differences.	   Potentially	   the	   most	   interesting	   result	   arising	  from	  this	  study	  was	  the	  ability	  of	  the	  technique	  to	  detect	  a	  change	  in	  motility	  driven	  by	   a	   pharmacological	   stimulus[21],	   [27].	   Neostigmine	   was	   capable	   of	   increasing	  motility	  and	  Buscopan	  conversely	  by	  decreasing	  motility	  against	  a	  placebo	  control	  in	  one	  of	  the	  first	  studies	  of	  its	  kind	  using	  MRI.	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  Can	   a	   pre-­‐registration	   respiratory	   motion	   correction	   step	   be	   used	   to	   extend	   the	  application	  of	  the	  optic-­‐flow	  technique	  to	  free	  breathing	  bowel	  motility	  data?	  	  	  	  In	   Chapter	   6	   I	   helped	   develop	   and	   validate	   the	   DRAM	   technique	   to	   correct	  respiratory	  motion	  and	  allow	  motility	  quantitation	  in	  free	  breathing	  data	  using	  optic	  flow	   as	   described	   before.	   The	   basis	   for	   chapter	   6	   evolved	   through	   intra-­‐departmental	   collaboration	   and	   partly	   through	   an	   emerging	   need	   from	   my	  collaborators	  outside	  of	  UCL	  looking	  to	  measure	  bowel	  wall	  motion	  in	  colonic	  data	  sets	  of	  120+	   images	   acquired	  using	   free-­‐breathing	  protocols.	   I	  was	   also	  becoming	  increasingly	   interested	   in	   extended	   protocols	   designed	   for	   the	   small	   bowel	   to	  examine	   other	   types	   of	   contractile	   actions	   such	   as	   the	   colon	   that,	   again,	   would	  require	  extended	  free-­‐breathing	  protocols.	  Registration	  using	  OF	  alone	  would	  result	  in	   reasonable	   motion	   correction	   especially	   in	   the	   pelvis	   where	   diaphragmatic	  movement	  was	  reduced	  but	  there	  was	  a	   large	  bias	   in	  the	  SD	  Jacobian	  score	  where	  respiratory	   motion	   was	   conflated	   with	   that	   of	   local	   deformation	   caused	   by	   the	  bowel.	   The	   RDDR	   pre-­‐processing	   step	   was	   effective	   at	   removing	   the	   respiratory	  motion	   and	   the	   subsequent	   application	   of	   optic-­‐flow	   resulted	   in	   good	   motion	  correction	  and	  similar	  results	  as	  those	  seen	  in	  chapter	  2.	  The	  ability	  to	  automatically	  propagate	   ROIs	   through	   the	   time	   series	   did	   not	   end	   up	   featuring	   particularity	  prominently	   in	   this	   thesis,	  with	  a	  preference	   instead	   for	   the	  SD	   Jacboian	  measure.	  Conversely,	   for	  our	  collaborators	  at	  UoN,	  contraction	  measurement	  was	  one	  of	  the	  primary	  means	  of	  analysing	  motility	  and	  therefore	  this	  technique	  has	  become	  very	  popular	  in	  subsequent	  studies	  at	  that	  institution	  with	  over	  300	  data	  sets	  analysed	  to	  date.	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  Can	   global	   small	   bowel	   motility	   analysis	   be	   used	   to	   quantitatively	   demonstrate	  physiological	   differences	   between	   healthy	   controls	   and	   Chronic	   Intestinal	   Pseudo	  Obstruction?	  	  Finally	   in	   Chapter	   7	   I	   explore	   the	   application	   of	   the	   global	   motility	   analysis	  technique	  to	  a	  cohort	  of	  CIPO	  patients.	  The	  data	  in	  this	  study	  demonstrated	  a	  clear	  difference	   in	  motility	  compared	   to	  healthy	  controls.	  The	  DRAM	  technique	  was	  not	  applied	  to	  this	  cohort	  for	  the	  sake	  of	  comparability	  with	  Chapter	  6.	  At	  the	  time	  this	  chapter	  was	  written,	  only	  7	  patients	  had	  been	  scanned	  owing	  to	  the	  extraordinary	  difficulty	   in	   recruitment.	  One	  of	   the	  key	   concepts	  emerging	   from	   this	   thesis	   is	   the	  measurement	  of	  the	  bowel	  as	  a	  system	  and	  ability	  to	  monitor	  change	  induced	  in	  this	  case	  through	  the	  use	  of	  medication.	  Neostigmine	  in	  particular	  acts	  at	  the	  level	  of	  the	  smooth	  muscle	  in	  the	  GI	  tract	  and	  therefore	  has	  a	  fundamental	  effect	  on	  contraction.	  The	  ability	  to	  non-­‐invasively	  probe	  the	  bowel	  opens	  up	  exciting	  opportunities	  with	  other	  pharmacological	  agents	  with	  a	  view	  to	  better	  exploring	  enteric	  pathology.	  	  	  
Future	  perspectives	  	  
	  A	   ‘gut	   feeling’	   is	   an	   almost	  daily	   occurrence	   for	  most	   of	   us	   in	   some	   respect	   and	  a	  cross-­‐cultural	  reference	  that	  demonstrates	  the	  intimate	  relationship	  we	  share	  with	  our	   viscera.	   The	   rich	   neurological	   input	   from	   our	   gut	   into	   our	   central	   nervous	  system	  modulates	  many	   aspects	   of	   our	  mood	   and	   general	  well	   being	  but	   remains	  poorly	  understood.	  Conditions	  like	  Irritable	  Bowel	  Syndrome	  affect	  as	  many	  as	  1	  in	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10	  people	  and	   radically	  decreases	   the	  quality	  of	   life	   for	  millions	  of	  people	  around	  the	  world,	  yet	  no	  test	  or	  biomarker	  exists	  outside	  of	  subjective	  and	  limited	  clinical	  scoring	   based	   on	   bowel	   habit.	   It	   may	   well	   be	   that	   aberrant	   motility	   is	   not	  responsible	   for	   the	   IBS	  phenotypes	  observed,	  but	  even	   if	   that	   is	   the	   case	  a	   test	   to	  rule	  true	  dysmotility	  in	  or	  out	  would	  benefit	  patients	  and	  healthcare	  providers	  alike.	  Few	  other	  systems	  remain	  as	  poorly	  understood	  as	  the	  gut	   in	  medical	  science	  and	  this	   is	   one	   of	   the	   primary	   driving	   factors	   influencing	   this	   PhD	   and	   the	   research	  themes	  discussed.	  	  This	  thesis	  presents	  some	  of	  the	  earliest	  validation	  into	  advanced	  motility	  assessment	  techniques	  that	  will	  hopefully	  go	  on	  to	  support	   further	  grants	  on	  the	  clinical	  practicality	  of	  the	  test,	  making	  the	  technique	  well	  poised	  to	  influence	  patient	   investigation.	  There	  are	  however	  two	  large	   limitations	  for	  progressing	  this	  research	  beyond	  the	  various	  smaller	  methodological	  points	  raised	  throughout	   this	  thesis.	  	  	  The	  first	  concerns	  how	  the	  technique	  will	  be	  used	  in	  the	  clinic.	  With	  the	  limited	  data	  presented	   here,	   a	   gastroenterologist	   (the	   potential	   user)	   simply	   does	   not	   have	  enough	   information	   to	   use	   MRE	   motility	   analysis	   in	   a	   meaningful	   way	   clinically.	  Even	   viewing	   the	   raw	   cine	   images	   is	   insufficient	   to	   add	   any	   information	   to	   the	  clinical	  work	  up,	  especially	  where	  even	  healthy	  subjects	  appear	  to	  have	  completely	  static	  segments	  of	  bowel.	  Is	  this	  a	  case	  of	  the	  clinically	  useful	  information	  not	  being	  there	  or	  the	  observer	  simply	  not	  knowing	  what	  to	  look	  for?	  Until	  large-­‐scale	  studies	  are	   performed	   in	   healthy	   controls	   and	   well	   characterised	   patient	   groups,	   we	  unfortunately	  will	  not	  be	  able	  to	  answer	  this	  question.	  Motility	  assessment	  has	  the	  potential	  to	  add	  value	  in	  the	  absence	  of	  structural	  abnormality	  (e.g.	  in	  autonomic	  or	  myopathic	  conditions	  affecting	  bowel).	  Ultimately	  the	  value	  will	  come	  down	  to	  not	  
	  	   240	   	  
	   	  
just	  the	  identification	  of	  dysmotility	  but	  also	  the	  practical	  capacity	  to	  do	  something	  with	  that	  information.	  What	  makes	  this	  research	  exciting	  is	  that	  there	  are	  already	  an	  array	   of	   medications	   for	   motility	   that	   are	   currently	   used	   in	   a	   trial-­‐and-­‐error	  approach	   to	   treat	   a	   range	  of	  bowel	   conditions	  and	   thus,	   the	   techniques	  presented	  here	  will	  be	  able	  to	  fit	  into	  a	  clinical	  framework	  in	  some	  capacity	  -­‐even	  if	  just	  to	  stop	  unnecessary	   prescription.	   The	   response	   to	   the	   technique	   has	   been	   positive	   with	  several	   grants	  written	   to	   date	   by	   other	   research	   groups	   outside	   of	   the	   Centre	   for	  Medical	   Imaging,	  using	   the	   techniques	  described	  here	  as	   the	  primary	  end-­‐point	   in	  diseases	   ranging	   from	   obesity,	   hypermobility	   disorders,	   IBS	   and	   Crohn’s.	   As	   the	  literature	   using	   the	   optic	   flow	   and	   DRAM	   techniques	   increases,	   there	   will	  theoretically	  be	  a	  broader	  move	  towards	  using	  these	  methods	  in	  trials,	  research	  and	  ultimately	  the	  clinic	  however	  this	  brings	  us	  to	  a	  second	  important	  point.	  	  	  A	   second	   major	   limitation	   I	   have	   now	   encountered	   has	   been	   distribution	   of	   the	  motility	  analysis	  techniques.	  The	  implementation	  of	  the	  registration	  code	  was	  split	  across	   several	   computer	   languages	   and	   operating	   systems	  making	   distribution	   of	  the	  source	  code	  difficult.	  Beyond	  this,	  users	  did	  not	  want	   to	  have	  to	   invest	   in	  new	  computers	   to	   run	   the	   relatively	   demanding	   algorithms	   nor	   troubleshoot	   the	  innumerable	  problems	  emerging	  from	  prototyped	  code.	  As	  a	  short-­‐term	  solution,	  I	  have	  been	  providing	   the	  registration	  result	  and	  returning	  key	  data	  as	  DICOM	  files	  (e.g.	  the	  SD	  Jacobian	  map	  or	  the	  key	  figures	  so	  that	  they	  might	  perform	  the	  further	  analysis	   in	   their	   DICOM	   viewer).	   A	   growing	   number	   of	   data	   sets	   have	   been	   now	  been	  processed	  from	  a	  range	  of	  institutions	  around	  the	  world.	  The	  demand	  for	  the	  techniques	  led	  me	  to	  founding	  the	  business	  Motilent	  Ltd.	  The	  goal	  of	  Motilent	  was	  to	  raise	  additional	   funding	  through	  the	  various	   investment	  opportunities	   for	  SMEs	  in	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London	  to	  re-­‐code	  all	  of	  the	  registration	  algorithms	  used	  and	  build,	  more	  formally,	  a	  product	   that	   might	   go	   on	   to	   not	   only	   serve	   as	   a	   research	   tool	   but	   also	   a	   clinical	  diagnostic	  tool.	  Funding	  could	  also	  be	  used	  to	  secure	  patent	  protection	  for	  emerging	  technology	  and	  establish	  a	  consultancy	  to	  drive	  technique	  use	  and	  development	  of	  the	  technique.	  	  In	  appendix	  4	  of	  this	  thesis	  I	  present	  a	  complete	  move	  away	  from	  the	  science	  all	   together	  and	  look	  at	  the	  commercial	  opportunities	  and	  route	  to	  market	  for	   a	   technique	   for	  motility	   evaluation	   to	   address	   the	   two	  big	   questions	   raised	   in	  this	  last	  section.	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APPENDIX	   2:	   POWER	   CALCULATION	   FOR	   GLOBAL	  
MOTILITY	  ASSESSMENT	  	  
	  The	  technique	  for	  global	  motility	  assessment	  proposed	  in	  chapter	  6	  had	  no	  existing	  counterpart	  or	  gold-­‐standard	  at	  the	  time	  of	  the	  study	  to	  which	  it	  could	  be	  compared.	  In	   the	  absence	  of	   literature	  values	  or	  external	  data	   to	  guide	  a	  power	  calculation	  a	  small	  cohort	  of	  Crohn’s	  disease	  patients	  were	  used	  both	  to	  help	  identify	  a	  suitable	  sample	   size	   for	   the	   study	   and	   to	   demonstrate	   proof	   of	   principle	   to	   the	   Research	  Ethics	  committee.	  Selection	  of	  a	  suitable	  sample	  size	   is	   important	  both	  in	  terms	  of	  reducing	  the	  chances	  for	  adverse	  events	  (especially	  when	  administering	  drugs)	  and	  effectively	   managing	   the	   study	   cost.	   Two	   small	   studies	   are	   summarised	   here	   in	  abstract	  form	  detailing	  that	  helped	  to	  determine	  our	  study	  numbers.	  	  	  
A2.1	  Baseline	  intra-­‐subject	  repeatability	  	  
A2.1.1	  Purpose	  	  Determine	   mean	   baseline	   motility	   values	   and	   mean	   within-­‐subject	   standard	  deviation	  for	  sample	  size-­‐calculation	  within	  the	  context	  of	  estimating	  the	  accuracy	  of	  the	  Bland-­‐Altman	  95%	  Limits	  of	  Agreement	  with	  the	  SD	  Jacobian	  metric.	  	  
A2.2.1	  Methods	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  Four	   patients	   (2	   male)	   were	   identified	   from	   our	   institutional	   database	   who	   had	  received	  two	  scans	  over	  a	  two	  year	  period	  and	  had	  not	  undergone	  any	  surgery.	  In	  all	  cases,	   radiology	   was	   reported	   as	   ‘unchanged’	   between	   scans.	   Patients	   had	  undergone	  institutional	  small	  bowel	  preparation	  as	  per	  chapter	  2.2.4	  with	  dynamic	  scanning.	   The	   entire	   small	   bowel	   was	   segmented	   and	   a	   global	   motility	   value	  calculated	   by	   averaging	   the	   mean	   SD	   Jacobian	   motility	   score.	   A	   sample	   size	  calculation	  was	  performed	  with	  a	  90%	  power	  (possibility	  of	  correctly	  rejecting	  the	  null	  hypothesis)	  with	  an	  alpha	  of	  0.05.	  	  
A2.3.1	  Results	  	  The	  mean	  global	  motility	  score	  for	  scan	  1	  was	  0.29AU	  (range	  0.25	  to	  0.34)	  and	  scan	  2	  was	  0.27AU	  (range	  0.24	  to	  29).	  The	  mean	  within-­‐subject	  standard	  deviation	  was	  10.04%.	   	  A	  sample	  size	  of	  20	  subjects	  based	  on	  these	  data	  would	  provide	  95%	  BA	  LoA	  to	  within	  7.5%	  of	  the	  true	  population	  value.	  
	  
A2.4.1	  Conclusion	  	  20	   subjects	   represented	   a	   reasonable	   compromise	   with	   negligible	   increase	   in	  accuracy	  up	  to	  5%	  and	  3%	  requiring	  46	  and	  128	  subjects	  respectively	  assuming	  the	  data	  is	  generalisable.	  These	  data	  were	  from	  a	  small,	  poorly	  characterised	  cohort	  of	  patients	   with	   small	   bowel	   disease	   and	   can	   therefore	   only	   serve	   to	   inform	   study	  design	  in	  a	  very	  general	  capacity.	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A2.2	  	  Subject	  response	  to	  drug	  administration	  
A2.1.2	  Purpose	  	  Determine	  the	  number	  of	  subjects	  necessary	  to	  demonstrate	  a	  significant	  change	  in	  motility	  following	  administration	  of	  IV	  drugs	  against	  placebo.	  	  
	  
A2.2.2	  Methods	  	  Three	  patients	  (1	  male)	  received	  an	  additional	  dynamic	  scan	  immediately	  after	  their	  IV	   Buscopan	   injection	   during	   routine	   clinical	   practice	   with	   the	   institutional	   MRE	  peroration	  as	  per	  chapter	  2.2.4.	  The	  entire	  small	  bowel	  was	  segmented	  and	  a	  global	  motility	  value	  calculated	  by	  averaging	  the	  mean	  SD	  Jacobian	  motility	  score	  for	  both	  pre	   and	   post-­‐Buscopan	   dynamic	   series.	   A	   sample	   size	   calculation	  was	   performed	  with	  a	  90%	  power	  with	  an	  alpha	  of	  0.05.	  
	  
A2.3.2	  Results	  	  Mean	   global	   motility	   score	   pre-­‐Buscopan	   was	   0.26AU	   (range	   0.24	   to	   0.31)	   and	  following	  Buscopan	  was	  0.17AU	  (range	  0.09	  to	  0.23).	  There	  was	  a	  mean	  difference	  of	  0.09AU	  (35%)	  between	  groups.	  Based	  on	  these	  data,	  we	  would	  require	  a	  sample	  size	  of	  just	  3	  subjects	  to	  determine	  a	  significant	  difference.	  10	  subjects	  should	  have	  sufficient	  power	  to	  detect	  a	  difference	  of	  10%	  between	  groups.	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A2.4.2	  Conclusion	  	  	  Although	  Buscopan	  appeared	   to	  have	  a	  potent	  effect	  on	  motility	   in	   these	  subjects,	  the	  global	  effect	  of	  neostigmine	  is	  relatively	  unknown	  and	  10%	  sensitivity	  was	  felt	  to	  be	  sufficient	  to	  detect	  a	  motility	  change	  against	  placebo	  whilst	  making	  use	  of	  all	  patients	  recruited	  for	  the	  baseline	  study.	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APPENDIX	  3:	  THE	  USE	  OF	  RPCA	  TO	  QUANTIFY	  MOTILITY	  
Small	   bowel	   motility	   assessment	   of	   3D	   MR	   time	   series	   data	   via	  
Robust	  Principal	  Component	  Analysis	  	  
	  
1P.	  Ferry,	  1A.	  Menys,	  2F.	  Odille,	  3A.	  Emmanuel,	  1S.	  A.	  Taylor	  and	  1D.	  Atkinson	  
1Centre	  for	  Medical	  Imaging	  and	  Centre	  for	  Medical	  Image	  Computing,	  UCL,	  2INSERM	  
U94,	  Nancy	  University,	  France,	  3Department	  of	  Gastroenterology	  and	  Nutrition,	  UCH	  	  
A3.1	  Introduction	  	  	  The	  small	  bowel	  spontaneously	  contracts	  to	  mix	  and	  move	  the	  intestinal	  contents	  -­‐	  this	   motion	   is	   referred	   to	   as	   small	   bowel	   motility.	   Motility	   is	   affected	   in	   many	  pathologies	   e.g.	   Crohn’s	   disease	   [1]	   and	   therefore	   might	   be	   used	   as	   a	   disease	  biomarker.	   Robust	   Principal	   Component	   Analysis	   (RPCA)	   has	   recently	   shown	   its	  ability	   to	  detect	  motion	   in	  dynamic	   image	  sequences	   in	  a	  variety	  of	   fields	  e.g.	   face	  recognition	   [2].	   Such	   a	   method	   applied	   to	   cine	   3D	   MR	   small	   bowel	   data	   can	  potentially	  provide	  a	  rapid	  assessment	  of	  motion	  and	  therefore	  provide	  functional	  information	  on	  disease	  presence,	  extent	  and	  response	  to	  treatment.	  	  	  	  	  	  
	  	   274	   	  
	   	  
A3.2	  Methods	  	  	  According	  to	  RPCA	  theory,	  a	  given	  matrix	  M	  can	  be	  decomposed	  into	  the	  sum	  of	  two	  components:	   L,	   a	   low	   rank	  matrix	   and	   S	   a	   sparse	  matrix.	   It	   is	   possible	   to	   exactly	  recover	   L	   and	   S	   by	   solving	   the	   following	   convex	   optimisation	   problem	   [1]:	    min!,! ‖𝐿‖∗ + 𝜆‖𝑆‖!       𝑠. 𝑡.        𝑀 = 𝐿 + 𝑆      where	     . ∗	  denotes	   the	   nuclear	   norm	   of	   a	  matrix	  i.e.	  the	  sum	  of	  its	  singular	  values,   . !	  denotes	  the	  l1-­‐norm	  i.e.	  the	  sum	  of	  the	  modulus	   of	   each	   element	   and	   lambda	   (λ)	   is	   a	   trade-­‐off	   parameter	   between	   the	  sparse	  and	  the	  low-­‐rank	  components.	  This	  parameter	  plays	  a	  key	  role	  in	  this	  matrix	  decomposition.	  
	  
Image	  acquisition:	  3T	  Philips	  Achieva	  scanner,	  coronal	  bTFE	  3D	  sequence,	  TR/TE	  3.51/1.66ms,	   slice	   thickness=10	   mm.	   15	   slices	   per	   volume	   and	   20	   temporal	  positions	  with	  temporal	  resolution	  1	  volume	  per	  second.	  Subjects	  fasted	  for	  4h	  prior	  to	   drinking	   1L	   2%	   mannitol.	   A	   prospective	   study	   was	   carried	   out	   in	   6	   normal	  volunteers	   who	   received	   a	   baseline	   scan,	   followed	   by	   the	   spasmolytic	   agent	  Buscopan.	  	  
Image	   processing:	   To	   reduce	   intensity	   variations,	   Contrast	   Limited	   Adaptive	  Histogram	   Equalization	   (CLAHE)	   [3]	   was	   applied.   The	   reference	   decomposition	  trade-­‐off	   parameter	  was	   chosen	   as	  𝜆0=1/√	   (max	   (dim	   (𝑀)))	  where	  M	   is	   the	   data	  arranged	   with	   the	   volume	   for	   each	   frame	   as	   a	   column.	   Subsequently,	   δ	   RPCA	  decompositions	  were	  performed	  on	  the	  data	  set	  with	  λ	  varying	  by	  δ	  steps	  over	  the	  range	  [0.5	  𝜆0;	  9	  𝜆0].	  The	  sparse	  volumes	  obtained	  were	  converted	  to	  binary	  values	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and	   the	   motility	   metric	   generated	   from	   a	   3D	   average	   sparse	   overlay	   as	  follows: 𝑆!"#   : , : , : =   𝑆!!"#!!!!!!"#!!!"#!!! : , : , : , 𝑡,   𝜆 	  with   s = (9− 0.5)  λ!/δ .	   ROIs	  were	  drawn	  around	  the	  whole	  small	  bowel	  or	  part	  of	  it	  in	  order	  to	  assess	  mean	  𝑆!"#	  value	  inside.	  3D	  RPCA	  results	  were	  correlated	  against	  the	  current	  gold	  standard	  2D	  method	   i.e.	   Optic	   flow	   registration	   technique	   assessed	   by	   standard	   deviation	   of	  Jacobian	   determinant	   [4]	   using	   linear	   regression	  model	   and	   Pearson’s	   correlation	  coefficient.	  Mean	  Pre	  and	  Post	  Buscopan	   injection	  motility	  measurements	   for	  both	  methods	  were	  compared	  using	  a	  paired	  T-­‐test.	  	  
A3.3	  Results	  	  
	  
Figure	   A3.1:	  Motility	   overlays	   in	   a	   normal	   volunteer	   pre	   Buscopan	   (a,	   c)	   and	   post	  
Buscopan	  (b,	  d).	  STD	  Jacobian	  determinant	  method	  (a,b)	  and	  3D	  RPCA	  with	  δ=25	  (c,d).	  	  The	   method	   is	   fast	   (~	   1min/	   RPCA,	   ~	   10	   min	   for	   complete	   map).	   CLAHE	   pre-­‐processing	  significantly	  reduces	  the	  sensitivity	  of	  the	  method	  to	  spatial	  variation	  of	  intensity	  -­‐	  emphasising	  bowel	  wall	  motion.	  Similar	  regions	  of	  bowel	  are	  highlighted	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by	  both	  methods	  (RPCA	  and	  STD	  Jacobian	  determinant).	  Moreover	  the	  small	  bowel	  wall	  is	  well	  detected.	  RPCA	  was	  able	  to	  detect	  Buscopan	  induced	  	  
	  
Figure	  A3.2:	  Motility	  scores	  in	  6	  volunteers	  using	  global	  small	  bowel	  ROIs,	  (a)	  mean	  
STD	  Jacobian	  determinant	  Pre	  and	  Post-­‐Buscopan	  injection,	  (b)	  mean	  3D	  RPCA	  value	  
(δ=10).	  	  changes	   in	   motility	   (Fig.	   A3.1	   and	   A3.2).	   The	   Pearson	   correlation	   coefficient	  between	  3D	  RPCA	  measurements	  and	  gold	  standard	  metrics	  on	  ROIs	  was	  0.87	  and	  the	  regression	  model	  R2	  was	  0.76.	  According	  to	  both	  methods	  Buscopan	  provokes	  a	  significant	  decrease	  in	  mean	  global	  small	  bowel	  motility	  of	  normal	  volunteers	  (P	  <	  0.001).	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normalize	   maps	   between	   patients	   and	   prospective	   application	   to	   assessment	   of	  bowel	  disease	  and	  treatment	  response.	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APPENDIX	   4:	   THESIS	   COMMERCIALISATION	   PLAN	   FOR	  THE	  EXPLOITATION	  OF	  THE	  RESULTING	  ADVANCES	  	  
Overview	  
This	  extended	  appendix	  has	  been	  included	  in	  the	  Thesis	  as	  part	  of	  the	  UCL	  Advances	  Enterprise	  Scholarship	  that	  funded	  an	  extension	  to	  the	  PhD	  to	  explore	  commercial	  opportunities	  arising	  from	  the	  research.	  The	  company	  Motilent	  Ltd	  was	  founded	  by	  the	  Thesis	  author	  and	  won	  the	  UCL	  Enterprise	  Award	  2014	  for	  best	  business	   idea	  along	  with	   a	   £10,000	   convertible	   loan	   for	   business	   development.	   For	   the	   sake	   of	  ease	   of	   communication	   (especially	   to	   a	   relatively	   lay	   audience),	   the	   ‘optic-­‐flow’	  registration	   algorithm	   was	   re-­‐branded	   to	   GIQuant.	   For	   this	   chapter,	   a	   modified	  version	   of	   an	   application	   to	   the	   Technology	   Strategy	   Boards:	   Biomedical	   Catalyst	  funding	   call	   has	   been	   used	   as	   the	   most	   comprehensive	   and	   thorough	   piece	   of	  business	   focused	  writing	   to	   date	   requesting	   £1,132,658	   to	   develop	   both	   business	  and	  academic	  objectives.	  This	  chapter	  has	  omitted	  scientific	  detail	  as	  it	  has	  already	  been	  discussed	  extensively	  leading	  up	  to	  this	  point.	  Instead,	  how	  the	  research	  can	  be	  commercialised	  is	  discussed	  in	  terms	  of	  market,	  need,	  opportunities	  and	  return	  on	  investment.	  Whilst	  not	  routinely	  the	  subject	  of	  a	  PhD,	  the	  construction	  of	  a	  business	  plan	   and	   this	   application	   has	   been	   incredibly	   valuable	   for	   distilling	   the	   value	   of	  research	  within	  the	  wider,	  social	  and	  business	  context	  and	  also	  in	  bringing	  together	  a	  larger	  group	  of	  researchers	  and	  individuals	  in	  an	  attempt	  to	  drive	  this	  technology	  beyond	  its	  singular	  application	  in	  research.	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Project	   Brief:	   Technology	   Strategy	   Board:	   Biomedical	  
Catalyst	  –	  Late	  Stage	  Award	  
Published	  by	  TSB:	  	  Across	   the	  world	  healthcare	  models	   are	   facing	   greater	   challenges,	   both	  physically	  and	   financially,	   in	   providing	   for	   a	   growing,	   ageing	   population	   with	   an	   increasing	  burden	   of	   disease.	   The	   long-­‐term	   sustainability	   of	   current	  models	   of	   provision	   is	  increasingly	  questioned	  with	  the	  upward	  trend	  in	  healthcare	  spending	  becoming	  a	  significant	   portion	   of	   a	   nation’s	   GDP.	   The	   drive	   therefore	   to	   deliver	   efficient	   and	  effective	  healthcare	  has	  never	  been	  more	  pertinent.	  	  	  In	  order	   to	  meet	   these	   challenges,	   both	   companies	   and	  academics	  must	   recognise	  the	   drivers	   behind	   them	   and	   work	   together	   towards	   developing	   innovative	  technologies	  and	  processes	  which	  provide	  solutions	  for:	  	  •	   Disease	   prevention	   and	   proactive	   management	   of	   health	   and	   chronic	  conditions	  	  •	   Earlier	   and	   better	   detection	   and	   diagnosis	   of	   disease	   leading	   to	   marked	  improvements	  in	  patient	  outcomes	  	  •	   Highly	   effective	   treatments	   that	   are	   tailored	   to	   patients’	   needs	   and	   either	  modify	  the	  underlying	  disease	  or	  offer	  potential	  cures	  	  The	   Medical	   Research	   Council	   and	   the	   Technology	   Strategy	   Board	   are	   working	  together	   to	   deliver	   the	   Biomedical	   Catalyst	   scheme	   providing	   responsive	   and	  effective	  support	  for	  the	  best	  life	  science	  opportunities	  arising	  in	  the	  UK.	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Grant	   funding	   through	   the	   Biomedical	   Catalyst	   is	   available	   to	   UK	   commercial	  businesses	  (who	  are	  SME’s)	  and	  researchers	  looking	  to	  develop	  innovative	  solutions	  to	  healthcare	  challenges	  either	  individually	  or	  in	  collaboration.	  	  
Late-­‐Stage	  award	  	  -­‐	  Key	  features	  	  Projects	  can	  range	  from	  1	  to	  3	  years’	  duration,	  the	  maximum	  grant	  available	  is	  £2.4	  million	  and	  the	  minimum	  project	  size	  is	  £250k.	  Businesses	  (who	  are	  SME’s)	  will	  be	  funded	   at	   up	   to	   60%	   although	   elements	   of	   projects	   judged	   to	   be	   ‘experimental	  development’	   will	   be	   funded	   at	   the	   lower	   intervention	   rate	   of	   35%.	   	   Late–stage	  awards	   enable	   applicants	   to	   take	   a	   well	   developed	   concept	   and	   demonstrate	   its	  effectiveness	   in	   a	   relevant	   environment.	   The	   award	   is	   designed	   to	   support	  applicants	   seeking	   to	   evaluate	   the	   clinical	   utility	   of	   their	   new	  product,	   process	   or	  service.	  	  	  The	  work	  required	  in	  these	  projects	  will	  be	  dependent	  upon	  the	  stage	  of	  maturation	  and	  the	  proposed	  application	  of	  the	  technology.	  We	  do	  expect	  that	  all	  projects	  will	  be	  based	  on	  significant	  prior	  research	  where	  the	  feasibility	  has	  been	  demonstrated	  in	  a	  model	  system.	  Examples	  of	  project	  work	  in	  this	  late-­‐stage	  award	  category	  may	  include:	  	  	  drug	  development	  projects	   looking	  to	  achieve	  clinical	  demonstration	  of	  safety	  and	  efficacy	   including	   the	   initial	   demonstration	   of	   drug	   safety	   (phase	   I)	   through	   to	  human	   proof	   of	   concept	   (phase	   II).	   Only	   where	   appropriate	   would	   we	   consider	  supporting	   a	   phase	   III	   trial,	   in	   this	   case	   the	   project	   work	   would	   be	   considered	  ‘experimental	  development’	  and	  attract	  the	  lower	  rate	  of	  intervention	  (it	  is	  assumed	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that	   in	   the	   majority	   of	   cases	   the	   funding	   offered	   through	   this	   scheme	   would	   be	  insufficient	  to	  conduct	  a	  phase	  III	  trial)	  	  
Project	   title:	   Gastrointestinal	  motility	   assessment	  with	  medical	  
imaging	  analysis	  
	  
Summary	  of	  proposed	  Project	  	  Motilent	   (the	   Micro	   SME)	   has,	   alongside	   academic	   partners,	   developed	   and	  validated	   software	   technology	   called	   GIQuant	   that	   for	   the	   first	   time	   allows	   non-­‐invasive	  assessment	  of	   gastrointestinal	   tract	   function	  based	  on	   routinely	   acquired	  medical	   images	   using	   Magnetic	   Resonance	   Imaging	   (MRI).	   Bowel	   dysfunction	   is	  extremely	  common	  and	  debilitating,	  affecting	  as	  many	  as	  1	  in	  10	  people	  in	  the	  UK.	  	  This	  project	  has	  two	  key	  objectives	  that	  enable:	  	  1)	  The	  development	  and	  subsequent	  commercialisation	  of	   the	  GIQuant	   technology	  for	  the	  clinical	  quantitative	  evaluation	  of	  gastrointestinal	  motility	  in	  disease.	  	  	  2)	   The	   crucial	   clinical	   testing	   in	   several	   of	   the	   country’s	   leading	   bowel	   disease	  centres	  to	  establish	  the	  effectiveness	  and	  utility	  of	  this	  form	  of	  imaging	  analysis	  in	  the	   clinical	   setting	   at	   the	   point	   of	   direct	   patient	   care	   for	   key	   conditions	   including	  Parkinson’s,	  Constipation	  and	  Irritable	  Bowel	  syndrome	  (IBS).	  	  	  	  
Academic	  Collaborators	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  Lead	  Academic	  Partner:	  Professor	  Stuart	  A	  Taylor,	  Centre	  for	  Medical	  Imaging,	  UCL.	  3rd	  Floor	  East,	  250	  Euston	  Road,	  London,	  NW1	  2PG	  	  Relevant	   Funding	   comes	   from	   NIHR	   and	   Biomedical	   Research	   Centre,	   UCLH	  who	  funded	   Motilent	   CEO’s	   IMPACT	   PhD.	   Motility	   analysis	   work	   supported	   by	   Royal	  College	  of	  Radiologists	  Kodak	  grant	  (£4900),	  Radiological	  Research	  Trust	  charities	  proof	  of	  concept	  grant	  (£4995)	  and	  most	  recently	  enteric	  HTC	  pump	  prime	  funding	  (£12,540).	   SA	   Taylor	   was	   awarded	   an	   NIHR	   HTA	   grant	   (11/23/01)	   ‘Diagnostic	  accuracy	   for	   the	   extent	   and	   activity	   of	   newly	   diagnosed	   and	   relapsing	   Crohn’s	  disease:	   Multicentre	   prospective	   comparison	   of	   MR	   imaging	   with	   small	   bowel	  ultrasound’	   (£908k)	   which	   will	   collect	   additional	   motility	   datasets	   on	   over	   200	  patients	  from	  sites	  around	  the	  UK.	  	  Summary	  of	  key	  collaborators:	  	  >>UCL:	  Centre	  for	  Medical	  Imaging	  –	  Prof.	  Stuart	  Taylor	  (Academic	  lead),	  Dr	  Anton	  Emmanuel	  (Gastroenterologist)	  and	  Dr	  David	  Atkinson	  (Physicist).	  	  	  >>University	  of	  Nottingham:	  Sir	  Peter	  Mansfield	  MR	  Centre	  	  -­‐	  Prof.	  Penny	  Gowland	  (Physicist),	  Prof.	  Robin	  Spiller	  (Gastroenterologist),	  Dr	  Luca	  Marciani	  (GI	  Phys)	  &	  Dr	  Caroline	  Hoad	  (physicist).	  	  	  >>Queen	  Mary’s	  University:	  Neurogastroenterology	  group	  –	  Prof.	  Charles	  Knowles	  (Surgeon)	  and	  Prof.	  Qasim	  Aziz	  (Gastroenterologist)	  &	  Dr	  Mark	  Scott	  (Physiologist).	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Section	  1:	  The	  business	  proposition	  
Question	  1:	  What	  is	  the	  Healthcare	  need	  that	  this	  project	  intends	  to	  
address	  and	  with	  what	  solution?	  	  
Healthcare	  need:	  Patients	  with	  long-­‐term	  bowel	  symptoms,	  including	  constipation,	  diarrhoea,	   abdominal	   pain	   and	   nausea	   suffer	   a	   profound	   and	   often	   lifelong	  reduction	   in	  quality	  of	   life.	  These	  symptoms	  are	  broadly	  collapsed	   into	  Functional	  gastrointestinal	  disorders	  (FGID)	  affecting	  10-­‐25%	  of	  the	  UK	  population	  with	  20%	  of	   these	   patients	   referred	   to	   a	   consultant	   contributing	   to	   between	   20-­‐50%	  of	   the	  gastroenterology	  workload.	  Functional	  gastrointestinal	  disorders	  are	  often	  chronic,	  mis-­‐diagnosed	  and	  under-­‐reported	  resulting	  in	  multiple	  physician	  outpatient	  visits,	  numerous	  medication	  trials	  and	  often	  unnecessary	  diagnostic	  testing	  in	  pursuit	  of	  a	  diagnosis.	   This	   results	   in	   large,	   ongoing	   direct	   costs	   to	   the	   healthcare	   provider	  ($10bn	  per	   year	   in	  US)	   and	   societal	   costs	   ($20bn)	  where	   sufferers	   take	   twice	   the	  number	  of	  sick	  days	  per	  year	  against	  controls.	  	  Motility	   and	   its	   dysfunction	   (dysmotility)	   is	   one	   of	   the	   cardinal	   patho-­‐aetiological	  determinants	   of	   FGID.	   While	   the	   definition	   of	   FGID	   requires	   that	   an	   organic	  diagnosis	   cannot	   be	   made	   using	   standard	   tests,	   it	   is	   acknowledged	   that	   more	  complex	   tests	   of	   structure	   and	   function	   can	   yield	   findings	   of	   pathophysiological	  significance.	  The	  healthcare	  need	  we	  are	  aiming	   to	  address	   in	   this	  proposal	   is	   the	  lack	  of	  non-­‐invasive	  and	  quantitative	  tests	  to	  investigate	  gastrointestinal	  motility	  in	  FGID.	  The	  clinical	  value	  of	   such	  a	   test	  would	   lie	   in	   its	  ability	   to	  sub-­‐categorise	   the	  FGID	   patient	   group,	   decrease	   time	   to	   diagnosis	   and	   phenotype	   (an	   important	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component	  of	  their	  disease)	  to	  direct	  existing	  and	  emerging	  new	  therapies.	  Further,	  rapid	   and	   accurate	   diagnosis	   would	   lead	   to	   large	   cost	   savings	   in	   health	   resource	  utilisation.	  	  
	  
Proposed	  Solution:	  Motilent	  (the	  SME)	  in	  collaboration	  with	  the	  Centre	  for	  Medical	  Imaging	   (UCL)	   has	   developed	   and	   validated	   an	   image	   registration	   software	   tool	  (GIQuant)	  to	  non-­‐invasively	  evaluate	  intestinal	  motility	  using	  data	  acquired	  as	  part	  of	   existing	   clinical	   routine	   (detailed	   section	   5).	   GIQuant	   is	   an	   increasingly	  widely	  used	   research	   tool	   however,	   the	   large	   amount	   of	   low-­‐level	   user	   input	   (bowel	  segmentation,	  registration	  etc.)	  makes	  it	  impractical	  as	  a	  clinical	  tool.	  In	  this	  project	  we	   aim	   to	  package	  GIQuant	   into	   a	   streamlined,	   validated	   and	   clinically	   integrated	  service.	   This	   service	  would	  be	   comparable	   to	  many	  other	   routine	  diagnostic	   tests	  and	   thus	   follow	  well	   validated	   clinical	   pathways	   as	   follows:	   	   1)	   Clinician	   requests	  MRI	  scan	  with	  GIQuant	  analysis	  at	   their	   institution.	  2)	  Patient	   is	  scanned	  and	  data	  transmitted	   to	   Motilent	   for	   analysis.	   3)	   Motilent	   technicians	   perform	   analysis	   to	  generate	  a	  paper/digital	  bowel	  physiology	  report	  (Fig	  A4.1).	  4)	  Report	  returned	  to	  requesting	   clinician.	   Through	   collaboration	   with	   our	   academic	   partners,	   we	   will	  have	   the	   opportunity	   to	   incorporate	   other	   measures	   of	   bowel	   function	   available	  from	   MRI	   to	   produce	   a	   comprehensive	   report	   of	   bowel	   motility.	   Ultimately,	   we	  envision	   a	   customisable	   report	   of	   evidence-­‐based	  quantitative	   features	   describing	  bowel	  function.	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Magnetic	  Resonance	  Gastrointestinal	  Physiology	  Report	  	  Patient	  Name:	  John	  Smith	   	   	   	   	   DOB:	  25/08/1972	  Hospital	  Number:	  4032781	   	   	   	   	   Address:	  250	  Euston	  Road,	  NW1	  Scan	  quality	  poor/moderate/good	   	   	   	   Hospital:	  UCLH	  (Prof	  Gastro)	  
	  Volume	  oral	  contrast	  consumed:	   	   1000Ml	  Time	  to	  scan:	   	   	   	   	   50	  mins	  Volume	  at	  scan:	   	   	   	   44Ml	  Gastric	  emptying	  rate:	   	   	   18ml/min	  Gastric	  motility:	   	   	   	   0.12	  AU,	  1	  contraction	  min-­‐1	  	  	  
Gastric	  Physiology	  
	  Distension:	   	   	   	   	   AC:	  yes/no	  	   TC:	  yes/no	  	   DC:	  yes/no	  Contractions:	  	   	   	   	   AC:	  yes/no	  	   TC:	  yes/no	  	   DC:	  yes/no	  Colon	  motility	  (mean):	   	   	   AC:	  0.21AU	  	   TC:	  0.22AU	  	   DC:	  0.02AU	  Colon	  motility	  (contractions	  min-­‐1):	   AC:	  1	  	   	   TC:	  2	   	   DC:	  0	  	  
Colon	  Physiology	  
Analysis	  by	  Motilent	  Technician	  on	  20/6/2014:	  Signed	  off	  by	  Radiologist	  21/6/2014	  
	  Volume	  oral	  contrast	  consumed:	   	   1000Ml	  Time	  to	  scan:	   	   	   	   	   50	  mins	  SB	  motility	  (mean):	   	   	   	   0.32	  AU	  (normal	  range	  0.2	  to	  0.45)	  SB	  variance	  (variance):	   	   	   0.02	  (normal	  range	  0.001	  to	  0.032	  
Small	  bowel	  Physiology	  
Figure	  A4.1	  Motilent	  small	  bowel	  physiology	  report	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The	   healthcare	   challenge:	   There	   is	   no	   uniform	   cure	   for	   FGID.	   Patients	   have	   a	  similar	   life	  expectancy	  to	  healthy	   individuals	  and	   it	   is	  often	  quoted	   for	   IBS	  that	  “it	  may	  not	  kill	  you	  but	  it	  ruins	  your	  life.”	  Treatment	  focuses	  on	  targeted	  management	  of	   specific	   symptoms	   over	   a	   long-­‐term	   e.g.	   analgesics,	   laxatives	   or	   anti-­‐diarrhoea	  agents.	  Treatments	  should	  begin	  with	  accurate	  diagnosis,	  however	  in	  the	  case	  of	  the	  FGID,	  diagnostics	  either	  do	  not	  exist	  or	  are	   limited	  to	  research	   investigations	  with	  limited	   clinical	   applicability	   and	   issues	   of	   interpretation	   (particularly	   quantitative	  diagnosis	   in	   the	   individual).	   The	   anatomical	   and	   functional	   complexity	   of	   the	  gastrointestinal	   tract	   makes	   the	   development	   of	   effective	   diagnostics	   very	   bowel	  challenging	   with	   the	   small	   bowel	   alone	   containing	   10^8	   neurons	   (similar	   to	   the	  spinal	  chord).	   Its	  deep	  anatomical	   location	   further	  makes	   it	   largely	   inaccessible	   to	  conventional	   invasive	   instrumentation.	   	   It	   is	   widely	   accepted	   that	   the	   current	  diagnosis	  of	   Irritable	  Bowel	  Syndrome	   for	  example	   (part	  of	   the	  FGID	  spectrum)	   is	  likely	  a	  heterogeneous	  collection	  of	  as	  yet	  un-­‐characterised	  diseases.	  In	  the	  absence	  of	  diagnostic	  tests	  to	  identify	  these	  phenotypes,	  the	  quality	  of	  care	  for	  these	  patients	  remains	   unsatisfactory	   and	   societally	   expensive.	   The	   outputs	   of	   this	   project	   will	  provide	  clinicians	  with	  a	  new	  investigative	  option	  that	  can	  be	  used	  across	  hospitals	  for	   negligible	   setup	   costs	   or	   staff	   training.	   Our	   proposal	  will	   focus	   specifically	   on	  contractility	   in	   these	   patients	   for	   which	   there	   are	   a	   number	   of	   existing	   and	   new	  drugs	   currently	   in	   late	  phases	  of	   clinical	  development.	  The	  outputs	  of	   this	  project	  will	  provide	  robust	  data	  to	  validate	  the	  proposed	  service	  which	  in	  turn	  will	  be	  used	  to	   indicate	   which	   patients	   will	   likely	   respond	   to	   such	   medication	   and	   serve	   to	  phenotype	  this	  heterogeneous	  patient	  cohort	  and	  expedite	  patient	  diagnosis.	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Figure	  A4.2.	  Radar	  plot	  to	  demonstrate	  area	  for	  opportunity	  with	  GIQuant	  analysis,	  
Scintigraphy	  transit	  study	  and	  Manometry.	  	  	  Comparison	  with	   existing	   technology:	   A	   radar	   plot	   analysis	   summarising	   existing	  technologies	   benefits	   can	   be	   found	   in	   Figure	   A4.2.	   	   Manometry	   is	   the	   current	  standard	  for	  motility	  assessment	  but,	  as	  an	  intraluminal	  test,	  is	  necessarily	  invasive.	  Investigation	   is	   largely	   restricted	   to	   the	   proximal	   and	   distal	   1	   meter	   of	   GI	   tract.	  Where	  superficial	  motility	  is	  examined	  (e.g.	  oesophagus	  or	  ano-­‐rectum)	  manometry	  costs	  around	  £500	  per	  scan	  in	  the	  NHS	  with	  approximately	  7000+	  procedures	  per	  year.	   Full	   colonic	   investigation	   costs	   over	   £2000	   and	   represents	   a	   major	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Reproducibility	   Dignity	  Additional	  diagnostic	  info	  
Low	  operational	  cost	  Ease	  of	  use	  Patient	  Comfort	  Sensitivity	  
Availability	  
GI	  Motility	  info	  
Low	  patient	  risk	  
GIQuant	   Scintigraphy	   Manometry	  
1. Reproducibility	  	  -­‐	  scan	  findings	  consistent	  by	  reader	  
2. Dignity	  –	  Provide	  dignity	  for	  patient	  	  	  
3. Additional	  diagnostic	  info	  –	  opportunity	  for	  extra	  investigational	  findings	  to	  aid	  
diagnosis	  
4. Low	  operation	  cost	  –	  cost	  to	  maintain	  equipment/staff	  
5. Ease	  of	  use	  –	  level	  of	  staff	  training	  required	  	  
6. Patient	  comfort	  –	  how	  well	  test	  is	  tolerated	  
7. Sensitivity	  –	  quantitative	  capabilities	  of	  test	  to	  detect	  changes	  in	  motility	  
8. Availability	  –	  number	  of	  centres	  capable	  of	  performing	  test	  
9. GI	  Motility	  info	  –	  unambiguous	  information	  to	  assess	  GI	  motility	  
10. Low	  patient	  risk	  –	  likelihood	  of	  patient	  no	  experiencing	  harm	  	  
	  	   289	   	  
	   	  
undertaking	  for	  physician	  and	  patient	  alike	  (full	  bowel	  preparation	  and	  colonoscopy	  +	  24hr	  recording	  and	  analysis).	  High	  resolution	  manometry	  is	  now	  being	  marketed	  costing	   between	   £1000	   and	   £3000	   per	   investigation.	   The	   test	   remains	   associated	  with	   existing	   limitations	   with	   respect	   to	   invasiveness,	   dignity,	   patient	   discomfort	  and	  limited	  range.	  Crude	  measures	  of	  whole	  gut	  transit	  can	  be	  obtained	  using	  radio-­‐opaque	   marker	   studies.	   These	   however	   yield	   little	   in	   the	   way	   of	   segmental	  functional	   data	   required	   to	   either	   understand	   disease	   pathophysiology	   or	   direct	  specific	   therapy	   in	   FGID.	  More	   complex	   techniques	   including	   isotope	   scintigraphy	  can	   give	   a	  measure	  of	   segmental	   transit	   time	   (e.g.	   small	   and	   large	  bowel	   but	   cost	  approximately	   £400	   per	   investigation).	   Both	   methods	   require	   ionising	   radiation	  making	  them	  unsuitable	  for	  chronic	  conditions	  or	  those	  that	  manifest	  in	  childhood.	  Further,	  colonic	  scintigraphy	  requires	  twice-­‐daily	  departmental	  visits	  for	  scans	  each	  day	   for	   5	   days.	   Emerging	   technologies	   including	   the	   ingestion	   of	   a	   ‘smart-­‐pill’	   to	  measure	   pH,	   pressure	   and	   transit	   along	   the	   GI	   tract	   and	   thus	   provides	   some	  information	  on	  motility	  costing	  £700	  per	  investigation.	  Cross-­‐sectional	  imaging	  and	  endoscopy	   are	   usually	   performed	   prior	   to	   capsule	   endoscopy	   and	   coherent	  information	  on	  motility	  is	  limited	  and	  it	  remains	  largely	  a	  research	  tool	  at	  present.	  The	  capsule	  must	  be	  recovered	  from	  the	  stool.	  	  In	  comparison	  with	  the	  above	  methods,	  the	  advantages	  of	  GIQuant	  are:	  	  1.	   Most	  patients	  will	  at	  some	  stage	  undergo	  cross-­‐sectional	   imaging	  (CT/MRI)	  even	  if	  they	  are	  having	  the	  above	  specialist	  motility	  tests	  and	  so	  many	  will	  already	  have	  available	  data;	  2.	   Widespread	  availability	  of	  GIQuant	  i.e.	  wherever	  an	  MRI	  scanner	  is	  installed.	  Little	  need	  for	  staff	  training	  or	  dependence	  on	  specialist	  GI	  facilities;	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3.	   GIQuant	   performs	   global	   (whole	   GI	   tract)	   and	   segmental	   assessment	   of	  motility	  not	  just	  in	  areas	  of	  easy	  accessibility;	  4.	   GIQuant	  also	  yields	  anatomical	  information	  from	  the	  standard	  MRI	  report;	  5.	   GIQuant	   assessment	   is	   non-­‐invasive,	   dignified	   and	   comfortable	   for	   the	  patient:	  an	  additional	  15	  minutes	  of	  scanning	  even	  if	  added	  to	  existing	  scan.	  6.	   GIQuant	  provides	  well-­‐validated	  direct	  high	  resolution	  images	  and	  metrics	  of	  global	  motility.	  	  7.	   GIQuant	   is	   considerably	   cheaper	   even	   where	   MRI	   is	   included	   (See	   also	  section	  4).	  	  
Healthcare	   Impact:	  Societally,	  £2.9bn	  per	  year	  is	  lost	  through	  loss	  in	  productivity	  in	   the	   UK	   arising	   from	   FGID,	   attributing	   to	   20%	   of	   all	   work	   absenteeism.	   Better	  diagnostics	  and	  targeted	  medical	  management	  will	  be	  central	   to	  reducing	  this	   this	  cost.	  For	  the	  first	  time,	  patients	  will	  have	  access	  to	  a	  safe	  radiation	  free	  non-­‐invasive	  quantitative	  test	  to	  examine	  global	  and	  segmental	  intestinal	  motility.	  	  	  	  	  
Question	  2:	  What	  is	  innovative	  about	  your	  idea?	  	  
Unique	  Selling	  Point:	  There	  is	  no	  clinical	  test	  to	  evaluate	  global	  contractile	  activity	  in	   the	   bowel.	   We	   have	   developed	   and	   validated	   a	   computational	   approach	   to	  assessing	  both	  global	  and	  segmental	  GI	  tract	  motility	  using	  routinely	  available	  MRI	  data	   allowing	   quantitative,	   objective	   assessment	   of	   motility.	   In	   this	   proposal	   we	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package	   this	   technological	   advance	   into	   a	   convenient	   clinical	   test	   ready	   for	   wide	  scale	  clinical	  adoption.	  	  	  
Commercial	   Innovation:	   Hospitals	   pay-­‐per	   scan	   for	   medical	   imaging	   analysis	  allowing	   straight-­‐forward	   costing	   into	   clinical	   care	   pathway.	   Low	   operating	   costs	  can	  be	  maintained	  by	  Motilent	  where	  data	  analysis	  takes	  place	  on-­‐site	  without	  the	  need	   for	   hardware	  manufacture,	   distribution	   and	   associated	   regulatory	   approval.	  	  The	  model	  has	  a	  precedent	  in	  the	  NHS	  with	  MRI	  quantification	  of	  liver	  iron.	  Service	  has	   ‘vertical’	  scalability	  where	  increased	  demand	  can	  be	  met	  quickly	  by	  increasing	  numbers	  of	  technicians,	  server	  space	  etc.	  at	  Motilent.	  	  Service	  has	  ‘lateral’	  scalability	  where	  novel	   technologies	   for	   image	   analysis	   can	  be	   incorporated	   into	  business	   to	  increase	   revenue.	   Proposed	   service	   compatible	   with	   all	   MRI	   data	   allowing	  international	   expansion	   of	   business	   without	   the	   need	   for	   new	   equipment	   or	  specialised	  personnel.	  	  	  	  
Scientific	   Innovation:	   In	   vivo	   validation	  work	   has	   demonstrated	   that	   GIQuant	   is	  sensitive	   to	   pharmaceutical	   stimulation	   of	   the	   gut,	   repeatable	   and	   robust	   to	   user	  error	   making	   it	   an	   excellent	   clinical	   tool	   for	   the	   evaluation	   of	   motility.	   Proof	   of	  principal	   has	   been	   shown	   in	   disease	   states	   including	   Crohns	   disease	   and	   chronic	  intestinal	  pseudo	  obstruction.	  This	  portfolio	  of	  validation	  data	  does	  not	  exist	  for	  any	  other	   competing	   software	   solution.	   A	   current	   total	   of	   8	   full	   publications	   and	   32	  abstracts	   and	   presentations	   have	   been	   generated	   over	   3	   years	   providing	   initial	  validation	   of	   the	   solution.	   	   	   In	   addition	   to	   GIQuant	   other	   analysis	   methodologies	  developed	  by	  the	  academic	  partners	  will	  broaden	  the	  scope	  of	  information	  provided	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by	  the	  service	  including	  gastric	  emptying	  rate,	  transit	  time,	  gastric	  accommodation	  all	  of	  which	  can	  be	  calculated	  from	  routine	  MRI	  images.	  
	  
Technical	   Innovation:	   	   MRI	   images	   are	   sent	   to	   Motilent	   and	   processed	   using	  GIQuant	   to	  produce	  a	  data-­‐file.	  This	   file	   is	   a	  key	  exploitable	  product	  generated	  by	  Motilent	  where	  it	  can	  be:	  1)	  Assessed	  onsite	  by	  a	  Motilent	  technician	  to	  produce	  the	  Motilent	   report	   (Figure	   A4.1).	   In	   this	   route	   to	  Market,	   Motilent	   will	   deal	   directly	  with	  the	  hospital,	  abstracting	  all	  time	  consuming	  analysis	  away	  from	  the	  clinic.	   	  2)	  Returned	   to	   the	   user	   in	   its	   raw	   format	   where	   the	   academic	   or	   pharmaceutical	  company,	  will	  be	  able	  to	  perform	  analysis	  themselves	  directly	  using	  the	  Motilent	  file	  reader.	   The	   exact	   combination	   of	   the	   above	   is	   likely	   to	   vary	   based	   on	   the	   users	  needs	  and	  flexibility	  in	  this	  respect	  is	  a	  core	  service	  image	  that	  Motilent	  is	  keen	  to	  adopt.	   	   Our	   business	  model	   places	  Motilent	   as	   a	   central	   hub	   to	   process	  MRI	   data	  returning	  either	  the	  raw	  data	  as	  a	  file	  to	  the	  user	  for	  further	  analysis	  or	  as	  a	  report.	  	  The	   key	   strength	   of	   this	   model	   is	   that	   data	   can	   be	   sent	   globally	   to	   the	   Motilent	  servers	  for	  analysis	  allowing	  high	  volume	  analysis.	  Use	  of	  the	  Motilent	  reader	  would	  further	   add	   important	   branding	   for	   the	   service.	   This	   process	   could	   be	   fully	  automated	  at	  minimal	  operating	  cost	  generating	  early	  stage	  revenue.	  	  
Timeliness:	   Patients	   with	   GI	   disease	   increasingly	   undergo	   MRI	   scans	   as	   part	   of	  their	   clinical	   evaluation	  with	  MRI	   advocated	   as	   the	   primary	   imaging	  modality	   for	  assessing	   the	   bowel	   by	   many	   international	   consensus	   committees.	   Where	   the	  number	  of	  MRI	  scanners	  across	  Europe	  is	  set	  to	  increase	  by	  15%	  over	  the	  next	  10	  years,	  the	  role	  of	  this	  modality	  is	  going	  to	  become	  increasingly	  prominent	  especially	  in	   the	   diagnosis	   and	   grading	   of	   chronic	   conditions	   and	   less	   expensive	   as	   the	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hardware	   technology	   improves.	   For	   example,	   multi-­‐parametric	   MRI	   has	   recently	  been	  indicated	  as	  first	  line	  diagnostic/surveillance	  tool	  for	  prostate	  cancer	  by	  NICE	  and	  as	  the	  leading	  biomarker	  to	  identify	  and	  grade	  dementias.	  Imaging	  with	  MRI	  is	  becoming	   increasingly	   versatile	   with	   the	   reporting	   of	   the	   digital	   images	   now	  decentralised	   from	   the	   point	   of	   acquisition	   and	   the	   value	   of	   secondary	   analysis	  adding	  even	  more	  value	  to	  the	  modality.	  	  Over	   20	   new	   image	   processing	   technology	   companies	   have	   appeared	   collectively	  demonstrating	  a	  growing	  trend	  towards	  this	  form	  of	  investigation	  although	  there	  is	  no	  med-­‐tech	  company	  that	  specialises	  in	  the	  analysis	  of	  the	  GI	  tract.	  This	  proposal	  gathers	  together	  UK	  leaders	  in	  this	  field	  to	  provide	  a	  service	  that	  would	  be	  scalable	  and	  generalisable	  across	  all	  healthcare	  providers	  where	  imaging	  is	  used.	  Analysis	  of	  GI	  function	  is	  arguably	  the	  most	  complex	  of	  imaging	  targets	  with	  minimal	  research	  at	  present.	  At	  UCL,	  UoN	  and	  QML	  we	  have	  contributed	  to	  some	  of	  the	  leading	  work	  in	   this	   field	   and	   importantly	   validated	   it	   in	   clinical	   cohorts.	   Beyond	   this,	   the	  collaborative	  partners	  have	   excellent	  working	   relations	  with	   the	  FGID	   community	  presenting	  an	  excellent	  opportunity	  to	  disseminate	  findings	  and	  technology	  during	  the	   project.	   GIQuant	   is	   now	   primed	   for	   commercialisation	   and	   the	   expansion	   of	  similar	  companies,	  albeit	   in	  other	   fields,	  makes	  this	  a	  crucial	  and	  timely	  step	   for	  a	  UK	  company	  to	  establish	  itself	  in	  this	  area.	  In	  the	  UK,	  the	  NHS	  is	  required	  to	  deliver	  £20bn	  of	  efficient	  savings	  by	  2015.	  In	  an	  independent	  report,	  Deloitte	  identified	  fast,	  accurate	  and	  widely	  available	  diagnostics	  as	  an	  essential	   long-­‐term	  contributor	   to	  cost	  savings	  as	  well	  as	  essential	  for	  improving	  the	  quality	  of	  life	  for	  the	  patient.	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Competitors:	  Competition	  comes	  from	  manufacturers	  of	  instrumentation	  designed	  to	  measure	  motility	   and	   software	   solutions.	   	   As	   discussed	   above,	   high	   resolution	  manometry	  and	  smart	  pills	  are	  now	  being	  marketed	  by	  companies	  (GIVEN	  etc)	  and	  financial	   reports	   from	   last	   year	   suggest	   uptake	   that	   is	   mainly	   limited	   to	   private	  healthcare	  providers	   in	   the	  US.	  A	  number	  of	  medical	   imaging	   software	  companies	  exist	   that	   have	   commercialised	   other	   existing	   technology	   focusing	   on	   mainly	  dementia	   (IXICO,	   Iconometrix),	   Cancer	   (Mirada,	   Texrad),	   musculoskeletal/body	  (Image	   Analaysis,	   AMRA,	   ResonanceHealth),	   inflammation/respiratory	   (Bioxydyn)	  or	   some	   combination	   of	   the	   above.	   In	   all	   of	   these	   fields	   the	   technology	   is	   more	  developed	  on	  account	  of	   its	  popularity	  as	  a	  research	  topic	  and	  largely	  open	  access	  however	  commercial	  viability	  has	  been	  established	  through	  applying	  the	  techniques	  to	  meet	  the	  needs	  of	  the	  Pharmaceutical	  industry	  users	  seeking	  regulatory	  approval.	  For	  many	  of	  these	  companies,	  advanced	  image	  analysis	  does	  not	  currently	  represent	  clinical	   benefit	   and	   therefore	   penetration	   into	   clinical	   practice	   has	   been	   limited.	  ResonacneHealth	   conversely	   have	   identified	   a	   clinical	   problem	   without	   a	  satisfactory	   clinical	   solution	   (liver	   iron	   overload).	   Despite	   the	   market	   size	   being	  small,	  they	  have	  established	  an	  international	  user	  base	  through	  having	  their	  service	  indicated	  in	  clinical	  guidelines,	  charging	  £250-­‐1000	  per	  scan	  for	  a	  single	  numerical	  measurement.	  The	  GI	  tract	  is	  less	  popular	  as	  a	  research	  topic	  but	  an	  expensive	  and	  important	  clinical	  discipline.	  We	  have	  developed	  the	  leading	  technology	  in	  this	  field	  to	  directly	  address	  a	  clinical	  need	  and	  are	  looking	  to	  commercialise	  it	  directly.	  	  There	  is	  only	  one	  direct	  software	  competitor	  that	  at	  present	  does	  not	  appear	  to	  be	  trading.	   	   Motasso	   by	   Sohard	   AG	   has	   been	   used	   by	   only	   one	   research	   group	   who	  helped	   to	   validate	   the	   tool.	   No	   attempt	  was	  made	   to	   develop	  Motasso	   beyond	   its	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research	   application.	   Motasso	   is	   not	   currently	   available	   and	   is	   of	   limited	   use	   for	  motility	  analysis	  providing	  assessment	  of	  segmental	  bowel	  motility	  only.	  GIQuant	  is	  conversely	  robustly	  validated	  with	  7	  papers	  in	  well-­‐respected	  journals.	  A	  further	  six	  papers	  are	  currently	  in	  development	  or	  in	  press	  with	  a	  collaborative	  partners	  across	  Europe	  all	  demonstrating	  clinical	  application.	  The	  technical	  barriers	  to	  duplicating	  our	   software	   are	   significant	   especially	   with	   respect	   to	   implementation.	   Robust	  validation	  would	  require	  time	  and	  money	  alongside	  clinical	   input	  to	  scan	  patients.	  All	  members	  of	   the	  proposal	   team	  hold	   senior	  positions	   at	   leading	   conferences	   in	  the	   field	   of	   gastrointestinal	   disease	   and	   regularly	   peer	   review	   the	   published	  literature.	   	   Although	   the	   number	   of	   papers	   on	   intestinal	   motility	   is	   increasing,	  assessment	   remains	   largely	   manual	   and	   impractical	   for	   clinical	   use.	   Two	   other	  research	  groups	  have	  proposed	  techniques	  to	  evaluate	  motility	  using	  MRI	  although	  neither	  are	  as	  well	  validated	  as	  GIQuant	  nor	  tested	  clinically.	  	  	  	  
Question	  3:	  How	  do	  you	  intend	  to	  exploit	  the	  opportunity?	  	  
Exploitable	  outputs	  from	  this	  project	  include:	  1)	  A	  clinical	  service	  to	  provide	  analysis	  of	  bowel	  motility.	  Exploit	  by	  integrating	  into	  clinical	  workflow	  and	  charging	  for	  the	  service.	  	  2)	   A	   data	   analysis	   service	   to	   provide	  motility	   analysis	   for	   academic	   and	   research	  users.	   Exploit	   by	   providing	   as	   a	   service,	   producing	   a	   GIQuant	   ‘motility	   file’	   and	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providing	  a	  reader	  tool	  for	  academics	  or	  pharmaceutical	  users	  to	  analyse	  their	  own	  data.	  	  	  	  
Market	  1:	  	  
Academic	  users.	  Approximately	  £5.04bn	  is	  spent	  globally	  per	  year	  on	  research	  into	  digestive	   diseases.	   As	   per	   the	   clinic,	   there	   are	   significant	   limitations	   in	   existing	  motility	   assessment	   techniques	   impeding	   current	   research.	   MRI	   is	   an	   emerging	  technique	   for	  motility	   analysis	   with	   a	   rapidly	   growing	   literature	   (+5%	   per	   year).	  
Why:	  1)	  provides	  scientific	  evidence	  base	  to	  support	  technique	  2)	  access	  academic	  clinicians	  who	  would	   bring	   into	   clinical	   practice	  where	   utility	   is	   seen	   3)	   generate	  early	   revenue	   at	   low	   running	   cost	   to	   Motilent.	   4)	   Few	   regulatory	   barriers.	  How:	  Design	   and	   implement	   a	   service	   that	   accepts	   research	   MRI	   data	   and	   returns	   the	  processed	  result	  for	  further	  analysis	  by	  the	  academic	  user.	  	  	  
Route	  to	  Market:	  Option	  1	  (Direct):	  We	  charge	  academics	  per	  data	  set	  returning	  to	  them	  a	  GIQuant	  data	  file	  containing	  the	  motility	  data.	  They	  then	  use	  a	  free	  ‘reader’	  to	  analyse	   their	   own	   data.	   This	   is,	   in	   principle,	   the	   same	   as	   Adobe’s	   PDF	   file,	  which	  Adobe	   charges	   to	   create	   but	   makes	   free	   to	   read.	   Without	   the	   need	   for	   Motilent	  ‘hands-­‐on’	   analysis,	   we	   can	   largely	   automate	   the	   computational	   processing	   and	  generate	  crucial	  early	  revenue.	  Option	  2	  (Indirect):	  We	  license	  the	  software	  to	  PACS	  providers	   eg	   Biotronics	   3D,	   Feedback	   PLC	   who	   have	   and	   interest	   in	   image	   post-­‐processing.	  Although	  we	   sacrifice	   revenue	  we	   achieve	   greater	  market	   penetration	  through	  accessing	  existing	  users	  with	  relevant	  provider	  subscriptions.	  	  
Market	  2:	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Clinical	   users.	   In	   the	   UK	   1.05m	   patients	   are	   seen	   in	   secondary	   care	   with	   FGID	  symptoms.	  Over	  half	  of	  these	  patients	  receive	  some	  form	  of	  medical	  imaging	  as	  part	  of	   their	   diagnosis	   (X-­‐ray,	   CT,	  MRI,	  US),	   £130m	   is	   spent	   on	  other	   clinical	   tests	   and	  £240m	   is	   spent	   on	  medications	   specifically	   for	   their	   symptoms.	   The	   cost	   of	   FGID	  symptoms	   comes	   from	   the	   failure	   to	   diagnose	   and	   identify	   an	   effective	   treatment	  strategy.	   Prevalence	   of	   FGID	   is	   similar	   across	   Europe	   and	   the	   US	   resulting	   in	  between	  21.19m	  to	  105.95m	  secondary	  care	  referrals	  per	  year	  in	  the	  US.	  	  Inpatient	  costs	   of	   motility	   disorders	   have	   been	   estimated	   at	   $1bn	   per	   year	   in	   the	   US	   for	  inpatients	  alone.	  Why:	   Large	   revenue	  potential	   if	   even	  a	   small	  uptake	   is	  achieved.	  	  
How:	  Provide	  clinically	  integrated	  service	  that	  abstracts	  all	  analysis	  away	  from	  the	  clinic	  running	  analysis	  as	  a	  service	  compatible	  with	  clinical	  pathways.	  	  	  
Route	  to	  market:	  Option	  1	  (Direct):	  Receive	  clinical	  data	  direct	  from	  hospitals	  and	  process	   to	   generate	   a	   motility	   report	   (Figure	   A4.1).	   Use	   in-­‐house	   technicians	   to	  provide	   time-­‐intensive	  analysis	   and	  cost	   into	   service.	  This	   represents	   the	  greatest	  opportunity	  for	  Motilent	  revenue.	  Option	  2	  (Direct):	  Return	  un-­‐analysed	  data	  as	  per	  part	  I.	  Hospital	  technician	  provides	  analysis.	  Option	  3	  (Indirect):	  License	  service	  to	  specialist	  clinics/centres	  who	  run	  GIQuant	  data	  and	  analyse	  themselves.	  	  
Market	  dynamics:	  Although	  several	  markets	  exist	  (academic,	  clinical,	  pharma	  etc)	  it	  is	  often	  the	  same	  individual	  acting	  in	  a	  different	  capacity	  in	  each.	  For	  example,	  an	  academic	  clinician	  may	  spend	  20%	  of	  their	  time	  running	  their	  research	  group,	  55%	  of	   their	   time	   working	   in	   their	   NHS	   clinic,	   20%	   in	   their	   private	   clinic	   and	   the	  remainder	  acting	  as	  a	  advisor	  to	  pharmaceutical	  companies,	  hospital	  commissioning	  boards,	   charities	  and	  other	   initiatives	   central	   to	   the	   success	  and	  clinical	  uptake	  of	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emerging	   diagnostic	   techniques.	   Appreciation	   of	   this	   interplay	   is	   central	   to	  Motilent’s	   route	   to	  market	   approach	  and	  our	  goal	   at	   this	   early	   stage	   is	   to	   identify	  and	  support	  these	  senior	  and	  high	  profile	  individuals	  in	  the	  GI	  motility	  community.	  	  Their	   initial	  research	  will	  provide	  them	  with	  product	  understanding	  and	  bring	  the	  potential	  for	  them	  to	  include	  it	  in	  the	  private	  setting	  where	  cost	  is	  transferred	  onto	  the	  patient.	  Motilent’s	  primary	  commercial	  barrier	   for	  entering	  the	  clinical	  market	  will	  be	  the	  existing	  clinical	  culture	  for	  gastrointestinal	  motility	  investigation.	  	  	  
Potential	   barriers:	   GIQuant	   has	   no	   direct	   commercial	   equivalent	   and	   clinicians	  have	   never	   had	   access	   to	   a	   quantitative	   tool	   to	   evaluate	   and	   detail	   global	   bowel	  motility.	  Many	   clinicians	  will	   not	   know	  how	  or	  when	   to	   request	   such	   tests	   in	   the	  absence	   of	   clinical	   guidelines	   and	   therefore	   we	   anticipate	   a	   substantial	   but	   not	  insurmountable	   barrier	   to	   short-­‐term	   acceptance	   of	   the	   technique.	   While	  publications	  using	  GIQuant	  have	  attracted	  citations	  and	  interest	  the	  technique	  itself	  is	   poorly	  understood	   along	  with	   its	   potential	   for	   clinical	   impact.	   Therefore	   in	   this	  project	   we	   need	   not	   only	   build	   up	   a	   commercially	   viable	   service	   but	   also	   the	  corresponding	  evidence	  base	  for	  technique	  use.	  This	  evidence	  will	  in	  turn	  be	  used	  to	  create	  clinical	  guidelines	  indicating	  the	  techniques	  use	  and	  result	  in	  clinical	  uptake	  especially	  in	  the	  NHS.	  As	  a	  result,	  our	  route	  to	  the	  ultimate,	  clinical	  market	  is	  multi-­‐layered	   commencing	   with	   the	   academic	   users	   and	   working	   through	   the	   less	  financially	   restricted	   private	   clinics	   until	  wide-­‐spread	   and	   evidence-­‐based	   service	  utility	  is	  achieved.	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Section	  2:	  The	  project	  details	  
Question	  4:	  Describe	  the	  Return	  on	  Investment	  
	  
Market:	   Academic/Pharma.	   Units	   p/a.	   3000.	   Cost	   per	   unit:	   £50.	   When:	   year	   2.	  Growth	  p/a:	  10%.	  Revenue	  p/a:	  £150,000.	  Gross	  Profit	  p/a:	  £135,000.	  Justification:	  Based	  on	  existing	  contracts	  and	  grants	  where	  GIQuant	  has	  been	  costed.	  Use	  as	  an	  endpoint	  for	  drug	  studies	  is	  currently	  driving	  estimated	  unit	  volume.	  	  
Market:	   Consulting/setup	   fees.	   Units	   p/a	   5.	   Cost	   per	   unit:	   £10,000.	   When:	  Immediate.	   Growth	   p/a:	   25%.	   Revenue	   p/a:	   £50,000.	   Gross	   profit	   p/a:	   £40,000.	  Justification:	  Many	  projects	  currently	  require	  intensive	  help	  to	  set	  up	  (eg.	  protocol	  development).	  Motilent	  will	   develop	   a	   consulting	   service	   largely	   to	   assist	   pharma	  projects.	  	  	  
Market:	   Clinical	   (private	   healthcare).	   Units	   p/a	   1200.	   Cost	   per	   unit:	   £500.	  When:	  year	  3.	  Growth:	  10%.	  Revenue	  p/a:	  £600,000.	  Gross	  profit:	  £420,000.	   Justification:	  The	  private	  healthcare	  sector	   in	  the	  UK	  is	   the	  primary	  consumer	  of	  GI	   techniques.	  We	  anticipate	  higher	  uptake	  driven	  by	  patient	  demand.	  We	  will	  offer	  a	  specialised	  GIQuant	   report	   with	   customisable	   analytics	   to	   meet	   clinical	   demand	   and	   charge	  more	  for	  this	  option.	  	  	  
Market:	   Clinical	   (NHS	   specialist	   tertiary).	   Units	   p/a:	   1900.	   Cost	   per	   unit:	   £250:	  When:	   Year	   3:	   Growth	   p/a:	   5%.	   Revenue	   p/a:	   £475,000.	   Gross	   profit:	   	   £190,000.	  Justification:	   Without	   clinical	   guidelines,	   uptake	   will	   only	   be	   seen	   in	   specialist	  centres	  as	  run	  by	  proposal	  applicants	  generating	  the	  stock	  GIQUant	  report	  (Figure	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A4.1).	  Value	  challenging	  to	  predict	  until	  clinical	  data	  becomes	  available,	  where	  value	  is	  demonstrated	  revenue	  in	  1%	  of	  FGID	  workload,	  revenue	  p/a	  could	  be	  as	  high	  as	  £25m.	  	  	  ROI	  based	  on	  the	  proposed,	  conservative	  values	  we	  anticipate	  becoming	  profitable	  by	   the	   end	   of	   year	   2.	   We	   have	   used	   UK	   values	   for	   clinical	   markets	   for	   financial	  analysis	  where	  we	  can	  base	  numbers	  on	  existing	  clinical	  experience.	  We	  anticipate	  that	  ROI	  on	  TSB	  funding	  will	  be	  seen	  by	  years	  6-­‐7	  based	  on	  UK	  revenue	  alone.	  This	  figure	  is	  however	  very	  diffiuclt	  to	  estimate	  at	  present.	  	  	  	  >>	  Building	  market	  share:	  The	  early	  stage	  of	  our	  business	  development	   is	  centred	  around	   stimulating	   interest	   in	   key,	   industry	   leading	   clinical	   users	   to	   both	   raise	  awareness	   through	   research	   and	   bring	   into	   their	   clinical	   practice.	   This	   is	   not	  however	  a	  long	  term	  market	  strategy	  and	  towards	  the	  end	  of	  the	  project	  we	  will	  be	  looking	  to	  actively	  engage	  with	  new	  users	  through:	  	  	  	  1)	  Direct	  engagement	  with	  GI	  community	  with	  a	  formal	  product	  launch	  at	  Digestive	  Diseases	   Week	   (15,000	   attendee	   conference),	   emphasising	   Motilent’s	   connection	  with	  academic	  partners	  and	  hosting	  educational	  sessions	  on	  the	  technology.	  	  	  2)	  Continued	  engagement	  with	  clinicians	  providing	  free	  trial	  data	  analysis,	  scanner	  setup	   assistance	   and	   1-­‐on-­‐1	   webcast	   demos	   on	   our	   website	   for	   training	   and	  educational	  purposes.	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3)	  Develop	  relationships	  with	  charities	  (eg.	  Bowel	  and	  Cancer	  Research,	  Crohn’s	  &	  Colitis)	  to	  engage	  with	  patients	  and	  build	  patient	  awareness	  of	  service.	  We	  consider	  patient	   awareness	   to	   be	   key	   to	   accessing	   the	   private	   market.	   Further	   Patient	  engagement	  will	  be	  achieved	  by	  directed	  advertising	  through	  information	  in	  private	  clinic,	  web	  questionnaires	  and	  patient	  forums.	  	  	  4)	   Dissemination	   of	   research	   generated	   by	   academic	   partners	   through	   popular	  media	  outlets,	  press	  releases,	  our	  website	  and	  social	  media	  in	  layman-­‐friendly	  terms	  to	  further	  increase	  awareness.	  	  5)	   Appoint	   specialised	   sales	   staff	   to	   develop	   and	   maintain	   existing	   relationships	  while	  engaging	  in	  non-­‐UK	  markets.	  This	  will	  involve	  deployment	  to	  specialist	  clinics	  and	   major	   conferences	   worldwide,	   targeting	   countries	   identified	   by	   OECD	   and	  IFFGD	  as	  having	  a	  high	  MRI	  machine	  per	  capita	   (eg.	  Germany	  &	  USA)	  and	   flexible	  user-­‐centric	  healthcare	  pricing.	  	  	  6)	   We	   will	   constantly	   review	   the	   efficiency	   of	   our	   systems	   and	   infrastructure,	  scaling	  to	  meet	  demand	  and	  evaluating	  quality	  management.	  For	  example,	  where	  a	  form	  of	  analysis	   is	  not	  used,	  we	  will	  not	  spend	  resources	  performing	  that	  analysis	  and	  use	  saving	  to	  either	  decrease	  service	  price	  to	  attract	  new	  customers	  or	  increase	  revenue.	  	  	  7)	  We	  will	  drive	  and	  fund	  research	  using	  Motilent	  technologies	  to	  build	  the	  volume	  of	  literature	  supporting	  efficacy	  and	  exploiting	  the	  potential	  for	  the	  technology	  to	  be	  applied	  in	  the	  diagnosis	  and	  management	  of	  other	  GI	  illnesses.	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Further	   development:	   Building	   on	   this	   project,	   we	   will	   look	   to	   add	   additional	  software	  techniques	  as	  ‘modules’	  to	  the	  report	  increasing	  the	  customisability	  of	  the	  service.	  TSB	  funding	  will	  enable	  us	  to	  set	  up	  a	  pipeline	  to	  translate	  the	  large	  amount	  of	  high	  quality	   research	   taking	  place	   in	   the	  UK	   into	  a	   suite	  of	  products	   to	  directly	  benefit	   the	   patient.	   Our	   close	   ties	   through	   Prof.	   David	   Hawkes	   at	   the	   Centre	   for	  Medical	   Image	   Computing	   will	   be	   central	   to	   this	   process.	   We	   plan	   to	   grow	   the	  business	   organically	   where	   possible,	   feeding	   profit	   back	   into	   research,	   both	  strengthening	   our	   business	   position	   and	   helping	   to	  maintain	   the	   UK’s	   position	   as	  leaders	   in	   this	   field.	   Penetrating	   markets	   outside	   of	   Europe	   will	   require	   further	  regulatory	   approval.	   Specifically,	   the	   ISO:13485	   certification	   will	   be	   required	   to	  enter	   clinical	   diagnostics	   however,	   we	   are	   aware	   of	   the	   requirements	   and	   have	  planned	  accordingly	  in	  our	  project	  to	  ensure	  equipment	  (eg	  servers)	  are	  in	  line	  with	  regulatory	  standards	  to	  facilitate	  this	  process	  at	  year	  3.	  By	  year	  3	  we	  hope	  to	  have	  established	   a	   robust	   product	   and	   at	   this	   stage,	   the	   business	   will	   undergo	   a	  marketing	   transition	  with	   respect	   to	   the	   GIQuant	   exploitation	   strategy	   placing	   an	  emphasis	   on	   sales	   to	   clinical	   users	   in	   order	   drive	   revenue.	   We	   will	   at	   this	   time	  appoint	  the	  appropriate	  staff	  and	  seek	  external	  input	  from	  investors	  to	  fully	  exploit	  the	  project	  deliverables.	  
	  
Question	  5:	  What	  technical	  approach	  will	  be	  adopted	  and	  how	  will	  
the	  project	  be	  managed?	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The	   project	   has	   been	   broken	   down	   into	   a	   number	   of	   objective-­‐focused	   Work	  Packages	   (WPs)	   that	   are	  deemed	  suitable	   to	   target	  main	  deliverables.	  The	  project	  will	  ensure	  that	  its	  objectives	  are	  met	  within	  the	  desired	  timescale	  and	  to	  budget	  by	  employing	  reliable	  project	  management	  and	  risk	  management	  system	  e.g.	  a	  tailored	  version	  of	  PRINCE2.	  WPs	  will	  be	  based	  on	  delivering	  predefined	  outcomes.	  	  The	   project	   will	   be	   overseen	   by	   a	   study	   management	   group	   (SMG)	   with	  responsibility	  to	  monitor	  the	  milestones.	  The	  SMG	  will	  meet	  every	  4	  months	  for	  the	  duration	  of	  the	  project	  (9	  meetings	  in	  total).	  The	  SMG	  will	  comprise	  the	  4	  applicants,	  1	  patient	  interests	  representative	  Deborah	  Gilbert	  (bowel	  and	  cancer	  Research),	  the	  lead	   technical	  developer	   to	   the	  project	   (Laurence	  Bourn)	  and	   the	  Motilent	  project	  manager.	  The	  group	  will	   thus	   include	  senior	  representatives	   from	  each	  partner	   to	  ensure	   that	   the	   views	   of	   those	   providing	   clinical,	   design,	   technical	   and	  marketing	  services	  are	  represented.	  Within	  the	  SMG,	  the	  WPs	  will	  be	  managed	  by	  the	  Clinical	  (CM:	   Stuart	   A	   Taylor)	   and	   Technical	   Manager	   (TM:	   Laurence	   Bourne)	   in	  consultation	  with	  the	  Project	  manager	  (PM:	  Katherine	  Prescott)	  to	  ensure	  efficient	  delivery.	  	  	  
Technical	   Rationale:	  Our	   techniques	  must	  work	  across	   institutions	   regardless	  of	  PACS	   provider	   to	   be	   commercially	   viable.	   Providing	   bespoke	   add-­‐ons	   to	   existing	  solutions	  is	  slow	  in	  terms	  of	  customised	  engineering,	  version	  turnaround,	  access	  to	  end-­‐users	   and	   the	   danger	   of	   commercial	   lock-­‐in	   limiting	   product	   dynamism	  essential	  to	  an	  SME.	  An	  alternative	  is	  to	  provide	  either	  turn-­‐key	  systems	  or	  bespoke	  end-­‐user	   software	   which	   still	   requires	   substantial	   SME	   support	   and	   generate	  integration	   challenges	   for	   clinical	   IT	   administrators.	   	   Increasingly,	   SMEs	   are	  using	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the	   web	   to	   offer	   their	   imaging	   services.	   Deploying	   services	   co-­‐located	   with	   the	  growing	   number	   of	   affordable	   certified	   (ISO:27001)	   secure	   data	   centres.	  Advantages	   include	   robust	   physical	   security,	   best-­‐in-­‐class	   web	   access,	   multiple	  redundant	  power	  backup	  and	  24/7	  secure	  access.	  Clinical	  institutions	  have	  readily	  adopted	   these	   services	   mainly	   to	   allow	   outsourcing	   of	   the	   reporting	   effort	   (e.g.	  3dnetmedical.com,	   pacsmail	   etc.)	  whilst	   decreasing	   risk	   to	   patient	   confidentiality.	  Furthermore,	   web-­‐based	   services	   can	   drastically	   reduce	   hardware	   and	   software	  maintenance	  costs	  on-­‐site.	  This	  will	  be	  essential	  for	  Motilent	  where	  business	  will	  be	  drawn	   through	   high	   volume	   processing	   from	   global	   data	   sites.	   Within	   academic	  environments	  data	  is	  anonymised	  and	  downloaded	  from	  PACS	  to	  allow	  customised	  and	  independent	  assessment	  with	  the	  most	  common	  platform	  Osirix	  (free,	  excellent	  UI)	  where	  an	  emphasis	  is	  placed	  on	  functionality.	  	  Our	  first	  project	  deliverable	  will	  be	   to	   create	   a	   plug-­‐in	   for	   Osirix	   for	   academic	   data	   analysis.	   This	   will	   ‘read’	   the	  Motilent	   data	   file	   and	   allow	   academic	   near-­‐immediate	   access	   to	   the	   service	   from	  project	   commencement.	   Replacing	   of	   our	   own	   UI	   will	   be	   necessary	   however	  secondary	   to	   IT	   infrastructure.	   (Key:	   A	   =	   academic,	   B	   =	   business,	   WP	   =	   work	  package)	  	  
Deliverable	  B1:	  Develop	  and	  validate	  data	  annotation	  toolset	  Objective:	   All	   processed	   data	   must	   be	   visualised	   for	   annotation	   either	   by	   a	  technician	  or	  an	  academic	  user.	  	  >WP	  B1.1	  (month	  0-­‐6)	  An	  Osirix	  ROI	  annotation	  plug-­‐in	  and	  MATLAB	  code	  for	  the	  analysis	  of	  GIQuant	  output	  data.	  Made	  available	  to	  the	  academic	  partners.	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>WP	  B1.2	   (Month	   8-­‐32)	   On-­‐line	   ROI	   tool	   for	   the	   (anonymised)	   analysis	   of	  MRI	   +	  GIQuant	   data.	   Enhancements	   to	   the	   online	   portal	   to	   support	   private	   clinicial	  institutions	  and	  personnel.	  	  
Deliverable	  B2:	  Develop	  and	  validate	  network	  back	  end	  of	  data	  handling	  Objective:	   Secure,	   robust	   and	   scalable	   network	   with	   web-­‐interface	   development	  alongside	  appropriate	  safety	  steps	  to	  insure	  patient	  data	  integrity.	  
• WP	   B2.1	   (Month	   6-­‐24)	   An	   automated	   online	   service	   for	   storage	   and	  processing	   of	   (anonymised)	   institution	   data	   delivering	   GIQuant	  segmentation	  fields	  compatible	  with	  the	  Osirix	  annotation	  plug-­‐in.	  	  
• WP	   B2.2	   (Month	   18-­‐36)	   Secure	   end-­‐to-­‐end	   data	   pathway	   suitable	   for	  handling	  and	  reporting	  patient	  data	  to	  and	  from	  our	  servers.	  Clinicians	  drive	  the	  uptake	  of	  new	  tech	  into	  their	  PACS	  environment.	  
• WP	  B2.3	  (Month	  36)	  Internal	  audit	  for	  ISO:13485	  certification.	  	  
Deliverable	  B3:	  Establish	  minimum	  requirements	  for	  Motilent’s	  GIQuant	  
report	  Objective:	  Together	  with	  academic	  partners	  to	  identify	  key	  features	  for	  the	  Motilent	  report	  and	  establish	  training	  protocol.	  
• WP	   B3.1	   (Month	   28-­‐30)	   Test	   a	   monitored	   and	   audited	   in-­‐house	   bespoke	  report	  creation	  and	  delivery	  through	  the	  on-­‐line	  service.	  	  
• WP	  B3.2	   (Month	   30-­‐32)	   Feedback	   from	   academic	   partners	   into	   the	   report	  generation	  process	  for	  specific	  diseases.	  
• WP	  B3.3	  (Month	  34)	  Report	  handover	  from	  academic	  partners.	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Clinical	  Deliverables:	  Eight	   clinical	   deliverables	   will	   develop	   scientific	   background	   to	   support	   GIQuant	  service.	  Each	  deliverable	   represents	  a	  unique	  data	   set.	   Scanning	  will	   take	  place	  at	  UCL	  and	  UoN	  where	  robust	  MR	  protocols	  and	   infrastructure	  already	  exist.	  Clinical	  investigations	   (manometry)	   will	   take	   place	   at	   Barts	   Health	   NHS	   Trust.	   Primary	  ethics	   application	  will	   take	   place	   through	  UCL	  with	   SSIs	   issued	   to	  UoN	   and	  Barts	  Health.	  All	  data	  will	  be	  anonymised	  immediately	  following	  collection.	  	  
Deliverable	  A1	  Healthy	   control	   scanning.	   Objective:	   Scan	   120	   healthy	   controls	   to	   establish	  normative	  data.	  Recruitment	  will	  be	  clustered	  by	  demographic	  categories	  to	  ensure	  community	  matching	  and	  generalisability	  for	  A2.	  Controls	  will	  be	  recruited	  through	  advertisement	  with	  key	  partners	  (charities,	  HEIs,	  enteric	  HTC)	  and	  by	  invitation	  of	  WP2	   patient	   spouses	   participation.	   All	   will	   be	   screened	   to	   exclude	   relevant	   GI	  disease	   and	   FGID,	   the	   latter	   by	   validated	   questionnaires.	   Control	   scans	   will	   last	  30min.	  
• WP	  A1.1	  (month	  8-­‐24)	  60	  healthy	  volunteers	  scanned/reported	  UCL	  
• WP	  A1.2	  (month	  8-­‐24)	  60	  health	  volunteers	  scanned/reported	  UoN	  	  
Deliverable	  A2	  	  Patient	   scanning.	   Objective:	   Clinically	   evaluate	   the	   GIQUant	   service	   in	   patient	  cohorts	   comparing	   GI	   motility	   to	   normal	   controls.	   Each	   centre	   has	   selected	   an	  important	  disease	  area	  in	  which	  they	  have	  a	  strong	  referral	  base	  and	  international	  academic	   reputation.	   Patients	   will	   temporarily	   stop	   relevant	   medication	   prior	   to	  their	  scan.	  Recruitment	  will	  take	  place	  through	  existing	  databases,	  outpatient	  clinics	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and	   advertisment.	   Patients	   will	   be	   scanned	   as	   per	   established	   MRE	   protocols	   to	  identify	   differences	   in	   gastric,	   small	   bowel	   and	   colonic	   motility	   compared	   to	  controls	  in	  regions	  relevant	  to	  the	  disease.	  	  
• WP	   A2.1	   (month	   8-­‐32)	   Scan/report	   30	   mid-­‐late	   stage	   Parkinson’s	   disease	  patients	  (UCL).	  	  
• WP	  A2.2	  (month	  8-­‐32)	  Scan/report	  30	  IBS-­‐Diarrhoea	  patients	  (UoN)	  
• WP	   A2.3	   (month	   8-­‐32)	   Barts	   Health	   /	   QMUL	  will	   perform	   high	   resolution	  pan-­‐colonic	  manometry	  in	  a	  cohort	  of	  15	  patients	  and	  15	  new	  controls	  all	  of	  whom	  will	  be	  sent	  to	  UCLH	  imaging	  department	  for	  MRI	  and	  thence	  GIQuant	  analysis.	  	  
Deliverable	  A3	  MRManometry	   probe	   development	   Objective:	   Validate	   the	   MRManometry	   probe.	  This	   technique	   prototyped	   by	   Motilent	   is	   promising	   method	   to	   produce	   high-­‐resolution	   spatiotemporal	   maps	   of	   bowel	   wall	   contraction	   powered	   by	   GIQuant.	  	  MRManometry	  would	  provide	  a	  direct	  alternative	  to	  invasive	  manometry.	  	  
• WP	   A3.1	   (0-­‐6months)	   Assessment	   of	   the	   MRManometry	   tool	   using	   a	  computer	  simulation	  will	  be	  performed	  to	  assess	  accuracy.	  Data	  visualisation	  methods	  will	  be	  developed	  for	  interpretation	  (UCL).	  	  
• WP	   A3.2	   (4-­‐8	   months)	   Using	   an	   MR	   compatible	   manometry	   catheter,	  invasive	  manometry	  will	  be	  performed	  simultaneously	  with	  MR	  to	  establish	  technique	  con-­‐concordance	  in	  2	  	  volunteers	  (UoN).	  	  
• WP	  A3.3	  (10-­‐32	  months)	  Using	  the	  MRI	  data	  from	  WP2.3,	  MRManometry	  will	  be	   performed	   to	   demonstrate	   the	   clinical	   application	   of	   the	   technique	   to	   a	  patient	  cohort.	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  Alternative	   technical	   solutions	   might	   involve	   packaging	   the	   core	   technology	   as	   a	  stand-­‐alone	   software	   solution	   to	   individual	   hospitals.	   We	   are	   cautious	   of	   this	  approach	  as	  it	  would	  require	  extensive	  system	  maintenance.	  The	  core	  processing	  is	  computationally	  expensive	  and	  lends	  itself	  well	  to	  parallelised	  network	  processing	  and	   the	   necessary	   hardware	   to	   perform	   locally	   would	   likely	   make	   the	   time	  requirements	   to	   perform	   analysis	   unviable.	   Alternatively,	   this	   system	   could	   be	  packaged	   as	   part	   of	   existing	   PACS	   or	   cloud	   based	   systems	   with	   processing	  capabilities	  (Biotronics	  3d).	  However,	  the	  need	  for	  manual	  annotation	  would	  again	  preclude	   from	   clinical	   applications.	   Employment	   of	   a	   technician	   for	   annotation	  purposes	   may	   be	   feasible	   and	   cost	   effective	   for	   service	   providers	   where	   high	  volumes	  of	  patients	  are	  scanned,	   in	  which	  case	  an	  on-­‐site	   licencing	  strategy	  might	  be	  used.	  	  
Question	   6:	   	   What	   are	   the	   risks	   	   (technical,	   commercial	   and	  
environmental)	   to	   project	   success?	   What	   is	   the	   project’s	   risk	  
management	  strategy?	  	  SWOT	  Analysis	  of	   the	  project	  plan	  resulted	   in	   the	  compilation	  of	   the	  Risk	   register	  below	   with	   RISK	   (low/medium/high)	   and	   IMPACT	   (low/medium/high)	   with	  MITIGATION	  strategy	  for	  key	  project	  risks.	  	  	  
1.	  Technical	  Risks:	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1.1	   RISK:	   MRI	   data	   variability	   is	   high	   (HIGH)	   IMPACT:	   Results	   from	   different	  scanners	  cannot	  be	  compared	  (High).	  MITIGATE:	   Introducing	  standardised	  scaling	  and	   noise	   estimation	   checks	   into	   the	   registration	   pathway.	   Such	   standardisation	  issues	  have	  been	  overcome	   in	  other	  areas	  quantitative	  MRI	   imaging	  (eg.	  Ferriscan	  by	  Resonance	  Health)	  and	  proposal	  team	  has	  extensive	  experience	  in	  this	  field.	  	  	  	  1.2	  RISK:	  Data	   transfer	   to	  Motilent	  not	   convenient	   or	   compatible	  with	   trust-­‐setup	  (Medium)	  IMPACT:	  Technical	  issues	  including	  data	  format,	  access	  to	  trust	  network,	  internet	   accessibility	   from	   PACS	   computers	   etc	   prevent	   Motilent	   accessing	   data	  (High).	  MITIGATE:	  Appoint	  experienced	  PACS	  systems	  engineer	  and	  ensuring	  data	  transfer	  can	  occur	   through	  multiple	  channels	   ranging	   from	  burning	   to	  DVD/	  web-­‐based	  transfer/	  PACS	  e-­‐transfer.	  1.3	  RISK:	  Motilent	  does	  not	  obtain	  regulatory	  approval	  (Medium)	  IMPACT:	  Cannot	  service	   clinical	   market	   (High).	   MITIGATE:	   Use	   team	   experience	   of	   ISO:13485	  approval	   and	   upkeep	   to	   design	   a	   robust	   process	   ready	   for	   approval	   during/upon	  project	  completion.	  	  1.4	  RISK:	  MRI	  scan	  protocol	  compliance	  is	  low	  (Medium).	  IMPACT:	  Bias	  introduced	  into	   data	   affecting	   quantitative	   result	   (Medium).	   MITIGATE:	   Auditing	   scanning	  through	   this	   study	   and	   publishing	   guidelines	   where	   user	   error	   affects	   results.	  Where	  necessary	  provide	  staff	  training.	  1.5	  RISK:	  Motilent	  cannot	  match	  demand	  for	  service	  (Low).	  IMPACT:	  Service	  quality	  is	   reduced	   and	   revenue	   decreased	   (High).	   MITIGATE:	   through	   implementing	  scalable	   systems.	   Use	   cloud-­‐processing	   paying	   per	   hour	   to	   match	   computing	  demand.	  	  
2.	  Commercial	  Risk:	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2.1	   RISK:	   Clinical	   uptake/demand	   is	   low	   (High).	   IMPACT:	   Business	   is	   not	  economically	  viable	   (HIGH).	  MITIGATE:	  by	  servicing	  a	  patient	  demographic	  where	  there	  is	  a	  large	  clinical	  need	  and	  few	  existing	  diagnostic	  options.	  Allocate	  sufficient	  funding	  across	  leading	  academic	  groups	  in	  the	  UK	  to	  conduct	  high	  impact	  research	  to	  gather	  evidence	  for	  service	  efficacy.	  Use	  evidence	  base	  and	  influence	  of	  academic	  team	  where	  relevant	  to	  incorporate	  service	  into	  clinical	  guidelines.	  Provide	  service	  to	   academic	   and	  pharmaceutical	  users	   to	   generate	   revenue	  and	   increase	  evidence	  base	  for	  service.	  	  Engage	  with	  users	  to	  identify	  key	  service	  needs	  adjusting	  analysis	  where	  necessary	  to	  match	  said	  needs.	  Invest	  in	  marketing	  and	  user	  communication	  (2.2).	  	  2.2	  RISK:	  Service	  visibility	  is	  low	  (High).	  IMPACT:	  Low	  revenue	  lose	  first	  to	  market	  advantage	   (HIGH).	   	   MITIGATE:	   by	   advertising	   direct	   to	   users	   at	   gastroenterology	  meetings	  and	  conferences.	  Ensure	  website	  has	  high	  visibility	  using	  search	  engines.	  Approach	   specialist	   clinics	   and	   offer	   discounted	   trials	   and	   financing	   options	   to	  encourage	  uptake.	  Continue	  to	  work	  with	  charities	  to	  increase	  company	  and	  service	  exposure.	  Make	  sales	  appointment	  a	  priority	  by	  project	  end.	  	  	  2.3	  RISK:	  Competitive	   services	  emerge	   (Medium)	   IMPACT:	  Lose	  market	   share	  and	  negative	   impact	   on	   revenue	   (Medium).	   MITIGATE:	   by	   planning	   for	   regulatory	  approval	  (1.3).	  Maximise	  visibility	  (2.2).	  Ensure	  data	  analysis	  occurs	  on	  time	  and	  to	  a	  high	  standard.	  Where	  necessary	  adjust	  cost	  or	  refine	  service	  at	  a	  reduced	  cost	  to	  meet	   exact	   user	   needs.	   Build	   product	   portfolio	   where	   new	   techniques	   become	  available.	  Service	  academic	  and	  pharmaceutical	  market	  segments.	  
	  
3.	  Managerial	  Risk:	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3.1	   RISK:	   Project	   cashflow	   (Medium).	   IMPACT:	  Motilent	   cannot	   pay	   staff	   or	   other	  direct/indirect	  costs	  (HIGH).	  MITIGATE:	  taking	  out	   low	  interest	  business	  loan.	  Use	  Motilent	  equity	  to	  attract	  external	  investment.	  Seek	  equity	  investment	  (eg.	  Feedback	  Plc).	   Quickly	   access	   research	   markets	   with	   have	   low	   barrier	   to	   entry	   with	   low	  running	  costs.	  Investigate	  multiple	  routes	  to	  maket.	  	  3.2	  RISK:	  Project	   is	  undercosted	   (Medium)	   IMPACT:	  Fail	   to	  deliver	  project	   (High).	  MITIGATE:	   using	   team	   experience	   of	   operating	   a	   technology	   SME	   to	   identify	   and	  factor	  key	  costs.	  Raise	  additional	  capital	  as	  per	  3.1.	  Academic	  costing	   for	  scanning	  and	  projects	  are	  well	  established	  and	  capacity	  for	  patient	  drop-­‐out.	  3.3	   RISK:	   Conflicts	   regarding	   IP	   research	   ownership	   (Medium)	   IMPACT:	   Delayed	  service	  development,	   additional	   cost	   to	   service	  and	  project	   (Medium).	  Not	  usually	  problematic	   where	   industrial	   funding	   is	   provided	   -­‐common	   across	   institutions	  (Medium).	   MITIGATE:	   Sign	   terms	   of	   service	   contracts	   with	   host	   institutions	   that	  stipulate	  IP	  arrangements.	  Where	  IP	  belongs	  to	  host	  institution	  negotiate	  licencing	  and	  cost	  into	  service.	  	  
4.	  Environmental	  4.1	   RISK:	   Concerns	   of	   patient	   confidentiality	   prohibit	   uptake	   (High).	   IMPACT:	  Motilent	   cannot	   interact	   with	   hospitals	   or	   clinicians	   are	   dissuaded	   from	   using	  service	  (HIGH).	  Acquire	  ISO	  regulatory	  approval	  to	  provide	  institutional	  assurances	  (1.3).	   Develop	   robust	   processes	   to	   safeguard	   patient	   information	   (eg.	   anonymise	  patient	   details	   for	   analysis).	   Require	  data	   anonymisation	  prior	   to	  Motilent	   upload	  for	  non-­‐clinical	  studies.	  Ensure	  Motilent	  servers	  have	  security.	  4.2	  RISK:	  There	  is	  not	  sufficient	  MRI	  capacity	  to	  support	  service	  (Medium).	  IMPACT:	  Motilent	   cannot	   extract	   revenue	   potential	   from	   market	   (HIGH).	   MITIGATE:	   by	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providing	   cost-­‐benefit	   for	   service	   (2.1).	   Establish	   partnerships	   with	   private	  scanning	  companies	  to	  increase	  capacity.	  Support	  proposals	  to	  invest	  in	  additional	  scanners.	  	  	  
	  
5.	  Other	  5.1	   RISK:	   Patient	   recruitment	   is	   low/slow	   (Medium).	   IMPACT:	   Study	   deliverables	  are	  not	  met	   and	   evidence	   for	   service	   efficacy	  not	  provided	   (HIGH).	  MITIGATE:	  by	  appointing	   full-­‐time	   clinical	   fellow	   specifically	   for	   recruitment.	   Utilising	   existing	  experience	  operating	  large	  studies.	  Utilise	  full	  available	  project	  length	  of	  3	  years.	  	  5.2	   RISK:	   Academic	   studies	   cannot	   take	   place	  without	   ethical	   approval	   (Medium)	  IMPACT:	   Study	   deliverables	   are	   not	   met	   and	   evidence	   for	   service	   efficacy	   not	  provided	   (HIGH).	   MITIGATE:	   Acquire	   all	   ethical	   approval	   for	   multi-­‐site	  investigations	  in	  advice	  of	  study	  commencement.	  Audit	  regularly	  to	  avoid	  breaches	  that	  might	  lead	  to	  study	  being	  closed	  down	  at	  one	  of	  the	  sites.	  	  To	   ensure	   risks	   are	  mitigated	   and	  managed	   a	   project	  manager	  will	   be	   appointed	  with	  the	  specific	  purpose	  with	  prior	  experience	  working	  on	  TSB	  and	  similar	  grants.	  Using	   a	   “light-­‐touch”	   PRINCE2	   methodology,	   the	   Motilent	   Project	   Manager	   will	  monitor	   the	   time,	   cost,	   quality,	   scope,	   risk	   and	   benefit	   performance	   goals	   of	   the	  project	   through	   monthly/weekly	   contact	   with	   investigators	   and	   the	  developer/UCLH	   fellow	   respectively.	   A	   mitigation	   strategy	   and	   re-­‐assessment	   of	  budget	   will	   be	   produced	   for	   any	   identified	   risks.	   Through	   performing	   detailed	  forecasting,	   Motilent	   is	   confident	   it	   can	   accommodate	   the	   cash-­‐flow	   required	   at	  project	  start	  with	  sufficient	   flexibility	   to	  allow	  for	  any	  delays	   in	  claims	  being	  paid.	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Academic	   institutions	   will	   invoice	  Motilent	   quarterly	   for	   equipment	   costs	   further	  helping	  cashflow.	  	  	  
Question	   7:	   Does	   the	   team	   have	   the	   	   right	   skills	   and	   experience	  	  
and	  access	  to	  facilities	  to	  deliver	  the	  project	  and	  exploit	  it?	  	  	  
Motilent:	  Responsible	   for	  exploiting	   the	  business	  deliverables	   for	   this	  project	  and	  addressing	  practical	  and	  regulatory	  barriers	  for	  the	  implementation	  of	  the	  proposed	  service.	   Alex	   Menys	   developed	   and	   validated	   the	   GIQuant	   technique	   for	   his	   PhD	  publishing	   6	   papers	   in	   the	   last	   3	   years	   on	   the	   topic	   and	   over	   30	   conference	  presentations.	   He	   has	   formed	   a	   collaborative	   network	   of	   leading	   GI	   specialists	  across	   the	  UK	  and	  Europe	  and	   is	  an	   invited	  speaker	  at	  GI	  meetings.	  He	  has	  driven	  the	   commercial	   exploitation	   of	   his	   scientific	   research	   underlying	   this	   project,	  founding	  Motilent	  and	  won	  the	  UCL	  Bright	  Ideas	  Enterprise	  award.	  Laurence	  Borne	  is	  Motilent	  head	  of	  technology	  and	  has	  expertise	  in	  software	  engineering	  and	  web-­‐based	   DICOM	   viewing	   and	   has	   formally	   worked	   for	   Biotronics	   3D	   where	   he	  developed	  the	  3DNet	  medical	  platform,	  currently	  the	  only	  web-­‐based	  PACS	  system.	  He	  has	  experience	  with	  ISO:13485	  approval	  and	  upkeep.	  Katherine	  Prescott	  is	  head	  of	   Motilent	   Operations	   and	   has	   extensive	   project	   management	   experience	   in	  technology	  SME’s.	  She	  has	  previously	  worked	  on	  both	  early	  and	  late	  stage	  projects	  funded	  by	  TSB.	  	  Prof.	  David	  Hawkes	  is	  Motilents	  lead	  advisor	  providing	  key	  business	  input	   for	   commercialsiation	   of	   medical	   imaging	   technology.	   He	   has	   40	   years	  experience	   in	  medical	   imaging	   research	   and	   a	   significant	   track	   record	   in	   bringing	  innovative	   imaging	   technology	   to	   the	   clinic	   and	   commercial	   exploitation.	   He	   has	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refereed	  350+	  publications	  in	  medical	  imaging.	  He	  was	  co-­‐founder	  of	  IXICO	  plc,	  that	  was	   listed	  on	  Aim	   in	  2013	  as	  well	   as	   scientific	   advisor	   to	   several	  other	   successful	  start-­‐ups	  (e.g.	  Dexela,	  recently	  bought	  by	  Perkin	  Elmer,	  and	  VisionRT).	  CMIC	  is	  one	  of	   the	   largest	   academic	   groups	   internationally	   applying	   novel	   computational	  imaging	   technology	   to	   provide	   healthcare	   solutions	   and	   has	   a	   significant	   track	  record	   with	   support	   from	   EPSRC,	  Wellcome	   Trust,	   DoH,	   NIHR,	   EU	   and	   industrial	  funding.	  	  	  
University	   College	   London:	  UCL	  already	  provides	   imaging	   for	  a	  number	  of	   large	  trials	  many	  with	  1000+	  patients.	  UCLH	  has	  a	  world-­‐leading	  gastroenterology	  service	  and	   access	   to	   National	   Hospital	   for	   Neurosurgery	   and	   Neuroscience	   (NHNN)	   for	  patient	  recruitment	  and	  a	  publication	  and	  grant	  award	  track	  record	  to	  demonstrate	  research	  delivery.	  Prof	  Stuart	  Taylor	  is	  a	  NIHR	  senior	  investigator	  and	  currently	  CI	  of	  two	  large	  multicenter	  HTA	  grants	  (£2M+)	  investigating	  the	  use	  of	  MRI	  in	  cancer	  staging	  and	  Crohn’s	  disease	  respectively.	  He	  has	  expertise	  in	  MRI	  enterography	  and	  has	   published	   widely	   on	   the	   topic.	   He	   sits	   on	   the	   European	   Society	   of	  Gastrointestinal	   and	   abdominal	   radiology/European	   Crohn’s	   and	   colitis	  organization	   joint	   guidelines	   committee	   for	   imaging	   in	   IBD	   and	   NICE	   advisor.	   Dr	  Anton	  Emmanuel	   is	  a	   specialist	   in	  neurogastroenterology	  and	  has	  published	  200+	  articles	  on	  functional	  bowel	  disease	  been	  awarded	  over	  1M	  in	  grants.	  He	  has	  a	  local	  and	   tertiary	   referral	  practice	   for	  patients	   for	  gut	  motility	  disorders,	   especially	   IBS	  and	   chronic	   constipation.	   The	   Unit	   attracts	   450	   such	   new	   referrals	   per	   year.	   In	  addition	  he	  has	  an	  appointment	  in	  the	  NHNN	  seeing	  300	  new	  patients	  per	  year.	  Dr	  David	   Atkinson	   provides	   technical	   expertise	   for	   clinical	  MR	   scanning	   and	  within-­‐
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hospital	   data	   transfer.	   He	   has	   a	   background	   in	   MR	   physics,	   and	   PI	   on	   numerous	  EPSRC	  grants	  totaling	  over	  £1M,	  author	  on	  over	  150	  peer	  reviewed	  publications.	  	  
Queen	  Mary’s	  University	  London:	  Prof	  Charles	  Knowles	  is	  a	  Clinical	  professor	  of	  Surgical	  Research	  at	  QMUL	  and	  a	  consultant	  colorectal	  surgeon	  at	  Bart’s	  Health	  NHS	  Trust	   (the	   largest	  new	  hospital	   in	  Europe).	  He	  has	  a	   strong	   track	   record	  of	  bowel	  disease	   research	   as	   briefly	   evidenced	  by	   90	  peer	   reviewed	  publications,	   and	   over	  £1M	  grant	   funding	   in	   last	   24	  months	   (inc.	   4	  NIHR	   grants	   for	   clinical	   trials).	  He	   is	  deputy	  director	  of	  the	  Bowel	  Function	  Health	  technology	  Cooperative	  (Enteric),	  one	  of	   2	   pilot	   DOH	   funded	   HTCs	   that	   aim	   to	   find	   innovative	   ways	   in	   which	   to	   bring	  together	   patients,	   carers,	   doctors,	   scientists	   and	   industry	   to	   develop	   new	   UK	  technologies,	  treatments	  and	  devices	  in	  the	  field	  of	  bowel	  disorders.	  	  Within	  this	  role,	  he	  has	  secured	  funding	  to	  pioneer	  the	  development	  and	  validation	  of	   several	   new	   technologies	   in	   the	   bowel	   disease	   field	   and	   developed	   a	   national	  clinical	   network	  of	   over	  20	   trial	   centres.	  He	   is	   joint	  director	  of	   the	  new	  proposed	  NIHR	  HTC.	  He	  is	  on	  2	  grant	  award	  panels	  of	  NIHR.	  Prof	  Quasim	  Aziz	  Currently	  he	  is	  an	  executive	  committee	  member	  of	  the	  European	  Society	  of	  Neurogastroenterology	  and	   Motility	   and	   also	   a	   member	   of	   the	   United	   European	   Gastroenterology	  Federation	   Education	   Committee.	   He	   has	   published	   numerous	   original	   articles	   in	  reputed	  medical	  journals	  such	  as	  Nature	  Medicine,	  Nature	  Neuroscience,	  Lancet	  and	  Gastroenterology	  on	  the	  interaction	  of	  the	  brain	  and	  bowel	  is	  recognised	  globally	  as	  a	  leading	  authority	  in	  bowel	  motility.	  Dr	  Mark	  Scott:	  is	  the	  author	  of	  over	  90	  peer-­‐reviewed	   publications,	   8	   book	   chapters,	   and	   has	   recently	   been	   Guest	   Editor	   of	   2	  journal	  supplements	  dedicated	  to	  the	  subject	  of	  chronic	  constipation.	  Together	  with	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Professor	   Charles	   Knowles	   and	  Mr	   Peter	   Lunniss,	   he	   leads	   a	   flourishing	   research	  programme	   centered	   on	   clinical	   GI	   (principally	   colorectal)	   physiological	  investigation,	  involving	  the	  supervision	  of	  several	  research	  fellows.	  	  	  
University	  of	  Nottingham:	  The	  Nottingham	  group	  have	  worked	  together	  over	  two	  decades	   to	   develop	   novel	  methods	   of	   imaging	   the	   function	   of	   the	   gastrointestinal	  tract	  in	  health	  and	  disease.	  Penny	  Gowland	  is	  a	  Professor	  of	  Physics	  with	  more	  than	  25	   years	   of	   experience	   of	   working	   on	   developing	   quantitative	   MRI	   methods	   to	  answer	  biomedical	  questions.	  She	  has	  published	  over	  180	  papers	  on	  application	  of	  MRI,	  held	  grants	  of	  >£16M	  	  and	  is	  a	  Fellow	  of	  ISMRM.	  Dr	  Luca	  Marciani	  is	  a	  physicist	  by	   background	   and	   specialist	   of	   MRI	   of	   gastrointestinal	   function	   for	  gastroenterology	  and	  food	  science.	  He	  translated	  to	  the	  NDDC	  and	  is	  now	  Assistant	  Professor	   in	   GI	   MRI	   and	   sits	   on	   the	   NIHR	   NDDBRU	   Strategy	   Board.	   He	   has	  coordinated	  many	  successful	  multi-­‐disciplinary	  research	  projects	  as	  CoI	  and	  PI	  with	  over	  50	  peer	  reviewed	  publications	  and	  over	  £4m	  funding.	  	  Prof	  Robin	  Spiller	  is	  an	  academic	  gastroenterologist	  and	  Co-­‐Director	  of	   the	  NIHR	  NDDBRU,	  Elected	  Senior	  NIHR	  Investigator	  and	  member	  of	  NIHR	  EME	  board.	  He	  has	  longstanding	  experience	  of	  interdisciplinary	  projects	  studying	  abnormalities	  of	  gastrointestinal	  function	  and	  sensation	   in	   functional	   bowel	   disorders.	   Dr	   Caroline	   Hoad	   is	   a	   physicist	   who	  specialises	   in	  developing	  MR	  methods	  for	  studying	  the	  GI	  tract.	  She	  authored	  over	  20	  peer-­‐reviewed	  publications	  on	  the	  development	  and	  applications	  of	  quantitative	  MRI	  in	  vivo.	  	  
Question	   8:	   Justify	   the	   project	   funding	   and	   describe	   the	   added	  
value?	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  We	   have	   modified	   the	   scope	   and	   aims	   of	   the	   proposed	   project	   following	   the	  feedback	  from	  our	  previous	  expression	  of	  interest.	  	  	  
Motilent	  costs	  	  Salary	  costs:	  (incl.	  NI,	  superannuation):	  	  Project	  Manager	  	   	   	   for	  3	  years	  @	  42,500/year	  =	  	  127,500	  Senior	  web	  developer	  	   	   for	  3	  years	  @	  62,500/year	  =	  	  187,500	  Senior	  medical	  imaging	  developer	  	  	  	  	  	  for	  3	  years	  @	  62,500/year	  =	  	  187,500	  50%	  FTE	  Principle	  Investigator	   for	  3	  years	  @	  30,000/year	  =	  	  	  	  	  	  90,000	  Senior	  Sales/Marketing	  Manager	  	  	  	  	  	  	  for	  6	  months	  @	  45,500/year	  =	  	  22,750	  >Total	  Salary	  for	  3	  years:	   	   	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  £622,250	  	  >>Equipment/Consumable	  Apple	  Macbook	  Pro:	   	   	   	   	   	   	  1400	  x	  2	  =	  2800	  Development	  workstation:	   	   	   	   	   	  1000	  x	  2	  =	  2000	  Microsoft	  Visual	  Studio	  2012:	   	  	  	   	   	   	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  850	  x	  2	  =	  1700	  Windows	  8.1	  Enterprise:	  	   	   	  	  	  	  	  	   	   	   	  	  	  	  270	  x	  2	  =	  	  	  540	  Dell	  PowerEdge	  R320:	  	   	   	   	  	  	  	  	  	  	  	   	   	   	  	  	  	  	  	  	  	  	  	  500	  Windows	  Server2012r2:	  	   	   	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	   	   	   	  	  	  	  	  	  	  	  	  	  600	  	  SQLExpress:	  	   	   	   	   	  	   	  	  	  	  	  	  	  	   	   	   	  	  	  	  	  	  	  	  	  Free	  >Total	  Equipment	  costs	  	   	  	  	  	  	  	  	  	  	   	   	   	   	   	  	  	  £8140	  	  >>Other	  costs:	  	  Server/Infrastructure	  (incl.	  DNS	  reg.&ISO:27001	  colocation	  at	  Telehouse	  East	  with	  4A	  power&100Mb	  2-­‐way	  connection):	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  5460	  /year	  =	  16,380	  Utilities:	  	  	   	   	   	   	   	   	  	  	  30,000/year	  =	  90,000	  Travel:	   	   	   	   	   	   	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  15,000	  Patient	  Outreach	  &	  Marketing:	   	   	   	  	  	  10,000/year	  =	  30,000	  Market	  Analysis	  Consultant	  	  (one	  off)	   	  	  	  	  	  	  	  	  	  	  	  	   	   	   	  	  	  	  	  7,000	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IP	  Protection:	  	   	   	   	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  25,000	  >Total	  Other	  Costs	  for	  3	  years:	   	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  £176,380	  	  __Total	  SME	  project	  costs	  over	  3	  years:	  £	  821755__	  __TSB	  SME	  funding	  over	  3	  years	  @	  60%:	  £493053__	  	  
Academic	  costs	  (80%	  FeC)	  	  Clinical	  Fellow	  UCL	  (100%	  FTE)	  	   	   for	  3	  years	  @	  36,402/year	  =	  	  109,207	  Post-­‐Doc	  UoN	  (50%	  FTE)	  	   	   	   for	  3	  years	  @	  19,471/year	  =	  	  	  	  58,413	  Research	  nurse	  UoN	  (10%	  FTE)	  	   	   for	  3	  years	  @	  2668/year	  =	  	  	  	  	  	  	  	  	  	  	  8,004	  7.5%FTE	  UCL	  Prof	  Stuart	  Taylor	   	   for	  3	  years	  @	  10,201/year	  =	  	  	  	  	  	  24,483	  2.5%FTE	  UoN	  Prof	  Penny	  Gowland	  	  	  	  	  	  	  	  	  	  	  	  	  	  for	  3	  years	  @	  5,000/year	  =	  	  	  	  	  	  	  	  15,000	  2.5%FTE	  QMuL	  Prof	  Charles	  Knowles	  	  	  	   for	  3	  years	  @	  5,000/year	  =	  	  	  	  	  	  	  	  15,000	  >Total	  staff	  costs:	   	   	   	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  £230,107	  	  	  >>Equipment/consumable	  cost	  Laptop	  computer	  UCL	   	   	   	   	  	  	  	  	  	   	   	  	   	  	  	  	  	  	  	  1,000	  MRI	  Scanner	  time	  UCL	  (60h	  @450/h):	  	   	  	  	   	   	   	  	  	  	  	  27,000	  MRI	  Scanner	  time	  UoN	  (50h	  @400/h):	  	   	  	  	  	   	   	   	  	  	  	  	  20,000	  Manometry	  costs	  QMuL	  (1000	  per	  investigation):	  	  	   	   	   	  	  	  	  	  	  30,000	  Subject	  recruitment	  (£20	  gift	  voucher	  for	  140	  controls):	  	  	  	  	   	  	  	  	  	  	  2,800	  Transport	  (patient	  and	  academic):	  	  	   	   	   	   	  	  	  	  	  12,000	  Total	  Equipment/Consumables	   	   	   	   	   	  	  	  	  92,800	  >>Indirect	  Costs	  Estates	  –	  Labs	  UoN	   	   	   for	  3	  years	  @	  10,989/year	  =	   	  	  	  	  32,967	  Infrastructure	  –	  Technicians	  UoN	  	  	  	  	  	  	  for	  3	  years	  @	  958/	  year	  =	  	  	  	  	  	  	  	  	  	  	  	  	  	  2,874	  Indirect	  Cost	  Rate	  UoN	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  for	  3	  years	  @	  33,657/year	  =	  	  	  	  	  100,972	  Estates	  -­‐	  UCL	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  for	  3	  years	  @	  18,921/year	  =	  	  	  	  	  	  	  56,765	  	  	  Infrastructure	  -­‐	  Lab	  Technicians	  UCL	  	  for	  3	  years	  @	  2255/year	  =	  	  	  	  	  	  	  	  	  	  	  	  	  6,765	  Indirect	  Cost	  Rate	  UCL	   	   for	  3	  years	  @	  38,785/year=	  	  	  	  	  	  	  116,355	  >>Total	  Indirect	   	   	   	   	   	   	   	  	  	  316,698	  
	  	   319	   	  
	   	  
	  Total	  UCL	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  £	  348,103	  	  	  	  	  	  	  	  	  	  	  Total	  UoN	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  £	  244,502	  Total	  QMuL	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  £	  	  47,000	  	  __Total	  academic	  costs	  =_________________________________£	  	  	  639,605	  	  	  
Technical	  justification:	  We	  looked	  at	  a	  variety	  of	  hosting	  models	  and	  locations	  for	  this	   application.	  Due	   to	   the	   sensitivity	   of	   patient	   data,	   it	   is	   essential	   that	  Motilent	  manages	  the	  server	  infrastucture	  co-­‐located	  with	  an	  ISO:27001	  data	  centre.	  Hands	  on	  experience	  will	  also	   facilitate	  deployment	  of	   server	  nodes	   in	  other	   locations	  as	  demand	  increases.	  This	  infrastucture	  provides	  sufficient	  resources	  for	  1000	  studies	  to	   be	   uploaded	   and	   processed	   per	   week	   sufficient	   to	   cover	   the	   academic	   and	  commercial	  goals	  for	  the	  first	  years.	  Development	  costs	  are	  largely	  to	  fund	  2	  expert	  level	   software	   engineers	   that	   can	   deliver	   the	   technical	   deliverables	   following	   a	  rigorous	   quality	   standard.	   A	   wide	   variety	   of	   technical	   expertise	   is	   required	   to	  deliver	   this	   project.	   The	   project	   manager	   will	   liaise	   with	   the	   academic	   partners,	  manager	  development	  deliverables	  and	  be	  responsible	  for	  timely	  delivery	  of	  project	  milestones.	   	  We	  have	  appointed	  a	  project	  manager	  through	  Motilent	  as	  this	  avoids	  HEI	  overheads	  and	   is	  more	   in	   line	  with	   the	  business	  objectives	  of	   the	  project.	  We	  have	  costed	  marketing	  consulting	  towards	  the	  end	  of	  the	  project	  as	  we	  feel	  this	  will	  be	   crucial	   to	   deliverable	   exploitation	   as	   well	   as	   the	   first	   6	   months	   of	   a	   sales	  appointment	  to	  drive	  uptake	  post	  completion.	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Clinical	   justification:	  Recruitment	  is	  invariably	  the	  rate	  limiting	  step	  for	  academic	  projects	   and	   we	   have	   proposed	   cautious	   numbers	   based	   on	   previous	   experience	  that	   optimise	   cost	   and	   study	   power.	   We	   have	   allocated	   the	   majority	   of	   the	   HEI	  moneys	  to	  the	  appointment	  of	  a	  clinical	  fellow	  who	  will	  be	  able	  to	  both	  recruit,	  scan	  and	  assess	  the	  data.	  UoN	  has	  a	  specialist	  GI	  research	  facility	  with	  experienced	  post-­‐doctoral	   scientists	   and	   a	   research	   nurse	   to	   address	   recruitment.	   Our	   academic	  partners	  have	  secured	  full	  research	  rates	  for	  scanning	  that	  is	  50%	  lower	  than	  usual	  commercial	   rates.	  Co-­‐investigators	  have	   taken	   lower	  %FTE	   to	  reduce	  project	  cost.	  We	  have	   costed	  patient	   travel	  based	  on	  previous	  experience	  averaging	  out	  at	  £20	  per	  study	  participant.	  Additional	  money	   is	   included	  as	  gift	  vouchers	   to	   incentivise	  healthy	  control	  recruitment.	  	  	  	  
Question	   9:	   How	   does	   financial	   support	   from	   the	   Technology	  
Strategy	  Board	  and	  its	  funding	  collaborators	  add	  value?	  	  The	  proposal	  applicants	  and	  their	  respective	  research	  groups	  represent	  a	  UK	  based	  consortia	  of	  world	  leading	  academics	  specialising	  in	  gastrointestinal	  disease	  with	  an	  outstanding	   track	   record	   in	   academic	   research.	   Together	   with	   their	   institutional	  colleagues,	  they	  have	  published	  over	  400	  papers	  in	  the	  top	  peer	  reviewed	  journals	  (Lancet,	   Nature	   Medicine,	   Gastroenterology,	   Gut	   etc)	   and	   generated	   in	   excess	   of	  £20m	  in	  grants	  as	  lead	  investigators	  and	  co-­‐PIs.	  GIQuant	  as	  been	  used	  as	  a	  research	  tool	  at	  UCL	  and	  UoN	  for	  the	  past	  18	  months	  and	  has	  demonstrated	  clear	  utility	  as	  a	  research	  tool	  and	  for	  clinical	  investigations.	  Dr	  Caroline	  Hoad,	  Prof	  Penny	  Gowland	  &	  Prof.	  Robin	  Spiller	  have	  recently	  been	  awarded	  a	  MRC	  ‘Confidence	  in	  Care,’	  grant	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for	   GIQuant	   analysis	   of	   colonic	  motility	  worth	   £55,000.	   Dr	   Asma	   Fikree	   and	   Prof	  Qasm	  Aziz	  are	  currently	  leading	  an	  application	  to	  investigate	  GI	  function	  in	  hyper-­‐mobility	  disorders	  worth	  £750,000.	  A	  number	  of	  smaller	  projects	  for	  pilot	  studies	  in	  Parkinson’s,	   Chronic	   Pseudo-­‐Obstruction,	   diabetes	   have	   also	   been	   awarded	   to	   a	  value	  of	  £50,000,	  all	  using	  GIQUant	  that	  will	  provide	  the	  preliminary	  data	  to	  support	  larger	   studies.	   	   This	   interest	   in	   GIQunat	   has	   emerged	   purely	   from	   the	   very	  preliminary	   studies	   published	   by	   Menys	   et	   al	   and	   as	   the	   literature	   using	   the	  technique	   grows,	  we	   expect	   to	   see	   an	  uptake	   in	  other	   areas	  of	  R&D.	  A	  number	  of	  other	   studies	   into	   motility	   in	   a	   range	   of	   diseases	   are	   planned	   and	   the	   academic	  partners	  have	  the	  track-­‐record	  to	  maximise	  the	  likelihood	  of	  success.	  	  From	   a	   strategic	   perspective	   the	   TSB	   Biomedical	   Catalyst	   funding	   provides	   an	  essential	  way	   for	  Motilent	   to	   raise	   initial	   funding.	   The	   status	   associated	  with	  TSB	  funding	  is	  such	  that	  it	  represents	  an	  excellent	  indicator	  to	  investors	  as	  to	  the	  quality	  of	   the	  USP,	   team	  and	  business	  stratergy.	  The	  TSB	   investment	   further	  drives	  down	  the	  amount	  of	  money	  needing	  to	  be	  raised,	  allowing	  Motilent	  to	  maintain	  a	  higher	  level	  of	  equity	   in	   the	  company	  and	  have	  better	  control	  over	   its	  direction.	  Motilent	  has	   already	   been	   approached	   by	   Feedback	   Plc.	   a	   company	   actively	   acquiring	  medical	   imaging	   technology	   companies	   (eg.	   TexRAD,	   Cambridge	   Computed	  Imaging)	   to	   develop	   a	   portfolio	   of	   services	   to	   exploit	   this	   burgeoning	   area	   of	  research.	   Feedback	   would	   be	   willing	   to	   assist	   Motilents	   growth	   in	   exchange	   for	  equity,	  however	  TSB	  funding	  would	  be	  central	  to	  Motilent’s	  negotiating	  position.	  At	  present,	  Motilent	  is	  early	  stage	  micro-­‐SME	  in	  a	  precarious	  position	  with	  respect	  to	  its	   IP,	   infrastructure	   and	   marketing	   experience.	   In	   order	   to	   maintain	   its	  technological	  advantage	  and	  USP,	  it	  is	  crucial	  that	  Motilent	  be	  ‘first-­‐to-­‐market’	  in	  GI	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function	   testing	   and	   this	   will	   involve	   early	   partnership.	   Feedback	   have	   extensive	  sales	  experience	  and	  knowledge	  of	  entering	  global	  markets	  with	  medical	  technology	  and	  therefore	  represent	  an	  excellent	  early-­‐stage	  candidate	  partnership	  for	  Motilent.	  	  We	  however	  are	  extremely	  keen	  to	  maintain	  as	  much	  control	  in	  the	  company	  at	  this	  stage	  and	  TSB	  funding	  will	  be	  essential	  to	  enabling	  us	  to	  do	  this.	  	  TSBs	   provision	   of	   100%	   FTE	   academic	   funding	   allows	   Motilent	   to	   bring	   in	   the	  countries	   leading	   academics	   and	   invests	   them	   early	   in	   the	   project.	   As	   stated	  throughout	   this	   application,	   leading	   clinical-­‐academics	   serve	   across	   research,	  clinical,	   regulatory	   and	   commercial	   disciplines	  making	   their	   input	   on	   this	   project	  crucial	   both	   in	   the	   early	   development	   and	   later	   stages	   for	   clinical	   uptake.	   By	  providing	  100%	  FTE	   (especially	   considering	   the	   current	  high	  HEI	  overheads)	   this	  permits	   a	   valuable	   reciprocal	   arrangement	   between	   Motilent	   and	   the	   partners	  allowing	   them	   to	  make	   additional	   staff	   appointments	   and	   generate	   new	   research	  and	   grants.	   TSB	   support	   of	   our	   parallel	  workflow	   between	   SME	   and	  HEIs	   further	  allows	  dynamic	  exchange	   to	  quickly	  produce	  a	  high	  quality	  user	   solution.	  Often,	   a	  commercial	  beta	  product	  is	  tested	  by	  its	  users	  and	  then	  reiterated	  taking	  time	  and	  impacting	  on	  user	  confidence.	  We	  believe	  that	  this	  proposal	  maximises	  the	  value	  of	  the	  Biomedical	  Catalyst	  using	  clinical	  feedback	  to	  direct	  product	  development	  at	  the	  earliest	  possible	  stage	  and	  as	  a	  team.	  It	  is	  well	  recognised	  that	  medical	  diagnostics	  take	   a	   long	   time	   to	   develop	   [Deloitte]	   and	   do	   not	   represent	   the	   ideal	   short-­‐term	  investment	  valued	  by	  venture	  capitalists	  despite	  often	  high	  eventual	  returns.	  	  The	  accrued	  interest	  on	  business	  loans	  makes	  financing	  of	  such	  projects	  by	  a	  small	  SME	   challenging.	   	   	   	   	   Biomedical	   Catalyst	   is	   extremely	   suited	   to	  Motilent’s	   current	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needs	  where	  an	  evidence	  base,	  product	  and	  service	  need	   to	  be	   created	   from	  new.	  The	   three-­‐year	   duration	   of	   the	   project	   is	   additionally	   of	   value	  where	   time	   can	   be	  invested	   in	   developing	   user-­‐interface	   components	   of	   the	   service	   that	   would	  otherwise	   be	   categorised	   as	   low-­‐priority.	   For	   example	   the	   user-­‐interface	   is	  essential,	  especially	  where	  we	  see	  the	  technique	  being	  used	  outside	  of	  radiology	  by	  users	   largely	  unfamiliar	  with	  medical	   imaging	   in	  research.	  This	   is	  widely	  accepted	  as	   one	   of	   the	   primary	   reasons	   medical	   imaging	   research	   is	   not	   translated	   to	   the	  clinic.	  	  Motilent	  will	   provide	   value	   to	   the	   UK	   economy	   through	   several	  ways	   both	   in	   the	  short	  and	  long	  term.	  First,	  it	  will	  provide	  jobs	  both	  directly	  by	  employing	  software	  engineers	  and	  technicians.	  	  As	  the	  business	  grows,	  marketing	  and	  client	  engagement	  will	   become	   increasingly	   important	   and	   result	   in	   further	   appointments.	   Jobs	   will	  also	  be	  provided	  indirectly	  through	  research	  applications	  using	  the	  technique,	  UCL	  is	   currently	   advertising	   a	   PhD	   and	   a	   post-­‐doctoral	   position	   focused	   around	  advanced	  GI	  quantitation	  techniques	  inspired	  by	  the	  success	  with	  GIQuant	  and	  this	  proposal	   will	   employ	   another	   1.5	   people	   to	   conduct	   research	   using	   this	   tool.	  Motilent	   will	   add	   value	   through	   stimulating	   research	   in	   the	   UK.	   GIQuant	   is	  compatible	  with	   a	  widely	   used	   imaging	  modality	   and	   therefore	   the	   ability	   for	   UK	  institutions	   to	   conduct	   research	   using	   the	   technique	   will	   be	   greatly	   increased	  following	  the	  development	  of	  a	  commercial	  product.	  The	  indirect	  value	  of	  research	  comes	   through	   the	   award	   of	   high	   value	   grants	   which	   help	   consolidate	   the	   UKs	  position	  as	  a	  global	  research	  centre	  and	  attract	  high-­‐calibre	  students	  and	  academics	  from	  around	  the	  world.	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During	   the	   course	   of	   the	   project	   Motilent	   will	   generate	   revenue	   through	   trading	  with	   academic	   users.	   Even	   if	   no	   clinical	   value	   in	   GIQuant	   exists,	   the	   academic	  findings	  from	  the	  project	  will	  have	  a	  major	  impact	  on	  our	  current	  understanding	  of	  the	   bowel	   dysmotility.	   If	   GIQuant	   never	   becomes	   more	   than	   a	   research	   tool,	   its	  commercialisation	  will	  be	  valuable	   to	   the	   research	  community	  and	  still	   capable	  of	  generating	   revenue	   through	   licensing	   to	   other	   PACS	   providers	   (Biotronics	   3D,	  Feedback,	  Osirix	  MD	  etc)	  at	  almost	  no	  running	  cost	   to	  Motilent.	   	  Motilent	  plans	   to	  generate	   additional	   revenue	   in	   exchange	   for	   equity	  where	   necessary	   as	   discussed	  above.	  Where	  clinical	  value	  is	  demonstrated,	  the	  GIQuant	  reporting	  service	  will	  be	  rolled	  out	  to	  specialist	  clinics	  and	  medical	  centres.	  Motilents	  business	  model	  means	  that	  all	  data	  will	  be	  processed	  in	  the	  UK	  and	  by	  UK	  based	  technicians	  maximising	  UK	  generated	  revenue.	  At	  5	  years	  following	  the	  conclusion	  of	  this	  project,	  we	  anticipate	  our	  inclusion	  into	  clinical	  guidelines	  which	  will	  significantly	  strengthen	  our	  market	  position.	  The	   infrastructure	  and	  paradigm	  developed	  during	   the	  project	  will	  allow	  the	  development	  of	  new	  tools	  both	  within	  and	  outside	  of	  the	  GI	  tract	  and	  expansion	  of	  the	  service.	  Motilent’s	  lead	  advisor	  (Prof.	  D.	  Hawkes)	  is	  the	  director	  of	  the	  Centre	  for	   Medical	   Image	   Computing	   (CMIC)	   one	   of	   the	   worlds	   leading	  medical	   imaging	  science	   groups.	   Key	   projects	   of	   relevance	   to	   GIQuant	   is	   the	   newly	   developed	   and	  validated	  Colon	  CTC	  registration	  algorithm	  for	  polyp	  detection	  in	  the	  bowel	  cancer	  screening	   program.	   The	   close	   connection	   between	   UCL	   and	   Motilent	   will	   enable	  translation	   of	   this	   work	   and	   produce	   competitive	   products	   to	   rival	   companies	  offerings.	  	  
